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Halfway Down an A. A. Milne poem 
Halfway down the stairs 
is a stair 
where i sit. 




i'm not at the bottom, 
i'm not at the top; 




Halfway up the stairs 
Isn't up 
And it isn't down. 
It isn't in the nursery, 
It isn't in town. 
And all sorts of funny thoughts 
Run round my head. 
It isn't really 
Anywhere! 
It's somewhere else 
Instead! 
And this is to that child who was unreminded – that halfway down was also halfway up instead. 
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Neuroblastoma (NB) is the second most diagnosed childhood solid tumour in high-income countries 
(HIC), but the incidence has not accurately been described in low- and middle-income countries 
(LMICs). The diagnostic difficulty, with limited treatment modalities, contributes to poor outcomes in 
LMICs. This PhD dissertation investigates the management of NB in South Africa with the aim to 
develop the first prospective national neuroblastoma treatment protocol/clinical trial to improve 
overall survival (OS). 
Using the South African Cancer Study Group’s Tumour Registry data, between 2000 and 2016 the 
incidence of NB in South Africa was found to be between 1.74 to 2.6 cases/million children, which was 
lower than the 10.5 cases per million children reported in HICs. South Africa had a higher number of 
patients with high-risk (HR) tumours (75.6%), mainly due to advanced disease (70%). The 2-year OS 
was excellent for very low risk (VLR) (94.1%) and low risk (LR) disease (81.6%), while acceptable for 
intermediate risk (IR) disease (66.7%) but poor for HR disease (27.6%) (p<0.001, 95% CI). Limitations 
in risk stratification included the low number of tumours tested for MYCN (38.4%), with more than 
half being MYCN-amplified (54%), and no other NB related genetic characteristics.      
Several treatment protocols were used in the different paediatric oncology units in South Africa during 
the study period (2000-2014) and the OPEC/OJEC (carboplatin, cisplatin, etoposide, 
cyclophosphamide and vincristine) induction chemotherapy regimen proved to be the least toxic with 
better metastatic remission rates for HR-NB. Ferritin had predictive value for complete metastatic 
remission rate, while LDH had predictive value for two-year OS and were found to be suitable tumour 
markers to use as surrogates for sophisticated genetic testing and mIBG-scans in the context of limited 
resources. Age at diagnosis, specifically the 18-month cut-point value, remained a significant 
prognostic factor, similar to HICs.  
Due to limited access to autologous stem cell transplants, the role of surgery and radiotherapy in the 
management of HR disease were investigated and found to significantly improve five-year OS with 
surgery and marginally with radiotherapy (p<0.001, 95% CI). Furthermore, the disparities in 
neuroblastoma health care provision in the different provinces in South Africa was found to exist and 
should be addressed to ensure equitable health care provision for all children as per the South African 
Constitution. 
The implementation of the newly developed national NB single arm clinical trial in South Africa, 
adjusted to available national resources, was a complex process with major navigational bureaucratic 
challenges. Yet the process might serve as a guideline for similar processes in LMICs. The recruitment 
of patients into the national NB clinical trial proved to be difficult due to both the COVID-19 pandemic 
and reluctance to recruit advanced stage patients into clinical trials. However, with careful 
investigation and in collaborative spirit, rare diseases such as neuroblastoma in South Africa could be 




Neuroblastoom (NB) is die tweede mees gediagnoseerde soliede tumor by kinders in 
hoëinkomstelande (HIL’e). Tog word die voorkoms daarvan in lae- en middelinkomstelande (LMIL’e) 
nie akkuraat beskryf nie. Die diagnostiese uitdaging, sowel as beperkte behandelingsmetodes, lei dus 
tot swak uitkomste in LMIL’e. Hierdie PhD dissertasie ondersoek die behandeling van NB in Siud Afrika 
ten einde die algehele oorlewingsyfer (AO) te verbeter. 
Deur van data tussen 2000 en 2016 van die Suid Afrikaanse Kinderkanker Studie Groep se Tumor 
Register gebruik te maak, was die voorkomssyfer van NB in Suid-Afrika as 1,74 tot 2,6 gevalle per 
miljoen kinders bereken, wat veel laer was as die aangemelde 10,4 gevalle per miljoen kinders in HIL’e. 
Suid-Afrika het ’n hoër getal pasiënte met hoërisiko- (HR-)tumore (75,6%), hoofsaaklik vanweë 
gevorderde siekte (70%). Die AO oor twee jaar het was uitstekend vir uiters laerisiko- (ULR-) (94,1%) 
en laerisiko- (LR-)siekte (81,6%), aanvaarbaar vir matigerisiko- (MR-) (66,7%), maar sleg vir HR-siekte 
(27,6%) (p<0,001, 95% CI). Beperkings in risikostratifikasie het ingesluit die klein aantal tumore wat vir 
MYCN getoets is (38,4%), met meer as die helfde met MYCN-amplifikasie (54%), en die onvermoë om 
NB-verwante genetiese kenmerke te bepaal.      
Verskeie behandelingsprotokolle was gebruik deur die verskillende kinderkanker eenheide in Suid 
Afrika gedurende hierdie periode (200-2014) en dit was getoon dat die OPEC/OJEC-regimen 
(karboplatien, sisplatien, etoposied, siklofosfamied en vinkristien) die grootste voordeel vir HR-NB 
inhou wat toksisiteit en metastatiese remissiesyfers betref. Ferritien het waarde om die metastatiese 
algehele-remissiesyfer te voorspel, terwyl LDH by die voorspelling van die AO oor twee jaar waardevol 
was en kan albei tumormerkers gebruik word as surogate van gesofistikeerde genetiese toetse en 
mIBG-skandering in omstandighede met beperkte hulpbronne. Soos wat in HIL’e bevind is, bly 
ouderdom ten tyde van diagnose, maar spesifiek die 18 maande afsnypunt, ’n beduidende 
prognostiese faktor. 
Met beperkte toegang tot outoloë stamseloorplantings, was die rol van sowel chirurgie as radioterapie 
ondersoek en dit was bewys dat chirurgie die AO oor vyf jaar noemenswaardig verbeter terwyl 
tumorbestraling ’n effens beter AO oor vyf jaar getoon het (p<0.001, 95% CI). Verder het ons 
aangetoon dat daar noemenswaardige hulpbron verskille tussen provinsies bestaan wat aangespreek 
moet word om regverdige gesondheidsorg aan alle kinders te besorg volgens die Soud Afrikaanse 
Grondwet.  
Met die implementering van ’n nasionale NB-protokol enkel arm kliniese studie in Suid-Afrika, met die 
doel om die benutting van nasionale hulpbronne te optimaliseer, was ‘n kompleks onderneming 
waartydens vele burokratiese uitdagings genavigeer moes word, maar kan as ‘n riglyn vir ander LMIL’e 
dien. Die proses om patiente vir die nasionale NB kliniese studie in te win was was uitdagend as gevolg 
van beide COVID-19 pandemie en die onwilligheid om patiente met gevorderde siekte by die studie in 
te sluit. Egter, met respekvolle ondersoek en ‘n gees van samewerking, kan seldsame siektes soos 
neuroblastoom in Suid Afrika volgens ‘n nasionale behandelingsprotokol behandel word met die doel 




Neuroblastoom (NB) is de tweede, meest gediagnosticeerde solide tumor bij kinderen in ‘high-
income countries’ (HIC), maar de incidentie is niet nauwkeurig beschreven in ‘low- and middle-income 
countries’ (LMIC's). De diagnostische problemen met de beperkte behandelingsmodaliteiten dragen 
bij aan een slechte prognose in LMIC’s. Dit proefschrift onderzoekt de behandelingsresultaten van NB 
in Zuid-Afrika met als doel de prognose te verbeteren.  
De data van het Tumor Register van de Zuid Afrikaanse Kinkerkanker Studie tussen 2000 en 2006 laten 
een incidentie van NB in Zuid-Afrika zien van 1,74-2,6 gevallen per miljoen kinderen, hetgeen lager is 
dan de 10,4 gevallen per miljoen kinderen die gerapporteerd worden in HIC. Zuid-Afrika heeft een 
groter aantal patiënten met hoog risico (HR) tumoren (75,6%), voornamelijk vanwege de gevorderde 
ziekte bij presentatie (70%). De 2-jaars ‘overal survival’ (OS) waren uitstekend bij zeer laag risico (VLR) 
(94,1%) en laag risico (LR) (81,6%), aanvaardbaar bij gemiddeld risico (IR) (66,7%), maar slecht bij HR-
ziekte (27,6%) (p <0,001, 95% CI). Beperkingen in risicostratificatie waren onder meer, het lage aantal 
tumoren dat op MYCN werd getest (38,4%), met meer dan het helft (54%) MYCN geamplificeerd, en 
het onvermogen om NB-gerelateerde genetische kenmerken te bepalen.     
Tijdens de studie periode (2000-2014) werden meerdere behandelingsprotocollen door verschillende 
pediatrische oncologie-eenheden gebruikt en bleek het OPEC/OJEC-regime (carboplatine, cisplatine, 
etoposide, cyclofosfamide en vincristine) de meeste voordelen te bieden met betrekking tot de 
toxiciteit en tumorremissie bij HR-NB. Ferritine blijkt belangrijk te zijn bij het voorspellen van het 
percentage van complete remissie, terwijl LDH van waarde is bij het voorspellen van tweejarige OS. 
Beiden zijn geschikte tumormarkers om te gebruiken als surrogaten voor geavanceerde genetische 
tests en mIBG-scans in de context van beperkte middelen. Leeftijd bij diagnose, met name de 18-
maanden ‘cut-off’, is een belangrijke prognostische factor zoals in HIC's. 
Gezien de beperkte toegang tot autologe stamceltransplantaties, werden de rollen van zowel chirurgie 
als radiotherapie bij HR ziekte bestudeerd, en blijkt de vijfjarige OS significant te verbeteren met 
chirurgie en marginaal met radiotherapie (p<0.001, 95% CI). Bovendien blijken er verschillen in de 
gezondheidszorg voor neuroblastoom in de verschillende provincies in Zuid-Afrika te bestaan en deze 
zouden moeten worden aangepakt om te zorgen voor een rechtvaardige gezondheidszorg voor alle 
kinderen volgens de Zuid-Afrikaanse grondwet.  
De implementatie van de nieuw ontwikkelde nationale NB klinisch studie in Zuid-Afrika, aangepast 
aan de beschikbare nationale middelen, was een complex proces met grote bureaucratische 
uitdagingen die moesten worden overwonnen. Toch zou het proces als richtlijn kunnen dienen voor 
soortgelijke processen in LMIC's. De rekrutering van patiënten voor de nationale NB klinische studie 
bleek moeilijk te zijn vanwege zowel de COVID-19 pandemie als de onwil om patiënten in een 
gevorderd stadium voor klinische studies te werven. Met zorgvuldig onderzoek en in een 
samenwerkingsgeest zouden zeldzame ziekten zoals neuroblastoom in Zuid-Afrika echter kunnen 
worden behandeld met behulp van nationale managementprotocollen, gericht op het verminderen 




Le neuroblastome (NB) est la deuxième tumeur solide de l’enfant la plus diagnostiquée dans les pays 
à revenu élevé (High-Income Countries en anglais, HIC), mais son incidence n'a pas été décrite avec 
précision dans les pays à faible et moyen revenu (Low and Middle-Income Countries en anglais, LMIC). 
La difficulté diagnostique, avec des modalités de traitement limitées, contribue à de mauvais résultats 
dans les pays à faible et moyen revenu. Cette thèse de doctorat a pour objectif de structurer la prise 
en charge du NB en Afrique du Sud dans le but éventuel de développer le premier protocole national/ 
essai clinique afin d’améliorer la survie globale (Overall Survival en anglais, OS). 
Les données provenant du registre du South African Cancer Study Group entre 2000 et 2016, 
rapportent une incidence du NB en Afrique du Sud de 1,74 à 2,6 cas/million d'enfants, ce qui est 
inférieur aux 10,4 cas/million d'enfants déclarés dans les HIC. L'Afrique du Sud a un nombre plus élevé 
de patients atteints de tumeurs de haut risque (HR) (75,6%), principalement en raison d'une maladie 
avancée (70%) et d'une amplification MYCN de 54% des tumeurs. La survie globale à 2 ans est 
excellente pour les maladies de très faible risque (VLR) (94,1%) et de faible risque (LR) (81,6%), tandis 
qu’elle est acceptable pour la maladie de risque intermédiaire (IR) (66,7%) mais pauvre pour la maladie 
HR (27,6%) (p <0,001, 95% CI). Les limites de la stratification des risques comprennent le faible nombre 
de tumeurs testées pour MYCN (38,4%), avec plus de la moitié étant MYCN-amplifié (54%) et sans 
autres caractéristiques génétiques du NB.  
Plusieurs protocoles de traitement ont été utilisés dans différentes unités de pédiatrie oncologique 
durant la période de l’étude (2000-2014). La cure d’induction OPEC/OJEC (carboplatine, cisplatine, 
étoposide, cyclophosphamide et vincristine) a rapporté le moins de toxicités avec un meilleur taux de 
rémission métastatique pour le neuroblastome de haut risque. La Ferritine présente une valeur 
prédictive pour le taux de rémission complet, tandis que la LDH a une valeur prédictive pour la survie 
globale à deux ans. Ces marqueurs tumoraux sont adéquats comme substitut pour des tests 
génétiques sophistiqués et des scans-mIBG dans le contexte des ressources limitées. L’âge au 
diagnostic, spécifiquement la valeur seuil de 18 mois, reste un facteur prognostique important, 
similaire au HICs. 
En raison de l’accès limité à la transplantation de cellules souches autologues, les rôles de la chirurgie 
et de la radiothérapie dans la gestion des maladies à haut risques ont été évalués. Il a été constaté 
une amélioration importante de la survie générale à 5 ans avec la chirurgie et marginalement avec la 
radiothérapie (p<0.001, 95% CI). En outre, des disparités de prise en charge du neuroblastome dans 
les différentes provinces d’Afrique du Sud ont été constatées et doivent être adressées pour assurer 
à tous les enfants une prestation de soin équitable conformément à la constitution Sud-Africaine. 
La mise en place de l’essai clinique national à bras unique portant sur le NB et nouvellement développé 
en Afrique du Sud, ajusté aux ressources disponibles, était un processus complexe avec des défis 
majeurs d’ordre bureaucratique. Le processus pourrait servir comme directive aux processus 
similaires dans les LMICs. Le recrutement des patients pour l’essai clinique du NB s’est avéré être 
compliqué en raison de deux facteurs, la pandémie du COVID-19 et la réticence à recruter des patients 
de stade avancé dans l’essai clinique. Cependant, avec une étude approfondie et un esprit collaboratif, 
les maladies rares tel que le neuroblastome en Afrique du Sud ont pu être gérées dans les protocoles 
de gestion national, visant à améliorer la survie générale et la guérison.    
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Neuroblastoma (NB), with ganglioblastoma (GB) and ganglioneuroblastoma (GNB), is a heterogeneous 
group of neural crest malignancies that accounts for the most extracranial solid tumours in 
childhood1,2. It is an aggressive, metabolically active and complex disease that clinically mimics many 
diseases. The heterogeneous pathophysiological presentation of NB, paired with the diverse 
prognostic outcome in different stages of the disease, makes the treatment of this disease an 
oncological challenge3,4. Advanced disease is present in both low- and middle-income countries 
(LMICs) as well as high-income countries (HICs). NB poses both clinical and management challenges 
and requires numerous resources during treatment4. 
Epidemiology 
The epidemiology of NB is not well documented in LMICs due to a lack of tumour registries in the 
context of limitations on resources5,6. Although NB is the most common sympathetic tumour in 
children, reliable paediatric cancer registries do not exist or are limited to single institutions or 
studies7,8. This limits the interpretation of data in Africa5. According to the world-age standardised rate 
(WSR), the incidence is about 12% across regions but less than 10% in Africa5. The WSR of 10.2 per 
million person-years in children in the USA is in contrast with the WSR of 2.7 per million person-years 
in Sub-Saharan Africa in populations with similar ethnicities5. Data from the South African Children’s 
Tumour Registry published in 2015 reported an age-standardised ratio (ASR) of 3.1/1 000 000 for NB 
and 3.0/1 000 000 for NB and GNB9.  
Clinical presentation 
NB has significant differences in prognosis between stages and biological characteristics. Stage 1 
disease has an excellent prognosis versus stage 4 disease with an extremely poor prognosis1,2,10, even 
in HIC. Without high-intensity treatment, advanced-stage disease has a poor outcome in LMIC with 
treatment being palliative rather than curative3,4. 
The clinical presentation can be diverse and therefore challenging to diagnose. Although nearly 65% 
of tumours present in the abdomen11, other sites include the anatomical distribution of the 
sympathetic chain from the brain to the kidneys and pelvic sites1,3. Other distinctive features of 
presentations are often due to metastatic manifestations such as bilateral proptosis, “racoon eyes”, 
bone pain, pancytopenia and constitutional symptoms11. Two paraneoplastic syndromes associated 
with NB include Vaso-intestinal peptide syndrome and Opsoclonus/Myoclonus syndrome11,12,13. Other 
neurological presentations are Horner syndrome, due to tumours in the neck14, and paraspinal 
symptomatology. In stage 4s, apart from the primary lesion, infants under 12 months may present 
with cutaneous lesions, bone marrow infiltration of less than 10% and/or liver lesions1. Therefore, NB 
could be classified as either local disease, metastatic disease or stage 4s disease11. The clinical 
presentation will be dependent on the locality of the tumour with local pressure effects, varying from 
para-spinal disease to a disseminated toxic presentation4,11.  
1
Stellenbosch University https://scholar.sun.ac.za
Molecular and genetic characteristics 
The basis of clinical presentation can be explained by the molecular, genetic and epigenetic diversity 
of NB15. All NB tumours develop from a common precursor, but the variability of genomic instability 
influences the development alterations responsible for the heterogeneous presentation15. NB has 
both germline and somatic mutations that are expressed in the clinical phenotype of the disease. 
Genetic aberrations are present at molecular, genetic and epigenetic levels15. The development of NB 
is dependent on the accumulation of mutations where the pre-malignant cells rapidly replicate in 
proliferating tissue during embryogenesis in the central nervous system16,17. The N-MYC proto-
oncogene is overexpressed in neurogenesis for the rapid expansion of progenitor cell populations16,17. 
Two types of somatic mutations are important in the pathogenesis18,19. Type 1 is characterised by 
whole chromosomal gains and losses and few segmental alterations, which predisposes to favourable 
biology like hyperdiploidy and MYCN-negative tumours18. These tumours express high levels of TrkA 
receptor19. Type 2 is characterised by segmental alterations of unbalanced deletions and alterations, 
with or without whole chromosome changes18. A further subtype 2A is mainly the 3p and 11q 
segmental deletions without MYCN amplification18. Subtype 2A is very aggressive18,20. Subtype 2B is 
MYCN amplified with 1p deletion and unbalanced 17q gain whilst expressing TrkB receptor. Tumour 
genetics is also important to identify genomic characteristics that cause chemotherapy resistance and 
poor treatment response21. At the epigenetic level, DNA methylation of tumour suppressors 
contributes to refractory disease22,23. 
Diagnosis and treatment 
Biological and clinical characteristics at presentation form an important part in the treatment of NB. 
International management protocols are based on risk stratification24,25. These risk classifications are 
based on the presence of prognostic factors such as age, image-defined risk factors (IDRF) and 
stage4,24. Children younger than 12 to 18 months have favourable outcomes as opposed to children 
older than 18 months4,24. IDRF is determined via x-rays, ultrasound, computer-tomography and 
magnetic resonance imaging and includes encasement, compression and infiltration of structures in 
local areas. The more structures involved or amount of metastasis, the more the treatment risks are 
upscaled24,26. Local complete resectable tumours are stage 1 and have a good prognosis whilst distant 
metastasis to bone, bone marrow, liver and lungs, or stage 4 disease, has a poor prognosis4,24. 
Metastasis is diagnosed by the presence of NB cells in bone marrow aspirates and bone marrow 
trephine biopsies, tumour-involved organs on advanced imaging or with the positive enhancement of 
nuclear isotopes of bones on bone scans and bone, bone marrow and soft tissue involvement on 
Iodine-123-metaiodobenzylguanidine (123I-MIBG) scans27.  
 By using the Modified Shimada or International Neuroblastoma Pathology Classification (INPC) 
classification, histology is classified into favourable and unfavourable prognostic classifications28. This 
is determined by the age of the patient and the morphological differentiation of the NB cells18. 
Undifferentiated or poorly differentiated morphology and age over five years are factors associated 
with unfavourable histology18,28. 
Other prognostic factors included in risk stratifications that determine the outcome of treatment in 
NB are translocations, ploidy and the presence of MYCN in molecular studies. MYCN is an adverse 
prognostic marker in NB, as are 11q aberrations and diploidy24,25. In LMIC, where either fluorescent in 
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vitro hybridization (FISH) or polymerase chain reaction (PCR) studies to detect the presence of MYCN 
are not available, ferritin and/or lactate dehydrogenase (LDH) can be used as surrogate markers to 
indicate an adverse prognosis4,25. Although not included into risk stratification failure of the tumour 
to respond to induction chemotherapy27, less than 95% tumour resection or debulking29 and a diffuse 
pattern of metastatic infiltration on 123I-MIBG scans are poor prognostic factors27. 
Based on these risk factors, treatment is stratified into very low risk (VLR), low risk (LR), intermediate-
risk (IR) and high-risk (HR) groups, with each risk group dictating various treatment schedules. Two 
internationally recognised clinical staging systems include the International Neuroblastoma Staging 
System/Children’s Oncology Group (INSS/COG) and the International Neuroblastoma Risk Group 
(INRG)1,2. The INSS is a surgical outcome-based system that was developed by the North America COG. 
The risk factors include tumour stage, age and biological characteristics1. Stage I is completely resected 
tumours, stage 2 is incompletely resected tumours with or without lymph node involvement, stage 3 
unresectable tumours and stage 4 metastatic disease1. Patients younger than 12 months of age have 
a better outcome than children younger than 18 months1. Patients older than 18 months have a 
poorer prognosis than younger children1. Biological characteristics such as the tumour-specific MYCN, 
poor tumour cell differentiation according to the Shimada classification and DNA ploidy incur a poorer 
prognosis with higher risk stratification1.  
The INRG system was developed in Europe by the International Society for Paediatric Oncology (SIOP) 
and also includes age, MYCN and tumour cell differentiation as risk factors. The difference is that this 
staging system is based mainly on pre-surgical assessment, relying on imaging, bone marrow 
morphology and nuclear studies. This staging system includes a very low-risk group1,2. INRG utilizes 
IDRF such as the encasement, compression and infiltration of structures in local areas to define the 
staging25,26. The staging is performed by clinical examination and various investigation modalities 
which include chest X-ray, abdominal ultrasound, computed tomography (CT), magnetic resonance 
imaging (MRI), meta-iodobenzylguanidine (MIBG) scan as well as bilateral bone marrow biopsies4,25. 
Furthermore, it includes 11q aberration as a biological risk factor1.  
Neuroblastoma in low- and middle-income countries 
Paediatric Oncology for Developing Countries (PODC), a dedicated group within SIOP, developed an 
adapted risk group classification based on imaging, availability of resources per setting, and the initial 
surgical status of the tumour to guide treatment4. The classification includes non-specific tumour 
markers such as LDH and ferritin as risk factors apart from surgical outcome and MYCN4. 
In the LR groups of both staging systems, surgery and observation are the standards of care, with 
chemotherapy as a second-line treatment modality for progressive disease1,21. This strategy obtains a 
five-year overall survival (OS) of up to 98%1,21. In the IR groups, the main treatment modalities are 
chemotherapy, surgery and to a lesser extent radiotherapy1,29,30, obtaining a five-year OS of up to 96%. 
The VLR strategy employs a “wait-and-see” approach1,29,30 with five-year OS outcomes of nearly 
100%1,31. Ideally, the treatment for high-risk disease comprises an induction with high-intensity 
chemotherapy, surgery and radiotherapy, autologous bone marrow transplantation, immunotherapy 
with anti-GD2 targeted therapy and tumour cell maturation therapy with cis-retinoic acid (CRA)29,32. 
Even with this treatment intensity, OS is only 50 to 60% in HIC1,31. In LMIC, advanced NB has a poor 
prognosis of less than 20% five-year survival3,4. 
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Due to limited resources and limited access to medical care, the full complement of treatment may 
not be available in resource-limited settings4. Many factors play a role in providing the ultimate care 
to patients with NB, including the stage of the disease, nutritional status at diagnosis, family resources, 
belief systems and personal autonomy. Resources, medicine security and expertise in institutions 
influence treatment decisions to a similar extent as treatment adherence and response to treatment. 
The ability of facilities to provide supportive care in terms of antibiotics, intensive care and granulocyte 
stimulating factors (G-CSF) determine the intensity of treatment4,6. In South Africa, the basic three 
treatment modalities of chemotherapy, surgery and radiotherapy, as well as good supportive care, 
are available and are part of the standard of care for children with NB. With the three modalities of 
chemotherapy, surgery and radiotherapy the prognosis varies from 96% five-year OS for stage 1 to a 
dismal less than 20% five-year OS for stage 41,2,4. Autologous transplantation and CRA for advanced 
disease are institution dependant and patients with private medical care32 mostly have greater access 
to funds. Immunotherapy with anti-GD2 is currently not available in South Africa. As the full 
complement of treatment available to HIC for a high-risk disease is not available in resource-
constrained countries, a high-risk disease has a poor prognostic outcome of less than 20 to 50% five-
year OS3,4.  
The evaluation of treatment response is important for two reasons. The incomplete response to 
induction treatment carries a poorer prognosis and indicates a very high-risk group of patients in the 
high-risk classification group33. This group includes patients with a metastatic bone disease that 
displays poor treatment response after induction chemotherapy33. To identify risk groups and 
evaluate the treatment response, basic, advanced and nuclear imaging form the basis for 
recommendations of criteria based on the International Neuroblastoma Response Criteria (INRC) of 
1993, the revised INRC criteria of 2017 and the soft tissue Response Evaluation Criteria in Solid 
Tumours (RECIST), which are validated tools to evaluate treatment response34. All three response 
evaluation tools grade the decrease or increase of tumour volume in primary and metastatic regions 
and correlate it to complete response, very good partial response, partial response, stable disease or 
progressive disease34. Treatment responses provide guidelines for possible further treatment actions. 
The International Society for Paediatric Oncology European Neuroblastoma group (SIOPEN), a multi-
national group which includes Europe, Israel, Japan and Australia, developed the INRG classification 
system, and are developing protocols together and sharing information to improve outcomes35. In 
rare diseases, such as NB, co-operative working groups promote treatment development and 
evaluation tools and improve outcomes36,37. Implementing clinical trials for new treatment options 
improves the statistical significance with pooled data37. This is evident in the improved outcomes for 
high-risk disease from the five-year OS of 20% to 57% due to co-operative research over the past 20 
years38.  
With the growing population in LMIC, the burden of malignancies in paediatrics will become a 
challenge for LMIC 4. Yet most advanced diagnostics and treatment developments are taking place in 
the HIC 4. As the field of translational oncology is still in its infancy, the translation of novel diagnostics 
and treatments at a laboratory level still has far to go concerning the application in the clinical setting. 
It is vitally important that clinicians research these translational aspects according to the capacity of 
their settings and population-based research to improve outcomes.  
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1.2 Problem Statement and Study Rationale 
 
Historically, the treatment strategies for NB in South Africa have been diverse and are based on the 
experience of the individual paediatric oncologists. Under the umbrella of the South African Children’s 
Cancer Group’s (SACCSG) commitment to developing national management protocols for common 
childhood cancer 4, the study retrospectively investigated the prevalence and outcome of NB, treated 
with various treatment protocols, as well as documented the development and initiation of a standard 
national NB management protocol for children in South Africa.  
 
1.3 Purpose and Objectives  
 
The purpose of the doctoral research 
 
The purpose of the research was to investigate neuroblastoma in South Africa for three purposes. 
Firstly, a retrospective review was done to evaluate the treatment approaches, morbidity and 
outcome over 14 years in all paediatric oncology units (POUs) in South Africa. Data were evaluated to 
compare the OS of different treatment strategies that included either chemotherapy, radiotherapy or 
surgery. The data were further compared to international data. Secondly, the doctoral study 
investigated what the associations were between known risk factors and mCR, OS and event-free 
survival (EFS) as outcomes. Age at diagnosis, specific and non-specific tumour markers and 123I-MIBG 
scans were evaluated for the respective outcomes. The impact of local treatment on the outcome of 
NB in South Africa was investigated to formulate recommendations for the prospective study. Thirdly, 
the prospective standard management protocol for all South African children diagnosed with biopsy-
proven neuroblastoma to describe and evaluate the implementation of the protocol was 
implemented. During the process, the researchers aimed to develop recommendations and resources 
for other LMICs to initiate similar projects. 
The objectives of the research 
1. To complete a literature review of the characteristics at diagnosis, prognostic factors and 
management of NB and OS with a focus on successful management strategies in LMICs with 
limited resources in comparison to HIC.  
2. To perform a retrospective analysis of the pathophysiology, EFS and OS of NB patients treated 
with various standard treatment protocols in South African POUs from 2000 to 2014.  
3. To determine the true incidence of NB in South Africa based on registrations at the South 
African Children’s Tumour Registry (SACTR). 
4. To investigate the prognostic value of age at diagnosis in South African patients and the 
association between the prognostic non-specific tumour markers LDH and Ferritin, specific 
tumour marker MYCN and the prognostic value of MIBG scan with post-induction remission 
and OS in children with NB. 
 
5. To evaluate the outcomes between the standard chemotherapy protocols and local 
management interventions for evidence-based practices in the South African setting to inform 
recommendations for a prospective protocol.  
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6. To describe the development and implementation of a national prospective management
protocol to improve the OS of patients diagnosed with NB and evaluate the implementation
of a national protocol in the South African setting.
7. To provide an interim analysis of the patients recruited on the South African national
neuroblastoma single-arm clinical trial.
1.4 Structure of the Dissertation 
This thesis, in a publication format, consists of a series of reviews and individual studies to 
chronologically document the development of a national prospective management protocol for 
neuroblastoma, each with the corresponding hypothesis and objectives. 
CHAPTER 2: The management of neuroblastoma in limited-resource settings (2020) 
In HIC, neuroblastoma is the most common extra-cranial solid tumour. Yet in LMIC, limited knowledge 
is available about NB beyond single institutional reports and abstracts. The last report on NB in South 
Africa was in the 1990s by Hesseling et al. From these few reports, patients in LMICs present at a later 
mean age at diagnosis, more advanced disease and with more high-risk prognostic indicators. The 
management is limited by the resource-poor settings without standardised approaches to treatment. 
This narrative review provided an extensive overview of the regional approaches of LMICs towards 
NB, summarised the presenting symptoms, disease characteristics at diagnosis and the prognostic 
factors. Due to the non-standardised reporting on the comparison of outcomes between LMICs and 
with HICs not being feasible, an overview of reported results was analysed. Finally, the review 
reflected on the barriers to the implementation of evidence-based treatment protocols and 
socioeconomic variables that influenced the diagnosis, management and follow-up of patients with 
NB. 
Hypothesis: The clinical and pathological characteristics and outcomes in LMIC are comparable to 
HICs. 
Objective: A literature review of the management and OS in the field of NB research in LMIC. 
CHAPTER 3: Reporting incidences of neuroblastoma in various resource settings (2020). Ethics no: 
S18/07/138 
Worldwide, NB contributes to 7% of all childhood malignancies that are diagnosed yearly. In sub-
Saharan countries, accurate incidences of paediatric malignancies have not been documented for 
various reasons including inaccurate recording in tumour registries. In South Africa, underreporting of 
up to 50% has been reported compared to HIC statistics. This heterogeneous spectrum of disease 
poses challenges to the diagnosis of NB and the subsequent inclusion into tumour registries in limited-
resourced settings. This study evaluated the context of NB in LMIC if HIC reporting standards were 
applied and calculated the expected incidences. South Africa had two tumour registries that include 
childhood malignancies. The researchers evaluated the NB data from both registries and included the 
patients from clinical files diagnosed from 2000 to 2016 to compare the NB patients in South Africa 
who were included in the two registries. The same methodology was applied for the age at diagnosis 
and sex in patients diagnosed with NB. 
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Hypothesis: Neuroblastoma is a rare disease in South Africa. 
Objective: To determine the prevalence of NB in South Africa through retrospective analysis and 
accessing a dedicated paediatric tumour registry. 
CHAPTER 4: Overall survival for neuroblastoma in South Africa between 2000 and 2014 (2019). 
Ethics no: S18/07/138 
For the development of a prospective national management protocol for neuroblastoma in South 
Africa, it was necessary to evaluate the local overall survival against international data to 
formulate management recommendations. The hypothesis was that the various neuroblastoma 
treatment strategies had varying outcomes in South Africa. A national multicentre chart 
review of newly diagnosed neuroblastoma patients over 14 years in nine POUs of South Africa 
was done. The data were sourced retrospectively where the known risk factors of NB including 
age, stage, non-specific tumour markers, pathology and biological disease characteristics were 
obtained. The various applied treatment modalities during management were evaluated. The 
outcomes, OS and EFS were determined for all patients registered with the SACTR from 2000 to 
2014. This information was used to evaluate the various treatment protocols used in South Africa 
and to facilitate the development of the prospective management protocol aligned with both 
international guidelines and local resources. 
Hypothesis: Various neuroblastoma treatment strategies had varying outcomes in South Africa. 
Objective: To determine the management and outcomes of NB in South African POUs. 
CHAPTER 5: Age at diagnosis as a prognostic factor in South African children with neuroblastoma 
(2020). Ethics no: S18/07/138 
Age at diagnosis has consistently been an important prognostic factor in determining treatment risk 
classifications regardless of the advances in treatment options. Observations from LMICs had reported 
older median ages at presentation for NB compared to HICs. During the retrospective study, a similar 
delay in the age of diagnosis was reported in South Africa. Internationally, children under the age of 
12 months have a favourable prognosis regardless of tumour biology and patients older than five years 
have poor outcomes. The research hypothesis is that the delayed age of presentation in South Africa 
would have prognostic implications for the risk stratification and therefore for the treatment. The 
researchers determined the 18-month cut-point value to be of prognostic significance concerning 
South African children, which is in keeping with international findings. 
Hypothesis: Various age groups had varying outcomes in South Africa. 
Objective: To determine the prognostic value of age at diagnosis of patients diagnosed with NB in 
South Africa. 
CHAPTER 6: The correlation of tumour markers and 123I-mIBG-studies in South African children with 
neuroblastoma (2020). Ethics no: S18/07/138 
An mIBG scan is part of the gold standard in the diagnosis and evaluation of NB treatment response, 
which is not freely available in LMICs. Furthermore, the production of radioisotopes is not reliable. In 
NB, it is important to administer chemotherapy at the indicated intervals and therefore it is important 
to be able to perform tests at the correct point of evaluation. Blood-based tests are part of the 
standard of care, are cheaper and need limited technology to perform. Non-specific tumour markers 
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lactate dehydrogenase (LDH) and ferritin have previously been validated in predicting treatment 
response and overall survival. The MYCN-gene is a specific tumour marker to NB and has been 
validated in predicting treatment response and overall survival as well. MYCN-amplification can be 
determined on both tissue from the NB tumour as well as the NB-cells in bone marrow aspirates yet 
requires lab-based technology that is often centralised in countries and more expensive than LDH and 
ferritin. LDH and ferritin predict two-year OS, where the modified Curie scores did not. LDH and ferritin 
may serve as surrogate tumour markers to the gold standard of mIBG-scans to assist in the 
management of NB in LMICs.  
Hypothesis: Non-specific tumour markers LDH and ferritin are as good as specific tumour markers 
MYCN and 123I-MIBG scans to indicate prognosis.  
Objective: To investigate the prognostic value of diagnostic non-specific tumour markers LDH and 
ferritin in comparison to specific tumour marker MYCN and the prognostic value of MIBG scan in terms 
of OS in children with NB in the South African context. 
CHAPTER 7: Induction chemotherapy for high-risk neuroblastoma in South African children (2019). 
Ethics no: S18/07/138 
The majority of patients (77%) diagnosed between 2000 and 2016 in South Africa with NB had high-
risk tumours. As metastatic remission after induction therapy in high-risk neuroblastoma (HR-NB) was 
of prognostic importance, this study investigated mCR after induction chemotherapy using three 
standard neuroblastoma protocols in the South African setting. The purpose was to identify an 
induction regimen for HR-NB based on remission rate, toxicity and OS that could be administered in 
al POUs in South Africa. There was no significant difference between the three induction regimens but 
OPEC/OJEC had the most favourable toxicity profile for the South African setting. 
Hypothesis: Various induction chemotherapy groups have varying outcomes in South Africa. 
Objective: To determine the outcomes of the three most commonly used induction-chemotherapy 
regimens in the treatment of NB in South African children. 
CHAPTER 8: The importance of local control management in neuroblastoma in South Africa (2020). 
Ethics no: S18/07/138 
Surgery and radiotherapy are important in the management of neuroblastoma. In patients with low-
risk tumours, surgery could be curative, whilst in patients with intermediate-risk tumours, surgery, 
chemotherapy and, in cases of residual tumours, radiotherapy are curative. HR-NB trimodal therapy 
(chemotherapy, surgery and radiotherapy) only secures OS of up to 20%. In higher-resourced settings, 
autologous stem cell transplants, molecular targeted therapies and maturation therapy have secured 
outcomes of up to 60% OS but decreased the significance of local therapies. The role of surgery in NB 
in South Africa, especially the degree of resection, has never been evaluated. The relevance of 
radiotherapy in curative and palliative management as part of trimodal therapy and in the absence of 
surgery has not been explored in the South African context. The researchers’ study concluded that a 
surgical resection between 90% to 100% has better outcomes than no surgery and that radiotherapy 




Hypothesis 1: Different degrees of NB tumour resection have varying outcomes in South Africa.
Objective: To determine the outcomes of the different degrees of tumour resection in the 
management of NB in South African children. 
Hypothesis 2: Radiotherapy has prognostic value in the management of NB in South African children. 
Objective: To determine the outcomes of irradiated and non-irradiated tumours during the 
management of NB in South African children. 
CHAPTER 9: The implementation of a national paediatric oncology protocol for neuroblastoma in 
South Africa (2020). Ethics no: S18/07/138 
Collaborative guidelines are important in establishing a standard of care for paediatric oncology in 
South Africa. The South African Children’s Cancer Study Group (SACCSG) has embarked on developing 
national management protocols for individual childhood malignancies. By evaluating the process of 
developing the neuroblastoma protocol by the NB-working group of South Africa, valuable resources 
and methodologies for future protocol development were documented. The SACCSG NB-2017 
protocol was an example where multiple international guidelines were incorporated for the local 
setting. The implementation research of this article may provide insight into the development and 
implementation of similar protocols in other LMICs.  
Hypothesis: International guidelines can be implemented for a national prospective NB management 
protocol in South Africa. 
Objective: To document the strategies in the development of a national prospective NB management 
protocol for South Africa. 
CHAPTER 10: Inequality in paediatric oncology in South Africa – the neuroblastoma case study 
(2020) 
In 1996, South Africa adopted its first democratic Constitution. The Bill of Rights included a section 
protecting children’s rights beyond the constitutional right to life and equality. With the guarantee of 
access to health services enshrined in the Constitution, lifesaving treatment for neuroblastoma should 
be included in the right to life-saving medical treatment. With a more equitable population-based 
distribution of the country’s budget and various administrative reforms, the national health services 
should after 20 years have established equal health care access to children with cancers. Based on 
the data from the researchers’ retrospective NB study between 2000 and 2014, they evaluated the 
equity of the human resources, the level of paediatric oncology services and the access to these 
services based on distance and travel duration and found inequity in access to these resources for 
children with cancer.  
Hypothesis: All children diagnosed with NB in South Africa have equal access to paediatric oncology 
services. 
Objective: To determine the resources available to children from different provinces in the 
management of NB. 
CHAPTER 11: An interim assessment of the prospective national neuroblastoma protocol (SACCSG 
NB-2017) in South Africa 
The SACCSG NB-2017 commenced in January 2019. The researchers summarised the initial inclusion 




The management of neuroblastoma in limited-resource settings: a narrative review 
(2020) 
Reference: van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. 
World J Clin Oncol 2020; 11(8): 0-0. https://dx.doi.org/10.5306/wjco.v11.i8.0000  
(Impact factor 2.81) 
A vast base of literature has been published on the clinical characteristics, pathology, genetics and 
treatment strategies of neuroblastoma. The majority of this knowledge is based on research from 
high-income countries (HICs). Although research into these aspects of neuroblastoma management in 
low- and middle-income countries (LMICs) has increased in recent years, there was no single 
publication that evaluated whether the clinical characteristics, pathology, genetics and treatment 
strategies of neuroblastoma in LMIC were the same and how these management aspects compared 
to literature in HICs.  
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Neuroblastoma (NB) is a heterogeneous disease with variable outcomes among 
countries. Little is known about NB in low- and middle-income countries 
(LMICs).
AIM 
The aim of this review was to evaluate regional management protocols and 
challenges in treating NB in paediatric oncology units in LMICs compared to 
high-income countries (HICs).
METHODS 
PubMed, Global Health, Embase, SciELO, African Index Medicus and Google 
Scholar were searched for publications with keywords pertaining to NB, LMICs 
and outcomes. Only English language manuscripts and abstracts were included. 
A descriptive review was done, and tables illustrating the findings were 
constructed.
RESULTS 
Limited information beyond single-institution experiences regarding NB 
outcomes in LMICs was available. The disease characteristics varied among 
countries for the following variables: sex, age at presentation, MYCN 
amplification, stage and outcome. LMICs were found to be burdened with a 
higher percentage of stage 4 and high-risk NB compared to HICs. Implementation 
of evidence-based treatment protocols was still a barrier to care. Many 
socioeconomic variables also influenced the diagnosis, management and follow-
up of patients with NB.
CONCLUSION 
Patients presented at a later age with more advanced disease in LMICs. 
Management was limited by the lack of resources and genetic studies for 
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improved NB classification. Further research is needed to develop modified 
diagnostic and treatment protocols for LMICs in the face of limited resources.
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Core tip: Neuroblastoma (NB) is a childhood malignancy of the sympathetic system that 
accounts for a large percentage of the childhood malignancy mortality. The heterogenous 
presentation contributes to various treatment challenges especially in low- and middle-
income countries (LMICs). NB in LMICs has not been investigated beyond single 
institutions, but the limited reports differ from those in high-income countries (HICs). The 
incidence of NB in LMICs has been reported to be lower than HICs, but the disease 
presents with a higher incidence of high-risk and advanced disease. Furthermore, the 
limited resources in these countries contribute to the challenges in the management of NB 
that leads to a high mortality rate. The genetic profile of NB in LMICs is also not known 
due to limited capacity to perform genetic investigations. This article aims to 
comprehensively describe NB in LMICs.
Citation: van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. 




The burden of disease in low- and middle-income countries (LMICs) is predominantly 
infectious in origin[1,2]. Yet, it is shifting towards non-communicable diseases such as 
congenital diseases, malignancies and road traffic incidents[2,3]. To date, the focus in 
research has been on communicable paediatric diseases with the World Health 
Organization’s initial integrated management of childhood illness programme being 
one example[2]. Building the capacity of health care professionals to identify childhood 
malignancies has not been optimal[4]. This possibly explains the 28%-49% childhood 
malignancy gap reported between LMICs and high-income countries (HICs)[5].
Neuroblastoma (NB) data from HICs are well documented, whereas data from 
LMICs are limited. NB, predominantly a childhood malignancy, remains a major 
contributor to childhood cancer mortality and accounts for up to 15% of paediatric 
malignancy-related deaths[6]. Even with increased-intensity treatment in HICs, the five-
year overall survival (OS) remains approximately 60%[7]. However, there is a major 
divide between HICs and LMICs due to the advances in diagnostics, treatment options 
and outcomes of NB in HICs[8].
Because of the variability of NB symptoms, they can easily be misdiagnosed as 
infections, bone marrow failure, neuropathology and obstructive enteropathies in 
LMICs by primary health care workers. Nurse-led primary care clinics or general 
practitioners may not have the expertise to recognise rare diseases in children and are 
often the first contact versus HICs where the first contact is usually more experienced 
health care workers[9].
Early diagnosis is crucial and necessitates a high index of suspicion with 
appropriate risk stratification and treatment[5]. The prognosis of NB is determined by a 
set of well-described prognostic factors that include patient factors (age at diagnosis), 
biochemical factors (lactate dehydrogenase and ferritin), tumour-related factors 
(primary site, tumour histology and stage), biological factors (MYCN amplification, 
ploidy and loss of chromosome 1p) and management factors (post-induction 
metastatic remission and degree of resection)[10,11]. NB pathophysiology and biological 
features, predominantly MYCN status, loss of chromosome 1p and ploidy, determine 
the spontaneous regression or aggressive growth and spread of metastases but do not 
explain the international difference in characteristics completely[6]. Similarly, notable 
differences in outcomes have been reported for risk classifications between LMICs and 
HICs with similar therapies[12-16]. The aim of this narrative review was to evaluate 
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regional variations in the diagnosis and management of NB in LMICs versus HICs.
MATERIALS AND METHODS
A comprehensive literature review of publications on PubMed, Global Health, 
Embase, SciELO, African Index Medicus and Google Scholar with medical subject 
headings pertaining to NB and outcomes relating to LMICs was done. Search terms 
included (but were not limited to) ‘neuroblastoma’, ‘limited resources’, ‘low-income’, 
‘middle-income’ and names of LMICs. The search was conducted from April 2019 to 
January 2020 with terms adapted according to search engines without limitations on 
the date or language, provided that English summaries or abstracts were included. 
Conference proceedings were included. No authors were contacted regarding 
publications.
Due to the variability in reporting, nonstandard application of definitions in the 
reported clinical results, heterogeneous data and paucity of information, the authors 
constructed limited tables to evaluate clinical and/or biological characteristics to 
report in the descriptive review.
The systemic literature search retrieved 127 articles, abstracts and documents on NB 
in LMICs. After removing 11 documents for possible duplicated reporting, the 116 
remaining documents consisted of 13 cancer registry-based reports and 103 non-
registry-based documents. Twenty-three non-registry-based, nonrandomised studies 
(two prospective studies and 21 retrospective studies) were selected. All 116 articles, 
including the remaining 83 articles that were not specific to NB but contained 
epidemiological and non-interventional data on NB, were utilised to draw descriptive 
conclusions regarding epidemiological elements and outcomes for NB in the 
respective countries. Despite significant population numbers, certain LMIC regions 
were underrepresented in this review due to possible publication bias of reports.
RESULTS
Data from Asia (China, India, Pakistan, Thailand and Vietnam)[13,17-22], the Middle East 
and North Africa (Egypt, Iran, Iraq and Morocco)[23-28] and the Americas (Argentina, 
Brazil, Chile, Cuba, Mexico and Uruguay)[12,16,29-35] were accessible, but reports from 
sub-Saharan Africa and the Pacific Ocean were limited to single reports from the 
French-African Paediatric Oncology Group (GFAOP) and reunion[15,36]. The differences 
between HICs and LMICs could be evaluated from these reports, but complete 
management and outcome data for interregional variations among LMIC regions were 
less robust.
Incidence of neuroblastoma in low- and middle-income countries versus high-
income countries according to international cancer registries
In sub-Saharan Africa, the incidence of NB was low, ranging from 0.4 cases per million 
in Niger to 5.9 cases per million in Kenya[37], compared to HICs such as North America 
and Europe where the respective incidences were reported as 10.5 and 11.6 cases per 
million per year in children younger than 15 years [11,38,39]. South Africa reported an 
incidence of 2.68 cases per million in children under 15 years of age between 1985 and 
2007[40]. In Argentina, intraregional variations in incidence were demonstrated with a 
higher incidence being associated with areas of high socioeconomic status[29]. Yet, the 
international incidences have remained stable regardless of economic status[41]. As 
perinatal and low-risk (LR) NB can be asymptomatic and/or spontaneously regress, 
underdiagnosis of cases is a possible reason[5,37] but the degree of discrepancy is not 
known.
Epidemiology of neuroblastoma in low- and middle-income countries
Difference in age at presentation: In LMICs, the majority of patients were under the 
age of 5 years, but the percentages of infants reported for China (16.3%) and India 
(5.9%) (Table 1) were low. The mean or median age of presentation was delayed in 
some LMICs. In Thailand, the median was 34.8 mo of age and in India as high as 48 
mo of age. The median age of presentation in the 16 paediatric oncology units (POUs) 
of the GFAOP study was 48 mo as well[15]. The age-standardised rates varied among 
countries, but the ratio of patients under 12 to 60 mo could be as low as 2.3:1 in 
Argentina and 1.2: 1 in Brazil compared to an HIC like Germany with a 4:1 ratio 
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Table 1 Age distribution at diagnosis
Country n < 12 mo < 18 mo < 60 mo < 120 mo < 180 mo Mean Median
Asia
China (2008-2013)[17] 59 44% 56% 24
China (2000-2006)[18] 98 16.3% 4.1% 53% 21.5% 4% 48
India (1990-2004)[19] 103 0%-5.9% 77%-98.1% 1.9% 41 -
Pakistan (2015-2016)[20] 70 30% 63% 7% 36
South America
Argentina (2000-2012)[29] 753 30% 52.2% 12.9% 45.3% 26.4
Brazil (1991-2012)[30] 258 29% 49% 17% 5% 40.5 28.9
Brazil (1990-2000)[16] 125 26% 13% 41% 20% 38.2 33
Middle East and North Africa
Egypt (2005-2010)[23] 142 24.2% 75.8% 30
Egypt (2001-2010)[24] 53 22.6% 77.4%
Iran (1974-2005)[25] 219 21.5% 78.5% 40.5
Iraq (2008-2014)[26] 62 30.6% 50% 16.1% 3.2% 37
Sub-Saharan Africa
Ethiopia (2010-2013)[79] 5 0 40% 40% 20%
Kenya (1997-2005)[44] 22 31.8% 50% 18.2% 60
(Table 2). However, other LMICs such as Cuba (4.8:1), with a good reputation for 
health care, and Reunion (2.7:1), a French territory in Africa, compared favourably 
with the United States of America (2.4:1) in this regard (Table 1). The median age of 
presentation in HICs was reported to be between 17 and 18 mo of age, of whom 
approximately 40% were diagnosed under 1 year of age[41]. Many studies have 
reproduced the 18-mo watershed dividing good prognosis (under the age of 18 mo) 
and poorer prognosis (over the age of 18 mo). Stage 4 patients were per definition 
below 12 mo of age with a good prognosis. In HICs, 90% of NB patients were younger 
than 5 years at diagnosis, with a median age at diagnosis of 19 mo, and 37% of patients 
had been diagnosed as infants[11]. The ATRX-gene is associated with advanced-age 
presentations, especially over 9 years of age, conferring a poorer prognosis in 
adolescents and adults[42]. The paucity of genetic studies in LMICs limited the 
interpretation of gene mutations related to age at diagnosis.
Gender distribution at diagnosis: The GFAOP reported that the male to female ratio 
for 16 African POUs was 2: 1[15]. In other LMICs, the male predominance as well as the 
greater male to female ratio was reproducible (Table 3). The ratios varied from 1.06: 1 
to 2: 1. Previous studies from Southern Africa reported a ratio of 1.7:1[43] in keeping 
with the male predominance, while a Mexican study reported a lower NB incidence of 
2.5-4.1 cases per million per year, in keeping with the situation in other LMICs, yet the 
male to female ratio of 1.1:1 was similar to HICs[32]. Kenya also reported a 1: 1 ratio in 
an LMIC setting[44]. The incidences based on gender have not been explained by other 
biological features. These findings were in contrast to the reported surveillance, 
epidemiology, and end results programme data from North America and European 
data, according to which a slight male predominance with a ratio of 1.1:1 was 
noted[38,45].
Population variations: Population variations related to epidemiology and 
pathophysiology contributed to a difference in the presentation of high-risk (HR) 
disease but not non-HR disease[46]. Independent from social circumstances, certain 
ethnicities were diagnosed at an older median age (> 20 mo) and had a higher 
prevalence of stage 4 disease and unfavourable histology tumours (undifferentiated 
cells)[46]. Studies amongst Alaskan indigenous ethnicities (a heterogeneous group of 
Eskimos, Native Indians and Aleuts) reported an incidence of 0.7 cases per million[47]. 
In Australia, Aboriginal and Torres Strait Island children were 1.83 times more likely 
to die from neuroblastoma than nonindigenous children while only contributing 3.7% 
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Table 2 Incidences of neuroblastoma according to the age at diagnosis
Country n < 12 mo < 60 mo Ratio < 12: < 60 < 120 mo < 180 mo Total incidence
South America
Argentina (2000-2012)[29] 753 32.9 14.6 2.3: 1 2.8 1.0 8.3
Uruguay (2001-2010)[35] 69 63.1 18.1 3.4: 1 2.3 0 9.1
Chile (2007-2012)[31] 88 21.9 6.7 3.2: 1 2.1 0.3 4.7
Brazil (1998-2002)[33] 372 15.3 12.4 1.2: 1 3.8 1.3 5.9
Central America and the Caribbean
Mexico (1996-2005)[32] 72 18.5 5.4 3.4: 1 1.1 0.2 3.8
Cuba (2001-2003)[34] 46 3.9 0.8 4.8: 1 0.5 0.2 0.1
Sub-Saharan Africa
Reunion (2005-2011)[36] 12 44.1 15.8 2.7: 1 4.1 0 9.6
of diagnoses[48]. The lower incidence of NB among indigenous ethnicities was not 
reproduced in LMICs of South America or the Pacific Islands[49,50].
Variations in tumour characteristics
Difference in stage during presentation: Many LMICs reported stage 4 rates upward 
of 50%, with India and Pakistan reporting 71.8% and 79% stage 4 tumours respectively 
(Table 4). Egypt, Pakistan and Iran did not report any patients with stage 1 tumours, 
while China and India reported 3% and 1% stage 1 diagnosis respectively[18-20,25]. The 
GFAOP reported metastatic disease for up to 80% of patients except Burkina Faso and 
Morocco, where it varied from 20% to 50%[15]. Kenya reported the highest percentage 
of metastatic disease at 92.3%[44]. The data suggested that presentation in LMIC was 
usually metastatic.
Difference in MYCN amplification: Molecular and genetic diagnostics were not 
available in the greater number of reports and were recorded as a challenge in the 
literature[13,15,51]. In the GFOAP study, only North African countries could determine 
MYCN status[15] with Namibia and South Africa reporting MYCN studies in Southern 
Africa[44]. MYCN is present in about 20% of tumours[51,52]. Limited data are available on 
biological studies, especially genetic studies, in LMICs mainly due to resource 
constraints. In Iran, MYCN amplification was reported in 80% of NB patients, while 
Vietnam, Argentina and Egypt respectively reported rates of 17.8%, 20% and 20.8% 
(Table 4)[14,17,19].
Intra-risk group classification variability: Age groups, biological information and 
treatment protocols were not standardised in the literature, due to the development of 
classifications and changing treatments during the review period. Of note, risk 
classification was either not possible or was done retrospectively. Management 
protocols focus on administering risk-based treatments after identification of the 
classification of each patient yet many patients were treated on the basis of stage[39]. 
LMICs concluded that optimal treatment was doubtful due to the suboptimal 
classification of tumours[9,15,19]. The International Neuroblastoma Risk Group 
classification and the Children’s Oncology Group classification rely on histological and 
genetic information (mitosis-karyorrhexis index, MYCN amplification, 11q aberration 
and DNA ploidy) to determine classification[11], which is not available in many 
resource-limited settings. Even when available, the lack of consistent cytogenetic 
evaluation, as was the case in Argentina, relegated patients in need of high-intensity 
treatment to LR categories and suboptimal treatment[12]. Due to the aggressive nature 
of especially HR NB, palliative rather than curative options have been pursued in 
LMICs[11]. Yet, variability in outcomes has been described within each risk class, 
highlighting that individual assessment is probably suboptimal Therefore, the 
International Society for Paediatric Oncology (SIOP)-Paediatric Oncology for 
Developing Countries (PODC) has adapted the approach to risk stratification with 
therapy based on available resources and utilising available diagnostic techniques[11]. 
The classification relies on age, stage and the common available nonspecific tumour 
markers ferritin and lactate dehydrogenase for risk classification[11]. Morocco has 
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Table 3 Distribution of sex at diagnosis
Country Total Male Female Ratio M: F
Asia
Pakistan (2015-2016)[20] 70 1.8: 1
India (2000-2017)[64] 85 57 (67%) 28 (33%) 2: 1
India (1990-2004)[19] 103 76 (74%) 27 (26%) 2.8: 1
Thailand (2000-2007)[21] 67 39 (58.2%) 23(34.3%) 1.7: 1
Vietnam (2010-2012)[22] 130 76(58.5%) 54 (41.6%) 1.4: 1
China (2008-2013)[17] 59 35 (59%) 24 (40.1%) 1.5: 1
China (2000-2006)[18] 98 1.3: 1
South America
Brazil (1991-2012)[30] 258 148 (57%) 110 (43%) 1.3: 1
Brazil (1990-2000)[16] 125 68 (54.4%) 57 (45.6%) 1.2: 1
Argentina (1999-2015)[12] 39 21 (54%) 18 (46%) 1.2: 1
Argentina (2000-2012)[29] 971 509 (52%) 462 (48%) 1.1: 1
Middle East and North Africa
Iran (1974-2005)[25] 219 1.9: 1
Iraq (2008-2014)[26] 62 37 (59.7%) 25 (40.3%) 1.5: 1
Morocco (2012-2015)[27] 40 26 (65%) 14 (35%) 1.8: 1
Egypt (2005-2010)[23] 142 68 (51.5%) 64 (48.5%) 1.06: 1
Egypt (2001-2010)[24] 53 35 (66%) 18 (35%) 1.9: 1
Egypt (2007-2011)[28] 271 169 (62.4%) 102 (37.6%) 1.65: 1
Sub-Saharan Africa
Northern Nigeria (2003-2009)[80] 14 10 (71.4%) 4 (28.6%) 2.5: 1
Southern Africa (South Africa and Namibia) (1983-1997)[43] 1.7: 1
Ethiopia (2010-2013)[79] 5 3 (60%) 2 (40%) 1.5: 1
Kenya (1997-2005)[44] 22 11 (50%) 11 (50%) 1: 1
implemented this classification system in the prospective NB protocol and has 
concluded that it allowed for more accurate diagnosis and systematic treatment[27]. For 
more accurate comparisons across resource-limited settings, classifications such as the 
SIOP-PODC classification should be standardly applied.
Variable reporting and treatment priorities
Reports from LMICs were predominantly single-institution reports. A multi-
institutional survey by the GFAOP[15] and a review from India including 17 institutions 
and 11 cities[3] described the epidemiology, heterogeneous management approaches 
and outcomes of NB in LMICs[5]. Sub-Saharan African countries reported lower 
incidences of NB (3%-7.5%) among childhood malignancies compared to North-
African countries (7%-30%)[15]. The same study identified the limitations of reporting: 
Plain radiography, ultrasonography, computed tomography and magnetic resonance 
imaging were available at all centres, but access to imaging studies was variable. None 
of the sub-Saharan centres had metaiodobenzylguanidine scans. The North African 
centres had these scans, but only Algeria had consistent access due to government 
funding[15]. In Honduras and the Philippines, diagnostic resources were available in 
large cities but were inaccessible to most patients living in rural areas[50]. This is a 
typical problem in LMICs[53]. An Indian multi-study review concluded that variability 
in India included treatment protocols, reporting of outcomes and calculation of 
survival rates[13]. This conclusion could also be applied to other LMICs. Morocco and 
Argentina were the only LMICs to describe prospective national studies regarding 
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Table 4 Disease characteristics of neuroblastoma at diagnosis
Country n Stage 1 Stage 4 Non-MYCN amplified MYCN amplified Non-HR HR
Asia
China (2008-2013)[17] 59 6.8% 37.3% 55% 45% 53% 47%
China (2000-2006)[18] 98 3% 50%
India (1990-2004)[19] 103 1% 71.8%
Pakistan (2015-2016)[20] 70 0% 79% > 61.1%
South America
Argentina (2000-2012)[29] 753 12% 55.5% 80% 20%
Brazil (1991-2012)[30] 258 15% 46% 75% 25%
Brazil (1990-2000)[16] 125 7% 64% 53% 47%
Middle East and North Africa
Egypt (2005-2010)[23] 142 0% 64.7% 24.2% 75.8%
Egypt (2001-2010)[24] 53 0% 67.9% 79.2% 20.8% 32% 68%
Iran (1974-2005)[25] 219 14.5% 53.8%
Iraq (2008-2014)[26] 62 1.6% 69.4% 45.2% 54.8%
Sub-Saharan Africa
Kenya (1997-2005)[44] 26 0% 92.3%
HR: High-risk.
NB[27,29]. This is representative of the diverse, nonstandardised approach to NB in most 
LMICs. Most studies found a lack of access to biological tests for stratification (based 
on HIC-validated data), the presentation of advanced disease, poor socioeconomic 
circumstances and a significant percentage of patients who absconded from 
treatment[23,24]. Advanced disease and higher than average percentages of HR disease 
were described (Table 4). The PODC committee of the SIOP has developed adapted 
guidelines for the management of NB in LMICs[11]. Yet, in the field of paediatric 
oncology, especially in sub-Saharan Africa, a prioritised, stepwise approach has been 
advised in limited-resource settings, prioritising pain management, supportive care, 
comorbid diseases and malignancies with a higher incidence and relatively 
uncomplicated treatment regimens above rare childhood malignancies[54]. In Africa, 
only Morocco has published data from standardised prospective NB protocols from 
four POUs based on the PODC guidelines[27].
Challenges in improving outcomes
Clinical presentation, index of suspicion and misdiagnosis: Because of its 
heterogeneous clinical presentation, NB can be challenging to diagnose[30]. The 
presenting signs of NB can be similar to those of non-malignant diseases and can 
confound recognition of the disease[10,55]. Symptoms of an NB abdominal mass can be 
misdiagnosed as more common childhood illnesses such as constipation[56]. In LMICs, 
similar to HICs, the most common presentation reported in 19%-87% of patients was 
an abdominal mass (Table 5)[18,19,23,30]. Other common presentations were nonspecific 
abdominal pain (22%-73.5%)[18,30] and fever (25%-65%)[18,19,23,30], metastatic manifestations 
such as bilateral proptosis (27%-42.4%)[19,23], bone pain (19%)[30] and pancytopaenia, and 
constitutional symptoms such as loss of weight[56]. The clinical progression of the 
tumour involves a spectrum of behaviour from aggressive advancement to metastatic 
disease or spontaneous regression and mature differentiation of cell types such as 
ganglioneuroma[29,57]. Health care practitioners must have a high index of suspicion for 
NB with a varied clinical picture[35]. Misdiagnosing NB from other abdominal tumours 
prevents accurate registration of the diagnosis[29]. In resource-limited settings, the 
diagnosis of asymptomatic benign clinical types is less common, possibly due to 
underdiagnosis. Early detection by screening in HICs neither impacted outcomes nor 
was it cost-effective[57]. While the incidence was increased during active screening of 
the disease in the European, North American and Japanese context, surgical 
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Table 5 Most common clinical presentations in low- and middle-income countries
Asia
China (2000-2006)[18] Abd pain (73.5%) Abd mass (54.1%) Fever (45.9%) Limb pain (25.5%)
India (1990-2004)[19] Fever (65%) Abd mass (54%) Bone pain (31%) Proptosis (27%)
South America
Brazil (1991-2012)[30] Fever (25%) Abd pain (22%) Abd mass (19%) Bone pain (19%)
Middle East and North Africa
Egypt (2005-2010)[23] Abd mass (87%) Pallor (57.6%) Fever (45.5%) Proptosis (42.4%)
Sub-Saharan Africa
Kenya (1997-2005)[44] Abd mass (53.8%) Bone pain (50%) Proptosis (38.5%) Fever (19.8%)
interventions were increased without improvement of survival[57].
Access to and assignment of treatment: The number and capacities of POUs varied 
substantially among LMICs, and capacities also varied among POUs in a single 
country[50]. Basic paediatric oncology components were not available in the Philippines 
and Senegal[50], while Venezuela and Egypt had adequate intensive care facilities and 
even transplant services[50]. This is also true of POUs in South Africa[44]. Furthermore, 
paediatric services may not even exist in certain countries or often compete with adult 
services for resources[54].
Current treatment protocols are based on risk stratification[11]. The LMIC reports 
included treatments over four decades[13,30]. Therefore, outcomes were predominantly 
reported per stage and, subsequently, as classification systems evolved, research 
describing the treatment of LR and intermediate-risk (IR) patients but focussing 
primarily on HR disease as the greatest NB burden was reported.
In many LMICs, NB treatment choices are limited to mainly chemotherapy, surgery 
and radiotherapy[1]. In HR NB, multimodal therapy is of vital importance for cure and 
five-year OS of up to 60% (Figure 1).
Due to advanced disease at diagnosis, palliative treatment is often the only plausible 
option (Figure 1). Other challenges for the management of NB include lack of surgical 
and radiotherapy skills or equipment as well as lack of chemotherapy[1,11]. Poor 
outcomes have necessitated the development of palliative strategies, yet many LMICs 
where drug insecurity is high do not have even basic medicines for palliation[58]. 
Resources, drug security and expertise in institutions influence treatment decisions to 
a similar extent as treatment adherence and response to treatment. The ability of 
facilities to provide supportive care, in terms of antibiotics, intensive care and 
granulocyte-stimulating factors, influences decision making regarding the intensity of 
treatment that patients receive[10,11].
Treatment protocols utilised in low- and medium-income countries and outcomes: 
Over the past decades, guidelines for the treatment of NB have changed as a result of 
an improved understanding of biological prognostic factors and changing 
classification systems yet chemotherapy remains based on etoposide and platinum 
(cisplatin and/or carboplatin) backbones plus dose- and time-intensive administration 
of chemotherapy[11]. Some approaches include doxorubicin in the regimens, while the 
SIOP-PODC treatment guidelines for NB are based on settings relating to the level of 
supportive care and resources available in a POU[11]. Indicators for reporting outcomes 
were not consistent over the same period. Some studies reported according to stage, 
while others reported according to risk classification.
The GFAOP administered various local and international protocols based on the 
standard backbone including doxorubicin[15]. Individual POUs reported a long-term 
OS of less than 10% for metastatic disease. Tunisia reported an OS of 78% for non-
metastatic disease, while Senegal reported an OS (metastatic plus non-metastatic) of 
38.9%. The report concluded that with all countries having access to surgical options, 
the outcomes were ‘generally poor’ and standardised protocols were being developed 
for multicentre use[15]. In Morocco, a GFAOP member, a national prospective protocol 
divided into an HR protocol and a non-HR protocol based on the risk-adapted SIOP-
PODC treatment guidelines was studied[11,15,27]. Long-term outcomes were not reported, 
but 60.6% of HR patients experienced a partial or very good partial response, receiving 
local control with surgery or consolidation therapy[27]. The study concluded that risk 
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Figure 1  Challenges of non-tumour-related factors during the treatment of high-risk neuroblastoma in low- and middle-income countries. 
ASCT: Autologous stem-cell transplant; HIC: High-income country; CRA: Cis-retinoic acid.
stratification and treatment guidelines adapted for LMICs improved the accuracy of 
diagnosis and access to systematic treatment[27]. The protocol was also suitable for 
multicentre use[27].
A Chinese study administered OPEC by modifying the Japanese study group 
protocol[18]. The five-year OS was 80% for stages 1 and 2 and 48.3% and 20% for stages 
3 and 4 respectively, which was less than the Japanese outcomes[18].
Egyptian and Indian centres based their HR treatment on the North American CCG-
3891 protocols, while other LMIC centres administered chemotherapy according the 
European protocols from France and the International Society of Paediatric Oncology 
European Neuroblastoma Research Network (SIOPEN)[59]. Indian institutions followed 
a non-standardised approach including OPEC/OJEC, doxorubicin-containing and 
Ifosfamide-containing regimens[13]. Iran and Egypt used OPEC/OJEC regimens[23-25], 
while Brazil, Thailand and China followed doxorubicin-based regimens[16-18,21,30]. Stage 1 
disease had a five-year OS of 100% in Brazil[16], China[17,18] and Thailand[21], while stage 4 
OS was under 20%[16,18]. The three-year OS for stage 4 disease in Thailand and China 
was less than 35%[17,21]. While the outcomes for stage 1 disease were comparable to 
HICs, the poorer stage 4 outcomes were less optimal than in HICs[10]. The same 
conclusion was reached in an Indian study with three-year OS and event-free survival 
for non-metastatic disease of 77% and 54% respectively[60].
Argentina alternated between rapid COJEC and the modified N7 for HR disease 
according to the SIOPEN HR NBL-1 protocol[12]. The five-year OS was 24%. The study 
concluded that improved supportive care, optimal treatment and maximising 
available resources were needed[12]. A second Argentinian study associated lower 
socioeconomic status with poorer outcomes independent of treatment[29].
In LMICs, no conformity was found in the management of NB amongst regions 
within countries. Failing to complete one aspect of the sequential treatment protocol 
relegates the outcome to being suboptimal. This is often the case in LMICs with 
limited access to health care and limited resources for optimal treatment[61]. It is 
possible that without genetic factors to distinguish more clearly between IR and HR 
disease, the IR cohorts in LMICs contain a number of HR patients, thereby affecting 
outcomes[11].
Main factors affecting outcomes: LMICs have identified treatment-related, tumour-
related and social factors that affect the outcomes of children with NB. Delayed 
diagnosis[30] and inaccurate diagnosis of tumours due to limited radiologic and 
pathology resources were cited as major obstacles[25,27,60]. The limited ability to perform 
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biological testing impaired accurate risk stratification[25,27,30,62]. Centres with higher 
levels of supportive care reported the inability to perform bone marrow transplants as 
a limitation to improving outcomes[24,60]. The variability of tumours and nonspecific 
presentation contributed to late diagnosis and the incidence of advanced 
disease[12,25,27,30,62]. Yet, the greatest problems were the abandonment of treatment and 
patients lost to follow-up of up to 50%[11,70,62], which were linked to social factors and 
the distance from treatment centres[12].
Social circumstances and outcomes: A Brazilian study reported intraregional 
variation in the incidence of NB based on socioeconomic status[33]. The study 
concluded that patients from regions with a lower socioeconomic status had poorer 
outcomes[33]. In South African populations, socioeconomic and/or cultural factors 
related to access to or utilisation of health care services are a possible contributing 
factor to poorer outcomes[1]. A large proportion of rural inhabitants have restricted 
access to medical facilities and thus experience a delay in treatment[1,63,64]. A Harvard 
study concluded that in the United States of America, NB diagnosis was influenced by 
social circumstances[65]. According to the study, the Human Development Index 
showed a direct relationship between socioeconomic status and the incidence of NB[65].
Factors influencing health-seeking behaviour: The heterogeneous and aggressive 
pathophysiology of NB demands prompt response and immediate medical 
intervention for nonspecific symptoms[66,67]. The economic structure of LMICs 
influences the affordability of healthcare and parental education[68-70]. These factors 
determine the promptness of the response to and the action taken with regard to 
nonspecific symptoms associated with the initial phases of childhood malignancies. 
The steadfast belief in traditional medicine as a first treatment option and cultural 
systems in which elders or a single authority figure decide about seeking medical 
intervention may delay action towards directed care[71,72]. Political stability and 
government policies have a direct impact on the availability, accessibility and quality 
of health care systems in treating childhood cancer[73,74].
Research priorities
The focus of research for LMICs should be on creating greater awareness in the 
diagnosis of NB, improving diagnostics and establishing social support strategies for 
successful, harmonised management protocols and homogenous treatment facilities to 
improve outcomes[55,75]. The main priority should be accurate tumour registries to 
document not only the most common or treatable childhood malignancies but also the 
rarer tumours such as NB[37]. In resource-limited settings, the need for genetic markers 
to develop more accurate risk classifications exists, especially to distinguish clearly 
between IR and HR patients. This is important in the case of stage 2 and stage 4 
patients with adverse biology tumours who have in a higher risk classification 
compared to patients with non-adverse biology tumours[11,25,29]. Genome and exome 
sequencing have improved the understanding of the pathophysiology of NB in 
HICs[76]. However, knowledge regarding genetics of NB in the diverse ethnicities in 
LMICs is limited. A further challenge would be to make treatments and advanced 
diagnostics, such as liquid biopsies and biological tests, more widely available to all 
countries, whether HICs or LMICs, to improve diagnostic capacities and outcomes[75]. 
In advanced disease, palliative research could contribute to a greater understanding of 
the role of metronomic therapies and disease control in the context of NB[77].
DISCUSSION
Childhood malignancy awareness and advocacy still face great challenges, especially 
in LMICs, notably countries with large rural populations and great geographical 
divides, in accurately diagnosing malignancies, especially heterogeneous tumours 
such as NB. The lack of uniform treatment protocols for this variable disease is still a 
barrier to care. Epidemiological data are reproducible in different international 
studies, but data from across the world are not uniform. More research regarding 
tumour biology, specifically genomics, is needed not only in HICs but also in LMICs to 
determine underlying differences in molecular biology of the tumours, genetic targets 
and drug processing of NB patients, especially in heterogeneous populations. This 
information must then be made available to treatment centres where biological 
investigation is not possible, ready for clinical application to achieve improved 
outcomes for NB worldwide.
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ARTICLE HIGHLIGHTS
Research background
Neuroblastoma (NB) is a well-documented childhood malignancy with the greatest 
source of knowledge originating from high-income countries. The management of NB 
in low- and middle countries (LMIC) is less robust due to various social and resource 
limitations.
Research motivation
The outcomes of various LMIC during the same period like South America, 
Francophone/North African countries, Asia and South Pacific Islands was evaluated.
Research objectives
This literature review was to evaluate regional development of management protocols, 
the challenges in treating NB in paediatric oncology units in LMIC as compared to 
high-income countries, new laboratory and clinical developments in the treatment of 
NB.
Research methods
A literature review of publications searched on PubMed, Medline, Global Health, 
Embase, SciELO and Google Scholar with keywords in keeping with NB and 
outcomes. Due to the variability in reporting, nonstandard application of definitions in 
the reported clinical results, heterogeneous data and paucity of information, the 
authors constructed limited tables to evaluate clinical and/or biological characteristics 
to report in the descriptive review.
Research results
Childhood malignancy awareness and advocacy still face great challenges, especially 
in LMICs, in accurately diagnosing malignancies, especially heterogeneous tumours 
such as NB. The lack of uniform treatment protocols for this variable disease is still a 
barrier to care. Epidemiological data are reproducible in different international 
studies, but data from across the world are not uniform.
Research conclusions
More research regarding tumour biology, specifically genomics, is needed not only in 
high-income countries but also in LMICs to determine underlying differences in 
molecular biology of the tumours, genetic targets and drug processing of NB patients, 
especially in heterogeneous populations.
Research perspectives
The focus of research for LMICs should be on creating greater awareness in the 
diagnosis of NB, improving diagnostics and establishing social support strategies for 
successful, harmonised management protocols and homogenous treatment facilities to 
improve outcomes. In resource-limited settings, the need for genetic markers to 
develop more accurate risk classifications exists. A further challenge would be to make 
treatments and advanced diagnostics, such as liquid biopsies and biological tests, more 
widely available to all countries. With advanced disease, palliative research could 
contribute to a greater understanding of the role of metronomic therapies and disease 
control in the context of NB.
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Abstract 
Background 
The incidences of neuroblastoma (NB) differ significantly between countries. The heterogeneous 
presentation, varying quality of cancer registries and underdiagnoses of NB complicate the recording 
of incidences in various resource settings.  
Purpose 
The aim was to evaluate current regional variations of NB as reported by international cancer 
registries. The primary objective was to evaluate the theoretical and reported differences in 
international incidences. The secondary objective was to evaluate South Africa as a case for variable 
reporting. 
Method 
A comprehensive literature review on registries reporting on NB was done to construct incidence 
tables. The Surveillance, Epidemiology, and End Results (SEER) Program incidence of 10.5/ million 
26
Stellenbosch University https://scholar.sun.ac.za
children for NB was used to calculate the expected number of cases for each country. Registry data of 
NB cases between 2000 and 2015 were requested from The South African National Cancer registry (SA 
– NCR) and the South African Children’s Tumour Registry (SACTR) for comparison.
Results 
Internationally incidences varied between -97.1% to +80% compared to the SEER program. Between 
2000-2015 the SA-NCR reported between 23 – 51 cases/ year whilst the SACTR reported between 18 
– 57 cases/ year for the same period. Both registries reported incidences less than HIC.
Conclusion 
Underdiagnosis of NB and undiagnosed cases due to spontaneous regression alone cannot explain 
the lower incidence of NB and further and improvement in the South African tumour registries are 
required to determine actual incidence. 
Article 
Introduction 
According to The Surveillance, Epidemiology, and End Results (SEER) program the incidence of 
childhood malignancies between 2011 and 2015 for children under 15-years were 16/ 100 000 
children compared to 953 malignancies per 100 000 adults [1]. Internationally neuroblastoma (NB) is 
the second most common solid tumour of childhood, after central nervous tumours, but only 
contributes to 7% of childhood malignancies [2]. NB has no single clinical presentation underlined by 
heterogeneous pathophysiologies which challenges surveillance and diagnosis in variable resourced 
settings challenging [2]. The incidence of neuroblastoma (NB) is well described in HIC. The SEER 
program of the National Cancer Institute of the United States of America reported an incidence of 10.5 
cases/ million for NB, but a lower incidence has been recorded in LMIC [3]. According to the 
International Agency for Research on Cancer (IARC) the HICs Canada and the USA reported age 
standardised rates (ASR) of 12.5/ million children under 15 years and 14.0/ million children under 15 
years for respectively [4]. In Europe the ASR varied between 8.3/ million children under 15 years (The 
Netherlands) and 19.0/ million children (Italy) [4]. The South American countries reported ASRs 
between 2.0/ million children under 15 years in Ecuador and 11.2/ million children under 15 years in 
Uruguay [4]. There is very little known about the epidemiology of the disease in Sub-Saharan Africa. 
In a region where communicable diseases, neonatal deaths, malnutrition and the HIV-epidemic 
contribute the greatest burden to health care systems, the incidences of rare diseases, such as NB, 
even in the presence of disease specific registers, are inaccurately recorded [5]. According to the 
IARC’s International Incidence of Childhood Cancer program the African region reported ASRs for NB 
of between 0.8/ million children under 15 years in Uganda to 10.4/ million children under 15 years in 
Egypt [4]. Due to the inaccuracies of cancer registers and lower than average diagnoses of childhood 
malignancies in these regions, it is not understood whether these incidences are false low values or a 
true incidence of NB in these regions [5,6].  
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South Africa (SA) is a country with a youthful age structure where 29.2% of the population is under 
15-years of age [4]. According to the IACR reports South Africa reported an ASR of 2.7/ million children
under 15 years for NB, which is much lower than reports from HICs. The South African Children’s
Tumour Registry (SACTR) is a clinical base registry compiled by data submitted from physicians treating
children with childhood malignancies established in 1987 by the South African Children’s Cancer Study
Group (SACCSG) [6].  The registry complies with international quality standards for cancer registries.
Cases with incomplete data are not included in reported data [6]. The South African National Cancer
Registry (SA – NCR) is the main cancer surveillance system in SA. Although it was established in 1986
as a voluntary, pathology-based cancer reporting system, the register was mandated through
legislation in 2011 to monitor and report the national cancer burden [7]. These two registries serve as
the main sources of information regarding the incidence of NB in South Africa.
The aim of the study was to evaluate current regional variations of NB as reflected by internal registries 
and incidence reports. The first objective was to evaluate the theoretical and reported differences in 
NB incidences around the world. The second objective was to determine the expected incidences of 
NB per country if the incidence were the same of SEER program. The third objective was to evaluate 
South Africa as a case study and describe the differences in the two local South African registries. 
Methodology 
African Index Medicus, ScieLo, Pubmed, Global Health, Embase, and Google Scholar were searched to 
perform a comprehensive literature review of publications with medical subject headings (MESH) in 
keeping with registries reporting on NB such as “registries”,” neuroblastoma”,” children” and country 
specific names. The search was conducted from April 2019 to January 2020. No limitations were set 
on the date or language provided English summaries or abstracts were included. Reports of tumour 
registries were used to construct incidence tables. If no reports were found data was requested 
electronically from relevant cancer registries of each country.  
The NB incidence of 10.5/ million children reported by the SEER Program was used to calculate the 
expected number of cases for each country. The percentage children under 15 years old per 
population and the population under 15 years old in each country were sourced or calculated from 
data from the World Bank [8] and the World Factbook website [9].  
Registry data were requested from The South African National cancer registry (SA – NCR) and the 
South African Children’s Tumour Registry (SACTR) for registered NB cases between 2000 and 2016. 
Patient data from the two registries were compared across the two data sets according to the number 




The systemic literature search retrieved 127 articles, abstracts and documents on NB which included 
13 cancer registry-based reports. The national incidence of NB varied between 0.2 – 18.9/million 
children under 15 years/ year (average 7.9/million) which varied between -97.1% to 80.0% according 
to the 10.5/ million reported by SEER data.  
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South African registries 
The SA-NCR reported between 23 – 51 cases/ year between 2000 and 2015, whilst the SACTR reported 
between 18 – 57 cases/ year for the same period (see Graph 1).  
The SA-NCR reported 11-27 males/year and 7-24 females/year whilst the SACTR reported 5-21 males 
and 7-19 females per year respectively (see Graph 2).  
The SA-NCR reported 1-48 children aged 0-18 months/year, 1-30 aged 19-60 months/year and 0-1 
children older than 60 months/year whilst the SACTR reported 3-15 children aged 0-18 months/year, 
6-22 aged 19-60 months/year and 3-11 children older than 60 months/year (see Graph 3).
The incidence reported by the SA-NCR varied between 1.5-2.8/ million children under 15-years per
year whilst the SACTR reported 1.74-2.6 cases/million children. This varied between 0.3-0.92
cases/million (see Table 1). The incidence of males reported by the SA-NCR varied between 1.8-3.5/
million males under 15-years per year whilst the SACTR reported 1.0-2.76 cases/million males. This
varied between 0.4-0.89 males/million (see Table 1). The incidence of females reported by the SA-NCR
varied between 1.6-2.3/ million females under 15-years per year whilst the SACTR reported 1.25-3.69
cases/million females. This varied between 0.14-2.09 females/million (see Table 1).
Discussion 
Neuroblastoma is a significant cause of childhood cancer deaths, and a burden on resources regardless 
of the country of diagnosis. Based on mortality estimates to calculate disability adjusted life years the 
burden disproportionately affects populations in resource-limited settings [10]. Yet since these 
calculations are in part based on population-based cancer registries, the burden might be 
underrepresented [10]. With the heterogeneous presentation of NB, the impact cannot be reliably 
determined as the national incidences are not accurately recorded.   
Availability of robust tumour registries 
The paucity of robust tumour registries contributes to the limited epidemiological data in LMIC 
[11,12]. Although NB is the most common extra cranial solid tumour in children, in Africa it is less 
common than nephroblastoma and retinoblastoma [13]. However, reliable paediatric cancer registries 
are variable or are limited to single institutions in LMICs [14]. This undermines the optimal 
interpretation of data to reflect the true burden of NB [11]. According to world-age standardised rate 
(WSR) the incidence is about 12% across regions but less than 10% in Africa [11]. The WSR of 10.5 per 
million person-years in children in the USA is in contrast with the WSR of 2.7 per million person-years 
in Sub-Saharan Africa [15]. In figure 1 the current reported number of cases are reflected with figure 
2 reflecting the countries that obtain the 10.5/ million incidence that is reported in the SEER database. 
The figures indicate a predominance of NB in westernised countries. Yet, in Figure 3 the expected 
number of NB cases for each country are reflected based on a HIC incidence (see Table 1). Each 
country’s total expected number of diagnoses was calculated as a value equal to a WSR 10.5 per 




Fig. 1. Reported incidence of NB cases in children under 15 years of age 
 




Fig. 3. Expected number of NB cases for each country based on an incidence of 10.5/ million children 
The limitations of surrogate inter-regional incidence rates 
 
In Table 1 the calculated incidence gaps as a percentage between the reported incidence and the SEER 
incidence are indicated. It is generally stated that the incidence of NB is lower in resource limited 
settings [10,11]. Yet HICs Singapore and Qatar have incidences of 5.9 and 6.6 respectively, whilst 
Reunion, a French territory in sub-Saharan Africa, has an incidence of 11.1/ million children. This is 
higher than the 10.5/million children reported for the United States [17]. 
South Africa as a case study 
Population based cancer registries report on the occurrence of cancer in a population, during a specific 
time period and is a tool to evaluate the impact of cancer on the community [18]. The medical system 
in South Africa is a dual public and private medical system that serves 85% and 15% of the population 
respectively [19]. To evaluate the incidence of neuroblastoma in the country both medical systems 
should be surveilled. Registration of cancers in both sectors are overseen by the SA-NCR based on 
voluntary pathology reporting that became compulsory in 2012. The limitation of this system is that 
neuroblastoma can be diagnosed on clinical signs in conjunction with radiological images and 
confirmed with urine catecholamine levels. Thereby no confirmatory biopsy is done. 
The SACTR is a clinical registry compiled by mainly paediatric oncologists in both the public and private 
sector. The limitation of this registry with regards to registering neuroblastoma is that it excludes 
patients not treated by paediatric oncologists, patients that died before referral for treatment and 
patients that was misdiagnosed. Together the two registries should account for nearly all patients that 
were biopsied and started with treatment in a healthcare facility with minimal impact on the incidence 
when diagnosed patients are not reported. As there are no common unique identifiers in both sets 
record linkage should be done using probabilistic record linkage techniques with variables such as 
name(s), surname, date-of-birth, date of diagnosis, sex and province of diagnosis to link the patients 




In South Africa non-diagnosis of childhood malignancies have led to a significant underreporting of 
childhood malignancies [20]. In relation to the patho-physiology of NB the non-diagnosed cases could 
either be explained by tumours that underwent maturation and remained undetected, neuroblastoma 
was misdiagnosed as non-malignant diseases or patients died undiagnosed.  
NB screening in infants for urine vanillylmandelic acid and homovanillic acid have identified cases that 
would have undergone spontaneous regression [21,22]. Screening studies only proved to identify 
more tumours with favourable histology, but not advanced disease, nor did it improve overall survival 
outcomes [21,22]. By adopting a “wait and see” management strategy, tumour regression in 
untreated patients have been seen in up to 47% of patients with localised stage 1 and 2 
neuroblastomas [21,22]. This represents 0.7 cases/ million infants screened [23]. 
Sudden unexpected death due to neoplastic disease in infancy and childhood is rare [24,25]. Autopsy 
case series have demonstrated that a variety of neoplasms including cardiac neoplasms and central 
nervous system (CNS) tumours account for the largest number of cases [24,25]. There are limited 
published paediatric autopsy registers available in South Africa to determine undiagnosed NB deaths, 
yet international reports concluded that neuroblastoma contributed less than 8% of autopsy cases 
[26]. 
Conclusion 
Even with meticulous registration of pathological and clinical cases of NB, undiagnosed and 
misdiagnosed cases will lead to underreporting of cases in many countries. Yet by calculating the 
percentage of underdiagnosis statistically, evaluating possible additional cases by autopsies and 
screening procedures, South Africa will still not have an incidence reported in Europe and North 
America. The paucity of genetic information regarding NB in LMIC may be a factor to understanding 
the difference in incidences.  
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Graph 2. The discordant number of neuroblastoma cases in the SA-NCR and SACTR per sex 
 
SACTR – South African Children’s tumour registry; SA-NCR – South African National Cancer Registry 
 
Graph 3. The discordant number of neuroblastoma cases in the SA-NCR and SACTR per age group 
 




Table 1: Epidemiological characteristics of neuroblastoma per country 
 
Country % Children 0-14 yrs per 
population (2017)1,2 
Population <0-14 yrs1,2 Expected number of cases 
(10.5 per million children) 
Reported number  
of cases 
Cases per year AIR/ASR/CIR 
(% incidence difference) 
Afghanistan 43 15.27 million 143 - - ND 
Albania 17 0.49 million 4 - - ND 
Algeria 29 11.98 million 111 112 (1996-2014) 6.2 7.2 (-31.4%)  
American Samoa 30 55 641 <1 - - ND 
Andorra 14 76 965 <1 - - ND 
Angola 47 13.99 million 130 - - ND 
Antigua and Barbuda 24 24 483 <1 - - ND 
Argentina 25 11.06 million 103 164 (1991-2013) 7.5 8.6 (-18.0%) 
Armenia 20 586 000 5 - - ND 
Aruba 18 18 947 <1 - - ND 
Australia 19 4.67 million 44 895 (1992-2014) 38.9 11.6 (+10.5%) 
Austria 14 1.22 million 11 345 (1990-2012) 15.6 13.3 (+26.6%) 
Azerbaijan 23 2.27 million  21 - - ND 
Bahamas, The 20 79 072 <1 - - ND 
Bahrain 20 298 600 3 28 (1998-2012) 2 9.6 (-8.5%) 
Bangladesh 28 46.1 million  430 - - ND 
Barbados 19 54286 <1 - - ND 
Belarus 17 1.61 million 15 355 (1990-2015) 14.2 9.3 (-11.4%) 
Belgium 17 1.92 million 18 216 (2004-2013) 11.3 13.4 (+27.6%) 
Belize 31 116 151 <1 - - ND 
Benin 43 4.8 million 44 - - ND 
Bermuda 17 65 441 <1 0 (2013-2018) 0 0 
Bhutan 27 218 054 <1 - - ND 
Bolivia 32 3.53 million 33 - - ND 
Bosnia and Herzegovina 14 490 980 4 - - ND 
Botswana 31 710 520 7 9 (2008-2012) 2.25 2.7 (-74.3%) 
Brazil 22 46.04 million  430 134 (1995-2012) 7.9 8.4 (-20%) 
British Virgin Islands 16 31 196 <1 - - ND 
Brunei Darussalam 23 98 600 <1 - - ND 
Bulgaria 14 994 280 9 178 (1990-2013) 7.7 7.1 (-32.3%) 
Burkina Faso 45 8.635 million 81 - <5 ND 
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Country % Children 0-14 yrs per 
population (2017)1,2 
Population <0-14 yrs1,2 Expected number of cases 
(10.5 per million children) 
Reported number 
of cases 
Cases per year AIR/ASR/CIR 
(% incidence difference) 
Burundi 45 4.88 million 45 - - ND 
Cape Verde 30 163 916 1 - - ND 
Cambodia 31 4.96 million 46 - - ND 
Cameroon 43 10.34 million 96 1 (2004-2006) <1 0.4 (-96.1%) 
Canada 16 5.85 million 55 1359 (1992-2013) 61.7 13.8 (+31.4%) 
Cayman Islands 18 61 559 <1 - - ND 
Central African Republic 43 2.0 million 19 - - ND 
Chad 47 5.4 million 50 - - ND 
Channel Islands 15 24 681 <1 - - ND 
Chile 20 3.61 million 34 59 (1993-2013) 2.9 4.2 (-60.0%) 
China 18 249.48 million 2331 389 (1990-2013) 16.9 8.6 (-18.1%) 
Colombia 3 11.29 million 105 59 (1992-2003) 5.3 4.0 (-61.9%) 
Comoros 40 325 564 3 - - ND 
Congo, Dem. Rep. 46 37.41 million  350 - <5 ND 
Congo, Rep. 42 2.2 million 20 - - ND 
Costa Rica 22 1.079 million 10 82 (1993-2012) 4 4.0 (-61.9%) 
Cote d'Ivoire 42 10.2 million 95 - <5 ND 
Croatia 15 623 100 6 113 (2000-2014) 8 13.2 (+25.7%) 
Cuba 16 1.84 million 17 193 (2000-2012) 16 8.5 (-19.4%) 
Curacao 19 30 593 <1 - - ND 
Cyprus 17 145 316 1 27 (1998-2013) 1.8 13.9 (+32.3%) 
Czech Republic 15 1.58 million 15 467 (1990-2012) 21.2 14.1 (+34.2%) 
Denmark 16 919 840  9 160 (1981-2000) 8 9.6 (-8.6%) 
Djibouti 31 296 665 3 - - ND 
Dominica 22 73925 <1 - - ND 
Dominican Republic 29 3.12 million  29 - - ND 
Ecuador 28 4.65 million 43 39 (1993-2013) 1.9 1.9 (-81.9%) 
Egypt, Arab Rep. 33 32.19 million  300 133 (1999-2010) 12 10.1 (-3.8%) 
El Salvador 27 1.722 million 16 - - ND 
Equatorial Guinea 37 469 160 4 - - ND 
Eritrea 49 2.45 million 23 - - ND 
Estonia 16 1.32 million 21 50 (1990-2012) 2.27 10.0 (-4.7%) 
Eswatini (Swaziland) 37 505 790 5 - - ND 
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Country % Children 0-14 yrs per 
population (2017) 1,2 
Population <0-14 yrs1,2 Expected number of cases 
(10.5 per million children) 
Reported number 
of cases 
Cases per year AIR/ASR/CIR 
(% incidence difference) 
Ethiopia 41 43.05 million 402 5 (2011-2013) 1.6 3.1 (-70.4%) 
Faroe Islands 20 51 095 <1 - - ND 
Fiji 28 253 540 2 - - ND 
Finland 16 880 480 8 26 (1987-2003) 1.6 2.9 (-72.3%) 
France 18 12.09 million 113 1847 (2000-2012) 142 14.2 (+35.2%) 
French Polynesia 23 65 091 <1 - - ND 
Gabon 36 729 000 7 - - ND 
Gambia, The 45 945 450 9 3 (2002-2011) 0.33 0.4 (-96.2%) 
Georgia 19 706 230 7 - - ND 
Germany 13 10.76 million 100 2314 (1996-2012) 136.1 13.7 (+30.5%) 
Ghana 39 11.24 million 105 - - ND 
Gibraltar 20 34 571 <1 - - ND 
Greece 14 1.5 million 14 160 (2009-2016) 9.4 14.4 (+37.1%) 
Greenland 21 56 171 <1 - - ND 
Grenada 26 28 034 <1 - - ND 
Guam 25 41 057 <1 - - ND 
Guatemala 35 5.9 million 55 - - ND 
Guinea 42 5.3 million 50 0 (2001-2010) 0 0 
Guinea-Bissau 41 763 010 7 - - ND 
Guyana 29 225 579 2 - - ND 
Haiti 33 3.62 million 34 - - ND 
Honduras 32 2.96 million 28 12 (2002-2012) 1.1 1.6 (-84.8%) 
Hong Kong  11 813 120 7 - - ND 
Hungary 14 1.37 million  13 563 (1991-2014) 24.4 17.0 (+61.9%) 
Iceland 20 67 669 <1 9 (1990-2014) 0.38 6.2 (-40.9%) 
India 28 374.9 million 3503 526 (1990-2013) 22.9 3.6 (+65.7%) 
Indonesia 27 71.28 million 666 - - ND 
Iran, Islamic Rep. 24 16.9 million 157 8 (2004-2011) 1 2.6 (-75.2%) 
Iraq 40 11.04 million 103 - - ND 
Ireland 22 1.05 million 10 159 (1994-2012) 9.3 10.9 (+3.8%) 
Isle of Man 16 84 287 <1 - - ND 
Israel 28 1.94 million 18 568 (1990-2012) 25.8 14.6 (+39%) 
Italy 14 8.48 million 79 142 (1998-2011) 10.9 18.9 (+80%) 
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Country % Children 0-14 yrs per 
population (2017) 1,2 
Population <0-14 yrs1,2 Expected number of cases 
(10.5 per million children) 
Reported number 
of cases 
Cases per year AIR/ASR/CIR 
(% incidence difference) 
Jamaica 23 664 700 6 36 (1982-2012) 1.8 6.8 (-35.2%) 
Japan 13 16.5 million 154 795 (1990-2013) 34.6 15.7 (+49.5%) 
Jordan 36 3.49 million 33 222 (2000-2012) 18.5 9.0 (-14.2%) 
Kazakhstan 28 5.05 million 47 - - ND 
Kenya 40 19.88 million 186 19 (2007-2012) 3.8 1.7-2.8 (-73.3% - - 83.8%) 
Kiribati 35 40 739 <1 - - ND 
Dem. People’s Rep of Korea 21 5.35 million 50 1130 (1999-2012) 86.9 11.3 (+6.7%) 
Rep. of Korea 13 6.69 million 62 - - ND 
Kosovo 25 1.831 <1 - - ND 
Kuwait 21 868 770 8 61 (1994-2012) 3.4 9.8 (-6.7%) 
Kyrgyz Republic 32 1.98 million 19 - - ND 
Laos 33 2.26 million 21 - - ND 
Latvia 15 292 500 3 - - ND 
Lebanon 23 1.4 million 13 33 (2008-2010) 11 10.6 (+0.01%) 
Lesotho 35 781 550 7 - - ND 
Liberia 42 1.99 million 19 - - ND 
Libya 28 1.78 million 17 22 (2003-2008) 3.7 8.1 (-22.6%) 
Liechtenstein 15 37 810 <1 - - ND 
Lithuania 15 427 200 4 55 (2000-2012) 4.2 9.8 (-6.7%) 
Luxembourg 16 94 506 <1 - - ND 
Madagascar 41 10.48 million 98 - 20 - 30 ND 
Malawi 44 5.58 million 52 9 (2003-2010) 1.125 2.8 (-73.3%) 
Malaysia 24 7.59 million 70 47 (2007-2011) 9.4 6.1 (-41.9%) 
Maldives 23 100 355 1 - - ND 
Mali 48 6.12 million 57 15 (2006-2014) 1.875 2.2 (-79.0%) 
Malta 14 64 441 <1 17 (1995-2015) 0.85 14.2 (+35.2%) 
Marshall Islands 34 53 127 <1 - - ND 
Mauritania 40 1.77 million 17 - - ND 
Mauritius 18 227 700 2 10 (2003-2012) 1.11 4.1 (-60.9%) 
Mexico 27 34.88 million 326 36 (1997-2013) 2.25 3.5 (-66.7%) 
Micronesia, Fed. States. 33 34 829 <1 - - ND 
Moldova 16 568 000 5 - - ND 
Monaco 10 38 695 <1 - - ND 
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Country % Children 0-14 yrs per 
population (2017) 1,2 
Population <0-14 yrs1,2 Expected number of cases 
(10.5 per million children) 
Reported number 
of cases 
Cases per year AIR/ASR/CIR 
(% incidence difference) 
Mongolia 30 922 800 9 - - ND 
Montenegro 18 112 044 1 - - ND 
Morocco 27 9.64 million  90 146 (2005-2012) 20.8 9.1-9.6 (- 8.6% - -13.3%) 
Mozambique 45 13.35 million 124 - - ND 
Myanmar (Burma) 27 14.4 million 134 - - ND 
Namibia 37 937 580 9 12 (2003-2011) 1.3 1.2 (-88.6%) 
Nauru 31 13 649 <1 - - ND 
Nepal 31 9.08 million 84 - - ND 
Netherlands 16 2.73 million 26 435 (1993-2013) 20.7 8.1 (-22.9%) 
New Caledonia 23 64 505 <1 16 (1990-2013) 0.6 12.9 (+22.9%) 
New Zealand 20 958 800 9 178 (1993-2012) 9.3 11.3 (+7.6%) 
Nicaragua 29 1.8 million 17 - - ND 
Niger 50 10.74 million 100 1 (2001-2009) 0.125 0.3 (-97.1%) 
Nigeria 44 83.99 million 785 9 (2003-2012) 1 1.9 (-81.9%) 
North Macedonia 17 350 000 3 - - ND 
Northern Mariana Islands 26 55 144 <1 - - ND 
Norway 18 945 000 9 173 (1990-2013) 7.5 9.2 (-12.4%) 
Oman 22 1.01 million 10 - - ND 
Pakistan 35 68.95 million 644 38 (1995-2012) 2.2 1.7 (-83.8%) 
Palau 19 21 729 <1 - - ND 
Panama 27 1.106 million 10 - - ND 
Papua New Guinea 36 2.97 million 28 - - ND 
Paraguay 29 1.98 million 18 - - ND 
Peru 27 8.69 million 81 - - ND 
Philippines 32 33.57 million 313 205 (1993-2012) 10.7 2.8 (-73.3%) 
Poland 15 5.76 million  53 111 (1999-2014) 7.4 13.9 (+32.4%) 
Portugal 14 1.44 million 13 227 (1990-2010) 11.35 10.9-16.5 (+3.8% - 57.1%) 
Puerto Rico 18 598 500 6 - - ND 
Qatar 14 369 460 3 19 (2002-2014) 1.6 6.6 (-37.1%) 
Reunion 26 227 906 2 16 (2002-2008, 2011) 2.28 11.1 (+5.7%) 
Romania 15 2.95 million 27 25 (2008-2012) 6.25 9.0 (-14.3%) 
Russian Federation 18 26.01 million 243 163 (1998-2015) 9.5 9.3-9.8 (-6.6 - 11.4%) 
Rwanda 40 4.8 million 45 - - ND 
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Country % Children 0-14 yrs per 
population (2017) 1,2 
Population <0-14 yrs1,2 Expected number of cases 
(10.5 per million children) 
Reported number 
of cases 
Cases per year AIR/ASR/CIR 
(% incidence difference) 
Samoa 37 72 682 <1 - - ND 
San Marino 15 33 400 <1 - - ND 
Sao Tome and Principe 43 87 860 <1 - - ND 
Saudi Arabia 25 4.78 million 44 198 (1994-2012) 11 6.3 (-40%) 
Senegal 43 6.81 million 63 - 5 - 20 ND 
Serbia 16 1.12 million 10.5 - - ND 
Seychelles 22 21 085 <1 - - ND 
Sierra Leone 42 3.17 million 29 - - ND 
Singapore 15 841 800 8 22 (2003-2007) 4.4 5.9 (-43.8%) 
Slovak Republic 15 815 250 7 122 (2000-2012) 9.3 12.8 (+21.9%) 
Slovenia 15 309 900 3 57 (1990-2013) 2.1 9.0 (-14.2%) 
Solomon Islands 39 238 423 2 - - ND 
Somalia 46 6.78 million 63 - - ND 
South Africa 29 16.4 million  153 197 (2008-2012) 49.25 2.7 (-74.2%) 
South Sudan 42 5.28 million 49 - - ND 
Spain 15 6.98 million 65 1011 (1990-2013) 42.1 13.8-14.6 (+31.4%– 39%) 
Sri Lanka 24 5.15 million 48 - - ND 
St. Kitts and Nevis 20 55 345 <1 - - ND 
St. Lucia 19 33 980 <1 - - ND 
St. Martin  26 32 125 <1 - - ND 
St. Vincent and the Grenadines 24 26 375 <1 - - ND 
Sudan 41 16.6 million 155 - - ND 
Suriname 26 146 484 1 2 (1980-2008) 0.1 0.2 (-98.1%) 
Sweden 18 1.8 million 16 291 (1990-2011) 13.2 9.4 (-10.4%) 
Switzerland 15 1.26 million 12 292 (1990-2013) 12.1 11.7 (+11.4%) 
Syrian Arab Republic 37 6.76 million 63 - - ND 
Taiwan 13 3.0 million 286 463 (1996-2010) 30.8 1.3 (-87.6%) 
Tajikistan 35 3.12 million 29 - - ND 
Tanzania 45 25.8 million 241 - - ND 
Thailand 17 11.73 million 109 156 (1993-2013) 7.8 4.6 (-52.1%) 
Timor-Leste 44 570 240 53 - - ND 
Togo 42 3.27 million 31 - <5 ND 
Tonga 36 38 887 <1 - - ND 
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Country % Children 0-14 yrs per 
population (2017) 1,2 
Population <0-14 yrs1,2 Expected number of cases 
(10.5 per million children) 
Reported number 
of cases 
Cases per year AIR/ASR/CIR 
(% incidence difference) 
Trinidad and Tobago 21 287 490 2 11 (2001-2006) 1.8 0.6 (-94.2%) 
Tunisia 24 2.76 million  25 121 (1993-2007) 8.6 7.7 (-26.7%) 
Turkey 25 19.9 million 186 134 (1993-2013) 6.7 10.6 (+0.01%)  
Turkmenistan 31 1.78 million 17 - - ND 
Turks and Caicos Islands 22 35 446 <1 - - ND 
Tuvalu 29 11 192 <1 - - ND 
Uganda 48 20.86 million 192 8 (2003-2012) 1 1.0 (-90.5%) 
Ukraine 15 6.724 million 62 633 (2000-2012) 52.7 8.2 (-21.9%) 
United Arab Emirates 14 1.316 million 12 - - ND 
United Kingdom 18 11.89 million 111 1099 (2000-2011) 91.9 9.6 (-8.6%) 
United States 19 61.88 million 578 9709 (1993-2012) 511 12.4 (+18.1%) 
Uruguay 21 725 970 7 148 (1993-2012) 7.4 11.2 (+6.7%) 
Uzbekistan 28 9.06 million 85 - - ND 
Vanuatu 36 99 447 1 - - ND 
Venezuela, RB 28 8.95 million 83 - - ND 
Vietnam 23 21.97 million  205 170 (1995-2013) 9.4 7.7 (-26.7%) 
Virgin Islands (U.S.) 20 21 453 <1 - - ND 
West Bank and Gaza 40 1.86 million 17 - - ND 
Yemen, Rep. 40 11.3 million 105 9 (1997-2006) 0.9 1.9 (-81.9%) 
Zambia 45 7.69 million 71 - - ND 
Zimbabwe 41 6.77 million 63 7 (2003-2012) 0.78 1.4 (-86.7%) 
Abbreviations: AIR- age specific incidence rate; ASR - age standardized incidence rate; CIR - crude incidence rate; ND – no data  
Table sources: 
1. Based on the statistics reported by the World Bank for 2017. https://data.worldbank.org/indicator. Accessed April 2019. 
2. The World Factbook, Central Intelligence Agency, United States of America. www.cia.gov/library/publications Accessed July 2019 
3. Georgakis, MK; Dessypris, N; Baka, M; et al. Neuroblastoma among children in Southern and Eastern European cancer registries: Variations in 
incidence and temporal trends compared to US. Int. J. Cancer 2018, 142(10): 1977-1985. 
4. Stefan, CS; Bray, F; Ferlay, J et al. Cancer of childhood in sub-Saharan Africa. ecancer 2017, 11:755 https://doi.org/10.3332/ecancer.2017.755 
5. Ba-Saddik IA, Childhood cancer in Aden, Yemen. Cancer Epidemiology 2013, 37(6): 803-806. 
6. Lui Y, Lo W, Chiang C, Yang Y, et al. Incidence of cancer in children aged 0–14 years in Taiwan, 1996–2010. Cancer Epidemiology 2015; 39(1): 21-28. 
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7. Steliarova-Foucher E, Stiller CA, Hesselinge P, Moreno F, Ries L, Shin H. International Incidence of Childhood Cancer Volume III Chapter IVa. 
Neuroblastoma and ganglioneuroblastoma. http://iicc.iarc.fr/includes/results/comparative/0401_Neuroblastoma.pdf Accessed April 2019. 
8. Schroeder H, Wacher J ,Larsson H, Rosthoej S , et al. Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–
2000: a population-based study. British Journal of Cancer (2009) 100, 853–857. 
9. Cancer in Finland, Finnish Cancer Registry https://cancerregistry.fi/statistics/cancer-statistics  Accessed April 2019. 
10. Mans D, Zijlmans W. Childhood Cancer in the Republic of Suriname (1980 Through 2008) The Open Epidemiology Journal, 2014, 7, 27-3. 
11. D. Cristina Stefan, Patterns of Distribution of Childhood Cancer in Africa, Journal of Tropical Pediatrics, 2015; 61(3): 165–173. 
12. Horton-Perinchief K. Bermuda National Tumour Registry. www.bermudahospitals.bm/cancer/tumour-registry.asp Accessed April 2019. 
13. Azizah Ab M, Nor Saleha IT, Noor Hashimah A, Asmah ZA, Mastulu W. Malaysian National Cancer Registry Report 2007-2011. 
https://nci.moh.gov.my/index.php/ms/pengumuman/340-national-cancer-registry-report Accessed April 2019.  
14. Moy TA, Ha C. Singapore Childhood Cancer Registry 2003-2007.  https://www.nrdo.gov.sg/docs/librariesprovider3/Publications-Cancer Accessed 
April 2019. 
15. Bodkyn C, Lalchandani S. Incidence of childhood cancer in Trinidad and Tobago. West Indian med. j. 2010; 59 (5): 465-468. 
16. Traoré, F; Eshun, F ; Togo, B ; et al. Neuroblastoma in Africa: A Survey by the Franco-African Pediatric Oncology Group. Journal of Global 
Oncology 2016; 2(4): 169-173. 
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Table 2: South African Neuroblastoma crude Incidence rates for children under the age of 15 years 
South African Neuroblastoma crude Incidence rates for children under the age of 15 years 
 Total U15 Male Female 
Year Subject SACTR SA-NCR Difference SACTR SA-NCR Difference SACTR SA-NCR Difference 
2000 NB 39 35  25 24  14 11  
 SA 15,084,120 15,084,120        
 Incidence 2.6 2.3 0.3       
2001 NB 25 26  16 13  9 13  
 SA 14,365,288 14,365,288  7,168,491 7,168,491  7,196,767 7,196,767  
 Incidence 1.74 2.5 0.76 2.23 1.8 0.43 1.25 1.8 0.55 
2005 NB 36 23  8 11  28 12  
 SA 15,150,381 15,150,381  7,624,900 7,624,900  7,568,700 7,568,700  
 Incidence 2.4 1.5 0.9 1.0 1.4 0.4 3.69 1.6 2.09 
2010 NB 30 44  20 27  10 17  
 SA 15,100,089 15,100,089  7,637,041 7,637,041  7,463,048 7,463,048  
 Incidence 1.98 2.9 0.92 2.61 3.5 0.89 1.4 2.2 0.8 
2011 NB 34 44  16 21  18 23  
 SA 15,812,268 15,812,268        
 Incidence 2.2 2.8 0.6       
2013 NB 27 36  15 19  12 15  
 SA 15,454,742 15,454,742        
 Incidence 1.74 2.3 0.56       
2014 NB 39 33  22 15  17 18  
 SA 15,812,268 15,812,268  7,969,880 7,969,880  7,842,388 7,842,388  
 Incidence 2.4 2.0 0.4 2.76 1.9 0.86 2.16 2.3 0.14 























CHAPTER 4  
Overall survival for neuroblastoma in South Africa between 2000 and 2014 
(2019)  
Ethics no: S18/07/138 
Reference: Van Heerden J, Hendricks M, Geel J, et al. Overall survival for neuroblastoma in South 
Africa between 2000 and 2014. Pediatr Blood Cancer. 2019; 66: e27944 
https://doi.org/10.1002/pbc.27944 
(Impact factor 2.442) 
At the onset of developing a national prospective protocol, the South African Children’s Cancer Study 
Group (SACCSG) set out to conduct a retrospective study to source baseline data and establish 
management strategies used in the local setting as possible recommendations in the treatment of NB 
in South Africa. With 10 paediatric oncology units in the public setting with varying levels of services, 
a retrospective study provided the knowledge for the prospective protocol development that would 
align with the resources of South African Paediatric Oncology units. 
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Background:Outcome data for neuroblastoma in sub-Saharan Africa are minimal, whereas poor
outcome is reported in low- and middle-income countries. A multi-institutional retrospective
study across South Africa was undertaken to determine outcome.
Methods: Patients treated between January 2000 and December 2014 in nine South African
pediatric oncology units were included. Kaplan–Meier curves and Cox regression models were
employed to determine two-year survival rates and to identify prognostic factors.
Results: Data from 390 patients were analyzed. The median age was 39.9 months (range,
0–201 months). The majority presented with stage 4 disease (70%). The main chemotherapy reg-
imens were OPEC/OJEC (44.8%), St Jude NB84 protocol (28.96%), and Rapid COJEC (22.17%).
Only 44.4% had surgery across all risk groups, whereas only 16.5% of high-risk patients received
radiotherapy. The two-year overall survival (OS) for the whole cohort was 37.6%: 94.1%, 81.6%,
and 66.7%, respectively, for the very-low-risk, low-risk, and intermediate-risk groups and 27.6%
for the high-risk group (P < 0.001, 95% CI). The median survival time for the whole group was
Abbreviations: CI, confidence interval; COG, Children’s Oncology Group; CR, complete response; CT, computed tomography; FDG/PET, 129Fluorodeoxyglucose positron emission tomography;
FNA, fine-needle aspiration; HFA, height for age; HIC, high-income countries; HIV, human immunodeficiency virus; HR, high-risk; IDRF, image-defined risk factors; INPC, International
Neuroblastoma Pathology Classification; INRC, International Neuroblastoma Response Criteria; INRG, International Neuroblastoma Risk Group; INSS, International Neuroblastoma Staging
System; IR, intermediate risk; LDH, lactate hydrogenase; LR, low risk; MIC, middle-income country; MRI, magnetic resonance imaging; NB, neuroblastoma; OMAS, opsoclonusmyoclonus ataxia
syndrome; OS, overall survival; PD, progressive disease; POU, pediatric oncology units; SACCSG, South African Children’s Cancer Study Group; SACTR, South African Children’s Tumour Registry;
TB, tuberculosis; US, ultrasonography; VIP, vasoactive intestinal peptide; VLR, very low risk;WFA, weight for age.
JVH is a PhD student at Stellenbosch University, South Africa, but a permanent staff member of the Antwerp University Hospital, Antwerp, Belgium.
Pediatr Blood Cancer. 2019;e27944. c© 2019Wiley Periodicals, Inc. 1 of 12wileyonlinelibrary.com/journal/pbc
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13 months (mean, 41.9 months; range, 0.1–209 months). MYCN-nonamplified patients had a
superior two-year OS of 51.3% in comparisonwithMYCN-amplified patients at 37.3% (P= 0.002,
95%CI).
Conclusions: Limited disease had an OS comparable with high-income countries, but advanced
disease had a poor OS. South Africa should focus on early diagnosis and implementation of a
national protocol with equitable access to treatment.
K EYWORDS
neuroblastoma, outcomes, overall survival, South Africa
1 INTRODUCTION
Neuroblastoma (NB) is a malignancy of the sympathetic nervous sys-
tem during early childhood with a worsening prognosis with increas-
ing age.1 NB presents various management challenges in high-income
countries (HICs) and more so in resource-limited settings.2 The varied
pathophysiological, biological, and genetic characteristics contribute
to differing treatment approaches for low-risk (LR) disease (local dis-
ease, favorable histology, no raised tumor markers, MYCN nonam-
plification, and no adverse genetics), with relatively little interven-
tion required beyond surgery. Intermediate-risk (IR) disease has LR
features combined with a single genetic aberration such as 11q and
diploidy or undifferentiated pathology.3 IR disease is treated with
chemotherapy and surgery with radiotherapy indicated for limited
indications.3 Multimodal therapy (chemotherapy, surgery, radiother-
apy,myeloablative stemcell transplantation, immunotherapy, andmat-
uration therapy) is vital for improved outcomes in high-risk (HR) dis-
ease (metastatic disease, unfavorable histology, raised tumor mark-
ers, MYCN amplification, and adverse genetics).3 Despite the use of
high-intensity treatment for HR disease, the outcomes for LR and HR
disease are vastly dissimilar.3,4 Epigenetics is emerging as a factor
influencing outcomes.5
South Africa is an upper-middle-income country with a hetero-
geneous healthcare system, consisting of public and private care
facilities.6,7 Most children with malignancies are treated in the public
sector where the level of care varies according to provincial resources
and institutional preference.6 The treatment of NB in South Africa,
like elsewhere in sub-Saharan Africa, is further complicated by sev-
eral factors, including an HIV epidemic and sociocultural differences
in disease interpretation, contributing to late presentation, advanced
disease, and increased abandonment rates.8,9 This retrospective study
aimed to review NB management and outcomes in South Africa with




There were 564 newly diagnosed registered cases of NB between
January 2000 and December 2014 from nine dedicated pediatric
oncology units (POUs) and the private health care sector in South
Africa (see flow diagram) in the South African Children’s Cancer Study
Group (SACCSG)SouthAfricanChildren’s TumourRegistry (SACTR).10
Data from174 (30.9%) patients’ fileswere not available. Access to files
from most private hospital facilities was not available, and incomplete
or loss of files from archives had to be omitted from data analysis.
2.2 Setting
The study was conducted in nine POUs, servicing both rural and
urban populations from varying socioeconomic backgrounds.11 Only
four POUs had access to stem cell transplant services and seven had
nuclear imaging services. There is still a disparity in resource allocation
betweendifferent POUs in the nine provinces in SouthAfrica.11,12 This
impacted on both the available human and physical resources avail-
ability. During the study period, autologous stem cell transplantation
andcis-retinoic acidwere largely limited topatientswithprivatehealth
care insurance. Immunotherapywith anti-GD2was and is not available
in South Africa.
2.3 Data collection
Age was defined in months. Endpoint was defined as two-year overall
survival (OS). Treatment failure was calculated from date of diagnosis
until date of diseaseprogression, or relapseor deathdue toNB.Refrac-
tory disease was defined as disease in which a complete response (CR)
with initial induction was not obtained. Early and late relapse were
respectively defined as relapse within or more than six months after
completion of therapy. Treatment abandonment was defined as fail-
ure to initiate or complete treatment with a curative intent, except
when the treating physician elected to opt for palliative management.
If a patient did not attend follow-up appointments and if contact with
family or caregivers was unsuccessful for a duration of two years, the
patient was considered lost to follow-up.
2.4 Staging and imaging
Investigations included ultrasonography (US), computed tomogra-
phy (CT), or magnetic resonance imaging (MRI) of the neck, chest,
and abdomen as well as bone marrow aspiration and trephine
biopsy. Patients were clinically and radiologically staged according
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to the International Neuroblastoma Staging System (INSS) or image-
defined risk factors (IDRFs).3 The INSS included unfavorable his-
tology or favorable histology and MYCN amplification as part of
the risk classification. Depending on institutional availability, staging
and skeletal screening were done by 123I-MIBG scan and/or bone
scan. In 123I-MIBG scan-negative patients, when available, staging
with 129fluorodeoxyglucose positron emission tomography/CT (FDG
PET/CT) was performed. Primary tumor andmetastatic response eval-
uations were performed according to institutional availability based
on the International Neuroblastoma Response Criteria (INRC).13–15
The treatment response evaluations were done according to the most
recent version of the criteria pertaining to the specific investigations
used to determine the response.
2.5 Risk classification
Risk classification was based on the Children’s Oncology Group (COG)
classification system (Appendix A) and the International Neurob-
lastoma Risk Group (INRG) Consensus Pre-treatment Classification
Scheme (Appendix B).3 Lactate hydrogenase (LDH) and ferritin were
used as nonspecific tumor markers as per the SIOP-PODC adapted
risk stratification and treatment guidelines2 that specify that a level of
>750 UI/L for LDH and >120 ng/mL for ferritin is indicative of a poor
prognosis. INRGwas used for statistical purposes.
2.6 Treatment
During the study period, different treatment protocols were used
according to either institutional preference or disease severity. Reg-
imens consisted of a surgical approach in very-low-risk (VLR), LR, IR
and HR disease, and chemotherapy in IR and HR disease (employed
as neoadjuvant or adjuvant chemotherapy) and with progression in LR
disease. Conventional radiotherapy was included according to proto-
cols in IR and HR disease. Surgical intervention was dictated by the
resectability of the tumor, response to chemotherapy, and surgical
expertise in the local institution.
2.6.1 Chemotherapy regimens
Patientswere, regardless of risk group, treatedwith a spectrumof reg-
imens ranging from observation to platin- and etoposide-based reg-
imens, which included OPEC/OJEC (carboplatin, cisplatin, etoposide,
cyclophosphamide, and vincristine),16 the St Jude NB84 protocol (cis-
platin, etoposide, doxorubicin, and cyclophosphamide),17 and Rapid
COJEC (carboplatin, cisplatin, etoposide, cyclophosphamide, and
vincristine).16 CCG-321-P2 (cyclophosphamide, doxorubicin, cisplatin,
and etoposide)18 and VACEpi (vincristine, actinomycin, cyclophos-
phamide, and epirubicin) were used to a lesser degree. CADO
(cyclophosphamide, adriamycin, and vincristine)2,19 or single-agent
oral cyclophosphamide was used as a palliative chemotherapy option
in certain centers.
2.6.2 Surgery
Surgery was performed for diagnostic reasons or as primary treat-
ment in patients with LR and IR disease with curative intent with
adequate neoadjuvant treatment. Other indications were palliative or
emergency purposes. Emergencies included spinal cord compression
or bowel, airway, and urinary tract obstructive symptoms. In patients
withHRdisease, surgerywasperformedbasedonupfront resectability
of the primary tumor or after demonstrable cytoreductionwith neoad-
juvant chemotherapy.
2.6.3 Radiotherapy
Radiotherapy was given according to the indications and doses of
either of the following protocols: St Jude NB84,17 CCG-321-P218,
or International Society of Paediatric Oncology European Neuroblas-
tomaGroup (SIOPEN)OPEC/OJEC or Rapid COJEC.2,16 Only six insti-
tutions offered maturation therapy of cis-retinoic acid after comple-
tion of primary treatment per the abovementioned protocols.17
2.6.4 Autologous stem cell transplant
Autologous stem cell transplantation was available to four POUs,
mainly for patients with private health care insurance.
2.7 Statistical analysis
Data were analyzed using Stata 15.0. Differences in medians and
means were assessed using the Mann–Whitney U test or Student t
test. In cohorts of fewer than five observations, the Fisher exact test
was applied. The Pearson chi-square (𝜒2) test was used to assess the
categorical association among covariates. OS as well as two-year sur-
vival, with associated 95% confidence intervals, was calculated and
described using Kaplan–Meier curves. Differences between bivariate
and multivariate survival curves by group were assessed using a log-
rank test. Multiple Cox regression modeling to assess statistical sig-
nificance of various prognostic factors was employed. The propor-
tional hazards assumption was also confirmed for the final multivari-
able model. A P value of less than 0.05 was considered significant for
all calculations.
3 RESULTS
3.1 Presentation and comorbid diseases
The final analysis included 390 patient records (see Supporting Infor-
mation Figure S1), after 174 patients’ files (30.9%) had been excluded
as data were lacking or the diagnosis had not been confirmed. There
was a male predominance with a male-to-female ratio of 1.08:1, and
patients had been most frequently diagnosed in the 18- to 60-month
category (50.7%). The median age was 39.9 months (range, 0–16.7
years; mean, 30.5 months). The diagnosis had been established by
core biopsy in 208 patients (53.3%), fine-needle aspiration (FNA) in
62 patients (15.9%), and bone marrow biopsy in 120 patients (24.4%)
with bone marrow involvement, with bone marrow infiltration by NB
in association with increased urine catecholamine levels or high index
of radiological suspicion. Chemotherapy data on 10 patients (2.7%)
were insufficient for analysis, and these records were excluded. In 168
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F IGURE 1 Kaplan–Meier curves of the two-year
OS for age (P= 0.049)
patients (47.5%), chemotherapy had to be interrupted or adjusted due
to comorbid disease, advanced disease, severe toxicity, or absconding.
The most common presentation was a clinically palpable mass
(43.3%) followedbymetastatic skull lesions (18.4%), bonepain (17.9%),
and loss of weight or anorexia (13.3%). A unilateral adrenal mass
(75.1%) was themost frequently detected primarymass, followed by a
thoracicmass (11.2%). A primary tumor could not be identified in eight
(2.1%) patients. Only 4.6% of the patients presented with spinal symp-
toms. Bone metastases were present in 47.4%, and the bone marrow
was infiltrated in 44.6% of patients.
Comorbid disease was present in 21 patients with 11 (2.8%)
being HIV positive: nine were on antiretroviral therapy at diagnosis.
Ten patients had tuberculosis (TB) (2.5%), with five (1.25%) on TB
treatment and five (1.25%) newly diagnosed. Opsoclonus myoclonus
ataxia syndrome (OMAS) and vasoactive intestinal peptide (VIP) were
present in 0.51% (n= 2) and 0.26% (n= 1) of the patients, respectively.
3.2 Diagnostics
Diagnostic investigations included chestX-rays (163, 23.1%), plain-film
skeletal surveys (45, 11.5%), and skull X-rays (41, 10.5%) (see Sup-
porting Information Table S2). Abdominal ultrasounds were done in
205 children (52.6%). CT/MRI scans of chest and abdomen were done
in 299 (76.7%) patients, and 136 (34.6%) of CT/MRI scans included
screening for skeletalmetastasis.Nuclear studies included157 (40.3%)
scintigraphy investigations and 143 (41.8%) 123I-MIBG studies. Three
hundred and twenty-one (82.3%) staging bone marrow aspirates were
done, of which 204 (63.6%) identified infiltration byNB cells. Only 163
(41.8%) had complete staging, which included biopsy proven disease, a
123I-MIBG scan, and bonemarrow aspirate.
3.3 Age, sex, stage, and risk classifications
Ageat diagnosiswas prognosticwith a better two-yearOSof 58.9% for
age less than 18 months compared with older than 18 months (25.8%;
P< 0.049, 95%CI) (see Figure 1; see Supporting Information Table S3).
Sex (P = 0.3, 95% CI) was not significant in either univariate or multi-
variate analysis (see Tables 1 and 2).
According to the INSS, 273 (70%) patients had stage 4 disease and
14 (3.6%) had stage 4S disease. Only 17 (4.3%) patients were classi-
fied as VLR, 26 (6.6%) as LR, 30 (7.7%) as IR, and 275 (75.6%) as HR.
The most commonmetastatic site was bone (n = 185, 47.4%) followed
by bone marrow at 44.6% (n = 174). Lung metastases were present in
3.8% (n = 15). The two-year OS for the cohort was 37.6%, with stage
being statistically significant forOS (P<0.01, 95%CI). According to the
INSS, patients with stage 1 and 2A disease had a two-yearOS of 100%,
those with stage 2B disease an OS of 74%, those with stage 3 disease
an OS of 63.4%, those with stage 4 disease an OS of 23.8%, and those
with stage 4S disease anOSof 64.4% (P<0.001, 95%CI) (see Figure 2).
According to risk classification, patients with VLR disease had a two-
year OS of 94.1%, those with LR disease an OS of 81.6%, those with
IR disease an OS of 66.7%, and those with HR disease an OS of 27.6%
(P< 0.001, 95%CI) (see Figure 3).
3.4 Histology and tumormarkers
NB was confirmed by core biopsy in 270 patients (53.3%), with 128
(31.8%) classified as unfavorable histology and 80 (20.5%) as favorable
histology (see Table 1 and Supporting Information Table S4). Sixty-two
(15.9%) patients were diagnosed by FNA without sufficient informa-
tion to distinguish between favorable and unfavorable histology. The
diagnosis in the remaining 120 (30.8%) patients was made through
bonemarrow cytology and/or imagingwith raised urine catecholamine
levels. Patients with favorable histology, according to the International
Neuroblastoma Pathology Classification (INPC), had a superior two-
year OS of 66.6% while those with unfavorable histology fared worse
at 32.8% (P= 0.002, 95%CI).
In patients with HR disease, the mean LDH level (n = 251, 78.7%)
was 2364 UI/L (median 1197, 255–11 520), and for those with IR dis-
ease (n = 27, 8.4%) and LR disease (n = 20, 6.3%), it was 930 UI/L
(median595, 184–1787) and498UI/L (median407, 241–806), respec-
tively (P < 0.01, 95% CI). In patients with HR disease, the serum fer-
ritin (n= 189, 80.4%) had amean of 483 ng/dL (median 263, 18–1650),
and in those with IR disease (n = 18, 7.7%) and LR disease (n = 15,
6.4%), it hadmean values of 97 ng/dL (median 239, range, 37–342) and
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TABLE 1 Prognostic factors and overall outcomes (univariate
analysis)








0–18 123 31.5% 58.9% < 0.049
18–60 191 49% 25.8%
>60 76 19.5% 33%
LDH
<750U/L 137 42.9% 54.8% < 0.0001
>750U/L 182 57.1% 25.2%
Ferritin
<120 ng/dL 75 31.9% 66.3% 0.0004
>120 ng/dL 159 69.1% 25.6%
MYCN
Total 145
Not amplified 64 44% 51.3% 0.002
Amplified 78 54% 37.3%




Normal 50 18.4% 63.4% < 0.049














1 16 4% 100% < 0.0001
2A 8 2.1% 100%
2B 10 2.6% 74%
3 68 17.4% 63.8%
4 273 70% 23.8%
4S 14 3.6% 64.6%
Risk classification
VLR 17 4.3% 94.1% < 0.0001
LR 26 6.6% 81.6%
IR 30 7.7% 66.7%
HR 295 75.6% 27.6%
Abbreviations: FNA, fine-needle aspiration; HR, high risk; INSS, Interna-
tional Neuroblastoma Staging System; IR, intermediate risk; LDH, lactate
hydrogenase; LR, low risk; VLR, very low risk.
64 ng/dL (median 244, range, 15–440), respectively (P< 0.01, 95%CI).
Patients with an LDH value of<750U/L at diagnosis had amore favor-
able two-yearOS of 54.8% versus 25.2% for an LDHvalue of>750U/L
(P< 0.0001, 95%CI), and those with ferritin levels<120 ng/dL at diag-
nosis had amore favorable two-yearOSof 66.3%comparedwith levels
>120 ng/dL (25.6%) (P= 0.0004, 95%CI).
MYCN was amplified in 54% (n = 78) of patients. Patients with
MYCN-nonamplified tumors (n= 64, 44%) had a two-yearOS of 51.3%
compared with 37.3% for patients with MYCN-amplified tumors,
whereas patients with a copy-number gain (1–9 copies, n = 3, 2%)
of MYCN had the best two-year OS of 66.6% (P = 0.002, 95% CI).
Raised urine catecholamine levels were detected in 81.6% (n = 221)
of patients. Patients with raised catecholamine levels at diagnosis had
a poorer two-year OS of 34.9% in comparison with 63.4% in patients
with normal urine values (P = 0.05, 95% CI). Patients with raised urine
catecholamine levels at diagnosis had a poorer two-year OS of 34.9%
as opposed to 63.4% in patients with normal levels (P< 0.049).
3.5 Nutritional status at diagnosis and outcome
Nutritional status was significant as patients with a weight for age
(WFA) above the −1 SD z-score (n = 162, 60%) had a better two-year
OS of 86.6% than wasted patients (WFA < −2 SD z-score, n = 55,
20.4%) at 79.3% (P = 0.04) (see Supporting Information Table S5).
Patients with a height for age (HFA) above the−1 SD z-score (n= 129,
49.8%) had a better two-year OS of 88.1% than stunted patients
(HFA<−2 SD z-score, n= 83, 32%) at 84.1% (P= 0.05).
3.6 Multivariate analysis
On multivariate analysis, age >18 months (P = 0.03, HR 0.96; 95% CI,
1.01–1.3), LDH > 750 U/L (P < 0.0001, HR 0.96; 95% CI, 1.3–1.9), fer-
ritin > 120 ng/dL (P = 0.02, HR 0.96; 95% CI, 1.01–1.5), and MYCN
gene amplification (P = 0.01, HR 0.96; 95% CI, 1.03–1.3) were signif-
icant covariates (see Table 2). Stage (P< 0.0001, HR 0.89; 95%CI, 1.6–
3.5) and risk classification (P< 0.0001, HR 0.96; 95%CI, 1.4–2.1) were
also significant. Pathology according to the INPC was not a significant
covariate (P= 0.37, HR 0.96, 95%CI, 0.8–1.3).
3.7 Management protocols
Two patients died before treatment was started (see flow diagram)
(Table 3). Only 253 (64.9%) patients were treated with curative intent,
although 354 (90.8%) patients received chemotherapy. Surgery as only
treatmentwas received by 24 patients (6.2%) for LR disease. Complete
excisions or debulking procedureswere performed only in 174 (44.4%)
patients (including 23 LR patients). In the IR, LR, and VLR groups, 11
(36.6%), 4 (16.6%), and 2 (11.8%) patients, respectively, were not oper-
ated on. VLR patients had a two-year OS of 100% independent of
surgical status. Tumors completely resected for IR and LR patients,
respectively, had an improved two-year OS of 83.3% and 84.4% ver-
sus a two-year OS of 42.8% and 42.8% (P< 0.01, 95% CI) for nonoper-
ated tumors. In the HR group, 185 (62.8%) patients were assessed as
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error Wald P value Exp Min Max
Age 0.1490 0.07038 4.4817 0.0343 1.1607 1.0111 1.3323
Race 0.09036 0.1066 0.7183 0.3967 1.0946 0.8882 1.3489
Sex −0.1366 0.1361 1.0084 0.3153 0.8723 0.6681 1.1389
MYCN 0.1622 0.06318 6.5943 0.0102 1.1761 1.0392 1.3312
LDH 0.4862 0.09801 24.6057 < 0.0001 1.6261 1.3419 1.9704
Ferritin 0.2230 0.09526 5.4786 0.0193 1.2498 1.0369 1.5063
INPC 0.09132 0.1025 0.7941 0.3729 1.0956 0.8962 1.3393
INSS 0.8876 0.1959 20.5212 < 0.0001 2.4293 1.6546 3.5667
Risk classification 0.5555 0.1106 25.2176 < 0.0001 1.7428 1.4031 2.1648
Abbreviations: INPC, International Neuroblastoma Pathology Classification; INSS, International Neuroblastoma Staging System; LDH, lactate hydrogenase.
F IGURE 2 Kaplan–Meier curves of the two-year OS for INSS (P< 0.001)
F IGURE 3 Kaplan–Meier curves of the two-year OS for risk classification (P< 0.001)
VLR, very low risk; LR, low risk; IR, intermediate risk; HR, high risk
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Never started 2 < 1%
Surgery only 24 6.2%










Rapid COJEC 49 22.17% 24.8% P = 0.01
OPEC/OJEC 99 44.8% 32.5%












Complete 98 56.3% 60.4% < 0.01
Incomplete 76 43.6% 57.3%
HR
Total 294
No surgery 185 62.8% 16.23% < 0.01
Surgery 109 37.7%
Incomplete 49 60% 51.4%
Complete 60 40%% 46.4%
IR
Total 30
No surgery 9 30% 42.8% < 0.01
Surgery 21 70%
Incomplete 14 66.6% 70.1%
Complete 7 33.3% 83.3%
LR
Total 26



















Yes 61 15.6% 44.8% < 0.01
No 329 84.4% 36.2%
HR
Total 224
















153 91.6% 17.3% < 0.01
No surgery with
radiotherapy
14 8.4% 25.8% < 0.01
Abbreviations: HR, high risk; IR, intermediate risk; LR, low risk; OS, overall
survival; VLR, very low risk
inoperable. Not all HR patients were operated on, and complete resec-
tion in HR patients (n = 60, 40%) had a two-year OS of 46.4% versus
nonoperated tumors (n= 185, 62.8%) at 16.2% (P< 0.01, 95%CI).
Different institutions used different chemotherapy protocols in HR
disease. OPEC/OJEC (n = 99, 44.8%), St Jude NB84 (n = 64, 28.9%),
and Rapid COJEC (n = 49, 22.2%) were the three main protocols, and
28.1% of the patients were treated with several other protocols. The
post-induction remission rate forHRpatientswas30.8%. The two-year
OS forOPEC/OJECwas32.5%comparedwith41% for the St Judepro-
tocol and 24.8% for Rapid COJEC (P= 0.05, 95%CI).
Patients who received radiotherapy to the primary tumor site had
an improved outcome with a two-year OS of 44.8% compared with
those without radiotherapy treatment with an OS of 36.2% (P < 0.01,
95% CI). HR patients who received radiotherapy treatment had a two-
year OS of 42.4% compared with those without radiotherapy treat-
ment with anOS of 26.1% (P< 0.01, 95%CI). Patients with HR disease
who never came for surgery but who did receive radiotherapy had a
superior two-year OS of 25.8% as opposed to 17.3% for those who did
not receive either surgery or radiotherapy (P< 0.01, 95%CI).
Of the 295 HR patients, only 11 (3.7%) (see Supporting Informa-
tion Table S6) received a single autologous stem cell transplant with
a significant two-year OS of 72.7% (P = 0.029, 95% CI). Only 13
(33.3%) patients had therapeutic MIBG treatment for refractory dis-
ease (n = 12) or relapse (n = 1) with a nonsignificant two-year OS of
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38.4% (P= 0.4917, 95%CI). Cessation of all treatment occurred in 168
(47.5%) patients due to either disease progression or refractory dis-
ease.
3.8 Follow-up
The median survival time of all patients was 13 months (0.1–209
months): for HR patients it was 7.5 months (0.1–87 months), for IR
patients it was 116 months (36–193 months), for LR patients it was
140months (76–199months), and for VLR patients it was 123months
(36–209months) (see Supporting Information Tables S7 and S8).
The reason for deathwasdocumented in260patients, ofwhom246
(94.6%) were disease related. The majority of HR patients (n = 153;
58.9%) had progressive disease (PD) while nine (3.1%) relapsed. For
those with IR disease, 11 (36.7%) had PD and three (10%) relapsed,
whereas for those with LR disease, three (11.5%) had PD and three
(11.5%) relapsed. Only one patient with VLR disease had PD.
Treatment toxicity contributed to 3.2% (n = 10) of the deaths,
whereas surgical complications contributed to 0.6% (n = 2) of the
deaths. Ten patients (2.6%) died secondary to neutropenic sepsis and
two (0.6%) to cardiotoxicity.
The time of death was documented in 56.7% of patients, with 95
deaths (24.4%) occurring within six months after diagnosis. A total of
88.7% of deaths occurred within two years from diagnosis.
Of the total cohort, 50 (12.8%) patients were lost to follow-up, con-
stituting 40% of surviving patients (P< 0.001, 95%CI), with 54% being
HR, 10% being IR, 10% being LR, and 6% being VLR patients.
4 DISCUSSION
This study represented the first documented multicenter retrospec-
tive cohort study of NB in sub-Saharan Africa. Although the majority
of cases were diagnosed in the 18- to 60-month age group, similar to
international trends, the median age was higher at 39.9 months com-
pared with 19 months in the United States (HIC) or 33.2 months in
Egypt (MIC).20
South Africa’s healthcare system suffers from various resource
challenges in the management of NB. Diagnostic imaging and staging
were done in the patients under study, ranging from less sensitive to
specific imaging. Plain X-rays are nonspecific with limited diagnostic
value beyond the silhouette of primary tumours21 or mixed sclerotic
and lytic lesions of metastasis.22 Skeletal screening was performed
by means of various imaging techniques, but only 41.8% of the study
group were surveyed by MIBG scan. Nonnuclear techniques such as
plain-film X-rays can be utilized at diagnosis but are not sufficiently
sensitive to evaluate skeletal treatment response ashealing lesions can
present as sclerotic lesions, similar to primary lesions.22 Themetabolic
response to therapy, demonstrated withMIBG scans, has a higher sen-
sitivity and proven prognostic value.23
In our study, stage 4 patients constituted 70% of the total cohort,
which is higher than the 40% reported by the INRG24 or the 41.9%
in European studies.25 Yet, the incidence of stage 4 disease was
comparable with studies in Indian (71.4%)26 and Kenyan (92.8%)27
hospitals. Although lung metastases were present in 3.8% of patients,
which is marginally higher than those reported in North America,28
only 76.7% of patients had CT or MR imaging and 41.8% a 123I-
MIBG scan to confirm metastasis. The percentage of lung metasta-
sis could be underestimated. Unknown origin of the primary tumor
occurred only in 2.1% of patients, as opposed to the 10% reported
internationally.23
Only 53.3% of the diagnoses in this cohort were confirmed by
biopsy, similar to MICs such as Egypt with 40% to 60%20 but less
than Argentina with up to 96%.29 Diagnoses were made through
FNA in 15.9% of patients due to institutional expertise and its being
a less invasive technique in emaciated patients with advanced dis-
ease. Quite a number of patients were diagnosed through disease-
associated imaging, bone marrow aspirates, and raised catecholamine
levels,which limited thenecessary testing forMYCN in37.1% (n=245)
patients.
The SIOP-PODC guidelines for LDH and ferritin in NB advise
750 UI/L and 120 ng/dL, respectively, as the threshold values for poor
and good prognosis,2 which was confirmed by our study. Our study
indicated that 54% of patients were MYCN amplified, which is higher
than the 20% reported internationally.30 MYCN copy-number gains
produced conflicting reports with regard to prognosis,31,32 but in this
study these were associated with a good prognosis. Even with a lim-
ited number of tumors’ MYCN status known (n = 145, 37%), a two-
year OS advantage was demonstrated between MYCN-amplified and
MYCN-nonamplified patients (P= 0.002). This compares with interna-
tional trends.2
All major historical HR induction chemotherapy regimens were
used in South Africa, according to institutional preference. The South
African doxorubicin-containing post-induction CR rate of 38.5% in HR
patients was less than that in the doxorubicin-containing COG A3973
studies with up to a 66.1% CR rate.33 The South African OPEC/OJEC
post-inductionCR rate of 29.7%was less than that in European studies
with a 38% CR rate.16 The South African Rapid COJEC post-induction
CR rate of 16.3%was considerably less than the 44%CR rate for Rapid
COJEC in Europe.10
Optimizing local control is important for improved survival and
cure.34 International definitions of complete resection were based on
more than 95% or more than 90%.34,35 In the COG A3973 studies,
resection of >90% had a better five-year OS of 57.3% compared with
49.4% for resection of <90% (P = 0.3), and in the HR-NBL1/SIOPEN
trial, complete resection had a better five-year OS compared with
incomplete resection (39% vs 30%).36 In our cohort, 62.8% of the HR
group had no surgery. Outcomes in resected patients in all risk groups,
regardless of the volume of tumor resection, had a better two-year OS
(46.4%) compared with those who had no resection at all (two-year
OS 16.23%). Various factors contribute to resectability of tumors, but
in this multicenter study where surgical skills and experience among
surgeons differed, it has been shown that, as in international studies,
surgery improved survival in patients with undetectable metastatic
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In keepingwith expert opinion in the SIOP-PODCguidelines,2 in the
absence of a surgical resection, radiotherapy to the primary tumor bed,
with or without metastatic sites, had a short-term benefit in patients
with a superior two-year OS in unresected patients receiving radio-
therapy versus patients not receiving radiotherapy.
European studies reported chemotherapy toxicity-related mortal-
ity of 3% for OPEC/OJEC and 4% for Rapid COJEC,37 which is com-
parable to the 3.2% toxicity-relatedmortality in this cohort, keeping in
mind that a less toxic OPEC/OJEC regimenwas used locally. Yet, it was
higher than the 2% to 2.5% toxicity reported in St Jude studies.38
The risk-based two-year OS of the South African cohort was lower
when compared with the outcomes reported in HICs (95% for LR dis-
ease, 90%–95% for IR disease and 50%–60% for HR disease)3 and
an MIC such as Argentina.29 The median survival of 12.2 months
was lower than reported in other MICs, such as India, China, and
Brazil.26,39 PatientswithHRdisease dominated in this cohort at 75.6%,
which was higher in comparison with INRG Task Force studies at
40%.24 A North American study concluded that biology was related
to race with HR disease more prevalent in black patients, possibly
explaining the finding.40 A combination of late presentation and poor
disease biology possibly explains the median time to death of six
months from diagnosis for 42% of patients. Malnutrition was a signif-
icant risk factor in our cohort, as reported in previous international
studies.41
Limitations included the retrospective data analysis of prospec-
tively collected data, where collection might not have been uniform.
There might also be a lack of documentation of crucial findings. The
limited access to genetic assessments such asDNAploidy,MYCNgene
amplification, and 1p36 deletion status might have impacted nega-
tively on risk stratification determination. Nonstandard documenta-
tion of management information, investigation reporting definitions,
surgical classifications, and treatment outcomes limits comparative
studies due to the heterogeneous nature of the data. During the study
period, the availability of investigations, such as isotopes for nuclear
imaging for staging and risk classification, was not always guaran-
teed. This could have contributed to staging and risk classification
being inaccurate, resulting in suboptimum treatment and poorer out-
comes. The treatment protocols were not standardized nationally.
Treatment was adapted with limitations of accurate risk classifica-
tion according to the clinical presentation and with palliative or cura-
tive intent. No accurate longitudinal comparisons could therefore be
made.
In resource-constrained settings, cost-effective management
options are of great importance.42 Even with limitations in diag-
nostic procedures, referral and treatment protocols, and the vari-
able availability of expertise in all fields, management should be
optimized to obtain the best possible outcomes. Our study indi-
cated that non-doxorubicin–containing and doxorubicin-containing
chemotherapy produced comparable outcomes. OPEC/OJEC is
an acceptable primary protocol, especially considering the favor-
able toxicity profiles, while attempting surgery. Even incomplete
surgical resections have a survival advantage versus no surgical
intervention.
5 CONCLUSIONS
The outcomes for NB patients varied according to different treatment
protocols used in South Africa. A uniform, nationally standardized
treatment strategy might ensure better risk classification, ensure
the appropriate intensity of chemotherapy, especially in LR and IR
disease. Harmonizing treatment might improve OS by creating equi-
table access to all treatment modalities, including surgical expertise,
autologous stem cell transplant, and maturation therapy. To this end,
a standardized protocol, incorporating risk-based therapy, should be
implemented.
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APPENDIX A: COG CLASSIFICATION
INSS Age MYCN Shimada DNA ploidy Risk group
1 Any Any Any Any Low
2A/2B < 365 d Any Any Any Low
> 365 d Nonamplified Any — Low
> 365 d Amplified Favorable histology — Low
> 365 d Amplified Unfavorable histology — High
3 < 365 d Nonamplified Any Any Intermediate
< 365 d Amplified Any Any High
> 365 d Nonamplified Favorable histology — Intermediate
> 365 d Nonamplified Unfavorable histology — High
> 365 d Amplified Any — High
4 < 548 d Nonamplified Any Any Intermediate
< 548 d Amplified Any Any High
> 548 d Any Any — High
4S < 365 d Nonamplified Favorable histology > 1 Low
< 365 d Nonamplified Any 1 Intermediate
< 365 d Nonamplified Unfavorable histology Any Intermediate
< 365 d Amplified Any Any High









L1/L2 Any GNmaturing GNB
intermittent
Any Any Any Any A: Very low risk
L1 Any Any, except GNmaturing Any nAmp Any Any B: Very low risk
GNB intermittent Amp Any Any K: High risk
L2 < 18 Any, except GNmaturing Any nAmp No Any D: Low risk
GNB intermittent Yes Any G: Intermediate risk
≥ 18 GNB nodular,
neuroblastoma
Differentiated nAmp No Any E: Low risk




Any Amp Any Any H: High risk
M < 18 Any Any nAmp Any Hyperdiploid F: Low risk
< 12 Any Any nAmp Any Diploid I: Intermediate risk
12 to
<18
Any Any nAmp Any Diploid J: Intermediate risk
< 18 Any Any Amp Any Any O: High risk
≥ 18 Any Any Any Any Any P: High risk
MS < 18 Any Any nAmp No Any C: Very low risk
Yes Any O: High risk
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Abstract: 
Purpose 
Low-and middle-income countries (LMICs) reported a higher median age at diagnosis compared to 
high-income countries. The aim was to determine if the optimal age at diagnosis, which maximizes the 
difference in overall survival between younger versus older patients in the South African population 
was similar to the internationally validated 18 months age cut-point. 
Methods 
Four hundred and sixty NB patients diagnosed between 2000-2016 were included. Receiver operating 
characteristic (ROC) curves were used to predict potential age cut-point values for overall survival in 
all risk group classifications. Risk ratios, sensitivity, specificity, positive and negative predictive values 
at the specific cut points were estimated with 95% confidence intervals, and time to mortality by age 
at the specific cut points was shown with Kaplan-Meier curves and compared using log-rank tests. 
Results 
The median age at diagnosis for the total cohort was 31.9 months (range 0.2-204.7). For high-risk (HR), 
intermediate-risk, low-risk, and very low-risk the median age at diagnosis was respectively 36 months 
(range 0.4-204.7), 16.8 months (range 0.7-145.1), 14.2 months (range 2.0-143.5) and 8.7 months 
(range 0.2-75.6). The ROC curves for the total NB cohort (area under the curve (AUC) 0.696; p<0.001) 
and HR (AUC 0.682; p<0.001) were analyzed further. The optimal cut-point value for the total cohort 
was at 19.1 months (sensitivity 59%; specificity 78%). The HR cohort had potential cut-point values 
identified at 18.4 months age at diagnosis (sensitivity 45%; specificity 87%) and 31.1 months 
(sensitivity 67%; specificity 62%). The 19.1 months cut-point value in the total cohort and the 18.4 





The 18 months cut-point value appears to be the appropriate age for prognostic determination despite 




Neuroblastoma (NB) is a sympathetic tumor presenting mainly in childhood with a median age at 
diagnosis of 19 months [1,2]. The majority of children are diagnosed under 5-years of age [1]. Age at 
diagnosis is an important risk factor in all international NB risk classification systems that predict the 
prognosis and influences the intensity of treatment. These include the Children’s Oncology Group 
(COG)-risk classification system, International Neuroblastoma Risk Group (INRG) staging system and 
the International Society for Paediatric Oncology – Paediatric Oncology for Developing Countries 
(SIOP-PODC) guidelines for the treatment of neuroblastoma in low- and middle-income countries 
(LMIC) [2,3,4]. The prognostic effect of age at diagnosis is evident by an almost 90% five-year overall 
survival in children diagnosed under one year of age compared to 52% in children diagnosed older 
than five years of age at diagnosis [5].  
Although the prognostic contribution of age is a continuum, the original age cut-off that predicted a 
binary outcome was 1 year of age [6]. While Shimada et al introduced an 18-month age cut point in 
the definition of International Neuroblastoma Pathology classification (INPC) to predict unfavorable 
histology [7], it was Breslow et al. who first proposed using age as a prognostic factor with an 18-
month cut point [6].   Subsequently multivariate analysis with clinically significant factors including 
stage, histology and MYCN-amplification, a cut-point value of 18 months remained of prognostic 
significance and 18 to 20 months were determined as an acceptable range [8].  
These established binary cut-point values were based on studies that were conducted in high-income 
countries (HIC) [8]. There is limited data available from LMIC, where the median age at diagnosis 
ranged from 24 to 48 months in Thailand, Iran and Egypt [9,10,11] with five-year overall survival that 
ranged from less than 10% to 48% [9,10,11]. We hypothesized that the South African population would 
follow similar LMIC trends and that the delayed median age at diagnosis (compared to HIC) would 
have prognostic significance. The aims of this study were threefold: the first aim was to estimate the 
median age at diagnosis in South Africa. The second aim was to identify a potential cut-point value for 
the age of diagnosis with overall survival (OS) as a primary endpoint in the South African population. 
The third aim was to evaluate whether the determined potential cut-point value and median age at 
diagnosis in the South African population was similar to the established 18 months international age 
cut-point value for prognosis. Thereby a possible optimal cut-point value for the age at diagnosis could 
be identified for the South African population. 
 
Materials and Methods 
A total of 460 children were diagnosed with NB in nine dedicated pediatric oncology units (POUs) in 
South Africa between January 2000 and December 2016. POUs were invited to participate in the study 
on a voluntary basis and the nine POUs represented all the regions of South Africa. The documented 
date of birth for each patient corresponded to the age stated on their birth certificates. Age at 
diagnosis was calculated as the period between the date of birth and the date of tumor biopsy, bone 
marrow aspiration, or raised urinary catecholamine levels, if biopsy was not possible. Patients were 
clinically and radiologically restaged according to the International Neuroblastoma Risk Group (INRG) 
classification system (Appendix A) [12]. The overall survival (OS) time was defined as the period from 
diagnosis to death or date last seen. The potential cut-point values were defined as the points that 
classified most of the individuals correctly with the “point closest-to-(0.1) corner” method in the ROC 
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plane or the point with the smallest Euclidean distance between the ROC curve and the (0.1) point 
[13]. The sensitivity refers to the proportion of patients diagnosed under the cut-point age who were 
still alive. The specificity refers to the portion of patients over the cut-point age who were dead [14]. 
For the study a high sensitivity was prioritized in the evaluation for the OS. An optimal cut-point value 
was defined as a statistically significant cut-point value with the highest sensitivity as determined by 
the “point closest-to-(0.1)” method on the ROC curve. 
The risk ratio or relative risk (RR) was interpreted as the ratio of the risk of death in those diagnosed 
above the cut point age to the risk of death of those diagnosed under the cut point age on the ROC-
curves [15]. The hazard ratio (HR) was defined as the instantaneous event rates of older patients 
(diagnosed above the cut-point age) compared to younger patients (diagnosed below the cut-point 
age) [15]. The Faculty of Health Sciences Research Ethics Committee of Stellenbosch University 
(S18/07/138) approved the study. 
 
Statistical analysis 
Data were analyzed using IBM SPSS version 25 (IBM Corporation, USA) statistical software and EpiCalc 
was used to determine predictive values for survival [16,17]. Since the high-risk cohort constituted a 
significant proportion of the total cohort, the study aims were applied to both the total study cohort 
and the high-risk cohort. The median age and age range for the cohorts were calculated from 
demographic data. Receiver operating characteristic (ROC) curves, with age as a continuous variable, 
were constructed for the purpose of identifying optimal cut-point values and estimating the 
sensitivities (true positive rate) and specificities (false positive rate) of the age at diagnosis against 
overall survival at several cut-points values [18]. The usefulness of the ROC curves was evaluated by 
the size of the area under the curve. AUC values between 0.7 and 0.8 identified age cut-points that 
were deemed acceptable to be able to discriminate between patients who died and those who did 
not, while AUCs of 0.5 or less were unable to perform this discrimination [19]. The “point closest-to-
(0.1) corner” method was used to identify the potential cut-point values for both the total cohort and 
the HR-cohort. A Cox Proportional Hazard model was used estimate HR and 95% confidence interval 
(CI) at each potential cut point age. Kaplan-Meier curves and log-rank tests in the total cohort (all risk 
groups) and the high-risk cohort separately visualize time to event for different age cut-points. There 
was survival data available for 442 patients in the total cohort and 346 patients in the HR-cohort. The 
95% CIs of both the sensitivities and specificities for the potential cut point values were compared to 
those of the internationally validated 18-months age at diagnosis to evaluate if the optimal cut-point 
values had similar prognostic value to the 18-month cut point. 
Cut-point values for the age of diagnosis were determined at the sensitivity increments of 10%. 
Thereafter the cut-point values were evaluated by using log-rank tests. The sensitivities, specificities, 
risk ratios, positive and negative predictive values for all potential cut-point values were determined 
to evaluate the overlap of the confidence intervals. The chi-squared test was used to test the 
association between age at different cut points and the occurrence of death as a binary endpoint. The 
log rank test was used to compare time-to-mortality at different cut-points for OS. P-values of less 
than 0.05 indicated statistical significance.  
Results 
There was a male predominance with a male to female ratio of 1:0.92 for the 460 included patients. 
The median age at diagnosis for the total cohort was 31.9 months (range 0.2-204.7) (Table 1 and Figure 
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1). There were 179 patients (38.9%) diagnosed before two years and 369 (80.0%) within five years. 
The remaining 19.9% was diagnosed older than age five years. The high-risk (HR) group contributed 
354 (77.0%) patients with a median age of 36 months (range 0.4-204.7).  Intermediate-risk (n=36; 
7.8%), low-risk (n= 30; 6.5%) and very low-risk (n=18; 3.9%) had median ages of 16.8 months (range 
0.7-145.1), 14.2 months (range 2.0-143.5) and 8.7 months (range 0.2-75.6) respectively. Twenty-two 
(4.8%) patients could not be classified. This group had a median age of 15.6 months and a range of 
0.4-108. 
Using age at diagnosis as a continuous variable to predict the OS, the area under the ROC curve for 
the total cohort was 0.696 (0.633 – 0.759; p<0.001) and 0.682 (0.594 – 0.770; p<0.001) for the HR 
cohort (Table 2) thus acceptable for evaluation purposes.  The cohorts for IR, LR and VLR were too 
small for valid ROC curve analysis. When evaluating the sensitivity and specificity coordinates for both 
the total cohort and the HR cohort, the sensitivities increased with increasing age at diagnosis, whilst 
the specificity decreased (Table 3). 
Determining cut-point values with ROC curves 
The ROC curves for the total cohort (all risk classifications) are presented in Figure 2 and the HR cohort 
in Figure 3. The sensitivity of each age was determined at several specificity levels. Selected 
sensitivities at the current international standardized prognostic age at diagnosis of 18 months and 
sensitivities at selected age of diagnosis representing increments of 10% were determined. These cut-
point values on the ROC curves in Figure 2 and Figure 3 are given in Table 3.  
The total cohort had an optimal age at diagnosis cut-point value at 19.1 months, which yielded a 
sensitivity of 59% and specificity of 78% (Fig 2, point A). The HR cohort had two optimal cut-point 
values at 18.4 months, sensitivity of 45%; specificity of 87% (Fig 3, point A) and 31.1 months, sensitivity 
of 67%; specificity of 62% (Fig 3, point B). 
The risk ratios and predictive values of the cut-point values 
When considering the risk ratios (RR) for the determined ROC curve cut-point values for the total 
cohort and HR cohort, the RR was the highest at 19.1 months for the total cohort (RR = 4.7). In the HR 
cohort the highest RR was at 18 months (RR = 4.2) (Table 3). For the 18 months cut-off the positive 
predictive value (PPV, interpreted as the percentage of those who were diagnosed at an age younger 
than the cut point who survived) for survival and the negative predictive value (NPV, interpreted as 
the percentage of those who were diagnosed at an age older than the cut point who died) were the 
highest for both the total cohort (PPV 36%; NPV 92%) and the HR cohort (PPV 36%; NPV 92%) (Table 
3). 
Determining the overall survival at the optimal cut-point value 
We determined the OS outcomes at the potential ROC curve cut-point values for both the total cohort 
(Fig 2, point A) and HR cohort (Fig 3 points A and B). To determine the significance of the OS we 
estimated the p-values and quantified the effect by determining hazard ratios for the relevant cut-
point values. 
For the total cohort: At the ROC curve potential cut-point value point A (sensitivity 59%; specificity 
78%; age at diagnosis of 19.1 months) (Figure 2) the difference in OS between the two age groups 
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(Hazard ratio 2.0), as illustrated by the Kaplan-Meier curve at 18 months, appears to be similar to the 
potential cut-point value (p<0.001) (Figure 4). Therefore, point A conforms to our definition of an 
optimal cut-point value. 
For the HR cohort: At the ROC curve potential cut-point value A (sensitivity 45%; specificity 87%; age 
at diagnosis at 18.4 months) the difference in OS between the two age groups (Hazard ratio 1.9), as 
illustrated by the Kaplan-Meier curve at 18 months, appears to be similar to the 18.4 months potential 
cut-point value (p <0.001) (Figure 5). Therefore, point A conforms to our definition of an optimal cut-
point value. At the ROC curve potential cut-point value point B (sensitivity 67%; specificity 62%; age 
at diagnosis at 31.1 months) was not statistically significant (p=0.178) and therefore did not meet our 
definition for an optimal cut-point value in the South African HR-cohort.  
For both the total cohort and HR cohort: The sensitivities, specificities, RR, PPV and NPV including their 
respective 95% CIs of the 19.1 months cut-point value of the total cohort as well as the 18.4 months 
cut-point value of the HR appeared to be similar to those of the international validated 18 month cut-
point values. (Table 3). There is large degree of overlap of the 95% CIs for the 18.0 months and 19.1 
months cut-points values of the total cohort as well as the 18.0 months and 18.4 months cut-points 
values of the HR cohort.    
Discussion 
In various studies age, stage and biological factors have individually and in multivariate analysis been 
shown to have prognostic significance in NB [2]. North American studies reported the median age at 
diagnosis as 19 months (range 12–20 months), while German studies reported median ages as low as 
15 months (range 10-23 months) [2,20]. Familial neuroblastoma often presents younger at a median 
of 9 months of age [21]. The median age at diagnosis for LR disease in the SIOPEN trial was 11 months 
[22] and varied between 5.4 to 18 months according to stage for IR in COG studies [23,24]. In two 
North American studies Kreismann et al. and Park et al. respectively concluded that the median age 
at diagnosis for patients with HR disease were 37.0 months (range 2.4 – 349.2 months) and 37.2 
months (range 23.0 – 53.6 months) [25,26]. The SIOPEN HR trial had a median age of 36 months (range 
26.4 – 52.8 months) [27]. An Indian review, representative of LIMC, reported median age at diagnosis 
between 30-42 months for NB [28], while a Chinese study reported a median age at diagnosis of 42 
months [29]. The total South African cohort had a median age at diagnosis of 31 months comparable 
to LMICs. When the South African median age at diagnosis for LR (11 months), IR (16 months) and HR 
(36 months) are individually evaluated, the median ages at diagnosis per risk group were comparable 
to HICs. In North America up to 36% of patients with NB were diagnosed before the age of two years, 
while 90% were diagnosed by five years [2]. In this South African cohort, we found that 38.9% was 
diagnosed before two years, while only 80.1% of the cohort was diagnosed by five years and the 
remaining 19.9% was diagnosed after five years, which differ from HICs (see Figure 1) [1]. 
A possible explanation for older median age at diagnosis in the South African study is that a greater 
percentage of the cohort (77% in South Africa versus <70% in HIC) [30] comprised of HR patients older 
than 18 months. HICs have superior diagnostic capacities to diagnose children at a younger age, which 
included the NB infant screening studies in Japan and Germany [30,31]. A German study concluded 
there was a substantial overdiagnosis of non-metastatic NB estimated at a rate of 7/100 000 children 
(95%CI, 4.6 to 9.2), while screening did not identify more metastatic NB [31]. Similarly, Japanese 
studies screening only benefited the younger age groups, including those tumors that would otherwise 
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have spontaneously regressed [30]. Therefore, the median age at diagnosis for the entire South 
African cohort was predominantly determined by the HR cohort with a higher median age at diagnosis.  
In the Children’s Oncology Group study, a range of significant ages at diagnosis between 12.2 and 20 
months were reported to be potential cut-point values [2]. The same was true for the total and HR-
cohort in the South African study (Table 3). When determining a potential cut-point value, or binary 
value, we prioritized a higher sensitivity. The range between 12.2 months and 20 months in the North 
American study [2] would include the South African 19.1 months potential cut point value for the total 
cohort. The HR cohort represented 77.0% of the South African cohort and had an optimal cut point 
value of 18.4 months. In the South African cohorts both the 18.4 and 19.1 months cut-point values 
were significant predicting OS according to the Kaplan-Meier curves. In the North American study, 
even adjusted for stage and MYCN status, it was found that the optimal adjusted age cut-off for a 
decreased risk of an event was at 19.7 months [2].  
Although the INRG risk classification incorporates the 18 months international age cut-point, the 
stratification was developed from an overall cohort [2]. Therefore, the South African HR cohort was 
not compared to the 18 months international age cut-point. Although the total cohort from the South 
African study was evaluated in terms of the total cohort of the North American study the South African 
study define OS as the end point and the North American study event free survival [2]. The South 
African OS is poor compared to HICs mostly due to high incidences of advanced disease at diagnosis 
and limited access to autologous stem cell transplantation, cis-Retinoic acid and no access to immune 




Data collection was retrospective and treatment in the various POUs were not standardized. The first 
international studies to determine an optimal cut-point value for the age of diagnosis predates the 
2000s. Our own cohort includes patients between 2000 and 2016. During these periods the diagnostic 
strategies have changed and may possibly affect the South African age estimates and comparisons.  
We acknowledge the relative bias in determining optimal cut-point values innate to the analysis of 
ROC-curves. In the determination of cut-point values the data were not adjusted for other prognostic 
factors such as stage and biological features. The INRG criteria was used for risk stratification and 
depend on a pre-determined age cut-point value. This possibly affected the analysis of the age cut 




Age is one of the most important prognostic factors in the management of neuroblastoma. This South 
African cohort for the age at diagnosis had a wide range of cut-point values up to 25 months with the 
possibility of prognostic significance for OS. The 18 months cut-point value appears to be the 
appropriate age for prognostic determination despite the higher median age at diagnosis in South 
Africa. 
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Table 1:  The age at diagnosis according to risk groups of the International neuroblastoma risk group 
(INRG) classification system in a cohort of 460 children with neuroblastoma in South Africa. 
 n (%) Median (months) Range (months) 
Total cohort 460 31.9 0.2-204.7 
HR cohort 354 (77.0%) 36.0 0.4-204.7 
IR cohort 36 (7.8%) 16.8 0.7-145.1 
LR cohort 30 (6.5%) 14.2 2.0-143.5 
VLR cohort 18 (3.9%) 8.7 0.2-75.6 
Unclassified 22 (4.8%) 15.6 0.4-108 
Abbreviations: HR – high-risk, IR – intermediate-risk, LR – low-risk, VLR – very low risk 
 
 
Table 2: Receiver operating characteristic curve’s area under the curve (AUC) for the age at diagnosis 
as a continuous variable [18]. 
  
N (%) AUC Std. Error p-value 
95% CI on the AUC 
Lower limit Upper limit 
Total cohort 460  0.696 0.032 <0.001 0.633 0.759 
HR cohort 354 (77.0%) 0.682 0.045 <0.001 0.594 0.770 
References for the usefulness of the ROC curves: AUC 0.5 – no discrimination/ inability to use as measure;  
0.7 to 0.8 – acceptable; 0.8 to 0.9 – excellent; > 0.9 – outstanding.   

















Table 3: Cut-points for age at diagnosis, sensitivity and specificity determined on the ROC-curves 
Total cohort (All risk groups) n = 460 (100%) 




































































HR cohort n= 354 (77.0%) 















































































 .p-values for sensitivity and specificity calculations at the cut points for age at diagnosis were assessed by chi-squared test ٭






















Figure 1: The distribution of the total South African NB age at diagnosis cohort (n = 460) compared 
to high income countries (HIC). 
 
HIC curve based on the “Distribution of age at diagnosis” data by London et. al. JCO. 2005, 23(27): 6461.  
 
Figure 2: ROC curve for the age at diagnosis in all neuroblastoma risk groups (total cohort) in South 
Africa between 2000 and 2016 (p<0.001) 
 
 
Total cohort n = 460 





Figure 3: ROC curve for the age at diagnosis in the HR neuroblastoma group in South Africa between 
2000 and 2016 (p<0.001) 
 
 HR-cohort n = 354/442 (77.0%) 
A – sensitivity of 45%; specificity of 87%; age of diagnosis 18.4 months 
























Figure 4: Kaplan Meier curves for OS of age at diagnosis of 19.1 months cut-point value for the total 
neuroblastoma cohort (p<0.001, Hazard ratio 2.0) 
 
 
 Total (n) 442; ≤ 19.1 months n (%) = 131 (29.6%); > 19.1 months n (%) = 311 (61.4%)  
 
Figure 5: Kaplan Meier curves for OS of age at diagnosis of 18.4 months cut-point value in HR 
neuroblastoma (p<0.001, Hazard ratio 1.9) 
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Diagnostic and post induction 123I-mIBG-scans have prognostic significance in the treatment of 
neuroblastoma (NB), but data from low- and middle-income (LMICs) countries are limited due to 
resource constraints.   
Objectives 
The objective was to determine the association between NB associated tumours markers (lactate 
dehydrogenase (LDH), ferritin and MYCN-amplification) and 123I-mIBG-scans (modified Curie scores 
and metastatic disease patterns) in predicting complete metastatic response rates (mCR) and overall 
survival (OS).   
Patients and Methods 
Ninety-eight patients diagnosed with NB between January 2000 and May 2018 in South Africa with 
diagnostic 123I-mIBG-scans were included. Data collection included LDH, ferritin and MYCN-
amplification at diagnosis. Two nuclear physicians independently determined the modified Curie 
scores and pattern of distribution for each diagnostic and post induction 123I-mIBG-scans with high 
interrater agreement (r=0.952) and reliability (K=0.805). The cut-point values for the diagnostic and 
post induction modified Curie scores of ≥7.0 (p=0.657) and 3 (p=0.182) were generated respectively. 
The association between the tumour markers and modified Curie score of the 123I-mIBG-scans, using 
post induction mCR and OS were determined. 
 
Results  
Only the diagnostic modified Curie scores predicted mCR (p=0.009). LDH (p=0.004), ferritin (p=0.005), 
diagnostic modified Curie scores (p=0.004) and post induction modified curie scores (p=0.05) 
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predicted 2-yr OS. Only ferritin correlated with diagnostic modified Curie scores (p=0.003) but had a 
low correlation coefficient of 0.353. On multivariable analysis the only significant co-variate for 2-yr 
OS at diagnosis was LDH <750U/L (p=0.003).  A post induction chemotherapy modified Curie score ≤ 
3.0 had a 2-yr OS of 41.0% compared to 31.2% for a score >3.0 (p=0.05). 
 
Conclusion 
LDH, ferritin and the diagnostic 123I-mIBG scans significantly predicted 2-year OS, but only ferritin and 
the modified Curie-scores correlated. MYCN-amplification neither correlated with any aspect of the 
123I-mIBG scans nor significantly predicted mCR or 2-year OS. LDH and ferritin are therefore 
appropriate neuroblastoma tumour markers to be used in LMICs with limited or no access to MIBG 
scans and/or MYCN amplification studies.  
Introduction 
Neuroblastoma (NB) is a metabolically active neuro-endocrine malignancy of the adrenal medulla and 
sympathetic nervous system with a spectrum of histopathological behaviour ranging between 
spontaneous regression, local maturation or aggressive proliferation of immature cells with 
metastases [1]. Tumour markers and mIBG-scans facilitate the diagnosis of the primary tumour and 
metastases, as well as the prognostic classification of the disease [2,3]. The tumour or the body 
produce non-specific NB tumour markers as part of the pathophysiological hallmarks of the 
malignancy [4]. Lactate dehydrogenase (LDH), especially subunit A, reduces pyruvate to lactate 
thereby bypassing oxidative phosphorylation; diverts pyruvate precursors into the pentose phosphate 
pathway to supply metabolic substrate for cancerous cell growth [5]. Elevated extracellular lactate 
levels promote a conducive microenvironment for tumour angiogenesis and immune evasion [5]. The 
acute phase inflammatory marker ferritin is present in both glycosylated and non-glycosylated forms, 
secreted by active and necrotic tumour cells respectively [6]. Clinically the presence of these two non-
specific tumour markers signals increased cell activity and have independently been proven to 
correlate with management outcomes in NB [7]. Both serum LDH and ferritin can be determined by 
blood tests accessible in resource limited settings. 
Amplification of the MYCN-gene, a specific NB tumour marker, plays a central role in regulating 
transcription and binding to DNA of other genes [8]. MYCN regulates the proliferation, self-renewal 
and angiogenesis of the primary tumour while promoting metastases by supressing differentiation 
and limit immune surveillance [8]. On an epigenetic level MYCN has a regulating role in histone 
methylation and acetylation [8]. MYCN amplification is associated with more aggressive features at 
diagnosis, an increased progression rate during induction chemotherapy and poorer survival due to 
relapse and disease progression [9]. MYCN-amplification of a tumour can be determined on a tumour 
biopsy sample as well as on NB-cells in a bone marrow aspirate [7]. The fluorescent in situ 
hybridization test for MYCN-amplification availability is resource dependant but are mostly available 
in high income countries (HICs) [7]. 
 
The response of NB to induction chemotherapy is an important prognostic factor [10]. Although 
bilateral bone marrow aspiration and trephine biopsy remain important for the detection of 
metastases, meta-iodobenzylguanidine (mIBG)-scans improve the accuracy of detecting and staging 
neuroendocrine tumours, such as neuroblastoma and pheochromocytoma [1,2,7]. Radio-labelled 
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meta-iodobenzylguanidine is actively taken up by the norepinephrine transporters of the sympathetic 
neurons of NB thereby increasing the diagnostic sensitivity [2]. The metastatic pattern of distribution 
as demonstrated with mIBG-scan at diagnosis, has proven to have prognostic significance with a 
diffuse spread denoting a poorer outcome [10]. There is an association reported between MYCN-
amplification and a diffuse metastatic spread [10]. MIBG-scans scored according to the modified Curie 
score is a validated scoring system, developed by the Children’s Oncology Group (COG), which 
correlates with prognosis and management outcomes [11]. The score divides the body into nine 
segments, with four degrees of nuclear differentiation for the extent of involvement [11]. The 
modified Curie score also assesses soft tissue involvement of NB [11]. Limitation in the use of MIBG 
scans include limited access in LMICs, the need for thyroid blockade pre-testing with potassium iodate 
or Lugol’s iodine solution and controlled timing in relation to chemotherapy for optimal evaluation 
[12]. In South Africa radio-isotope availability is not guaranteed due to trade embargoes, plant 
closures and production subject to national holidays, research guidelines and the lack of manpower 
[13].   
The literature relating to mIBG-studies and the prognostic relationship between tumour markers and 
123I-mIBG-scans in NB are limited. The primary objective of this study was to determine the association 
between NB associated tumours markers (LDH, ferritin and MYCN-amplification) and modified Curie 
scores using post induction metastatic complete response (mCR) and 2-year overall survival (OS) as 
end points. The secondary objective was to evaluate the association of these tumour markers with 
metastatic disease pattern on a diagnostic 123I-mIBG-scan and mCR and 2-yr OS.   
Materials and Methods 
Patient population 
Only 98 children with NB diagnosed between January 2000 and May 2018 from five paediatric 
oncology units met inclusion criteria namely a diagnostic 123I-mIBG-scans and serial LDH, ferritin and 
MYCN-amplification. Exclusion criteria included incomplete or lost files, no or paper-based images 




Data collection included demographic data (age at diagnosis, sex, disease stage), LDH, ferritin and 
MYCN at diagnosis and test results (radiological and nuclear imaging as well as bone marrow 
aspiration) to evaluate remission status after induction chemotherapy Primary tumour and metastatic 
evaluations were performed subject to availability of institutional resources, based on the 
International Neuroblastoma Response Criteria (INRC) [14,15,16]. Diagnostic and post induction 123I-
mIBG-scans from each participating hospital were scored according to the modified Curie score 
(Appendix A) by two nuclear physicians who were blinded to each other’s scores. The metastatic 
pattern of nuclear radio-isotope distribution was reported according to the research done by Bleeker 
et.al [10]. The mCR was defined as the disappearance of all demonstrable signs of neuroblastoma cells 






Interrater agreement and reliability 
Interrater agreement was evaluated for both the pattern of distribution (focal versus diffuse) and the 
continuous variables of the modified Curie scores (0 to 30) for each 123I-mIBG scan. The modified Curie 
score interrater agreement was 0.952 (High interrater agreement) (p<0.001) [17] and the level of 
reliability on the Cohen’s Kappa measure of agreement was strong (K=0.805) [18].  
Statistical analysis 
The differences in means or medians were assessed using the Mann-Whitney U test or Student’s t-
test, using IBM SPSS version 25 (IBM Corporation, USA) statistical software [19]. After continuous 
variables of LDH and Ferritin did not show significant association with the continuous variables of the 
diagnostic and post induction modified Curie scores, receiver operating characteristic (ROC) curves 
were constructed for the purpose of identifying an optimal binary cut-point value for the both the 
diagnostic and post induction modified Curie scores to predict post-induction complete metastatic 
remission (mCR) [20]. The “point closest-to-(0.1) corner” method was used to identify the potential 
cut-point values for the modified Curie scores. We prioritized a higher sensitivity to be able to include 
the greatest number of patients in possible metastatic remission. Sensitivity was defined as the 
proportion of patients without residual metastatic disease (in remission) who had modified Curie 
scores below the cut-point value. Specificity was defined as the proportion of patients with residual 
metastatic disease (not in remission) who had modified Curie scores above the cut-point value. The 
modified Curie score as a binary variable was then used to evaluate the association with the tumour 
markers: LDH, ferritin and MYCN. For statistical analysis the internationally validated prognostic cut 
point values of 750U/L and 120g/dL for LDH and ferritin were used respectively [7]. The cut point 
values for LDH and ferritin were validated in the same population of South African children by the 
SACCSG neuroblastoma tumour working group [21].  Categorical association between independent 
variables such as tumour marker categories and mIBG score categories, and overall survival (OS) was 
assessed using the Pearson Chi-square (χ2) test or, when appropriate, the Fishers exact test. OS and 
associated 95% confidence intervals (CI) were calculated and described using Kaplan-Meier curves 
with differences evaluated using log rank tests. To estimate the effect of prognostic factors on OS, 
univariate and multivariable Cox regression modelling approach was employed. The proportional 
hazards assumption was also confirmed for the final multivariable model. An area under the curve 
(AUC) of 0.7 and higher was defined as acceptable to discriminate between values [22]. For all 
calculations a p-value less than 0.05 was considered significant. 
Ethical approval (S18/07/138) for the study was obtained from The Faculty of Health Sciences 
Research Ethics Committee of Stellenbosch University, South Africa. 
Results 
Diagnostic epidemiology and disease profile  
Final analysis included 98 patients with diagnostic 123I-mIBG scans (Supplemental table 1). There was 
a male: female ratio of 1:1 with the majority in the 18.1 to 60 months age group (n=51, 52.0%). The 
median age was 28.9 months (range 1.6 to 196.3 months, mean 43.2 months). The most frequent 
origin was the adrenal gland (67.3%), followed by a non-adrenal abdominal mass (14.3%) and 
paraspinal masses in eight (8.2%) patients. LDH-values were available in 97 (99.0%) patients with 
57.1% (n=52) greater than 750 U/L. Ferritin values were available in 79 (81.6%) patients with 62.2% 
78
Stellenbosch University https://scholar.sun.ac.za
(n=61) greater than 120 ng/dl. MYCN-amplification was determined in only 61 (62.3%) tumours of 
which 33 (33.7%) were MYCN-amplified. Ninety-eight diagnostic modified Curie scores were 
determined with a mean of 10 (median 5, range 0 – 29), while 42 (42.9%) post induction chemotherapy 
modified Curie scores were determined with a mean of 7 (median 1, range 0 – 20). Of the diagnostic 
123I-mIBG scans, 50 (51.0%) had focal and 43 (43.9%) diffuse metastatic patterns, while 5 (5.1%) were 
limited to the primary tumour. 
Association of continuous variables  
When evaluating continuous variables of LDH, ferritin and the diagnostic modified Curie scores the 
only statistically significant correlation coefficients were LDH: ferritin (p=0.004) and ferritin: diagnostic 
modified Curie score (p=0.001), with low correlation coefficients (r) of 0.324 and 0.353 respectively 
(Table 1). Since no clear linear trend could be distinguished between ferritin and the modified Curie 
score, associations between categories of variables were performed.   Comparing categorical values 
of LDH (≤/> 750 U/L), ferritin (≤/> 120 g/dL) and MYCN-amplification (non-amplified vs amplified) with 
the continuous variables of the diagnostic modified Curie scores, LDH (p=0.029) and ferritin (p<0.001) 
were significantly associated with the continuous distribution of the diagnostic mIBG-scores, but not  
MYCN-amplification (p=0.518 (Table 2 and Figure 1).  
Clinical data analysis and binary cut-point value determination  
The ROC curve for the diagnostic modified Curie scores (n=98) against remission is presented in Table 
3 and Figure 2.  The AUC was 0.657 (p=0.012). The sensitivity of each score was determined at several 
specificity levels. The optimal cut point value A was at a modified Curie score of ≥7.0 with a sensitivity 
of 71.9% and specificity of 56.1%. The ROC curve for the post induction modified Curie scores (n=42) 
(Table 3 and Figure 3) had an AUC of 0.661 (p=0.182). The optimal cut point value A was at a modified 
Curie score of 3.0 with a sensitivity of 92.6% and specificity of 38.6%.  
Associations between categorical variables 
Only the categorical ferritin values (≤/> 120 g/dL) were associated with the categorical 7.0 cut point 
values of the diagnostic modified Curie scores (p=0.003) (Table 4) in predicting post induction mCR. 
The categorical ferritin and LDH values (≤/> 750 U/L) were associated with the metastatic pattern of 
distribution (p=0.008 and p=0.026 respectively) in predicting post induction mCR (Table 4). The 
probability that a ferritin level ≤120ng/dl was determined when the diagnostic modified Curie score 
was <7.0 was 63.3% and a ferritin level >120ng/dl when a diagnostic modified Curie score was ≥7.0 
was 77.8% (p=0.003). The probability that a ferritin level ≤120ng/dl was determined when the mIBG 
scan pattern was focal was 80.0% and a ferritin level >120ng/dl when the pattern was diffuse was 
58.3% (p=0.008). MYCN-amplification was not associated with either the categorical 7.0 cut-point 
value for the diagnostic MIBG scores (p=0.554) or pattern of distribution (p=0.887). 
Univariate and multivariate analysis predicting post induction mCR and 2-yr OS (Table 5, 6 and 7) 
Diagnostic LDH (p=0.072), ferritin (p=0.372), MYCN-amplification (p=0.202) and the mIBG pattern of 
distribution (p=0.527) were not significant predictors of remission. Patients with an LDH value at 
diagnosis <750U/L had a more favourable 2-yr OS of 40.0% versus 17.5% ≥750U/L (p<0.004) and those 
with ferritin levels at diagnosis of <120ng/dl had a more favourable 2-yr OS of 56.0% compared to 
19.1% for levels ≥120ng/dl (p=0.005) (Figure 4). A diagnostic modified Curie score <7.0 had a 2-yr OS 
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of 36.0% compared to 23.0% for a score ≥7.0 (p=0.004). MYCN-amplification and the distribution of 
the mIBG-scan pattern at diagnosis did not reach significance in predicting 2-yr OS. On multivariable 
analysis the only significant co-variate for 2-yr OS at diagnosis was LDH <750U/L (p=0.003, HR 0.39, 
95% CI, 0.21-0.73) (Figure 5). Ferritin <120 ng/dl (p=0.293, HR 0.66, 95% CI, 0.3-1.44) and the 
diagnostic modified Curie score > 6.5 (p=0.837, HR 0.94, 95% CI, 0.53-1.66) did not remain significant 
covariates. A post induction chemotherapy modified Curie score ≤ 3.0 had a 2-yr OS of 41.0% 
compared to 31.2% for a score >3.0 (p=0.052).  
Discussion 
Neuroblastoma is a heterogenous tumour, which present challenges in accurate diagnosis and 
management [7]. To be able to predict the possibility of remission in NB is of value win the context of 
settings with limited resources [7]. A wide range of investigations can be utilised, but the availability 
varies according to health care resources in countries and POUs [7]. Therefore, evaluating the 
correlation of more affordable, readily available tests with specialised, costly, but less accessible tests 
could assist in more robust neuroblastoma management in LMICs.  
In the current study ≥7.0 was determined to be the cut-point value for diagnostic mIBG-scans and 3 
for post induction mIBG-scans. Various international studies have determined prognostic cut-point 
values for diagnostic mIBG-scores to be between 2 and 10 and values between 0 and 6 for post 
induction mIBG-scores [11,23]. In the SIOPEN/HR-NBL1 dataset a diagnostic Curie score was of 
prognostic significance for 5-year OS at a cut-point value of 12 (p=0.013) [26], but Yanik et al. reported 
a diagnostic Curie score of 9 [11]. This is higher than the 7.0 cut-point value in our study, yet in our 
cohort 7.0 did carry prognostic significance at 2-yr OS (p=0.004). For the post induction the prognostic 
significance at a cut-point value of 3.0 (p=0.052) was comparable to the results by Katzenstein et al. 
[23] and close to the prognostic cut-point value of 2 for the post induction Curie score in the 
SIOPEN/HR-NBL1 dataset [24]. The main conclusion in both studies were that patients with residual 
mIBG-avid sites after induction had inferior OS even after further treatment which included an 
autologous stem cell transplant [24]. Schmidt et al. reported that the 123I-mIBG status of the primary 
tumour site had no influence on outcomes while the metastatic burden identified by an mIBG-scan 
significantly determined prognostication [11,23,25,29]. 
Bleeker et al described two distinct metastatic patterns of 123I-mIBG distribution in stage 4 NB [10]. 
Patients with MYCN amplified tumours were associated with focal metastatic lesions and had an 
improved event free survival (EFS) and OS [10]. The diffuse metastatic groups were associated with 
MYCN single copy numbers [10]. This correlation between the pattern of the 123I-mIBG-scans and 
MYCN amplification could not be reproduced in our study, nor were the two diagnostic tests of 
prognostic significance. 
 
LDH and/or ferritin can be used as surrogate markers to predict both treatment response and overall 
survival in LMIC where the detection of MYCN with either polymerase chain reaction (PCR) studies or 
fluorescent in vitro hybridization (FISH) is not available, [7, 27]. Pang et al. concluded that a higher 
LDH-value at diagnosis predicted a poorer treatment response with a poorer outcome [27].  We 
reproduced the prognostic significance of LDH in 2-year OS (p=0.004), but not in predicting mCR 
(p=0.072) although the effect of a small cohort size cannot be excluded. In our study the diagnostic 
123I-mIBG-scan did significantly predict outcomes for both mCR (p=0.009) and 2-year OS (p=0.004). 
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Yet the correlation of LDH and the diagnostic modified Curie scores did not significantly correlate 
(p=0.114). Morgenstern et al. reported that higher diagnostic ferritin predicted poorer treatment 
response and outcomes in NB [28]. This finding was reproduced in this study and the correlation 
between ferritin and modified Curie scores were significant (p=0.003). Metastatic neuroblastomas 
have higher infiltration of tumour associated macrophages than loco-regional tumours [29]. Patients 
with a higher metastatic burden will have an increase in the tumour associated inflammatory cells 
[29]. The higher metastatic burden will be reflected in the higher modified Curie score where the 
radio-isotopes are stored in NB-cells and imaged during an mIBG-scan [30].  Morgenstern et al. 
demonstrated that LDH and ferritin were of prognostic significance when an autologous stem cell 
transplant (ASCT) was part of the management [28]. The significance was not evaluated in the South 
African context, because only 3.7% of high-risk patients received an ASCT [21].  
 
The study results prove the prognostic value of LDH and ferritin in risk stratification and can be used 
in in LMIC in the absence of access to mIBG-scans and MYCN studies. Ferritin can be used as a 
surrogate predictor for the modified Curie scores in predicting metastatic remission. Although 123I-
mIBG-scans are more sensitive and specific in evaluating metastatic response [11], ferritin is more 
affordable and readily available in LMIC. LDH and ferritin must be used in in conjunction with imaging 
and bone marrow aspiration to evaluate the degree of remission status. MYCN-amplification neither 
correlated with any aspect of the 123I-mIBG scans nor did it significantly predict mCR or 2-year OS in 
our study. Yet non-secreting tumours are less likely to have an adrenal primary, bone metastasis or 
secreted catecholamine, but are more likely to be MYCN-amplified [31]. The utilisation of MYCN-
amplification is used to identify a patient with higher risk in Stage 2 and 4s tumours, which normally 
are low-risk tumours, but have increase poor outcome if MYCN is amplified [7]. In the absence of 
MYCN-testing, LDH and ferritin can be used to determine risk stratification, but our findings should be 
validated in larger cohorts. 
Limitations included retrospective data collection and a small cohort. Although the statistical analysis 
was based on the assumption of small cohorts, the significance of results may still be affected. This 
speaks to the urgent need for LMICs to initiate prospective data collection. The data were not adjusted 
for other prognostic factors when determining cut-point values. The modified Curie score is a 
validated system, but a small possibility of subjectivity in score allocations exists.  
Conclusion 
 
High levels of LDH, ferritin and the 123I-mIBG scans were significantly associated with each other but 
did not predict mCR. On univariate analysis LDH, ferritin and the diagnostic 123I-mIBG scans significantly 
predicted 2-yr OS. When adjusting for LDH and ferritin, the modified Curie-score was not a significant 
predictor for 2-yr OS. However, LDH remained the only significant predictor of 2-yr OS. MYCN-
amplification neither correlated with any aspect of the 123I-mIBG scans nor significantly predicted mCR 
or 2-yr OS. LMICs should use LDH and Ferritin in the management of neuroblastoma when there is no 
access to MIBG or MYCN studies. 
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Abbreviations: NB – neuroblastoma; SACTR – South African Children’s Tumour Registry; POUs – Paediatric Oncology Units 
 
n=660 NB patients on SACTR and 
POUs clinical files from 2000 to 
2018 
n=99 with a diagnostic  
123 I-mIBG-scans and post-
induction chemotherapy data 
from 5 POUs 
 
n=174 with diagnostic 123 I-
mIBG-scans from 9 POUs 
486 excluded because no 123 I-mIBG-scans 
were done or due to a lack of data 
 
28 excluded due to non-participation 
in study 
6 excluded due inability to 
access images 
1 excluded because diagnostic 123 I-mIBG-scan 
was after first chemotherapy administration 
 
n=98 with a diagnostic  
123 I-mIBG-scans and post-
induction chemotherapy data 
 
12 excluded because images not readable 
due to outdated camera technology 
27 excluded because images only available 
on paper 
2 excluded because of too few images to 




Table 1: Spearman’s rho correlation between tumour markers with continuous variables and 






LDH Correlation Coefficient 1.000 0.324 0.167 
P-value  0.004 0.103 
N 97 78 97 
Ferritin Correlation Coefficient 0.324 1.000 0.353 
P-value 0.004  0.001 
N 78 79 79 
Diagnostic modified 
Curie score 
Correlation Coefficient 0.167 0.353 1.000 
P-value 0.103 0.001  
N 97 79 98 
 
Table 2: Association between tumour markers (categorical variables) and diagnostic modified Curie 









P-value Lower Upper 
Diagnostic modified 
Curie score 
<750 45 (46.4%) 3 1 17 0.029 
≥750 52 (53.6%) 7 3 22  
Total 97     
 Ferritin N (%)  
Diagnostic modified 
Curie score 
<120 18 (18.4%) 3 1 3 <0.001 
≥120 61 (62.3%) 10 4 23  
Total 98     
 MYCN N (%)  
Diagnostic modified 
Curie score 
Non-amplified 28 (45.9%)  7 3 21 0.518 
Amplified 33 (54.1%) 9 3 24  
Total 61     
 
Table 3: Receiver operating characteristic curve’s area under the curve (AUC) for the diagnostic and 
post induction modified Curie scores with mCR as outcome  
 
  
N (%) AUC Std. Error 
95% CI  
P-value Lower Bound Upper Bound 
Diagnostic modified Curie scores  98 (100%) 0.658 0.055 0.549 0.766 0.012 
Post induction chemotherapy 
modified Curie scores 
42 (42.9%) 0.661 0.097 0.471 0.852 0.182 





Table 4: Cross tabulation of tumour markers (categorical variables) and diagnostic modified MIBG 






P-value <750 >750 
Diagnostic modified Curie 
scores 
≥7.0 N (%) 17 (37.8%) 28 (53.8%) 45 (46.4%) 0.114 
<7.0 N (%) 28 (62.2%) 24 (46.2%)  52 (53.6%) 





P-value <750 >750 
Pattern of distribution Diffuse N (%) 13 (32.5%) 29 (55.8%) 42 (45.7%) 0.026 
Focal N (%) 27 (67.5%) 23 (44.2%)  50 (54.3%) 






Diagnostic modified Curie 
scores 
≥7.0 N (%) 4 (22.2%) 38 (63.3%) 42 (53.2%) 0.003 
<7.0 N (%) 14 (77.8%) 23 (37.7%) 37 (46.8%) 





P-value <120 ≥120 
 Pattern of distribution Diffuse N (%) 3 (20%) 35 (58.3%) 38 (50.7%) 0.008 
Focal N (%) 12 (80%) 25 (41.7%) 37 (49.3%) 





p-value NA Amplified 
 Diagnostic modified  
 Curie scores 
≥7.0 N (%) 14 (51.9%) 16 (50.0%) 30 (50.8%) 0.554 
<7.0 N (%) 13 (49.1%) 16 (50.0%) 29 (49.2%) 





P-value NA Amplified 
 Pattern of distribution Diffuse N (%) 14 (50.0%) 19 (57.6%) 33 (54.1%) 0.887 
Focal N (%) 14 (50.0%) 14 (42.4%) 28 (46.9%) 












Table 5: Univariate analysis of the categorical variables predicting post induction complete 






P-value Yes No 
 LDH <750 N (%) 19(42.2%) 26 (57.8%) 45 (100.0%) 0.072 
≥750 N (%) 13 (25.0%) 39 (75.0%) 52 (100.0%) 
Total N (%) 32 (33.0%) 65 (67.0%) 97 (100.0%) 
 Ferritin 
 
<120 N (%) 7 (38.9%) 11 (61.1%) 18 (100.0%) 0.372 
≥120 N (%) 17 (27.9%) 44 (72.1%) 61 (100.0%) 
Total N (%) 24 (30.4%) 55 (69.6%) 79 (100.0%) 
 MYCN NA N (%) 12 (42.9%) 16 (57.1%) 28 (100.0%) 0.202 
Amplified N (%) 9 (27.3%) 24 (72.7%) 33 (100.0%) 
Unknown N (%) 11 (29.7%) 26 (70.3%) 37 (100.0%) 
Total N (%) 32 (32.7%) 66 (67.3%) 98 (100.0%) 
 Diagnostic modified 
Curie scores 
≥7.0 N (%) 9 (19.6%) 37 (80.4%) 46 (100.0%) 0.009 
<7.0 N (%) 23 (44.2%) 29 (55.8%) 52 (100.0%) 
Total N (%) 32 (32.7%) 66 (67.3%) 98 (100.0%) 
 Pattern of distribution Diffuse N (%) 12 (27.9%) 31 (72.1%) 43 (100.0%) 0.527 
Focal N (%) 17 (34.0%) 33 (66.0%) 50 (100.0%) 


























P-value Alive Death 
 LDH <750 N (%) 12 (27.3%) 32 (72.7%) 44 (100.0%) 40.0% 0.004 
≥750 N (%) 3 (5.9%) 48 (94.1%) 51 (100.0%) 17.5% 
Total N (%) 15 (15.8%) 80 (84.2%) 95 (100.0%)  
 Ferritin <120 N (%) 6 (35.3%) 11 (64.7%) 17 (100.0%) 56.0% 0.005 
≥120 N (%) 5 (8.3%) 55 (91.7%) 60 (100.0%) 19.1% 
Total N (%) 11 (14.3%) 66 (85.7%) 77 (100.0%)  
 MYCN NA N (%) 6 (22.2%) 21 (77.8%) 27 (100.0%) 25.0% 0.156 
Amplified N (%) 3 (9.1%) 30 (90.9%) 33 (100.0%) 21.3% 
Total N (%) 9 (15.0%) 51 (85.0%) 60 (100.0%)  
 Diagnostic modified 
Curie scores 
≥7.0 N (%) 2 (4.4%) 43 (95.6%) 45 (100.0%) 23.0% 0.004 
<7.0 N (%) 13 (25.5%) 38 (74.5%) 51 (100.0%) 36.0% 
Total N (%) 15 (15.6%) 81 (84.4%) 96 (100.0%)  
 Pattern of distribution Diffuse N (%) 3 (7.0%) 40 (93.0%) 43 (100.0%) 29.9% 0.595 
Focal N (%) 11 (22.0%) 39 (78.0%) 50 (100.0%) 31.1% 
Total N (%) 14 (15.1%) 79 (84.9%) 93 (100.0%)  
 Post induction modified 
Curie scores 
>3.0 N (%) 0 (0.0%) 13 (100.0%) 13 (100.0%) 31.2% 0.052 
≤3.0 N (%) 7 (24.1%) 22 (75.9%) 29 (100.0%) 41.0% 
Total N (%) 7 (16.7%) 35 (83.3%) 42 (100.0%)  
NA – non-Amplified 
 
 
Table 7: Multivariate Cox regression analysis for predicting time to mortality 
 
 HR 
95% CI  
P-value Lower Upper 
LDH < 750U/dl 0.39 0.21 0.73 0.003 
Ferritin < 120g/dL 0.66 0.30 1.44 0.293 
Diagnostic modified Curie 
scores > 6.5 









Supplemental table 1: Diagnostic epidemiology and disease profile 
Prognostic factor N (%) 
Total 98 
Sex  
Male 49 (50.0%) 
Female 49 (50.0%) 
Age at diagnosis  
Range (months) 1.6 – 196.3 
Mean (months) 43.2 
Median (months) 28.9 
   0 -18 months 26 (27.0%) 
   18.1 - 60 months 51 (52.0%) 
   >60 months 21 (21.4%) 
Primary tumour  
  Adrenal 66 (67.3%) 
  Abdominal 14 (14.3%) 
  Pelvic 2 (2.0%) 
  Paraspinal 8 (8.2%) 
  Cervical 6 (6.2%) 
  Other sites 2 (2.0%) 
LDH  
   <750 U/L 45 (42.9%) 
   ≥750 U/L 52 (57.1%) 
   Unknown 1 (1.0%) 
Ferritin   
   <120 ng/dl 18 (18.4%) 
   ≥120 ng/dl 61 (62.2%) 
   Unknown 19 (19.4%) 
MYCN  
   Not amplified 28 (28.6%) 
   Amplified 33 (33.7%) 
   Unknown 37 (37.3%) 
Pathology  
   Favourable histology  13 (13.3%) 
   Unfavourable histology 31 (31.6%) 
   Bone marrow cytology 54 (55.1%) 
INSS  
   1, 2, 4s 2 (2.0%) 
   3 14 (14.3%) 
   4 82 (83.7%) 
Risk classification  
   VLR, LR 7 (7.1%) 
   IR 5 (5.1%) 
   HR 84 (85.7%) 
   Unknown 2 (2.0%) 





Total 98 (100%) 
Range 0 – 29 
Mean 10 
Median 5 
Hospital investigator post induction modified 
Curie scores 
Total 42 (42.9%) 
Range 0 – 20 
Mean 7 
Median 1 
Hospital investigator diagnostic 123I-mIBG pattern 
of distribution 
Focal 50 (51.0%) 
Diffuse 43 (43.9%) 
N/A 5 (5.1%) 
Post induction remission 
Remission 32 (32.7%) 
Not in remission 66 (67.3%) 
Abbreviations: INSS – International neuroblastoma staging system; VLR – very low risk; LR – low risk; IR – intermediate risk; HR – high risk 
Figures 
Figure 1: Box and Whisker plots of the correlation between categorical variables of tumours markers 
associated with neuroblastoma and the continuous variables of the diagnostic modified Curie scores 
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Figure 2: ROC curve for the hospital investigators modified Curie scores (AUC = 0.657; p=0.012) 
 
A – sensitivity of 71.9%; specificity of 56.1%; modified Curie score of 7.0 
 
Figure 3: ROC curve for the hospital investigators post induction chemotherapy modified Curie 
scores (AUC = 0.661; p=0.182) 
 






Figure 4: The Kaplan-Meier curve for ferritin in predicting 2-year overall survival on univariate 
analysis (p=0.005) 
 
Total (n) 79; < 120 ng/dl n (%) = 18 (37.8%); ≥ 120 ng/dl n (%) = 61 (62.2%) 
Figure 5: The Kaplan-Meier curve for LDH in predicting 2-year overall survival on multivariate 
analysis (p=0.003) 
 





Appendix 1: Modified Curie score 
The scoring system divides the skeleton into 9 compartments. 





Scoring of MIBG scan  
Level of lesion certainty: 
0 = unknown  
1 = possible  
2 = probable  
3 = definite  
 
Extent of uptake: 
0 = no uptake/ no foci per segment  
1 = one focal lesion per segment  
2 = more than one focal lesion per segment  
3 = diffuse involvement (≥50% of segment  
       involved)  
 
Intensity of uptake: 
0 = no sites of uptake 
1 = doubtful uptake  
2 = obvious but mild uptake  
3 = obvious and intense uptake 
 
Soft-tissue lesions scoring system: 
0 = no MIBG involvement 
1 = one MIBG-avid soft-tissue lesion present  
2 = more than one MIBG-avid soft-tissue lesion   
       present  
3 = MIBG avidity in a soft-tissue lesion that  
       occupies 50% of the chest or abdomen  
 
*Maximum attainable score is 30  
*Focal uptake: uptake with clearly defined    
   margins  
* Diffuse uptake: is indistinguishable from  
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ABSTRACT
Achieving remission after induction therapy in high-risk neuroblastoma
(HR-NB) is of significant prognostic importance. This study investigated
remission after induction-chemotherapy using three standard neuro-
blastoma protocols in the South African (SA) setting. Retrospective data
of 261 patients with HR-NB diagnosed between January 2000 and
December 2016, who completed induction chemotherapy with standard
treatment protocols were evaluated. The treatment protocols were either
OPEC/OJEC or the St Jude NB84 protocol (NB84) or rapid COJEC
(rCOJEC). The postinduction metastatic complete remission (mCR) rate,
2-year overall survival (OS) and 2-year event free survival (EFS) were
determined as comparative denominators. The majority (48.3%; n¼ 126)
received OPEC/OJEC, while 70 patients received (26.8%) rCOJEC and 65
(24.9%) NB84. Treatment with NB84 had the best mCR rate (36.9%), fol-
lowed by OPEC/OJEC (32.5%) and rCOJEC (21.4%). The 2-year OS of treat-
ment with NB84 was 41% compared to OPEC/OJEC (35%) and rCOJEC
(24%) (p¼ 0.010). The 2-year EFS of treatment with NB84 was 37% com-
pared to OPEC/OJEC (35%) and rCOJEC (18%) (p¼ 0.008). OPEC/OJEC
had the least treatment-related deaths (1.6%) compared to rCOJEC
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(7.1%) and NB84 (7.5%) (p¼ 0.037). On multivariate analysis LDH
(p¼ 0.023), ferritin (p¼ 0.002) and INSS stage (p¼ 0.006) were identified
as significant prognostic factors for OS. The induction chemotherapy was
not significant for OS (p¼ 0.18), but significant for EFS (p¼ 0.08)
Treatment with NB84 achieved better mCR, OS and EFS, while OPEC/
OJEC had the least treatment-related deaths. In resource-constrained set-
tings, OPEC/OJEC is advised as induction chemotherapy in HR-NB due to
less toxicity as reflected in less treatment-related deaths.
Introduction
Achieving metastatic remission after induction chemotherapy in high-risk (HR) neuro-
blastoma (NB) is of prognostic significance, even though the treatment is of high inten-
sity with potentially severe toxicity.1,2 NB induction chemotherapy is characterized by
the delivery of increasingly intensive multimodal therapies. European approaches under
the EU-20592 or CCLGNB-1990-11 protocols have studied decreasing time by reducing
administration of OPEC/OJEC from 28-day cycles to 21-day cycles.3 Rapid COJEC
(rCOJEC) chemotherapy is highly intensive therapy, administered every 10 days regard-
less of toxicity.3 Although this ensures that a patient reaches the consolidation treatment
phase sooner, there is a greater likelihood of chemotherapy-induced toxicity.4
South African doxorubicin-containing protocols approaches are based on North
American protocols such as the Memorial Sloan Kettering Hospital N6 protocol,5 and
the St Jude NB84 protocol.5 In the N6 protocol, seven cycles have resulted in either
complete remission (CR) or very good partial response (VGPR) in 87% of patients. In
the N7 and N8 protocols, a reduction from seven to five cycles of chemotherapy have
resulted in outcomes of 79% CR or VGPR and less toxicity in 87 patients.5
When comparing the European induction protocols OPEC/OJEC and rCOJEC, a
Cochrane review has concluded there is no clear difference regarding the efficacy
obtaining a complete response, treatment-related mortality, overall survival and event-
free survival.4 It was concluded that prospective trials are needed as there is low level of
evidence and due to the changes in risk classifications during the trial periods.4 The
review relied mainly on the CCLG-ENSG-5 randomized controlled trial of 262 patients
with HR-NB.6 In this study, 132 patients were randomized to receive OPEC/OJEC and
130 patients to receive rCOJEC induction chemotherapy.6 Pearson et al. concluded that
there was an increasing difference in EFS after three years with the rCOJEC induction
protocol.6 With the same cumulative dose, rCOJEC at 10-day cycles had better 10-year
EFS (27%) versus a 21-day cycle (18%) (p¼ 0.085). The hypothesis was that earlier initi-
ation of myeloablative therapy contributed to improved outcome6 and could benefit
patients in countries with access to autologous stem cell transplant services.
Limited information is available comparing doxorubicin-containing and nondoxorubi-
cin-containing regimens. The objective of the SIOPEN randomization of modified N5-
MSKCC induction protocol with rCOJEC in the HR-NBL-1.7/SIOPEN study was to
compare these regimens.7 The study concluded that rCOJEC was less toxic and there
was no difference in the postinduction remission rates, OS and EFS.7
In resource-limited settings, with suboptimal supportive care, high-intensity chemo-
therapy poses a risk of increased morbidity and mortality.8 Challenges include
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inconsistent access to blood products, limited antimicrobial agents, access to intensive
care units and the high chemotherapy costs.8 Malnutrition and advanced disease also
impact on the choice of regimen as they both may independently contribute to poorer
outcomes.8 It is important to select a regimen with the highest remission rate and the
most favorable toxicity profile for the local setting.8
The treatment of HR-NB in SA has been administered according to various protocols
and institutional experience.9 This study investigated remission after standard induction
NB chemotherapy in SA POUs as the South African Children’s Cancer Study Group
(SACCSG) aims to create a standardized prospective treatment protocol based on evi-
dence generated by retrospective studies regarding management of NB in SA.
Materials and methods
Patient population
South Africa is a middle-income country with marked disparities between the resources of
POUs. Patients with HR-NB were identified retrospectively from 10 dedicated pediatric
oncology units (POUs). The study population included new cases of HR-NB diagnosed
from January 2000 to December 2016. High-risk disease was defined by the presence of
metastatic disease, unfavorable histology, a raised serum LDH and ferritin, amplified
MYCN and adverse genetics based on the Children’s Oncology Group (COG) classifica-
tion system (supporting information Appendix A) and the International Neuroblastoma
Risk Group (INRG) consensus pretreatment classification scheme (supporting information
Appendix B). Cases were confirmed by core biopsy, fine needle aspirate or NB-defining
imaging with NB infiltration of the bone marrow and elevated urine catecholamine levels.
Method
There were 354 patients included with high risk (HR) disease, of whom 93 were
excluded, either because of treatment abandonment during induction, or because they
were palliated from diagnosis, or the regimen cohorts were too small to be representa-
tive and/or because they were treated with a nonstandard induction regimen for HR-
NB. The 261 remaining patients received either St Jude NB84 protocol, OPEC/OJEC or
rCOJEC as induction regimens (flow diagram Figure 1).
Data collection and analysis
Researchers from participating centers conducted retrospective chart reviews and
entered data on Excel spreadsheets after ethical approval was granted. The data were
linked to a unique study number and data analysis was anonymous.
Staging was determined according to the International Neuroblastoma Staging System
(INSS). Metastatic remission was defined as complete remission (mCR) according to the
International Neuroblastoma Response Criteria (INRC) revised in 1993 and 2012 (sup-
porting information Appendix C).10,11 Death before the end of induction was defined as
induction failure. Nutritional parameters were applied according to WHO definitions.12
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Abandonment of treatment was defined as the failure to start therapy or complete cura-
tive therapy after missing therapy for four or more consecutive weeks. Patients considered
to be lost-to-follow-up were defined as those who did not return for follow-up after cura-
tive treatment for one year and who were unreachable despite efforts to contact them.
Chemotherapy regimens
Induction regimens included OPEC/OJEC (Carboplatin, Cisplatin, Etoposide, Cyclophos-
phamide and Vincristine),4 the St Jude NB84 protocol (Cisplatin, Etoposide, Doxorubicin
Figure 1. Flow diagram 1: Induction chemotherapy for high-risk neuroblastoma (HR-NB) in South
Africa 2000–2016.
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and Cyclophosphamide)13 and rCOJEC (Carboplatin, Cisplatin, Etoposide, Cyclophos-
phamide and Vincristine).4
Statistical analysis
All analyses were performed in R version 3.4.4 (R foundation for Statistical Computing,
Vienna, Austria).14 Data were summarized as percentages and compared between sub-
groups using the chi-squared test (v2). EFS and OS were computed and visualized by
Kaplan-Meier curves. Median EFS and OS, together with 95% confidence intervals (CI)
were reported.
Differences between survival curves by chemotherapy group were assessed by
log-rank test. Additionally, simple and multiple Cox regression models were built to
determine the effect of various prognostic factors. A full multiple Cox regression model
demonstrated the effect of chemotherapy on EFS and OS, respectively, after correction
for the other prognostic factors. Similarly, simple and multiple logistic regression mod-
els were constructed to assess the effect of chemotherapy on metastatic complete remis-
sion while correcting for other factors.
Due to the retrospective methodology, numerous data on prognostic factors were not
available and stated per category. Assuming data were missing at random, multiple
imputation with chained equations were performed to correct for missing data. The
imputation models included all variables in the analysis. Ten imputed data sets were
generated and analyzed in Cox and logistic regression models as described above.
Results of the imputed data analyses were pooled to obtain parameter estimates and
confidence intervals.
Descriptive and simple comparisons of patients with or without complete metastatic
remission were on the raw un-imputed data, while all models were based on multiple
imputation, as stated in each table.
Results
Two hundred and sixty-one patients were eligible for inclusion in the analysis: 126
(48.3%) treated with OPEC/OJEC, 70 (26.8%) with rCOJEC and 65 (24.9%) were treated
with the NB84 protocol. Table 1 provides the demographic data, the high-risk factors per
treatment protocol and disease profile of the groups. There was a slight male predomin-
ance with a male:female ratio of 1:0.89. The majority (58.2%) of patients were in the
18–60months category and median age was 36.1months (interquartile range 20.2–55.7).
Outcomes
A total of 80 (30.7%) HR patients were in mCR post-induction chemotherapy. The
highest mCR was obtained by treatment with NB84 (36.9%), followed by OPEC/OJEC
(32.5%) and rCOJEC with 21.4% (p¼ 0.12). Treatment with NB84 had the best 2-year
OS of 41% (95% CI, 30%–56%) compared to OPEC/OJEC with 35% (95% CI,
27.0%–45.0%), while OJEC/OPEC performed better than rCOJEC with 24% (95% CI,
16.0%–38.0%, p¼ 0.010) (see Figure 2). Treatment with NB84 had superior 2-year EFS
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of 37% (95% CI, 26%–52%) compared to OPEC/OJEC with 35% (27–45%) and rCOJEC
at 18% (95% CI, 10%–32%) (p¼ 0.008) (see Figure 3) (see flow diagram Figure 1).
Toxicity
The least treatment-related deaths were seen in patients treated with OPEC/OJEC
(1.6%), compared to the St Jude NB84 protocol with 7.5% and rCOJEC with 7.1%
(p< 0.05). There were no documented doxorubicin cardiac-related deaths in the St Jude
NB84 protocol group (see flow diagram 1).
Prognostic factors
With multivariate analysis (see Table 2), statistically significant differences were demon-
strated in the remission rates associated with age > 18months (p¼ 0.038), INSS stage 4
(p< 0.001), ferritin > 120 ng/dl (p< 0.001), and unfavorable pathology according to the










Male 138 (52.9%) 31/65 (47.7%) 66/126 (52.4%) 41/70 (58.6%)
Female 123 (47.1%) 34/65 (52.3%) 60/126 (47.6%) 29/70 (41.4%)
Age
0 – 18 m 51 (19.5%) 14/65 (21.5%) 28/126 (22.2%) 9/70 (12.9%)
18.1 – 60 m 152 (58.2%) 31/65 (47.7%) 76/126 (60.3%) 45/70 (64.3%)
> 60 m 58 (22.2%) 20/65 (30.8%) 22/126 (17.5%) 16/70 (22.9%)
INSS
Stage 4 223 (85.4%) 48/65 (73.8%) 111/126 (88.1%) 64/70 (91.4%)
Other stage 38 (14.6%) 17/65 (26.2%) 15/126 (11.9%) 6/70 (8.6%)
LDH
< 750 87 (33.3%) 34/65 (52.3%) 33/122 (27.0%) 20/62 (32.3%)
> 750 162 (62.1%) 31/65 (47.7%) 89/122 (73.0%) 42/62 (67.7%)
Unknown 12 (4.6%)
Ferritin
< 120 50 (19.2%) 18/52 (34.6%) 25/88 (28.4%) 7/49 (14.3%)
> 120 139 (53.3%) 34/52 (65.4%) 63/88 (71.6%) 42/49 (85.7%)
Unknown 72 (27.6%)
INPC
Favorable 27 (10.3%) 1/8 (12.5%) 23/85 (27.1%) 3/38 (7.9%)
Unfavorable 104 (39.8%) 7/8 (87.5%) 62/85 (72.9%) 35/38 (92.1%)
Unknown 130 (49.8%)
MYCN
Nonamplified 38 (14.6%) 4/11 (36.4%) 26/81 (32.1%) 8/25 (32.0%)
Amplified/extra copies 79 (30.3%) 7/11 (63.6%) 55/81 (67.9%) 17/25 (68.0%)
Unknown 144 (55.2%)
WFA
> -1 SD 116 (44.4%) 20/45 (44.4%) 64/94 (68.1%) 32/55 (58.2%)
-1SD to -2 SD 41 (15.7%) 8/45 (17.8%) 19/94 (20.2%) 14/55 (25.5%)
< -2SD 37 (14.2%) 17/45 (37.8%) 11/94 (11.7%) 9/55 (16.4%)
Unknown 67 (25.7%)
HFA
> -1 SD 97 (37.2%) 16/45 (35.6%) 59/93 (63.4%) 22/52 (42.3%)
-1SD to -2 SD 30 (11.5%) 6/45 (13.3%) 14/93 (15.1%) 10/52 (19.2%)
< -2SD 63 (24.1%) 23/45 (51.1%) 20/93 (21.5%) 20/52 (38.5%)
Unknown 71 (27.0%)
LDH – lactate dehydrogenase; INPC – International neuroblastoma pathology classification; INSS – International neuro-
blastoma staging system; WFA – weight for age (z-score); HFA – height for age (z-score); SD – standard deviations.
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International Neuroblastoma Pathology Classification (INPC) (p¼ 0.023). Nonsignificant
differences were demonstrated between induction chemotherapy regimens with better
remission achieved with NB84 than OPEC/OJEC (p¼ 0.12). rCOJEC had the worst out-
comes (p¼ 0.12). Multivariate risk factor analysis confirmed that ferritin >120 ng/dL
(p¼ 0.051) and INSS stage 4 (p< 0.002) were significant predictors of achieving mCR.
The choice of induction chemotherapy regimen was not significant to achieve remission
(p¼ 0.65). Significant prognostic factors associated with OS (see Table 4) were INSS stage
4 (p¼ 0.006) and ferritin > 120 ng/dl (p¼ 0.002), LDH >750 (p¼ 0.023) and low WFA
(p¼ 0.081). The particular induction chemotherapy protocol was not shown to influence
survival (p¼ 0.18). Significant prognostic factors, on univariate and multivariate analyses,
associated with EFS (see Table 5) were INSS stage 4 (p¼ 0.017), ferritin > 120 ng/dl
(p< 0.001) and the induction chemotherapy regimen (p¼ 0.08).
Figure 3. Kaplan-Meier curves of the two-year EFS of the induction regimens (p¼ 0.008).
Figure 2. Kaplan-Meier curves of the two-year OS of the induction regimens (p¼ 0.010).




Patients with a weight for age (WFA) above the -2SD z-score had a slightly improved,
though nonsignificant remission rate (>-1SD with 33.6%; -1SD to -2 SD with 36.6%)
compared to wasted patients (24.3% for WFA below -2SD z-score) (p¼ 0.47). Body
mass index for age and weight for height were not statistically significant as prognostic
factors for survival (see Table 2).
Limitations of the study
The retrospective nature of the data limits the study because of the absence of random-
ization. Treatment was not standardized as regimens were based on institutional prefer-
ence and disease severity. Different POUs administered similar regimens for either








Male 138 (52.9%) 37/138 (26.8%) 101/138 (73.2%)
Female 123 (47.1%) 43/123 (35.0%) 80/123 (65.0%)
Age 0.038
0 – 18 m 51 (19.5%) 23/51 (45.1%) 28/51 (54.9%)
18.1 m – 5 y 152 (58.2%) 43/152 (28.3%) 109/152 (71.7%)
> 5 y 58 (22.2%) 14/58 (24.1%) 44/58 (75.9%)
INSS <0.001
Stage 4 223 (85.4%) 56/223 (25.1%) 167/223 (74.9%)
Other stage 38 (14.6%) 24/38 (63.2%) 14/38 (36.8%)
LDH 0.16
< 750 87 (33.3%) 33/87 (37.9%) 54/87 (62.1%)
> 750 162 (62.1%) 46/162 (28.4%) 116/162 (71.6%)
Unknown 12 (4.6%)
Ferritin <0.001
< 120 50 (19.2%) 27/50 (54.0%) 23/50 (46.0%)
> 120 139 (53.3%) 36/139 (25.9%) 103/139 (74.1%)
Unknown 72 (27.6%)
INPC 0.023
Favorable 27 (10.3%) 15/27 (55.6%) 12/27 (44.4%)
Unfavorable 104 (39.8%) 31/104 (29.8%) 73/104 (70.2%)
Unknown 130 (49.8%)
MYCN 0.37
Nonamplified 38 (14.6%) 17/38 (44.7%) 21/38 (55.3%)
Amplified/extra copies 79 (30.3%) 27/79 (34.2%) 52/79 (65.8%)
Unknown 144 (55.2%)
WFA 0.47
> -1 SD 116 (44.4%) 39/116 (33.6%) 77/116 (66.4%)
-1SD to -2 SD 41 (15.7%) 15/41 (36.6%) 26/41 (63.4%)
< -2SD 37 (14.2%) 9/37 (24.3%) 28/37 (75.7%)
Unknown 67 (25.7%)
HFA 0.76
> -1 SD 97 (37.2%) 29/97 (29.9%) 68/97 (70.1%)
-1SD to -2 SD 30 (11.5%) 11/30 (36.7%) 19/30 (63.3%)
< -2SD 63 (24.1%) 21/63 (33.3%) 42/63 (66.7%)
Unknown 71 (27.0%)
Chemo regimen 0.12
St Jude NB84 65 (24.9%) 24/65 (36.9%) 41/65 (63.1%)
OPEC/OJEC 126 (48.3%) 41/126 (32.5%) 85/126 (67.5%)
Rapid COJEC 70 (26.8%) 15/70 (21.4%) 55/70 (78.6%)
LDH – lactate dehydrogenase; INPC – International neuroblastoma pathology classification; INSS – International neuro-
blastoma staging system; WFA – weight for age (z-score); HFA – height for age (z-score); SD – standard deviations.
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curative or palliative intent. The prognosis and OS were influenced by nonstandard
management indications related to surgery and radiotherapy administration. Risk strati-
fication was limited by the availability of genetic testing especially with regard to
MYCN status, deletions and mutations. The degree of supportive care differs among
European, North American and South African POUs as well as between different South
African POUs. The curative and palliative treatment intent differed between South
African POUs with the degree of supportive care dictated by the treatment intent.
Discussion
This study compared the most commonly used induction chemotherapy protocols for
HR-NB in South African POUs to identify the most effective, least toxic mCR induction
Table 4. Simple and multiple Cox regression model for Overall survival (OS) (with mul-
tiple imputation).
Simple Cox model Multiple Cox model
HR (95%CI) p-Value HR (95%CI) p-Value
Sex: Female 0.63 (0.47 – 0.84) 0.002 0.67 (0.50 – 0.91) 0.011
Agea 0.030 0.42
18 m – 5 y 1.73 (1.15 – 2.60) 0.008 1.11 (0.71 – 1.75) 0.64
> 5 y 1.63 (1.02 – 2.60) 0.040 0.86 (0.49 – 1.51) 0.60
INSS: Stage 4 2.75 (1.70 – 4.43) <0.001 2.11 (1.24 – 3.57) 0.006
LDH: > 750 1.87 (1.37 – 2.54) 0.001 1.51 (1.06 – 2.16) 0.023
Ferritin: > 120 2.82 (1.82 – 4.39) <0.001 2.25 (1.35 – 3.75) 0.002
INPC: Unfavorable 1.61 (1.04 – 2.49) 0.035 1.33 (0.83 – 2.13) 0.23
MYCN: Amplified 1.19 (0.79 – 1.77) 0.41 0.97 (0.62 – 1.54) 0.91
WFA: < -2SD 1.40 (0.96 – 2.06) 0.082 1.60 (0.94 – 2.70) 0.081
HFA: < -2SD 1.16 (0.84 – 1.59) 0.37 1.13 (0.74 – 1.71) 0.57
Chemo regimenb 0.010 0.18
O/O 1.13 (0.79 – 1.61) 0.50 0.91 (0.60 – 1.38) 0.65
Rapid COJEC 1.75 (1.18 – 2.60) 0.005 1.28 (0.82 – 2.01) 0.28
aReference category < 18m.
bReference category St Jude NB84.
Table 3. Simple and multiple logistic regression model for Remission (with multiple imputation).
Simple logistic model Multiple logistic model
OR (95%CI) p-Value OR (95%CI) p-Value
Sex: Female 1.47 (0.86 – 2.49) 0.16 1.36 (0.74 – 2.49) 0.33
Agea 0.041 0.64
18 m – 5 y 0.48 (0.25 – 0.92) 0.029 0.69 (0.32 – 1.49) 0.35
> 5 y 0.39 (0.17 – 0.88) 0.024 0.73 (0.27 – 1.99) 0.54
INSS: Stage 4 0.20 (0.09 – 0.40) <0.001 0.26 (0.11 – 0.61) 0.002
LDH: > 750 0.62 (0.36 – 1.08) 0.095 1.12 (0.53 – 2.36) 0.76
Ferritin: > 120 0.29 (0.15 – 0.57) <0.001 0.45 (0.20 – 1.00) 0.051
INPC: Unfavorable 0.41 (0.18 – 0.93) 0.041 0.45 (0.17 – 1.17) 0.10
MYCN: Amplified 0.75 (0.35 – 1.59) 0.46 0.72 (0.28 – 1.83) 0.49
WFA: < -2SD 0.64 (0.29 – 1.41) 0.27 0.42 (0.14 – 1.28) 0.13
HFA: < -2SD 1.11 (0.57 – 2.15) 0.77 1.52 (0.59 – 3.90) 0.38
Chemo regimenb 0.13 33 0.65
O/O 0.82 (0.44 – 1.54) 0.55 0.98 (0.45 – 2.13) 0.95
Rapid COJEC 0.47 (0.22 – 1.00) 0.050 0.70 (0.29 – 1.71) 0.44
aReference category < 18m.
bReference category St Jude NB84.
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chemotherapy regimen. In European studies mCR rates of 26.6–36.0% have been reported
in patients treated on rCOJEC and 31.6–41.0% on OPEC/OJEC.4,7 While the SA mCR of
32.5% on OPEC/OJEC is comparable to European studies, the mCR of 21.4% on rCOJEC
is poorer than that described in European studies. The reasons were not clear, but nutri-
tional status and available supportive care may have been different for studies in Europe.
The St Jude NB84 protocol and Memorial Sloan Kettering’s (MSK) N6 protocol,
doxorubicin-containing protocols from North America, achieved postinduction mCR of
77.0% (n¼ 154)13 and 62.5% (n¼ 24),15 respectively. The 36.9% mCR achieved in the St
Jude NB84 protocol in SA is lower than remission rates in North America, but is the
same as the 37% of the doxorubicin containing N5-MSKCC randomization reported
during the HRNBL1.5/SIOPEN trial from 2013 to 2017.7 The patients in the two North
American studies were staged according to the Pediatric Oncology Group (POG)13 and
Children’s Cancer Group (CCG).13 The POG staging included stage B patients over the
age of 12months in the cohort,13 while MSK staged without factoring in MYCN,13
which was different from the SA POUs where the INRG classifications were used. The
varied regional risk classifications create an unequal staging and biological profile for a
standardized comparison.
The 2-year OS of the St Jude NB84 protocol (1984–1988) was 68.0%13 while the 3-
year EFS was 24.2% for patients in the OPEC/OJEC group and 31.0% for those in the
rCOJEC group during European studies between 1990 and 1999.4 More recent 2-year
OS was 69.0% for rCOJEC,7 but the protocol included an extended induction with topo-
tecan, vincristine and doxorubicin. In our study the 2-year OS was 39.1% for the St
Jude NB84 protocol, 30.7% for OPEC/OJEC and 16.3% for rCOJEC. Whereas the
OPEC/OJEC outcomes compared well to the European studies, both rCOJEC and the
doxorubicin-containing protocol performed worse. Although the differences in 2-year
EFS of our study did not reach significance, the values were comparable to the 3-year
EFS of the international studies. In a similar low- and middle income countries setting
in India, doxorubicin-containing induction regimens achieved a long-term OS of 35.7%
and CR of 17.6%.16
Table 5. Simple and multiple Cox regression model for Event-free survival (EFS) (with mul-
tiple imputation).
Simple Cox model Multiple Cox model
HR (95%CI) p-Value HR (95%CI) p-Value
Sex: Female 0.62 (0.46 – 0.85) 0.003 0.66 (0.47 – 0.92) 0.016
Agea 0.007 0.49
18m – 5yr 1.94 (1.21 – 3.13) 0.006 1.23 (0.72 – 2.10) 0.46
> 5y 2.31 (1.36 – 3.91) 0.002 0.99 (0.51 – 1.90) 0.97
INSS: Stage 4 2.70 (1.59 – 4.61) <0.001 2.09 (1.14 – 3.83) 0.017
LDH: > 750 1.63 (1.18 – 2.26) 0.003 1.16 (0.79 – 1.70) 0.46
Ferritin: > 120 4.46 (2.42 – 8.24) <0.001 3.52 (1.76 – 7.06) <0.001
INPC: Unfavorable 1.61 (0.93 – 2.77) 0.095 1.32 (0.76 – 2.30) 0.32
MYCN: Amplified 1.12 (0.76 – 1.67) 0.57 1.02 (0.64 – 1.63) 0.92
WFA: < -2SD 1.40 (0.92 – 2.13) 0.12 1.43 (0.79 – 2.62) 0.24
HFA: < -2SD 1.24 (0.88 – 1.75) 0.22 1.22 (0.79 – 1.87) 0.38
Chemo regimenb 0.008 0.08
O/O 0.95 (0.65 – 1.39) 0.81 0.72 (0.46 – 1.13) 0.15
Rapid COJEC 1.66 (1.09 – 2.52) 0.018 1.10 (0.67 – 1.79) 0.70
aReference category < 18m.
bReference category St Jude NB84.
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In North America, the treatment related mortality rate (TRM) during the St Jude
protocol was reported to be 2.5%.13 No patients were reported to have developed
anthracycline-related cardiac failure.13 Although there were no cardiac-related deaths in
the SA study, the TRM was (7.5%) mainly due to myelosuppression. In Europe, the
OPEC/OJEC and COJEC studies reported TRM rates of 3.2% and 4.1%,4 respectively,
whereas in the SA study they were 1.6% and 7.1%, respectively.
The doxorubicin-containing modified POG 9341 induction regimen has been used in
Morocco with no toxicity-related deaths.17 Limiting the use of doxorubicin in favor of
optimizing the platinum backbone results in a superior response rate to the CCG3891
protocol, with improved intensity compared to CAdO/PE,18 and has a more favorable
acute toxicity profile than N719 or rCOJEC.1
In general, there is limited data comparing doxorubicin and nondoxorubicin contain-
ing regimens. SIOPEN randomized rCOJEC and N5-MSKCC regimens with the aim of
comparing the two protocols.7 The study concluded that rCOJEC was less toxic and no
differences in postinduction remission, OS and EFS.7 In our study, rCOJEC accounted
for more toxicity-related deaths than the doxorubicin-containing St Jude NB84 protocol.
OPEC/OJEC accounted for less toxicity-related deaths than both the other two proto-
cols. The St Jude NB84 protocol had the best remission rate and 2-year OS and EFS but
had a higher toxicity than OPEC/OJEC.
As in the North American studies,13 LDH >750U/L, ferritin >120 ng/dl, stage 4 disease
and the choice of induction chemotherapy were significant prognostic denominators in the
SA study. In keeping with international trends7 and as in other middle-income countries
(MIC),20 more male patients were diagnosed with high-risk disease, yet sex was not a signifi-
cant factor on multivariable analysis. HR-NB was mostly diagnosed in the 18–60months age
group, as in other LMIC,21 and the median age of 36.1months is higher compared to
33.2months reported in Egypt, another MIC.20 The greatest proportion of patients in the
cohort had stage 4 disease and a larger proportion of tumors were MYCN amplified. The
rate of malnutrition at diagnosis was marginally higher than in high income countries,8
which is a cause for concern and suggests a need for more aggressive nutritional support.
The SA study reproduced the findings of both European and North American studies
that various NB induction regimens were comparable to each other despite different
therapeutic approaches.4,6,7 A Cochrane review concluded that the only benefit of
rCOJEC above OJEC/OPEC was the more rapid progress to autologous transplant.4 In a
MIC with limited access to transplant facilities, this benefit has little relevance. In
randomized trials, rCOJEC had improved EFS compared to OPEC/OJEC through dose
intensification, but was not superior to North American and other European regimens.6
The results of this study should be viewed in the South African context with compar-
isons between different HR-NB induction protocols among different centers with differ-
ent supportive care guidelines, nonstandardized treatment and different treatment
intents of management. The application in other countries should be evaluated accord-
ing to local POUs and resources.
Conclusion
Reduction of the primary tumor size and complete remission of metastases by the end
of induction chemotherapy are important prognostic factors in the treatment of NB.
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With a marginal difference in outcomes with the various standard NB treatment proto-
cols, the more favorable toxicity profile of OPEC/OJEC, especially considering malnour-
ished children, is the most suitable induction regimen for SA. The ease of
administration, favorable toxicity profile and rendering G-CSF support unnecessary are
also important considerations for the future implementation of OPEC/OJEC as the
standard induction regimen in HR-NB in South Africa.
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prognostic value of the degree of surgery and radiotherapy in the South African setting with access 
only to mainly trimodal therapy. The recommendations would guide paediatric surgeons to establish 
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Abstract
Purpose To investigate the impact of local therapies on high-risk neuroblastoma (HR-NB) outcomes in South Africa.
Methods Data from 295 patients with HR-NB from nine pediatric oncology units between 2000 and 2014 were analysed. 
All patients received chemotherapy. Five-year overall (OS) and event free survival (EFS) were determined for patients who 
had received local therapy, either surgery or radiotherapy or both.
Results Surgery was performed in only 35.9% (n = 106/295) patients. Surgical excision was done for 34.8% (n = 85/244) 
of abdominal primaries, 50.0% (n = 11/22) of thoracic primaries; 22.2% (n = 2/9) neck primaries and 66.7% (n = 8/12) of 
the paraspinal primaries. Only 15.9% (n = 47/295) of all patients received radiotherapy. Children, who had surgery, had an 
improved five-year OS of 32.1% versus 5.9% without surgery (p < 0.001). Completely resected disease had a five-year OS of 
30.5%, incomplete resections 31.4% versus no surgery 6.0% (p < 0.001). Radiated patients had a five-year OS of 21.3% versus 
14.2% without radiotherapy (p < 0.001). Patients who received radiotherapy without surgical interventions, had a marginally 
better five-year OS of 12.5% as opposed to 5.4% (p < 0.001). Patients who underwent surgery had a longer mean overall 
survival of 60.9 months, while patients, who were irradiated, had a longer mean overall survival of 7.9 months (p < 0.001). 
On multivariate analysis, complete metastatic remission (p < 0.001), surgical status (p = 0.027), and radiotherapy status 
(p = 0.040) were significant predictive factors in abdominal primaries.
Conclusion Surgery and radiotherapy significantly improve outcomes regardless of the primary tumor site, emphasizing the 
importance of local control in neuroblastoma.
Keywords Neuroblastoma · Surgery · Radiotherapy · South Africa · Local therapies · High-risk · Intermediate-risk
Abbreviations
COG  Children’s Oncology Group
EFS  Event-free survival
FH  Favorable histology
GTR  Gross total resection
HIC  High-income countries
HR  High risk
IDRF  Image define risk factors
INSS  International Neuroblastoma Staging System
LMIC  Low- and middle-income countries
NA  Not amplified
NB  Neuroblastoma
nGTR  Near gross total resection
OS  Overall survival
PFS  Progression-free survival
PTR  Primary tumor site relapse
POUs  Pediatric oncology units
RT  Radiotherapy
STR  Subtotal resection
UH  Unfavorable histology
Introduction
Neuroblastoma is a solid tumor of the sympathetic nerv-
ous system and contributes to 7–10% of all childhood can-
cer deaths [1]. Outcomes are poor in the absence of local 
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therapies, such as surgery and radiotherapy, especially in low 
and middle income countries [1, 2]. The tumor is chemo-
therapy and radiotherapy sensitive [1], but can develop 
significant treatment resistance without local treatment 
interventions [1]. Cure in high-risk (HR) neuroblastoma 
is determined by the stage, tumor biology, chemotherapy 
response, and local treatment [1, 2]. Therefore, in HR dis-
ease (metastatic disease, unfavorable histology, raised tumor 
markers, MYCN amplification and adverse genetics), sur-
gery and radiotherapy are mandatory for cure as components 
of multimodal management [1, 2]. Local therapies have 
increased importance in resource limited settings, where 
access to autologous transplant and molecular targeted thera-
pies as part of standard of care, are limited [2].
Resection of the tumor is not always a feasible therapeutic 
modality due to the macroscopic encasing of vital structures, 
such as significant blood vessels, including the aorta and 
inferior vena cava [3]. With encasement, surgery becomes 
challenging, with a high surgical morbidity and mortality. 
Encasement of the abdominal arteries is the single worst 
prognostic indicator during surgery [3]. IDRF are a set of 
anatomical site-specific signs that confer a poorer progno-
sis and assists in surgical decisions toward resection in NB 
[4]. Before the standardization of image defined risk factors 
(IDRF) to assess operability post-induction chemotherapy, 
decisions regarding surgery were made by multi-disciplinary 
teams (MDTs).
Radiotherapy is used for local control, focal metastatic 
spread, and symptom control in curative and palliative set-
tings [2]. In HR metastatic disease, the role of radiotherapy 
for local control and survival in the era of supplementary 
multimodal therapies remains unclear. Yet complementary 
radiotherapy, when used as a component of trimodal therapy 
alongside chemotherapy and surgery, has survival advan-
tages [5]. By utilizing radiotherapy, the same response rates 
can be achieved in the primary tumor bed, as well as at meta-
static sites, for both large and minimal residual tumors [5].
In HR disease, where autologous transplant and molecu-
lar targeted therapies are not available, the extent of resec-
tion has an impact on the overall (OS) and event-free sur-
vival (EFS) [3]. In high-income countries (HIC), a favorable 
surgical outcome is mandatory for autologous transplant, 
radiotherapy and targeted therapy, securing an overall sur-
vival of up to 60% [2]. Historically, in HIC, chemotherapy, 
surgery and radiotherapy obtained an OS of approximately 
20%, compared to less than 20% in resource-limited set-
tings [2]. In combination with curative care options, local 
therapies contribute to the prolongation of progression free 
survival (PFS) and quality of life [6, 7].
A retrospective review was done to determine the value 
of local therapies on the outcomes of children diagnosed 
with HR-NB in South Africa, where autologous bone 
marrow transplants and molecular targeted therapies are 
readily not available. The objective was to develop stand-
ardized national treatment protocols for local therapies, 
including identifying limitations in the current manage-
ment of NB in South Africa.
Materials and methods
A total of 295 children with HR-NB were diagnosed in 
nine dedicated pediatric oncology units (POUs) in South 
Africa from January 2000 to December 2014 (see Sup-
plementary Figure 1). Diagnosis was confirmed through 
either a biopsy, bone marrow investigations, or raised uri-
nary catecholamines if biopsy was not possible.
Patients were clinically and radiologically staged 
according to the International Neuroblastoma Staging Sys-
tem (INSS), using ultrasonography, computed tomogra-
phy or magnetic resonance imaging of the neck, chest and 
abdomen, as well as bone marrow aspirate and trephine 
biopsy. Depending upon the available facilities, staging, 
and skeletal screening were done by 123I-MIBG scan and/
or bone scan. Where available, staging with 129fluorode-
oxyglucose-positron emission tomography was done in 
patients with 123I-MIBG scan non-avid tumors. Risk clas-
sification was based on the International Neuroblastoma 
Risk Groups (INRG) classification system (see Appendix), 
to identify patients with HR disease [1].
Univariate and multivariate analysis for five-year OS 
were only calculated for abdominal primaries due to insig-
nificant results in the small cohorts of other primary sites.
Guidelines for local therapies
Data was not robust enough to retrospectively restage 
patients post induction chemotherapy (pre-operatively) 
according to IDRF. Most patient records and imaging were 
stored in non-electronic formats, with incomplete or lost 
IDRF information. The indication for surgery and exter-
nal beam radiotherapy treatment was based on risk-based 
treatment protocols according to the Children’s Oncology 
Group (COG) [8, 9] or the International Society of Paedi-
atric Oncology European Neuroblastoma group (SIOPEN) 
approaches [10]. In South Africa, the choice of protocol 
was according to institutional preference and the applica-
tion decided by MDTs and guided by institutional exper-
tise. Emergency surgery was performed for the allevia-
tion of neurological or obstructive symptoms. It was not 
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standard practice in South Africa to perform post resection 
imaging to assess the completeness of resections.
Definitions
Metastatic remission was defined as complete remission 
according to the International Neuroblastoma Response 
Criteria (INRC), revised in 1993 and 2012 [11, 12]. Com-
plete resection was defined as greater than 90% resection 
as reported by surgeons. Incomplete resection was defined 
as resection less than 90%, or surgical reports stating an 
incomplete resection. No surgery was defined as the absence 
of any surgical excision of the primary tumor, and/or if only 
a biopsy was done. Radiotherapy treatment was defined as 
any radiotherapy to the local tumor bed or to metastatic sites 
for curative or palliative indications.
The overall survival (OS) time was defined as the period 
from diagnosis to death or date last seen, and event-free 
survival (EFS) was calculated from the date of diagno-
sis until disease progression on chemotherapy, or relapse, 
or treatment abandonment, death or date last seen. Pro-
gression-free survival (PFS) was calculated from the date 
of diagnosis until disease progression on chemotherapy, 
or relapse or death. Lost to follow-up was defined as any 
patient who did not return for follow-up appointments for 
one year and was unreachable despite efforts to contact 
the family.
Ethical approval was obtained from The Faculty of Health 
Sciences Research Ethics Committee of Stellenbosch Uni-
versity and the National Department of Health.
Statistical analysis
Data were analyzed using IBM SPSS version 25 (IBM Cor-
poration, USA) statistical software [13]. Medians were used 
to determine estimations using Student’s t test. Where esti-
mations could not be determined by median values, the mean 
values were used. In cohorts of fewer than five observations, 
Fisher’s exact test was applied. The Pearson chi-square test 
(χ2) was employed to assess the categorical associations 
among covariates. Two-year and five-year overall survival 
(OS), event-free (EFS) survival, and progression-free sur-
vival (PFS), with associated 95% confidence intervals, 
were calculated using Kaplan–Meier curves. Multiple Cox 
regression modelling was employed to assess the statistical 
Table 1  Surgical and radiological interventions according to primary site
Local therapies according to anatomical site of primary
Primary site Both local therapies n (%) Surgery only n (%) Radiotherapy only n (%) No therapy n (%)
Abdominal 28 (11.5%) 60 (24.6%) 15 (6.1%) 141 (57.8%)
Thoracic 2 (9.0%) 10 (45.5%) 0 (0%) 10 (45.5%)
Neck 1 (11.1%) 1 (11.1%) 0 (0%) 7 (77.8%)
Paraspinal 0 (0%) 8 (66.7%) 0 (0%) 4 (33.3%)
Other 0 (0%) 0 (0%) 1 (12.5%) 7 (87.5%)
Total 31 (10.5%) 79 (26.8%) 16 (5.4%) 169 (57.3%)
Surgical intervention according to anatomical site of primary
Primary site Operated n (%) Not operated n (%) Total
Abdominal 85 (34.8%) 159 (65.2%) 244
Thoracic 11 (50.0%) 11 (50.0%) 22
Neck 2 (22.2%) 7 (77.8%) 9
Paraspinal 8 (66.7%) 4 (33.3%) 12
Other 0 (0.0%) 8 (100.0%) 8
Total 106 (35.9%) 189 (64.1%) 295
Radiotherapy according to anatomical site of primary
Primary site Radiated n (%) Not radiated n (%) Total
Abdominal 43 (17.6%) 201 (82.4%) 244
Thoracic 2 (9.1%) 20 (90.9%) 22
Neck 1 (11.1%) 8 (88.9%) 9
Paraspinal 0 (0%) 12 (100.0%) 12
Other 1 (12.5%) 7 (87.5%) 8





significance of various prognostic factors. The proportional 
hazards assumption was also confirmed for the final multi-
variable model. A p value of less than 0.05 was considered 
significant for all calculations. Some cohorts were too small 
(less than five) for meaningful calculations and were not 
included in the final tables.
Results
The majority of patients were diagnosed with abdominal 
primaries (adrenal and extra-adrenal) (82.7%; n = 244/295) 
followed by thoracic primaries (7.5%; n = 22/295), paraspi-
nal (4.0%; n = 12/295), neck (3.0%; n = 9/295); primary not 
found (2.0%; n = /295); bone only (0.4%; n = 1/295) and one 
in the soft tissue of the cheek (0.4%) (see Table 1, Supple-
mentary Figure 1).
The majority of patients were not operated (64.1%; 
n = 189/295). Surgery excision was done for 34.8% 
(n = 85/244) of the abdominal primaries, 50.0% (n = 11/22) 
of thoracic primaries; 22.2% (n = 2/9) of neck primaries and 
66.7% (n = 8/12) of the paraspinal primaries. The majority of 
patients did not receive radiotherapy (84.1%; n = 248/295). 
Irradiation to the tumour bed was done for only 17.6% 
(n = 43/244) of the abdominal primaries, 9.1% (n = 11/22) 
of thoracic primaries; 11.1% (n = 1/9) of neck primaries and 
none of the paraspinal primaries. Eleven patients (3.8%) 
received an autologous bone marrow transplant after induc-
tion chemotherapy, surgery, and radiotherapy.
The main reasons why patients were not operated were 
the failure to achieve metastatic remission after induction 
chemotherapy (49.2%; n = 93/189), local progression of dis-
ease (26.5%; n = 50/189); metastatic progression of disease 
(6.3%; 12/189) or death during induction chemotherapy 
(4.2%; n = 8/189) (see Supplementary table 1). Nine (4.7%) 
patients were palliated from diagnosis and five (2.6%) aban-
doned induction chemotherapy.
Patients, who underwent surgery, had a better five-year 
OS of 32.1% and EFS of 30.2%, compared to patients not 
operated with a five-year OS of 5.9% and a five-year EFS 
Table 2  Surgical outcomes
OS overall survival, EFS event free survival
Outcomes for surgical intervention according to site of primary tumour
Primary site 5 years OS 5 years EFS
Operated Not operated p value Operated Not operated p value
Abdominal 28.2% 5.7% < 0.001 25.9% 5.1% < 0.001
Thoracic 63.6% 9.1% 0.001 63.6% 9.1% 0.003
Neck 50.0% 0.0% 0.225 50.0% 0.0% 0.030
Paraspinal 25.0% 0.0% < 0.001 25.0% 0.0% 0.001
Other 12.5% 12.5% NS 12.5% 12.5% NS
Total 32.1% 5.9% < 0.001 30.2% 5.3% < 0.001
Outcomes for the extent of surgical resection according to site of primary tumour
Primary site 5 years OS
Complete resection Incomplete resection No resection p values
Abdominal 28.6% 25.6% 5.8% < 0.001
Thoracic 57.1% 60.0% 10.0% 0.017
Neck 0.0% 100.0% 0.0% 0.271
Paraspinal 0.0% 33.3% 0.0% < 0.001
Other – – 12.5% NS
Total 30.5% 31.4% 6.0% < 0.001
Primary site 5 years EFS
Complete resection Incomplete resection No resection p values
Abdominal 26.5% 23.1% 5.2% < 0.001
Thoracic 57.1% 60.0% 10.0% 0.030
Neck 100.0% 0.0% 0.0% 0.095
Paraspinal 0.0% 33.3% 0.0% 0.003
Other – – 12.5% NS
Total 30.5% 27.5% 5.5% 0.001
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of 5.3% (p < 0.001) (see Table 2). There was also a signifi-
cant improved five-year OS per anatomical site for patients 
operated versus patients not operated: abdominal primary 
28.2% compared to 5.7% (p < 0.001) (see Fig. 1); thoracic 
primary 63.6% compared to 9.1% (p = 0.001) and paraspinal 
25.0% compared to 0.0% (p < 0.001). The significant five-year 
EFS per anatomical site for patients that could be operated 
and patients not operated were: abdominal primary 25.9% 
compared to 5.1% (p < 0.001); thoracic primary 63.6% com-
pared to 9.1% (p = 0.003); neck 50.0% compared to 0.0% 
(p = 0.03) and paraspinal 25.0% compared to 0.0% (p = 0.001).
The five-year OS was significantly improved for patients 
regardless of primary site with either complete resection 
or incomplete resection, at 30.5% and 31.4% respectively, 
compared to 6.0% in patients who did not receive any sur-
gery (p < 0.001) (see Table 3). Only two operated patients 
Fig. 1  Kaplan–Meier curve for 
OS of surgical status in HR-NB 
with abdominal primaries 
(p < 0.001)
Table 3  Radiotherapy outcomes
OS overall survival, EFS event free survival
Outcomes for radiotherapy according to site of primary tumour
Primary site 5 years OS 5 years EFS
Irradiated Not irradiated p value Irradiated Not irradiated p value
Abdominal 18.6% 12.5% 0.008 16.3% 11.5% 0.035
Thoracic 0.0% 40.0% 0.518 0.0% 40.0% 0.518
Neck 100.0% 0.0% 0.107 0.0% 12.5% 0.192
Paraspinal 16.7% 16.7% NS 16.7% 16.7% 0.126
Other 100.0% 0.0% 0.110 100.0% 0.0% NS
Total 21.3% 14.2% < 0.001 17.0% 13.8% 0.076
Outcomes for radiotherapy without prior surgery
Primary site 5 years OS 5 years EFS
Radiotherapy only No therapy p value Radiotherapy only No therapy p value
Abdominal 6.7% 5.8% < 0.001 6.7% 5.0% < 0.001
Thoracic – 10.0% 0.007 – 10.0% 0.013
Neck – 0.0% 0.271 – 0.0% 0.095
Paraspinal – – NS – 0.0% 0.001
Other 100.0% 0.0% 0.110 100.0% 0.0% 0.126
Total 12.5% 5.4% < 0.001 12.5% 4.8% 0.001
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(1.9%) died from surgical complications due to post-opera-
tive bleeding (Fig. 2). 
Patients, who were irradiated, had a better five-year OS 
of 21.3% and EFS of 14.2% compared to patients that were 
not irradiated with a 5-year OS of 17.0% (p < 0.001) and 
5-year EFS of 13.8% (p = 0.076) (see Table 3). The five-
year OS for patients with irradiated abdominal primaries was 
18.6% compared to 12.5% in patients that were not irradi-
ated (p = 0.008) (see Fig. 3). The five-year EFS for patients 
with irradiated abdominal primaries was 16.3% compared 
to 11.5% in patients who were not irradiated (p = 0.035).
Patients who received only radiotherapy in combination 
with chemotherapy had a better five-year OS of 12.5%, com-
pared to 5.4% in those who received chemotherapy alone 
(p < 0.001), with similar findings for EFS (12.5% with radio-
therapy versus 4.8% without radiotherapy) (p < 0.001). (see 
Table 3).
Operated patients had a longer mean OS of 60.9 months 
(80.6 months versus 19.7 months) (median 12.8 months) 
compared to those, who did not receive any surgery 
Fig. 2  The Kaplan–Meier curve 
for OS of the extent of resec-
tion in HR-NB with abdominal 
primaries (p < 0.001)
Fig. 3  Kaplan–Meier curve of 
OS of radiotherapy status for 
HR-NB with abdominal prima-
ries (p = 0.008)
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(p < 0.001) (see Table 4). In patients who were irradiated, 
the mean OS was an average of 7.9 months longer (46.2 
months versus 38.3 months)(median 9.7 months) compared 
to those who did not receive any radiotherapy (p < 0.001) 
(see Table 4).
On univariate analysis only thoracic primaries were 
of prognostic value compared to abdominal primaries 
(p = 0.006) in determining OS (see Table 5). The significant 
prognostic factors on multivariate analysis were age less 
than 18 months (p < 0.001), LDH < 750 U/L (p < 0.001) and 
Table 4  Overall survival advantage for surgical, radiotherapy, and transplant interventions
OS overall survival, HSCT hemopoietic stem cell transplant
Overall survival advantage HR abdominal NB according to surgery treatment
Surgery total (mean) Estimate (months) Std. error 95% confidence interval
Lower limit Upper limit p value
Not operated 19.747 3.304 13.271 26.222 < 0.001
Operated 80.613 9.366 62.256 98.971
Abdominal (mean)
 Not operated 19.455 3.530 12.536 26.374 < 0.001
 Operated 69.664 9.751 50.552 88.776
Thoracic (mean)
 Not operated 23.015 12.102 0.000 46.735 0.001
 Operated 160.233 26.001 109.272 211.195
Neck (mean)
 Not operated 10.981 3.696 3.736 18.226 0.225
 Operated 49.567 25.244 0.089 99.044
Paraspinal (mean)
 Not operated 3.958 1.741 0.547 7.370 < 0.001
 Operated 62.896 24.042 15.773 110.019
Overall survival advantage HR abdominal NB according to extent of resection
Surgery (mean) Estimate (months) Std. error 95% confidence interval
Lower limit Upper limit p value
Complete 77.896 12.540 53.318 102.473 < 0.001
Incomplete 77.680 12.598 52.988 102.372
None 19.466 3.250 13.096 25.836
Overall survival advantage HR abdominal NB according to radiotherapy treatment
Radiotherapy total 
(mean)
Estimate (months) Std. error 95% confidence interval
Lower limit Upper limit p value
Irradiated 46.229 8.102 30.349 62.110 0.007
Not irradiated 38.350 4.578 29.377 47.324
Abdominal (median)
 Irradiated 18.900 1.552 15.859 21.941 0.008
 Not irradiated 8.967 0.859 7.283 10.651
Thoracic (mean)
 Irradiated 29.350 18.383 0.000 65.381 0.518
 Not irradiated 10.367 1.066 8.277 12.456
Overall survival in high risk according to autologous hemopoietic stem cell transplant (HSCT)
HSCT (mean) 5 years OS Estimate (months) Std. error 95% Confidence interval
Lower limit Upper limit p value
With 40% 37.867 10.115 18.042 57.691 0.268





favourable histology (p = 0.042). For abdominal primaries, 
metastatic remission status after induction chemotherapy 
(p < 0.001), surgical status (p = 0.027), and radiotherapy 
status (p = 0.040) were of prognostic importance for OS 
(see Table 6).
Operated patients relapsed with metastatic disease 
(24.5%; n = 26/106), which was similar for irradiated 
patients with metastatic relapse (10.6%; n = 5) and metastatic 
progression (42.6%; n = 20) (see Supplementary Table 2).
Table 5  Univariate analysis of prognostic factors in HR-NB
Univariate analysis of the primary site as prognostic factor in HR-NB
Hazard ratio 95% CI for HR p value
Lower limit Upper limit
Primary site (abdominal comparator) 0.053
Thoracic vs abdominal primary 0.456 0.260 0.800 0.006
Neck vs abdominal primary 1.020 0.503 2.067 0.956
Paraspinal vs abdominal primary 0.765 0.406 1.443 0.408
Other sites vs abdominal primary 1.479 0.696 3.146 0.309
Univariate analysis of prognostic factors in HR abdominal NB
Surgical status (operated comparator) Hazard ratio 95% CI for HR p value
Lower limit Upper limit
 Not operated vs operated 2.647 1.968 3.560 < 0.001
Resection status (complete surgery comparator) < 0.001
 Incomplete vs compete surgery 1.019 0.626 1.658 0.939
 No surgery vs compete surgery 2.604 1.811 3.744 < 0.001
Radiotherapy status (irradiated comparator)
 Not irradiated vs radiated 1.615 1.128 2.314 0.009
Age group (< 18 months comparator) < 0.001
 18–60 months 2.626 1.732 3.980 < 0.001
> 60 months 1.975 1.226 3.181 0.005
Stage (Stage 1, 2 and 4s comparator) 0.001
 Stage 3 1.852 0.630 5.440 0.263
 Stage 4 3.609 1.329 9.800 0.012
LDH (< 750 U/L comparator) < 0.001
> 750 U/L vs < 750 U/L 1.729 1.254 2.386 0.001
Unknown vs < 750 U/L 3.115 2.043 4.750 < 0.001
Ferritin (< 120 g/dl comparator) 0.006
> 120 g/dl vs < 120 g/dl 1.713 1.200 2.445 0.003
Unknown vs < 120 g/dl 1.699 1.180 2.447 0.004
Pathology (FH comparator) 0.019
 UH vs FH 1.953 1.206 3.161 0.006
 Unknown vs FH 1.880 1.177 3.002 0.008
MYCN status (NA comparator) 0.047
 Amplified vs NA 0.871 0.537 1.412 0.575
 Unknown vs NA 1.292 0.844 1.977 0.239
Post-induction metastatic remission status (in remission 
comparator)
< 0.001
 Not in remission vs in remission 5.153 3.435 7.729 < 0.001
 Unknown status vs in remission 8.903 3.619 21.901 < 0.001
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Discussion
Surgery is the most fundamental treatment modality in 
the multi-modality treatment of neuroblastoma with cura-
tive intent to ensure loco-regional control of the disease, 
regardless of metastasis [2, 14]. In stage III patients, com-
plete resection affords better survival, especially in those 
with unfavorable tumor biology [15, 16]. In stage IV tumors, 
either complete resection or gross total resection (GTR) of 
95% was recommended when possible. The COG A3973 
study concluded that even a near GTR of greater than 90% 
obtained superior OS [17]. After surgery, age and tumor 
biology are the most powerful determinants of outcome in 
patients with neuroblastoma. In this study, only age below 
18 months was significant as a prognostic factor. Surgical 
skill and experience may influence the subjective evalua-
tion of resectability by the surgeon [18]. Improvements in 
EFS and OS in resected tumors may thus be a reflection of 
a more favorable biological profile and those who could not 
be resected had an adverse prognosis at diagnosis.
During the HR-NBL1/SIOPEN trial between 2002 and 
2015, 98% of patients underwent surgery compared to 
only 35.9% of the patients with HR disease reported in 
this South African study, while only 15.9% of HR dis-
ease tumors received radiotherapy compared to 88% in the 
HR-NBL1/SIOPEN trial [19]. This may have been due to 
Table 6  Multivariate analysis of prognostic factors in HR abdominal NB
CI confidence interval, HR high-risk, NB neuroblastoma, FH favorable histology, UH unfavorable histology
Multivariate analysis of prognostic factors in HR abdominal NB at diagnosis
Hazard ratio 95% CI for HR p value
Lower limit Upper limit
Age group (< 18 months comparator) < 0.001
 18–60 months 2.331 1.529 3.554 < 0.001
 > 60 months 1.806 1.106 2.948 0.018
LDH (< 750 U/L comparator) < 0.001
 > 750 U/L vs < 750 U/L 1.698 1.215 2.372 0.002
 Unknown vs < 750 U/L 2.922 1.910 4.470 < 0.001
Pathology (FH comparator) 0.042
 UH vs FH 1.808 1.109 2.948 0.018
 Unknown vs FH 1.796 1.116 2.889 0.016
Multivariate analysis of prognostic factors in HR abdominal NB during management
Hazard ratio 95% CI for HR p value
Lower limit Upper limit
Age group (< 18 months comparator) 0.017
 18–60 months 1.842 1.172 2.895 0.008
 > 60 months 1.425 0.848 2.396 0.182
LDH (< 750 U/L comparator) 0.004
 > 750 U/L vs < 750 U/L 1.602 1.149 2.233 0.005
 Unknown vs < 750 U/L 2.016 1.276 3.186 0.003
Post-induction metastatic remission status (in 
remission comparator)
< 0.001
 Not in remission vs in remission 3.732 2.405 5.792 < 0.001
 Unknown status vs in remission 4.130 1.543 11.057 0.005
Surgical status (operated comparator)
 Not operated vs operated 1.541 1.052 2.258 0.027
Radiotherapy status (irradiated comparator)





a combination of factors including inequitable access to 
paediatric surgical expertise, shortage of operating slots, 
availability of radiotherapy facilities, and a chemotherapy-
only strategy for metastatic patients [20].
The evidence of the prognostic significance and ideal 
extent of resection is conflicting. Multiple changes in sys-
temic treatment, such as the quality and quantity of autolo-
gous transplants and molecular targeted therapies, as well 
as revisions of risk classification systems have complicated 
evaluations [21, 22]. Retrospective studies at Memorial 
Sloan Kettering (MSK) have proven superior survival 
outcomes for children with complete surgical resections 
(CSR) versus partial surgical resections (PSR), especially 
in metastatic disease [23, 24]. The MSK two-year survival 
rates of CSR compared to PSR were 80% versus 38%. On 
the basis of this, it is possible to conclude that CSR was 
superior to PSR, even for stage IV patients with bone mar-
row involvement [24–26]. This could not be validated in 
other reports [23]. The difference in survival outcomes 
for MYCN amplified tumours compared to non-amplified 
tumours were proportional to surgical outcomes for PSR 
compared to CSR [27]. This study demonstrated signifi-
cant survival advantage if patients had tumor resection, 
regardless of extent if more than 50%. On multivariate 
analysis, the extent of resection did not reach significance, 
with metastatic remission being the most significant prog-
nostic factor.
In the HR-NBL1/SIOPEN Trial, complete resection had a 
better five-year OS compared to incomplete resection (39% 
vs 30%) [19]. A meta-analysis of 19 studies in patients with 
HR-NB concluded that GTR did confer an OS advantage 
above subtotal resection (STR) at both three years and five 
years. However, this was only true for STR over biopsy only 
at three years [21]. Only in asymptomatic stage II patients 
with LR disease did less than 50% resection confer excel-
lent outcomes with surgery alone [28]. Chemotherapy was 
restricted to patients with progression of symptomatic disease 
or less than 50% resection [28]. In South Africa, a survival 
advantage was demonstrated across all risk classifications at 
2 years and 5 years with complete or incomplete resections.
The role of radiotherapy has been investigated in emer-
gency presentations, palliation and local and metastatic 
disease in relation to chemotherapy and surgery, as has the 
role of in the transplant setting [4, 5]. Radiotherapy plays 
a significant role in high-risk disease, regardless of resec-
tion or nodal involvement [29, 30]. In Egypt, patients who 
received radiotherapy to primary sites had a superior three-
year OS of 57.6% compared to 23.4% in patients who were 
not irradiated (p = 0.007) [31]. Similarly this was reflected 
in the three-year EFS rate, with 42.5% for irradiated patients 
compared to 19.5% in patients not receiving radiotherapy 
(p = 0.032) [31].
Reports estimate that 40% of HR patients will relapse 
[32]. Local relapses at the primary tumor and metastatic 
sites play a major role in mortality, especially in high-risk 
patients [30, 31]. The NB97 radiotherapy approach focused 
on residual tissue of the primary tumor site to compensate 
for the outcome disadvantage of incomplete response to 
induction therapy [32]. It was concluded that the admin-
istration of radiotherapy could compensate for the residual 
tumor [32]. Patients who were irradiated at metastatic sites 
had better OS than patients who did not receive radiation to 
metastatic sites [33]. Metastatic recurrence was less likely 
in previously irradiated sites than in unirradiated sites [34]. 
In this study, patients who could undergo surgery relapsed 
mainly at metastatic sites (24.5%) as compared to the pri-
mary tumor bed (6.6%). The reason could be that less than 
16% of patients were irradiated (see Supplementary Fig-
ure 1). Metastatic progression was the main event in both 
patients that were not irradiated (57.7%) as well as irradiated 
patients (42.6%).
In keeping with expert opinion in the SIOP-PODC guide-
lines, in the absence of a surgical resection, radiotherapy to 
the primary tumor, with or without metastatic sites, had a 
short-term benefit in patients, with a superior two-year OS 
in unresected patients receiving radiotherapy versus patients 
not receiving radiotherapy [2].
It is not clear to what extent local therapies influence out-
comes in HR-NB in therapies that include single or tandem 
autologous transplants, molecular targeted therapy and matu-
ration therapy [20]. Yet, in variable resource settings where 
chemotherapy, radiotherapy and surgery are the only treat-
ment options, the impact of surgery with or without radiother-
apy on survival has been advantageous. The benefit is ampli-
fied with a combination of both. In settings where autologous 
transplants and targeted therapies are not available, other treat-
ment modalities are paramount in metastatic sites, especially 
if there were isolated or limited number of metastatic sites [2].
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Table 7  INRG classification
INRG stage Age (months) Histologic category Grade differentiation MYCN 11 q aberration Ploidy Pretreatment risk group
L1/L2 Any GN maturing
GNB intermittent
Any Any Any Any A—very low risk
L1 Any Any, except GN maturing
GNB intermittent
Any nAmp Any Any B—very low risk
Amp Any Any K—high risk
L2 < 18 Any, except GN maturing
GNB intermittent
Any nAmp No Any D—low risk
Yes Any G—intermediate risk
≥ 18 GNB nodular, neuroblas-
toma





Any Amp Any Any H—high risk
M < 18 Any Any nAmp Any Hyperdiploid F—low risk
< 12 Any Any nAmp Any Diploid I—intermediate risk
12 to < 18 Any Any nAmp Any Diploid J—intermediate risk
< 18 Any Any Amp Any Any O—high risk
≥ 18 Any Any Any Any Any P—high risk
MS < 18 Any Any nAmp No Any C—very low risk
Yes Any O—high risk
Amp Any Any R—high risk
Limitations
The study was retrospective with non-randomized cohorts 
and treatment protocols between POUs were not standard-
ized. The determination of risk stratification was limited by 
the absence of genetic information on the tumors. Docu-
mentation of the extent of resection was not standardized. 
Certain cohort samples were too small to determine signifi-
cant results.
Conclusion
Where possible, resections should be attempted, regardless 
if a resection is a complete total resection, near gross total 
resection or incomplete resection, provided that resections 
are not mutilating or increase the risk for mortality. Radio-
therapy as standard of care should be part of standard man-
agement and metastatic control with autologous bone mar-
row transplants should be considered, if possible, in LMICs. 
A national treatment protocol should be introduced to stand-
ardize assessment and management of HR neuroblastoma 
with the aim of improving outcomes.
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The aim of the World Health Organization-International Paediatric Oncology Society is to improve 
childhood cancer survival in low- and middle-income countries to 60% by 2030. This can be achieved 
by using standardised evidence-based national treatment protocols for common childhood cancers.  
Objectives: 
The aim of the study was to describe the development and implementation of the SACCSG NB-2017 
neuroblastoma (NB) treatment protocol as part of the treatment harmonisation process of the South 
African Children’s Cancer Study Group.  
Methods: 
The Consolidated Framework for Implementation Research was used to identify factors that could 
influence the implementation of the national NB protocol as a health care intervention. The evaluation 
was done according to five interactive domains for implementation: intervention characteristics, inner 
setting, outer setting, individual or team characteristics and the implementation process. 
Results: 
The protocol was developed over 26 months by 26 physicians involved in childhood cancer 
management. The process included an organisational phase, a resource identification phase, a 
development phase and a research ethics approval phase. Challenges included nationalised inertia, 
variable research ethical approval procedures with unnecessary delays and uncoordinated clinical trial 
implementation.  
Conclusion: 
The implementation of the national NB protocol demonstrated the complexity of the implementation 
of a national childhood cancer treatment protocol. However, standardised paediatric cancer 
treatment protocols based on local expertise and resources in limited settings are feasible.   
Keywords: 






According to both the European Commission (ORPHA number 635: neuroblastoma) [1] and the United 
States Rare Diseases Act of 2002 [2], childhood malignancies such as neuroblastoma (NB) are classified 
as rare diseases. Although great clinical and biological advances have been made with regard to 
paediatric tumours worldwide, the multitude of approaches demand significant human and financial 
resources [2]. A disadvantage is the isolated development of management protocols that are not 
reproducible in other settings due to non-standardisation [2]. A good example regarding NB was the 
development of various classification systems and treatment approaches in North America by the 
Children’s Oncology Group (COG), the International Society of Paediatric Oncology Europe 
Neuroblastoma Group (SIOPEN) and other paediatric oncology societies in Japan, Australia and New 
Zealand [3,4]. An international collaboration of various NB workgroups therefore led to the 
establishment of the International Neuroblastoma Risk Group (INRG) and the development of the 
INRG classification system, based on pooled data from multiple countries. This collaboration led to 
clinical trials with standardised protocols with a greater number of included participants, which 
improved statistical significance [5]. The initiative of the INRG and international NB clinical trials is 
evident in the improved outcomes for high-risk (HR) disease from five-year overall survival (OS) of 20% 
to 57% due to this cooperative research over the past 20 years [6]. Yet, due to the lack of advanced 
laboratory capacities in low- and middle-income countries (LMICs), the genetic information standardly 
used as part of this classification system in high-income countries (HICs) limits the use of the NB 
stratification system in LMICs.  
The South African Children’s Cancer Study Group (SACCSG) established a South African Children’s 
Tumour Registry in 1987 [7,8]. Limited data on the treatment of NB beyond a single institutional report 
by Hesseling et al. in 1990 was available in South Africa prior to the start of the process to develop a 
national NB treatment protocol [9]. To date, treatment strategies for NB in South Africa have been 
diverse and based on the experience of individual paediatric oncologists [10]. The treatment of NB 
was managed according to the available resources and used multiple international protocols. The 
SACCSG supported the development of a national NB management protocol in 2016, which led to the 
SACCSG NB-2017 study. The protocol was developed in line with the World Health Organization 
(WHO)-International Paediatric Oncology Society (SIOP) aim to improve childhood cancer survival in 
LMICs to 60% by 2030 [11]. 
 The aim of this article is to describe the development and implementation of the SACCSG NB-2017 
clinical trial according to a validated implementation research framework. The Consolidated 
Framework for Implementation Research (CFIR) domains and associated constructs were used for 
evaluation purposes based on the data gathered during the various phases of the development of the 
protocol [12]. Based on the CFIR domains and constructs, tables were constructed from e-mails, 
meeting notes and workshop discussions during the development of the clinical trial [12,13]. The CFIR 
was chosen because it allowed for both system-level evaluation and linking of the influence of 
individual action and behaviour during the implementation process [13,14]. The CFIR allowed for the 
evaluation of the national governance structures, paediatric oncology units (POUs) and individuals 
involved in the implementation process [13,14]. A descriptive overview of the analysis or 
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interpretation was used to describe the thematic content of the clinical trial development and 
implementation process. 
Setting 
South Africa has a heterogeneous medical system [15]. Public health care is proportionally funded by 
the central government in each of the nine provinces. The health authorities within each province 
determine the financial expenditure for development of medical services in that province. The private 
health care system is funded on a pay-for-service business model, and private medical insurance plans 
are available to those who can afford the contribution tariffs [15]. Since the inception of democracy 
in 1994, the government has introduced several development strategies to improve health care and 
increase access to and affordability of cancer care services and research [16]. One example is the free 
primary health care for children under five years [16,17]. Access was addressed by expanding the 
health care network to decrease travel distances [17]. 
Several regulatory processes that support development of national treatment protocols for rare 
diseases have been developed since 1994 in South Africa. The National Cancer Registry is managed 
under the umbrella of the National Institute of Communicable Diseases [18]. The National Health 
Research Ethics Council, established under the National Health Act No 61 of 2003, provides guidance 
regarding health care research in line with international guidelines [19]. 
Development of the national neuroblastoma clinical trial 
The SACCSG initiated the harmonisation of management for paediatric tumours in 2010. The aim was 
to standardise the management of childhood malignancies across all South African POUs. Individual 
tumour workgroups with a principal investigator were established to develop national treatment 
protocols. The workgroups consisted of collaborations among various health care teams in the 
management of childhood malignancies and included paediatric oncologists, surgeons, radio-
oncologists as well as laboratory and imaging services from several hospitals. Each workgroup was 
responsible for evaluation of the resources of all the POUs across South Africa to manage 
malignancies, evaluation of contemporary clinical trials for the relevant tumours and development of 
a standard of care management protocol that could be implemented and executed in all POUs of the 
country and adapted for the local context [20,21,22]. 
An NB workgroup was established in 2016, and a treatment protocol was developed. To prepare for 
this national clinical trial, a retrospective study was undertaken to evaluate the management of NB 
between 2000 and 2014 as well as a survey to evaluate currently available resources for the 
management of NB in South Africa, which resulted in a publication in 2019 [10]. The protocol 
development was done via online discussions, document reviews, paediatric oncology meetings and 
tumour-related workshops. After finalisation of the management protocol through consensus, 
research ethics approval was obtained. 
Study objectives 
The study objectives were as follows: 




2) To assess the facilitators of and barriers to both the development and implementation of a 
national paediatric oncology clinical trial. 
Methods and analysis 
The evaluation was done according to five interactive domains for implementation: intervention 
characteristics, inner setting, outer setting, individual or team characteristics and the implementation 
process. The first author (JvH) allocated the themes and described the relevance for the evaluation of 
the implementation of the trial. The second author (MK) critically evaluated and edited the text, 
tables, themes and descriptions. The implementation evaluation was completed by consensus 
between the two authors. 
 
Development of the SACCSG NB-2017 clinical trial 
 
South Africa has 13 public POUs and six private health care POUs, situated in seven of the nine 
provinces (Table 1). These POUs are linked to seven universities where the research was conducted. 
The SACCSG NB-2017 clinical trial was developed mainly by paediatric oncologists, including the 
principal investigator (PI) and co-principal investigator, as well as 12 additional paediatric oncologists. 
Four additional clinical contributors (not the primary paediatric oncologists) also participated. The 
sub-discipline guidelines were developed by eight discipline-specific experts in conjunction with the 
PI. These experts included paediatric surgeons (n = 2), radio-oncologists (n = 2), anatomical 
pathologists (n = 2), a nuclear physician (n = 1) and a laboratory haematologist (n = 1). 
 
The first SACCSG NB protocol meeting was held in 2016 whereafter the protocol development took 26 
months (Table 2). The process of developing this protocol constituted four parts (Figure 1 and 
Appendix A), namely establishing need and consensus, identifying the local health care resources, 
including medical experts and project managers, facilitating and contributing to the development of 
the protocol and ethics approvals. 
Establishing need and national paediatric oncology organisation approval 
The SACCSG process for any national paediatric oncology study involved presentation and approval at 
an official SACCSG meeting with a minimum of one representative per South African POU present. The 
NB protocol was presented at the SACCSG protocol workshop in Durban, South Africa, in September 
2016. The presentation included the scope, aims and academic studies associated with the protocol 
development. The consensus for development served as an invitation for interested physicians to 
involve themselves in the protocol development. 
Establishing resources for protocol development 
Local medical expertise: Each POU identified a physician responsible for local data management, 
interdisciplinary management and protocol oversight. These physicians became members of the 
SACCSG NB working group who evaluated the literature and protocol drafts and contributed to ensure 
feasibility in their local setting. The group also included physicians with an interest in palliative care to 




Sub-disciplinary expertise: Physicians with NB experience in the fields of paediatric surgery, radio-
oncology, pathology, laboratory haematology and nuclear medicine were invited and participated in 
creating guidelines for the management of NB by each sub-discipline. These physicians developed 
discipline-specific management guidelines and amended protocol drafts and adapted the 
international standards for the local setting. 
Local logistics: During November 2016, a survey was completed by each local hospital investigator. 
The survey evaluated the resources available in the respective hospitals for treating children with NB 
(Appendix B). 
National NB experience: A retrospective study to evaluate the management and outcomes of NB in 
South Africa between 2000 and 2014 was approved by the hospital investigators. In January 2017, the 
protocol was approved by the University of Kwa-Zulu Natal Biomedics and Research Ethics Council 
(BREC Ref no: BE572/16) and the data collection was started, which resulted in a publication in 2019 
[10]. 
International experience: The members of the SACCSG NB working group reviewed the literature for 
evidence-based NB management from international NB working groups to guide decisions during the 
protocol development. International experts in NB management were consulted.  
Financial resources: The vzw Kinderkankerfonds, Belgium, provided developmental funds [23]. 
Clinical trial initiation and development 
The SACCSG NB-2017 clinical trial aimed to standardise an NB management protocol as a single-arm 
clinical trial in South Africa to improve outcome. As the protocol served as an exercise for 
implementation, the decision by the NB working group was to include only OS (two years and five 
years) and event-free survival (two years and five years) in the protocol as primary endpoints. 
The development was done according to two parallel action plans: 
Consensus decisions were based on four key criteria: established international research evidence, 
local expertise, availability of resources for the clinical trial in all POUs in South Africa, and financial 
costs and sustainability. Protocol-specific consensus recommendations can be seen in Table 1. 
Firstly, regarding tumour-related diagnostic and chemotherapy protocols, the diagnostic and 
evaluation requirements, risk stratification and protocols relating to chemotherapy were 
collaboratively developed by die paediatric oncology physicians (hospital investigators). The 
treatment approaches were adopted by all POUs of the NB working group. The development was done 
in three stages: Firstly, the management principles were established during the SACCSG protocol 
development meeting at the Stellenbosch Institute for Advanced Study in May 2017 (Appendix C). 
Summaries of the literature review were presented, and recommendations were proposed for the 
protocol section. It was concluded that the protocol would primarily be a standard of care, curative 
treatment protocol and would secondarily be supported by a palliative section. There would be a 
single treatment arm with no randomisation. Due to the complexity of the pathology, the operational 
research data and outcome-based indicators should be collected prospectively. The second meeting 
was an online SACCSG NB working group meeting hosted on the web-based Cure4Kids platform, Africa 
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Room, St. Jude Children’s Research Hospital, in January 2018 (Appendix C). The sections on which 
consensus had been reached during the first and second draft reviews were discussed, and the 
concluded sub-discipline guidelines were presented to the NB working group. Consensus was not 
reached on the induction chemotherapy for HR NB nor on the scope of the autologous stem cell 
transplant (ASCT) section. The third meeting was an NB working group meeting at the Radisson Hotel, 
Sandton, in April 2018 (Appendix C). The remaining sub-discipline guidelines were presented. Final 
consensus was reached on all sections after pre-prepared two-member debates on the positive and 
negative aspect for implementation in the South African setting. 
Secondly, associated sub-discipline guidelines were developed by the principal investigator and sub-
discipline experts based on literature reviews, expert opinions and practical considerations for the 
South African setting. The guidelines were incorporated as guidelines that allowed for the adaptation 
during management, subject to available local health care resources.  
The protocol was developed for all NB-related management aspects independent of risk stratification 
or funding options. Therefore, private funding would benefit those who wanted greater access to 
advanced treatment options such as ASCT or treatment options such as targeted therapy that are not 
available in the country. 
Ethics reviews and implementation 
During this period, all the necessary documentation was prepared for academic evaluation and ethics 
clearance by universities and for ethics clearance by governmental (provincial and national) and 
hospital authorities. Approval of the protocol constituted 42 applications to different authorities. The 
duration of the ethics review committee evaluations varied from 1 month to 20 months (1 still 
pending) (range 1-20 months, mean = 5 months, median = 2 months). The total duration for an 
application (academic and research ethics review) for the POUs varied from 2 months to 20 months 
(still pending) (range 2-20 months, mean = 10 months, median = 12 months) (Table 2).  
Facilitators of and barriers to development and implementation of a national paediatric oncology 
clinical trial  
The implementation of the SACCSG NB-2017 clinical trial was important in establishing a 
multidisciplinary, national standardisation of the treatment of this rare tumour in children. The 
management of NB necessitates multiple disciplines in the diagnosis, treatment and continued 
evaluation of the pathology. These interactions in a resource-strained setting are often challenged by 
varied experience in management and perceived treatment goals [24]. The CFIR provided an 
organising framework to identify implementation factors and essential lessons during the 
development and implementation of the protocol (Table 3).  
Development and sustainability 
A collaborative clinical trial is only possible when each collaborator remains continually responsible 
for his/her delegated functions through ownership and contribution of local knowledge [24,25]; 
therefore, hospital investigators functioned as liaison between the protocol and other disciplines, 
which prevented unilateral implementation. The NB workgroup was established to ensure that each 
POU had resources in place to execute the SACCSG NB-2017 clinical trial. The prescribed benefits by 
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private medical insurance for treatments and investigations dictate and to a large degree guide the 
management of treatment in private hospitals. Health care systems managing fixed budgets are 
attentive to problems of implementation in order to maximise the health care funds [24,25]. 
Individual factors 
Historically, POUs in South Africa were self-determining departments. The NB management protocols 
were based on strong evidence from international protocols, systematic reviews and clinical practice 
guidelines [26]. In some instances, a deviation from known local practices was required to achieve a 
single standard of care that would be feasible in all POUs regardless of unequal access to resources. 
In general, established clinical practice is slow to change, referred to as ‘clinical inertia’ [27], which 
was present especially in determining the standard induction chemotherapy for HR NB. The 
retrospective review showed numerous induction regimes that were used from 2000 to 2014 [10,26]. 
Yet, in the South African context, none proved superior when considering post-induction remission 
and outcomes although the toxicity profile of OPEC/OJEC proved more beneficial than the RAPID 
COJEC protocol and doxorubicin-containing protocols [26].   
The interests and priorities of each POU and team determined their culture or attitude towards the 
clinical trial and its implementation. A mayor contributing factor was the lack of time and resources 
to facilitate implementation and complete administration. The protracted process for state research 
ethics applications increased the lapse of time between training on the study procedures and initiation 
of the study after approval had been granted. Two sites delayed ethics application by requiring new 
academic evaluations after an academic evaluation had been done at the principal investigator’s site. 
External regulatory environment 
The National Cancer Strategic Framework for South Africa 2017-2022 does not address the needs of 
paediatric oncology frameworks [27], nor does it acknowledge paediatric oncology as a discipline 
independent from adult oncology services. Therefore, development of the SACCSG NB-2017 clinical 
trial was initiated by the SACCSG and the NB workgroup on the basis that management of NB would 
be based on international evidence with the available national resources.  
Systems and technologies 
Each POU had its own system of data documentation, retrieval and storage. These included files 
(paper-based) or basic computerised data capture systems, each with its own advantages and 
disadvantages. Understanding the challenges of transitioning from traditional data systems to an 
online system such as REDCap [28], the study was started with paper-based and Excel-based databases 
with transition to REDCap. With the PI hosting the database at a single university, access restrictions 
had to be navigated for the workgroup with university approval needed for each collaborating 
researcher.    
Implementation process 
No standardised implementation process existed for national paediatric oncology clinical trials in 
South Africa. After the national retinoblastoma clinical trial initiated in 2012 [21], the SACCSG NB-2017 
clinical trial is one of three newly developed national clinical trials for implementation. Due to varying 
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duration of research ethics approvals, a coordinated implementation was not possible. During this 
period, two POUs were established for treating children with malignancies, from which research ethics 
approval had to be obtained. The movement of evidence-based practices into routine clinical practice 
demands focused efforts; therefore, the protocol was based on current POU practices [24,25]. Yet, 
linked to resources, a greater number of training sessions in the utilisation of datasets and 
documentation were needed in order to activate the team. 
Resources 
The lacking resources in NB management identified were human resources, provision of supportive 
care during chemotherapy toxicity and advanced treatment options such as ASCT [24,25]. A 
multidisciplinary team representing multiple departments is needed to manage patients with NB. The 
outcome of a patient is therefore linked to treatment modalities that collectively determine a 
treatment result. If treatment response is inadequate, surgery is not possible and the administration 
of radiotherapy becomes more important. The inconsistent availability of isotopes for mIBG scans 
limited the important treatment evaluation modality. 
Another constraint was time as the implementation of a clinical trial requires a great amount of time 
from each investigator. In the South African context, the paediatric oncologist has a dual role as 
clinician and researcher, added to numerous other duties, which include both undergraduate and 
postgraduate education. Some POUs have one clinician who is the proxy hospital researcher for all 
tumour-specific clinical trials. Research assistants could strengthen the research capacity in POUs. 
Challenges 
Evidence-based, practice-changing clinical trials in POUs to improve the health systems that currently 
govern the institutions should support research initiatives, ethics committees should contribute to the 
ease of implementation of quality research and the vision of each POU should promote the 
implementation of clinical trials. This includes a balance between clinical duties and research. 
Introducing new standardised protocols and new technologies such as REDCap for data capturing into 
an established administrative system necessitates training and increasing the skills of the staff of a 
POU to initiate and maintain databases [12,28]. The continued functionality of the data system is 
reliant on more than a single person to ensure sustained function of the system.  
The reliability of the initial data whilst implementing the clinical data system could be limited since 
only a small number of participants were enrolled in this study [24,29]. This was the knock-on effect 
of the delayed ethics approvals, staggered guidance with initiating enrolment of patients and 
development of various paper, electronic and online data tools.  
As part of the health care system in South Africa, the development of paediatric oncology services 
faces obstacles that include unequal distribution of resources, increased disease burden of both 
communicable and non-communicable diseases, limited management and leadership experience to 
transform the health care system, and limited research support and development to optimise the 
implementation of national clinical trials [16]. 
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International implementation of paediatric health care initiatives 
The components of national childhood malignancy strategies in LMICs include accredited POUs, 
financial coverage of paediatric oncology treatment, paediatric cancer registries and a national 
paediatric oncology governing body [30]. Of great importance is the development of national 
standards. In South Africa, the same challenges of non-standardisation and limited resources were 
cited in the treatment of Hodgkin lymphoma and retinoblastoma [20,21]. In contrast to HIV/AIDS and 
tuberculosis care in South Africa in which improvement of outcomes has been achieved by making 
treatment available over a great network, standardised care in childhood cancer relies on early 
detection and referral to centralised POUs [31,32,33]. Yet, common denominators for childhood 
cancer, HIV/AIDS and tuberculosis programmes were the variable needs of patients and medical staff 
and an increased need for resources and support during implementation of programmes and doing 
research [31,32]. Increased resources proved beneficial for improved outcomes during the 
implementation of acute lymphoblastic leukaemia protocols in South America [33]. A national 
standardised protocol based on resources and availability of supportive care in the Dominican 
Republic improved the two-year OS for children diagnosed with acute lymphoblastic leukaemia from 
40% to 70% by reducing the intensity of treatment and toxicity [34]. Morocco introduced the risk-
adapted stratification and treatment guidelines for NB, which has decreased the challenges for the 
accurate diagnosis and optimal treatment of NB [35]. 
Recommendations 
The development and approval of a national clinical trial would be facilitated by reciprocal or 
centralised ethics and academic approvals [36,37]. The same applies to external regulation of the 
government as well as hospital and provincial approvals. A homogenous approach to the application 
systems at universities would provide the first step in simplifying the process.  
Acknowledging the need for funding and research support by both governmental and non-
governmental organisations for national projects should gain greater priority. This would improve 
establishing national data collection platforms and contribute to the financial sustainability of health 
care systems.  
The National Department of Health has to implement a strategic policy relating to the care of children 
with oncological diseases in South Africa. Greater government support and endorsement would 
highlight the care of children with cancer in South Africa.  
Worldwide, health care settings are becoming more dynamic and more resource constrained yet 
interconnected due to electronic resources and are driven by equally complex political and economic 
factors [38]. Accordingly, maximising health care results has become a policy requirement 
internationally [38]. Therefore, even in LMICs, health care systems and health sciences should develop 
in parallel to meet the services need [29,38]. 
Conclusion 
LMICs, such as South Africa, have the capacity to establish a framework for improved clinical care, 
greater research capacity and continued sustainable evaluation of management for better outcomes 
in NB management. The SACCSG NB-2017 collaborative national clinical trial constitutes the 
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confluence of local experience and multiple incorporated international guidelines. This 
implementation evaluation can serve as the stimulus for other LMICs to establish NB programmes 
according to their individual resources. 
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Figure 1: The protocol and guidelines development process 
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Approval to conduct a national retrospective review 
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Initiation of the retrospective study 
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Literature review including international 
protocols 
Literature review including international 
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guidelines and evaluation for local settings 
Practical execution and management debate 
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Table 1: Consensus protocol recommendations based on the four key criteria 
Recommendations for SACCSG NB-2017 International evidence Local expertise Resource availability 
and implementation 
Cost and sustainability 
Diagnosis 
- Clinical evaluation plus NB-defining imaging
plus raised u-catecholamine levels
- Tissue biopsy




NB in LMICs 
Variable availability of 
diagnostic 
investigations 
Protocol should be 
flexible 
Resources that are 
available to each POU 
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
Staging 
Investigations as part of staging: 
- Skeletal survey







NB in LMICs 
Variable availability of 
diagnostic 
investigations 
Protocol should be 
flexible for each POU 
to complete staging 
Must include BMAT 
Resources that are 
available to each POU 
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
Laboratory investigations 






NB in LMICs 
SIOP-PODC 
recommendations for 
NB in LMICs 
Resources that are 
available to each POU 
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
Nuclear investigations 
Where available, the following investigations 
should be done: 
- Nuclear GFR





NB in LMICs 
- mIBG scan not sooner
than two weeks post
chemotherapy
- Just before following
course of
chemotherapy
- Not all units have
access to nuclear
investigations




Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
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scan should be done
- PET scan in +/- 10%
mIBG-non-avid
patients
- Bone scan can be




dependent on isotope 
production  






- Use of the Boston
ototoxicity scale
Tumour sampling 











- Core biopsy according
to guidelines of COG 
and SIOPEN protocols 
Resources that are 
available to each POU 
Consider not sampling 
patients with a possibly 
poor outcome with 
advanced disease 
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 






NB in LMICs 
SIOP-PODC 
recommendations for 
NB in LMICs 
Resources that are 
available to each POU 
Standard of care 
benefits public medical 
service costs and 
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- MYCN and genetics adheres to private 




- MYCN and staging
SIOP-PODC 
recommendations for 
NB in LMICs 
Indications: 
- Diagnosis
- MYCN and staging
Resources that are 
available to each POU 
Standard of care 
benefits public medical 
service costs and 
adheres to private 







- Where not available
on site to be
determined off site
Resources that are 
available to each POU 
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
Risk stratification 
- Determine which risk classification system is
preferred




- LDH and ferritin
should be utilised more
- MYCN should be used
especially in patients
when it determines
whether a patient will
be upstaged
- Choice of a
radiological-based risk
stratification
- Upstage the following
patients with MYCN-
amplification:
Stage 4 and Stage 4s
tumour < 18 months,
all Stage 2 tumours and
Stage 3 in the absence
of known LDH and
ferritin values
Few VLR and LR 
patients documented. 
The approaches are 
comparable; therefore, 
only an LR stratification 
will be used, which 






- Protocol to be a curative protocol with a palliative section
- One protocol rather than separate protocols for each risk stratification
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
Sustainability 
dependent on access 
to chemotherapy 
LR and VLR 
Approach to patients with VLR and LR tumours 
SIOP-PODC 
recommendations for 





Request to define 
‘symptomatic tumour 
pathology’ – the 
Philadelphia score was 
included  
IR 





challenge is to define
true IR compared to
false IR due to
limitations in genetic
testing
- Utilise LDH and
ferritin to decide on
upstaging from IR to
HR
- Limited options for
relapse patients;
therefore, rather
upstage a patient than
trying to salvage a
false-IR patient
- Developing a risk
stratification for South
African purposes
- Based on LDH and
ferritin as surrogates
for MYCN and genetic
aberrations





Approach to patients with HR tumours 
SIOP-PODC 
recommendations for 














chosen to be the
induction
chemotherapy
- Rapid COJEC could be
used where private
funding was available,
where a POU could
ASCT dependent on 
ability of referral 
transplant centres to 
treat patients 
ASCT dependent on 












- Surgery is important
- Guidelines and











the absence of surgery
- Radiotherapy should
be done if up to five
localised metastatic
lesions are present




for ASCT should be
done
provide supportive 
care and where an 









- Active participation of
paediatric surgeons
- Resection of 90-100%
should be aim (not
100% only)
Consolidation 
- All four transplant











availability of busulfan 
and melphalan  
 
MRD treatment 
- CRA is advised in 
conjunction with ASCT 




Approach to patients with Stage 4s tumours 
 SIOP-PODC recommendations for NB in LMICs Request to define 
‘symptomatic tumour 
pathology’ – the 
Philadelphia score was 
included 
Standard of care 
benefits public medical 
service costs and 
adheres to private 




Approach to patients with perinatal NB tumours 
- A small adrenal mass detected before birth until 
six months postnatal age has a favourable 
outcome (> 95% four-year OS) without surgical or 
medical treatment 
- Monitoring: Physical exam and ultrasonography 
every 6-8 weeks until the mass resolves or until 
surgical resection is indicated for growth or mass 
causes symptoms 
Request to define 
‘symptomatic tumour 
pathology’ – the 
Philadelphia score was 
included 
Palliative treatment 
Palliative options that included chemotherapy 




- Experience limited to standardised 
symptomatic palliative care, dexamethasone and 
radiotherapy  
 
- Protocol for chemotherapy-based guidelines 
needed 
Standard of care 
benefits public medical 
service costs and 
adheres to private 









etoposide and valproic 







radiotherapy for bone 
pain 
Surgery 
- Indications for surgery 
- Objectives of surgery 
LR – only symptomatic 
or progressive tumours 
IR – non-mutilating > 
50% resection 
HR – non-mutilating > 
90% resection 
Lymph node biopsies  
Preliminary data 
suggested 
LR and IR tumours 
should be resected 
because of high 
absconding and lost to 
follow-up rate, thus 
long-term follow-up 
not always viable 
 
HR 
- Resection of 90-100% 
should be aim (not 
100% only) 
- 50-90% resection still 






Standard of care 
benefits public medical 
service costs and 
adheres to private 






viable option to gain 
complete resection 
Radiotherapy 
- Indications for radiotherapy
- Objective of radiotherapy
SIOP-PODC 
recommendations for 
NB in LMICs 
Guidelines to be developed by radiotherapy 
services 
LR no indication for radiotherapy 
Enlarging hepatic mass, no radiotherapy should 
be used as liver fibrosis is a common 
complication. Liver transplant options are not 
possible. Therefore, chemotherapy should be 
used for enlarging liver tumours. 
IR – With residual tumour, radiotherapy is 
indicated to prevent progression or relapse 
HR – Radiotherapy as single local therapy should 
be administrated even in the absence of surgery. 
Radiotherapy should be done if up to five 
localised metastatic lesions are present. 
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
Sustainable but limited 
to competing 
indications of adult 
oncology services and 
other paediatric 
tumour types with a 
better prognosis 
ASCT 
- Indications for ASCT
- Objective of ASCT
SIOP-PODC 
recommendations for 
NB in LMICs 
- Transplant specialists most experienced with
Bu/Mel
- Request for standardised indications for ASCT
and referral
Standard of care 
benefits public medical 
service costs and 
adheres to private 
health care benefits 
Sustainability 





services and capacity 
of transplant services 
National standardisation 
- Germ cell tumours prospective protocol

















Public versus private 
funding 
Equal access and best 
possible care 
Best care based on 
international evidence, 
toxicity, provision of 
supportive care and 
POU capacity 






- Starting with paper
database










protocol’ as part of
implementation of
research
Abbreviations: ASCT – autologous stem cell transplant; CRA – cis-retinoic acid; CT – computerised tomography; FDG-PET – fluorodeoxyglucose positron emission tomography; FISH – fluorescent 
in situ hybridisation; GFRs – glomerular filtration rate; GPR – good partial response; HCTZ – hydrochlotiazide (diuretic); IHC – immunohistochemistry; 123I- MIBG – metaiodobenzylguanidine; 
INPC – International Neuroblastoma Pathology Classification; H&E – hematoxylin and eosin stain; LDH – lactate dehydrogenase; mCR – metastatic complete response; MRI – magnetic resonance 
imaging; NB – neuroblastoma; POU – paediatric oncology unit; PR – partial response; RT-PCR – reverse transcription polymerase chain reaction 
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Site A Yes Yes PI site 1 PI 2 Yes 
Yes 
Yes 
Site B Yes Yes No (initiated after 
application) 
4 Both 9 Yes 
Site C No N/A No 2 PI 5 Yes Yes 
Site D No N/A No 2 Both 9 Yes 
Site E No Yes Yes 1 PI 1 Yes Yes 
Site F No Yes 
Site G No Yes No 4 PI 12 Yes Yes 
Site H No Yes No PI 12 Yes Yes 
Site I No Yes (separate 
applications) No 
9 HI 14 Yes 
Yes Site J No Yes (separate 
applications) 
8 HI 14 Yes 
Site K No Yes No 2 PI or HI 12 Yes 
Site L No Yes No 2 HI 13 Yes 
Site M No Yes No 20 (pending) HI 20 (pending) Yes Yes 
Subtotal 2 9 1 Mean 5 (1-20) 
Median 2 
Mean 10 (1-20) 
Median 12 




Done in two 
academic 
centres 











Site P2 With Site C No HI Yes Yes 
Site P3 N/A No HI Yes Yes 
Site P4 N/A No HI Yes Yes 
Site P5 With Site J No HI Yes Yes 
Yes Site P6 N/A No HI Yes 
Abbreviations: N/A – not applicable; HI – hospital investigator; PI – principal investigator
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Table 3: Mapping of the SACCSG NB-2017 management protocol according to the Consolidated Framework for Implementation Research 
Domains Constructs 
Intervention characteristics Facilitator Challenge 
Source - SACCSG harmonisation initiative
- PI interest
- Higher degree purposes
Developing interest in all POUs 
Evidence and strength - International studies (mainly HICs)
- Guidelines for LMICs (SIOP-PODC)
Generating South African-based evidence 
Relative advantage - Standardisation of national management
- Multidisciplinary approach
- Optimising national resources
- Collective management opinion
Determining standards in South Africa 
Adaptability - Based on the SIOPEN protocols
- Integration of the SIOP-PODC adapted risk stratification
and treatment guidelines: Recommendations for NB in
LMIC settings
- Integration of evidence-based studies
Availability of protocol modalities in HICs differ from South Africa 
Complexity - NB has distinct heterogenous entities
- Historical evidence delineated clear starting points
- Both senior health care workers and health care
workers with local knowledge in several disciplines were
available as resources
- Standardised protocol for each heterogenous clinical group
- Evidence is based on the HIC experience whilst published
guidelines could be implemented in various ways
- Standardisation required compromise from POUs
Design quality and packaging - Standardised SACCSG formats were in place
- Visual flow diagrams were included to supplement text
- An abbreviated guidelines document was produced
- Electronic backup was provided as USB-sticks
- Electronic ‘fill-in’ documents and Excel database were
provided
- Consent and assent forms were translated into eight
official languages of South Africa




Costs - Standard of care without additional costs - Private health care management limitations
- Private health care is not always aligned with international
consensus
- Public care directives have not been updated or never been




- Various meeting platforms available
- Electronic communication facilitated discussion
- Increased interdepartmental collaboration
- Pooling of national resources
- Limited availability of time and managing it as resource
- Need for consistent workgroup meetings
- Clarity around the responsibility of HIs
Culture - Historically independent development of POUs and
protocols
- Work structure limits research time
- Networking and gaining second opinions
- REDCap and other databases are not readily used by everyone
- Changing staff in POUs prevents continuity of oversight
- Obtaining consent or assent in a palliative setting is challenging
Structural characteristics - Need to standardise national procedures and reporting - Staffing changes and shortages
- Limited capacity for research administration
- Continual need for orientation
- Need for electronic database development
Implementation climate - Varied availability to facilitate implementation
- Electronic protocols available to various team members
- Varied response to changes
- Limited orientation towards the protocols




- Clinically, the protocol was designed to be standard of
care
- Paper-based data collection at start
- Obtaining consent and assent is time consuming
- Development of REDCap database to be completed
- Time for data capturing is a scarce resource
Outer setting 
Patient needs and resources Consent and assent forms translated into eight official 
South African languages  
External policy and 
incentives 
- Inter-POU communication and exchange of expertise
- Governmental resource management
Added administration 
Peer pressure - Level of quality assurance on national and international
level
Other LMICs have superior management programmes with better 
outcomes than South Africa 
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- Personal development in research and tumour-based
knowledge
- Develops sustainable systems
Individual or team 
characteristics 
Knowledge and beliefs about 
intervention 
- Limit unequal management approaches
- Management is not oncologist dependent
Individual POUs have historical preferences 
Common goal Harmonisation of management and optimising resources - Establishing a common goal is challenging
- Remaining motivated to achieve the goals is challenging
Self-efficacy Individual researchers Individual motivation towards the project differs 
Combined efforts SACCSG has an agreed mandate to develop national 
protocols 
- Support from senior leadership in the SACCSG
- Support for others to pursue interests that are not common to all
POUs
Implementation process 
Planning - National: PI
- Local: Hospital investigators with local sub-discipline
departments
- Time needed for implementation support
- Various needs from different POUs for implementation
Engaging - Learning skills regarding research and cooperative
studies
- Development of interdepartmental relations in each
hospital
- Need for engagement of PI
- Need for constant follow-up of PI
Executing - Learning the protocol is important
- Continuous administration is needed
Each hospital investigator to self-regulate her/his units 
Reflecting and evaluating - Operational research is part of the NB protocol
- Interim evaluations have been planned
Implementation evaluations should be more frequent 
Abbreviations:  SACCSG – South African Children’s Cancer Study Group; PI – principal investigator; POUs – paediatric oncology units; HICs – high-income country;  NB – 




Appendix A: Timeline of the protocol development 
Date Action 
September 2016 SACCSG Durban protocol meeting  
National consensus to develop an NB management protocol 
October 2016 Initiation of the NB working group 
October 2016 Initiation of the retrospective NB study 
November 2016 Survey of hospital resources to treat children with NB 
January 2017 Initiation of development of protocol 
April 2017 Initiation of pathology guidelines 
May 2017 SACCSG protocol development meeting in Stellenbosch 
June 2017 Initiation of radiotherapy guidelines 
July 2017 Initiation of autologous bone marrow transplant guidelines 
July 2017 Initiation of nuclear medicine guidelines 
September 2017 First draft evaluation (supervisor) 
November 2017 Second draft evaluation (NB working group) 
January 2018 Online NB working group meeting on the Cure4Kids platform 
February 2018 Initiation of consent and assent forms 
March 2018 Third draft evaluation (NB working group) 
April 2018 SACCSG NB-2017 management protocol workshop 
April 2018 Preliminary retrospective study findings presented 
May 2018 Initiation of palliative care guidelines 
June 2018 Translation of consent and assent forms into eight official languages 
August 2018 Ethical approval SU 
September 2018 Ethics application UKZN 
October 2018 Academic evaluation of protocol UCT 
December 2018 Ethics application UCT 
January 2019 First and second site initiated for protocol 
February 2019 Ethics application Wits 
March 2019 Ethics application UFS 
March 2019 Ethics application Frere Hospital East London 
March 2019 Ethics application University of Limpopo 
April 2019 Third site opened 
March 2019 Ethics application Eastern Cape Provincial Department of Health 
May 2019 UCT ethics clearance 
May 2019 Eastern Cape Provincial Department of Health ethical clearance 
June 2019 Fourth site opened 
August 2019 Ethics applications UP and SMU 
September 2019 UFS ethics clearance 
December 2019 Wits ethical clearance 
December 2019 UP ethics clearance 
February 2020 SMU ethics clearance 
Abbreviations: SACCSG – South African Children’s Cancer Study Group; NB – neuroblastoma; SU – Stellenbosch University; 
UKZN – University of Kwa-Zulu Natal; UCT – University of Cape Town; Wits – University of the Witwatersrand; UFS – 
University of the Free State; UP – University of Pretoria, SMU – Sefako Makgatho Health Sciences University 
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Appendix B: Survey establishing the resources for the treatment of neuroblastoma in South Africa 






















Urine catecholamine levels 
Diagnostics 













































Abbreviations: CT – computerised tomography; MRI – magnetic resonance imaging; mIBG – meta-Iodobenzylguanidine; PET 
– positron emission tomography; INPC – International Neuroblastoma Pathology Classification; H&E – hyosine and eosine;
FISH – in situ fluorescent hydridasation; IV – intravenous; PO – per os (orally); G-CSF – granulocyte colony-stimulating factor
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Appendix C: Outcomes of protocol development meetings 
Stellenbosch Institute for Advanced Study, Stellenbosch, May 2017 
The protocol would be a standard of care, curative treatment protocol. 




- Stage 4s disease.
- Emergency presentations.
The protocol would be supported by a palliative section.  
There would be no randomisations, but a singular treatment arm was proposed to be implemented 
nationally.  
Operational research data and outcomes-based indicators should be collected.  
The primary study question should be based on the outcomes of a national protocol. 
There would be no secondary study questions. 
Web-based Cure4Kids platform, Africa Room, St. Jude Children’s Research Hospital, January 2018 
The sections on which consensus had been reached during the first and second draft reviews were 
discussed. 
Sub-discipline guidelines were presented to the NB working group. 
- Nuclear medicine guidelines were discussed and accepted.
- Radiotherapy guidelines were discussed and accepted.
- Radiotherapy without surgery would be a strong recommendation.
- Chemotherapy recommendations were discussed.
- De-escalation of treatment for LR disease (from OPEC/OJEC) was recommended.
- French-based Adriamycin-containing protocol for IR disease was accepted.
- Consensus was not reached on induction chemotherapy for HR NB.
- Doxorubicin-containing protocols were excluded, but the discussion of the choice between
rapid COJEC and OPEC/OJEC was not concluded.
The scope of the ASCT section was not determined.  
A multi-arm approach to the palliative care guidelines should be adopted. 
- Symptomatic palliation.
- Chemotherapy based (OPEC/OJEC).
- Metronomic therapy based.
- Role of mIBG-therapy.
NB working group at the Radisson Hotel, Sandton, April 2018 
Overview, aims and objectives of the protocol. 
- Signed off with unanimous consensus.
Diagnosis, inclusion criteria and staging systems. 
- Presented and discussed – signed off with unanimous consensus.
Treatment approaches and chemotherapy and discussion. 
- Treatment in emergency situations: Preference for radiotherapy in paraspinal emergency
but chemotherapy in hepatic emergencies.
- LR and IR disease – signed off with unanimous consensus.
- Stage 4s and perinatal NB – need a better definition of ‘symptomatic’ disease: Philadelphia
score suggested.
- HR disease – discussion between rapid COJEC and OPEC/OJEC. OPEC/OJEC approved for




- Rapid COJEC is still recommended for induction chemotherapy with HR NB but only has




- ASCT transfer documentation accepted.
- Concern regarding access to chemotherapy for ASCT.
- Aim of operative research to evaluate ASCT services for future improvements on
recommendations.
The remaining sub-discipline guidelines were presented. 
- Pathology and cytology were discussed and accepted.
- Surgery recommendations were debated and accepted.
Palliation. 
- Recommendations were evaluated and accepted.
- The aim of operative research is to evaluate palliation services for future improvements on
recommendations.
Documentation and reporting. 
- Electronic formats of paper-based documents will be provided.
- Excel spreadsheet will be provided for local records.
- Online database (REDCap) will be developed in the future.
Final consensus was reached on all sections. 
Final approval will be done electronically once suggestions have been included. 
Abbreviations: HR – high risk; IR – intermediate risk; LR – low risk; VLR – very low-risk; NB – neuroblastoma; 
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ASCT  Autologous stem cell transplant 
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LIC Low- income country 
LP Limpopo 
LR Low-risk 
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MP Mpumalanga 
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NW North West 
OS Overall survival 
POU Paediatic Oncology Unit 
SA South Africa 
SIOP International Society for Paediatric Oncology  
UN United Nations 





According to the South African Constitution, adopted in 1996, everyone has the right to access health 
care services, but children also have the right to health care that will ensure their survival. The aim 
with this study was to determine whether there was access to equitable paediatric oncology services 
for the management of neuroblastoma in South Africa. 
Methods 
A literature review was carried out, focusing on access to health care in South Africa for children with 
neuroblastoma who had been diagnosed between 2000 and 2014. The paediatric oncology units 
(POUs) were classified from Setting 1 to 4 in accordance with the International Society of Paediatric 
Oncology resource settings for neuroblastoma diagnosis. In addition, supplementary data from a 
retrospective study of the management of neuroblastoma in South Africa during the study period was 
evaluated. 
Results 
The neuroblastoma care services in South Africa were not uniformly resourced and accessible across 
the provinces in the period 2000 to 2014. The Gauteng and Western Cape provinces (2/9 provinces) 
had excellent health care services that included access to transplant facilities, while Mpumalanga, 
Northern Cape and North-West (3/9 provinces) had no paediatric oncology services. Traveling 
distances to health care services pose major challenges due to distances from health care centers, 
while number of medical staff to provide oncology care for children were unequally distributed. The 
South African Constitution did not define basic health care for children, nor did the National Cancer 
Control plan acknowledged childhood cancer as a defined entity without provision until 2022.   
Conclusion 
Children diagnosed with neuroblastoma do not have equitable access to health care as stated in the 
South African Constitution. The case of neuroblastoma highlights the inequitable access to childhood 
care as a whole in South Africa. As the health of children is a national priority, it is therefore necessary 
to sensitize policy makers to the needs of children with cancer. 
ARTICLE 
Introduction 
When the Republic of South Africa ratified the United Nations (UN) Convention on the Rights of the 
Child in 1995 and subsequently enshrined children's rights to health care in 1996 in its Constitution, 
the country committed to  provide children with equitable health care.[1] Section 27 of the South 
African Constitution affords children access to health care as citizens of South Africa, and they have 
the right to basic health care services under section 28.[2] These two rights in the Bill of Rights facilitate 
the access to health care.[1] Children may lodge a claim against the state for the provision of health 
care services when their parents are unable to afford health care services.[1] 
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The South African Constitution states that the state should also take reasonable action to comply with 
the provision of health care.[2,4] It does not fully define the nature of the health services beyond 
emergency medical care and basic health services, which may be interpreted as primary health care 
or preventative health care.[3] Section 28 of the Bill of Rights stipulates that children have a right to 
basic nutrition, shelter, basic health care services and social services.[2] The Constitution protects the 
right to life, and as oncological diseases are life-threatening, oncological health care should be defined 
as an essential health care service.[2]. The government should provide health care in accordance with 
its available resources but may not allocate a disproportionate share of the budget to one sector of 
health care, and thereby create shortages for other health care services.[3] To be able to prioritise 
health care services, major public health needs should be identified for state funding [4].  
Childhood cancer is one of the leading causes of mortality in high-income countries.[5] Yet, 90% of the 
world’s paediatric population lives in low- and middle-income countries where 84% of the global 
childhood cancer burden occurs.[6] This is the estimate, taking into account that there may be a 10% 
to 45% underestimation of childhood cancer incidences, partially due to the lack of cancer registries 
and poor access to oncological health care.[6] In South Africa, the number of underdiagnosed patients 
is estimated to be in the same region as in other low- and middle-income countries.[7] As section 37 of 
the Constitution states that emergency health care is a right, children with cancer should have the 
right to life-saving treatment regardless of where in South Africa they live. 
According to the World Health Organization (WHO), the definition of access to medical care pertains 
to physical access, economic access to information about health care.[8] Physical access is defined as 
that ‘health facilities, goods and services must be within safe physical reach for all sections of the 
population, especially vulnerable or marginalized groups’. Economic accessibility is defined as ‘a 
measure of people’s ability to pay for services without financial hardship. It takes into account not 
only the price of the health services but also indirect and opportunity costs (e.g. the costs of 
transportation to and from facilities and of taking time away from work)’.[8] Access consists of services 
that can provide the needed care, timeliness of receiving the care when it is recognised, a workforce 
that can provide the care, and coverage or the means to access health care.[9,10]  
We aimed to evaluate access to equitable paediatric oncology services for the treatment of 
neuroblastoma (NB), a childhood malignancy, in line with the stipulations of the South African 
Constitution. The three issues for evaluation were equal access to NB care, equal paediatric oncology 
services, and other equal resources needed for childhood cancer diagnosis and treatment. 
Furthermore, we wished to determine whether the state had taken reasonable action for NB health 
care towards achieving the aim of the WHO International society for Paediatric Oncology (SIOP) to 
improve childhood cancer survival in low- and middle-income countries (LMICs) to 60% by 2030.[11] 
Materials and methods  
Electronic literature reviews were conducted on the constitutional, legal, and ethical issues pertaining 
to equality of medical care and access to medical care in the South African setting. Searches were 
conducted on PubMed, Google Scholar, WorldCat and JSTOR with search terms ‘access to medical 
care’, ‘rights to medical care’, ‘equal medical care’, ‘cancer’, ‘children’ and ‘South Africa’. The 





South Africa consists of nine provinces, subdivided into nearly 300 districts. [12,13] The health care in 
the country is administrated by three systems: The national, provincial and the district health systems. 
[12,13] The national Department of Health (DoH) coordinates the public and private health care services 
at national, provincial and district levels, while administrative, financial, and supportive services are 
regulated at the provincial and district levels.[14] In 2012, South Africa’s DoH initiated a National Health 
Insurance (NHI) plan as an efficient, equitable and sustainable health system.[15] This social health 
insurance plan was developed to make health care more accessible and affordable for citizens who 
have no other way of funding such care individually, but it has not yet been implemented due to 




Based on the South African Children’s Cancer study group’s retrospective study of the management 
and outcomes of NB between 2000 and 2014, we evaluated the burden of three prognostic factors, 
age at diagnosis, stage, and risk stratification, associated with NB in each province of South Africa. 
Furthermore, we evaluated the human resources and paediatric oncology services during this period 
by comparing the provincial paediatric oncology services that manage children diagnosed with NB. 
Paediatric oncology services were evaluated according to the International Society of Paediatric 
Oncology (SIOP) resource settings for NB diagnosis, staging, and risk stratification (Appendix A).[16] A 
multidisciplinary team including subspecialist doctors, nurses and laboratory staff was involved in 
managing childhood malignancies.[16] We surveyed only former and current paediatric oncologists and 
paediatric surgeons attached to paediatric oncology services to establish the number of physicians 
working in paediatric oncology associated with individual POUs. Where possible, annual departmental 
hospital reports were cross-referenced for confirmation. To evaluate access to POUs, three random 
furthest points with a named settlement in each province were chosen. The distance and travel 




Data from a retrospective study on the management and outcomes of South African children 
diagnosed with NB between 2000 and 2014 were used to determine the overall survival (OS) and 
associated 95% confidence intervals (CI) for each province. These data were described using Kaplan 
Meier curves with differences evaluated using log rank tests. The Kaplan Meier curves were assessed 
using IBM SPSS Version 25 (IBM Corporation, USA) statistical software.[18] For all calculations a p-value 





Nearly a third (n=124, 32.2%) of the 385 children diagnosed with NB in South Africa between 2000 
and 2014 (Figure 1) were treated in the Western Cape (WC), (n=114, 29.6%) were treated in Gauteng 
(GP), and (n=62, 16.1%) in the Free State (FS), followed by KwaZulu-Natal (KZN) (n=55, 14.3%) and the 
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Eastern Cape (EC) (n=30, 7.8%). Data from Limpopo (LP) was not included in this study because 
permission to access data could not be obtained.  
Figure 1: The provinces and cities of South Africa with paediatric oncology units from 2000 to 2014 
Abbreviations: EC – Eastern Cape; FS – Free State; GP – Gauteng; KZN – KwaZulu-Natal; LP – Limpopo; MP – Mpumalanga; 
NC – Northern Cape; NW – North West; WC – Western Cape 
Age at diagnosis 
The median age at diagnosis for the total cohort was 39.9 months (interquartile range (IQR), 15.4-49.6 
months) (Table 1). The median age at diagnosis of patients from EC was 34.3 months (IQR, 19.1-48.2 
months), 36.6 months (IQR, 12.2-81.9 months) for patients from FS, 36.8 months (IQR, 16.6-51.4 
months) for patients from GP, 26.5 months (IQR, 13.5-41.4 months) for patients from WC, and 21.3 
months (IQR, 13.5-48.0 months) for patients from KZN. In all the provinces the largest age group was 
the 19- to 60-month-old children. FS had the highest percentage (32.3%) of children older than five 
years. In all POUs the predominant age group was the 19- to 60-month-old children (Table 2). 
Johannesburg was the POU with the highest percentage (32.3%) of children over five years. 
Tumour staging at diagnosis 
Stage 4 or metastatic disease was the most prevalent (n=273, 70.9%) (Table 3). All provinces 
predominantly had Stage 4 disease, but EC (83.3%) and KZN (80.0%) had the highest percentages 
compared to 68.5%, 68.4% and 66.1% in WC, GP and FS respectively. WC had the highest percentage 




The POUs (Table 4) with the highest percentages of patients with Stage 4 or metastatic disease were 
Pietermaritzburg (KZN), East London (EP), and Pretoria (GP), with 100%, 83.3% and 82.1% respectively. 
Rondebosch in Cape Town (WP) (n=9, 9.9%) and Johannesburg (GP) (n=3, 5.9%) had the highest 
percentage of Stage 1 or localised disease. 
 
Risk stratification at diagnosis 
 
High-risk (HR) disease was the most prevalent (n=294, 76.4%) (Table 5). All provinces predominantly 
had HR disease, but EC (90.0%) and FS (95.2%) had the highest percentages compared 81.6%, 65.3% 
and 61.8% in GP, WC and KZN respectively. The percentage of HR disease must be seen in the context 
of 29.1% of KZN patients not being able to be risk stratified. WC had the highest percentage of low-
risk (LR) disease (n=26, 21.0%). The four POUs (Table 6) with the highest percentages of patients 
diagnosed with HR disease were Pietermaritzburg (KZN), Bloemfontein (FS), Pretoria (GP), and East 
London (EP), with 100%, 95.2%, 92.3% and 90% respectively followed by Johannesburg (GP) (82.4%), 
Parow in Cape Town (WP) (81.8%), Soweto (GP) (62.5%), Rondebosch in Cape Town (WP) (59.3%) and 
Durban (KZN) (57.1%). Rondebosch in Cape Town (WP) (n=22, 24.4%), Johannesburg (GP) (n=7, 13.7%) 
and Parow in Cape Town (WP) (n=4, 12.1%) had the highest percentage of LR disease followed by 
Pretoria (GP), Soweto (GP), Durban (KZN), East London (EL) and Bloemfontein (FS) with 7.7%, 4.2%, 
4.1%, 3.3% and 3.2% respectively. Pietermaritzburg (KZN) had no patients with LR disease. 
 
Evaluation of access to paediatric oncology services in South Africa (Table 7) 
 
GP was the province with the smallest surface area (18 176 km2), with the shortest travelling distances 
to services (83.5 km – 119.0 km), and with the shortest travel duration (59 min – 1 h 34 min). NC was 
the province with the largest surface area (372 889 km2), with the furthest travelling distances to 
services (283.7 km – 1 105.5 km) and the longest travel duration (2 h 55 min – 16 h 32 min). WC, with 
established paediatric oncology services, had comparable distances (427.4 km – 595.8 km) and travel 
durations (4 h 22 min – 6 h 45 min), with MP (141.1 km – 435.1 km; 1 h 48 min – 4 h 56 min) and NW 
(336.1 km – 641.8 km; 3 h 40 min – 6 h 46 min), who had no paediatric oncology services. 
 
National access to neuroblastoma care 
 
Based on geographical distances in South Africa (Figure 1), road access and travelling time to cover 
the distances as well as transport options for patients – timeliness (Table 7) of access to care were not 
equal. The Constitution guarantees the facilitation of gaining access to health care.[2] Both the 2009 
public inquiry into access to health care services and the 2017 Foundation for Human Rights paper on 
monitoring the right of access to health care in South Africa documented ongoing limited resources 
and access to both patient transport services and emergency transport.[19,20] The greatest burden fell 
on children and patients from rural areas who needed interprovincial transfers.[21, 22] Not only did 
patients in MP, NC and NW not have NB medical services in their own provinces, but there was also 




Anti-neoplastic agents are important for the treatment of NB.[21] Until 2016, approximately 20 basic 
and essential anti-neoplastic agents listed in the WHO essential anti-cancer medications had not been 
listed on the South African Essential Drugs list.[23] Subsequent Essential Medicines Formularies for 
Tertiary and Quaternary Care did also not include anti-neoplastic agents as needed for childhood 
malignancies.[24, 25]
A multidisciplinary team is crucial for the management of NB. The disciplines should include paediatric 
oncologists, paediatric surgeons, radio-oncologists, radiologists, pathologists, nuclear physicians, 
bone marrow transplant specialists, and supportive care services (blood transfusion services, 
pharmacy services and dieticians), but of special importance is the nursing staff.[16] If the provinces 
without paediatric oncology services are not taken into account, GP and WC, who had the smallest 
percentage of children under the age of 15 years (respectively 24.5% and 26.7%),[26] had the best 
access to health care between 2000 and 2014, with more paediatric oncologists and paediatric 
surgeons than the other provinces (Table 8 and 9). Even in the context of this disproportionate 
distribution of human resources, both the 2009 public inquiry and the 2017 Foundation for Human 
Rights working paper concluded that there was a shortage of skilled health care workers, especially 
nursing staff, in the public sector, and that their numbers were still decreasing.[20,27]  
Equality of the paediatric oncology services delivering neuroblastoma care 
The management of NB includes chemotherapy, surgery, and radiotherapy.[28, 29] In localised NB 
trimodal therapy is curative, but in metastatic NB or NB with adverse biology, trimodal therapy leads 
to a survival of only 20%.[16, 28, 29] Autologous bone marrow transplant preceded by ablative bone 
marrow therapy, immunotherapy and maturation therapy with cis-retinoic acid are vital, but were not 
available in South Africa during this time.[28, 29].
Between 2000 and 2014 the POUs in South Africa delivered different levels of neuroblastoma 
management based on the available health care resources in each hospital (Table 10). Important in 
the management of high-risk NB was autologous bone marrow transplant. Pietermaritzburg (KZN) and 
Polokwane (LP) were Setting 1 POUs with access only to basic levels of health care (Appendix A). 
Bloemfontein (FS), Durban (KZN), and East London (EC) were Setting 2 POUs with access to the full 
range of health care management needed, excluding access to bone marrow transplant facilities for 
children. Rondebosch and Parow (Cape Town, WC), Johannesburg, Pretoria and Soweto (GP), with 
autologous transplant capabilities, were Setting 3 POUs with access the full range of health care 
management facilities, including bone marrow transplant. None of the POUs were classified as Setting 
4 POUs, since South Africa does not provide immunotherapy for the treatment of NB. 
The existence of a facility does however not guarantee access to it, or that access to it would be 
gained.[30] In South Africa, when a paediatric surgeon was not available, a general surgeon performed 
surgical interventions when diagnosing NB with the aid of a biopsy or operated on the primary tumour. 
Radiotherapy services did not routinely reserve time for paediatric NB patients who needed 
irradiation. Moreover, in both these situations children had to compete not only for resources, but 
also with the adult population to gain access to life-saving services.[31] High-risk NB had poor outcomes, 
high relapse rates and a high need for resources.[16] When the justice principle is applied for access to 
limited surgical, radiotherapy and transplantation services, these characteristics might work against 
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patients with NB due to competition for resources rather allocated to burden of disease of adult non-
communicable diseases. This situation was compounded when paediatric oncology services competed 
with adult services.[31]   
The right to life – a right to be treated for neuroblastoma and treatment-related complications 
Worldwide localised NB without adverse biology (low- and intermediate-risk disease) had five-year 
overall survival (OS) rates of upwards from 80%.[16,28,29] In metastatic NB or NB with adverse biology 
(high-risk disease) with multimodal therapy, including autologous stem cell transplant (ASCT) and 
immunotherapy, the five-year OS rates were 60%.[15,27,28] In South Africa, with limited access to ASCT 
and no immunotherapy, the five-year OS was approximately 20%.[32] The inequitable distribution of 
NB management-related resources had an impact on the survival, as the two provinces GP and WC, 
with a full range of health care services, had survival rates above the national average of 22.6% (Table 
11). KZN did not have a paediatric oncologist to complement the multidisciplinary team until 2013 (the 
end of the study period) and had the lowest survival rate of 5.5%. The effect of inequitable access to 
NB care could be demonstrated by comparing Pretoria and Soweto with Johannesburg. All are Setting 
3 paediatric oncology services, but during the study period Johannesburg received referrals from 
Southern GP (roughly 9 088 km2) and Soweto received referrals from Southern GP and NW (113 970 
km2), while Pretoria received referrals from Northern GP, MP and LP (until a POU was opened in Ga-
Rankuwa) (roughly 211 337 km2), which were significantly further away from the child’s residence. 
This potentially may have led to late diagnosis and delays in referrals to central hospitals, contributing 
to a poorer 10-year OS for Pretoria (5.1%) and Soweto (16.7%), compared to 39.2% in 
Johannesburg.[17] 
Chronic care or long-term life-saving health care 
Since 2009, non-communicable diseases in South Africa, including cancer, have contributed the 
greatest percentage to the burden of disease in the country.[20] It is estimated that one in every five 
children up to late adolescence in South Africa were in need of long-term lifesaving health care or 
chronic health care due to a previously life-limiting condition, such as with cancer and palliative care 
[33]. Yet, when the right to life-saving health care on the basis of a chronic condition was challenged 
in the Constitutional Court in the Soobramoney case: Soobramoney v Minister of Health (KwaZulu-
Natal) 1998 (1) SA 765 (CC), the Court decided that emergency medical treatment did not include 
chronic treatment.[34] Therefore, autologous stem cell transplant (ASCT), which contributes a 15% to 
20% increase in survival in high-risk NB,[16] is not guaranteed as a right to life under the determination 
of the Constitutional Court and neither is any part of paediatric oncology care apart from acute life-
threatening emergencies such as acute emergencies at diagnosis such as spinal cord compression 
symptoms and respiratory distress or neutropenic fever, heart failure caused by chemotherapy-
induced anaemia, bleeding due to thrombocytopaenia.[16]  
Discussion 
Neuroblastoma is a childhood malignancy of the neuro-endocrine system, contributing 15% of the 
total deaths in the paediatric oncology population and only 20% of cases survive for longer than five 
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years due to late diagnosis and advanced disease in low- and middle-income countries.[35] .[16] The five-
year OS rate in South Africa is 27% in at country with a youthful population of 34.3% of the population 
under the age of 15 years.[21].[36] Since the start of democracy in 1994, the DoH has developed 
beneficial programmes for children, which include the national integrated nutrition programme, the 
programme for the prevention of maternal HIV to child transmission, and the early childhood 
development and basic education programmes.[36] Free basic child health care services for children under 
the age of five years are included in these programmes. A bias in favour of younger children and 
preventative medicine is evident in all these programmes, with the health needs of children with 
chronic diseases, older children and adolescents being neglected.[37] Provincial health departments 
have directed resources towards paediatric oncology care with initiatives such as the Essentials for 
Palliative Care and the KwaZulu-Natal paediatric outreach programmes,[33] but paediatric oncology 
resources through South Africa remain unequal. Gauteng had the highest number of children under 
the age of 15 years, and the Western Cape only the fifth highest with respectively 17.7% and 11.5%.[26] 
Yet both provinces had the most resources to manage NB.  Mpumalanga, with 36.1% of the children 
under 15 years, and Limpopo with 39.1%, were the two provinces with the least resources and the 
highest percentage of children in the country [26]. In 2020 Mpumalanga still had no paediatric 
oncology services and referred children with NB to Pretoria.  
The WHO-SIOP joint goal is to achieve a 60% childhood cancer cure rate worldwide.[37,38] The South 
African government lacked the stewardship to implement National Core Standards, including 
programmes related to cancer care, in the country.[39] Most cancer-related programmes were adult-
centred.[40] The Ministerial Advisory Committee on the Prevention and Control of Cancer (MACC) was 
established in 2013 and the Strategic Plan for the Prevention and Control of Non-Communicable 
Diseases ran from 2013 to 2017, but childhood cancer was not a priority, as the focus was again on 
prevention rather than cure, not applicable in childhood cancer.[40] In the 2017 to 2022 National 
Cancer Strategic Framework for South Africa the commitment to paediatric cancers was not stated 
beyond a paragraph on childhood cancer epidemiology.[41] Therefore, although NB has a peak 
incidence in children between the ages of two and five years,[16] the paediatric programmes’ bias in 
favour of younger children does not include non-communicable disease management. Access to 
treatment in the private health care setting for childhood cancers, thus for NB, is better than in the 
public setting. The two-tiered health system benefits the financially independent of the population or 
those who can afford private health insurance.[42]  
Although NB is classified as a rare disease, [43,44] optimising its management in South Africa is important 
from the principle of justice as part of setting a basic standard of health care for rare diseases.[45] The 
international age-standardised rate of NB in countries with standardised cancer registries is 10.6 cases 
per million.[46] In South Africa, with at least a 50% under-diagnosis of childhood malignancies,[7] the 
incidence is far less, at 2.7 cases per million.[7] Therefore, improving the quality of awareness of 
neuroblastoma, as with all childhood cancers, improving diagnostic capabilities and bringing about 
increased access to paediatric oncology care are basic, life-saving health care services to which 
children have a right under the Constitution. 
The absence of a definition in the Bill of Rights for ‘basic health care services’ as they pertain to 
children may be due to the relatively young Constitution or a means for the government not to commit 
to defined services. As a signatory of the UN Convention on the Rights of the Child, the South African 
government must prioritise the needs of children as the most vulnerable members of the South 
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African society.[31] Section 7(2) of the Constitution requires the state to ‘respect, protect, promote and 
fulfil the rights in the Bill of Rights’. Concerning the right of access to health care services, respect 
determines that the state not unreasonably limit people’s access to health care services, whether in 
the public or private sector.[34] Thus, a reasonable measure to ensure that children, including children 
with malignancies, not only survive, but also thrive and reach their full capabilities according to the 
UN Convention, is to address discriminatory policies and practices:[34] defining basic health care for 
children and acknowledge the need for chronic health care services for children in South Africa. After 
25 years of democracy, the scope of paediatric oncology should be acknowledged and a separate 
national cancer control plan for children formulated to address the paediatric epidemiology, 
pathophysiology and management needs of children with cancer. 
Conclusion 
In the case study of children diagnosed with neuroblastoma, it was determined that the patients were 
not afforded equitable access to care, were not afforded the same level of care based on resources, 
and were not afforded the right to life by means of access to medical services as laid down by the 
South African Constitution. This case of neuroblastoma illustrates the measure of access to care for all 
paediatric malignancies in South Africa, which is currently a low priority in national cancer control 
because of the paucity of initiatives by policymakers for children with oncological diseases.  
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Table 1: Neuroblastoma age groups at diagnosis from 2000 to 2014 per province in South Africa 
Province EC FS GP KZN WC Total 














Age 0-18 mo N(%) 5 (16.7%) 16 (25.8%) 32 (28.1%) 17 (30.9%) 39 (31.5%) 109 (28.3%) 
19-60 mo 22 (73.3%) 26 (41.9%) 60 (52.6%) 27 (49.1%) 67 (54.0%) 202 (52.5%) 
>60 mo 3 (10.0%) 20 (32.3%) 22 (19.3%) 11 (20.0%) 18 (14.5%) 74 (19.2%) 
Total N 30 62 114 55 124 385 
Abbreviations: EC – Eastern Cape; FS – Free State; GP – Gauteng; KZN – Kwa-Zulu Natal; WC – Western Cape; mo - months 
Table 2: Neuroblastoma age groups at diagnosis from 2000 to 2014 per city in South Africa 
Province EC FS GP KZN WC 
Total City EL BLN JHB PTA SWT DBN PMB PRW RBH 




























































Total N 30 62 39 51 24 49 6 33 91 385 
Abbreviations: EC – Eastern Cape; EL – East London; FS – Free State; BLN – Bloemfontein; GP – Gauteng; JHB – 
Johannesburg; PTA – Pretoria; SWT – Soweto;  KZN – Kwa-Zulu Natal; DBN – Durban; PMB – Pietermaritzburg; WC – 
Western Cape; PRW – Parow (Cape Town); RBH – Rondebosch (Cape Town); mo - months 
Table 3: Neuroblastoma staging at diagnosis from 2000 to 2014 per province in South Africa 
Province EC FS GP KZN WC Total 
INSS Stage 1 N(%) 0 (0.0%) 2 (3.2%) 3 (2.6%) 1 (1.8%) 10 (8.1%) 16 (4.2%) 
Stage 2 1 (3.3%) 1 (1.6%) 9 (7.9%) 0 (0.0%) 5 (4.0%) 16 (4.2%) 
Stage 3 3 (10.0%) 16 (25.8%) 20 (17.5%) 5 (9.1%) 22 (17.7%) 66 (17.1%) 
Stage 4 25 (83.3%) 41 (66.1%) 78 (68.4%) 44 (80.0%) 85 (68.5%) 273 (70.9%) 
Stage 4s 1 (3.3%) 2 (3.2%) 4 (3.5%) 5 (9.1%) 2 (1.6%) 14 (3.6%) 
Total N 30 62 114 55 124 385 
Abbreviations: INSS – International Neuroblastoma Staging System; EC – Eastern Cape; FS – Free State; GP – Gauteng; KZN 
– Kwa-Zulu Natal; WC – Western Cape 
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Table 4: Neuroblastoma staging at diagnosis from 2000 to 2014 per city in South Africa 
Province EC FS GP KZN WC 
Total City EL BLN JHB PTA SWT DBN PMB PRW RBH 




































































































Total N 30 62 39 51 24 49 6 33 91 385 
Abbreviations: EC – Eastern Cape; EL – East London; FS – Free State; BLN – Bloemfontein; GP – Gauteng; JHB – 
Johannesburg; PTA – Pretoria; SWT – Soweto; KZN – Kwa-Zulu Natal; DBN – Durban; PMB – Pietermaritzburg; WC – 
Western Cape; PRW – Parow (Cape Town); RBH – Rondebosch (Cape Town) 
Table 5: Neuroblastoma risk stratification at diagnosis from 2000 to 2014 per province in South 
Africa  
Province EC FS GP KZN WC Total 
Risk LR N(%) 1 (3.3%) 2 (3.2%) 11 (9.7%) 2 (3.6%) 26 (21.0%) 42 (10.9%) 
IR 1 (3.3%) 1 (1.6%) 10 (8.8%) 3 (5.5%) 14 (11.3%) 29 (7.5%) 
HR 27 (90.0%) 59 (95.2%) 93 (81.6%) 34 (61.8%) 81 (65.3%) 294 (76.4%) 
Unknown 1 (3.3%) 0 (0.0%) 0 (0.0%) 16 (29.1%) 3 (2.4%) 20 (5.2%) 
Total N 30 62 114 55 124 385 
Abbreviations: INSS – International Neuroblastoma Staging System; EC – Eastern Cape; FS – Free State; GP – Gauteng; KZN 
– Kwa-Zulu Natal; WC – Western Cape; LR- low-risk; IR – intermediate risk; HR – high-risk
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Table 6: Neuroblastoma risk stratification at diagnosis from 2000 to 2014 per city in South Africa 
Province EC FS GP KZN WC 
Total City EL BLN JHB PTA SWT DBN PMB PRW RBH 
















































































Total N 30 62 39 51 24 49 6 33 91 385 
Abbreviations: EC – Eastern Cape; EL – East London; FS – Free State; BLN – Bloemfontein; GP – Gauteng; JHB – 
Johannesburg; PTA – Pretoria; SWT – Soweto; KZN – Kwa-Zulu Natal; DBN – Durban; PMB – Pietermaritzburg; WC – 




Table 7: Provincial distances and traveling times to the nearest paediatric oncology unit during 2000 
to 2014 
Destination to nearest POU Distance Travel time 
Eastern Cape (168 966 km2) 
Elyolo to Port Elizabeth 
Aliwal North to East London 




3 h 45 min 
3 h 53 min 
6 h 29 min 
Free State (129 825km2) 
Memel to Bloemfontein 
Maseru (border with Lesotho) to Bloemfontein 




4 h 37 min 
1 h 47 min 
2 h 23 min 
Gauteng (18 176 km2) 
Klipdrif to Soweto 
Loding to Pretoria  




1 h 8 min 
1 h 34 min 
59 min 
Kwa-Zulu Natal (94 361 km2) 
Manguzi to Durban 
Port Edward to Durban 




5 h 3 min 
1 h 35 min 
2 h 22 min 
Limpopo (125 754 km2) 
Musina to Polokwane 
Dwaalboom to Polokwane 




2 h 19 min 
3 h 54 min 
2 h 32 min 
Mpumalanga (76 495 km2) 
Mbuzini to Pretoria 
Delfkom to Pretoria 




4 h 56 min 
4 h 21 min 
1 h 48 min 
North West (104 882 km2) 
Vorstershoop to Bloemfontein 
Vorstershoop to Pretoria 




5 h 46 min 
6 h 46 min 
3 h 40 min 
Northen Cape (372 889 km2) 
Mier to Cape Town 
Mier to Bloemfontein 
Alexander Bay to Cape Town 





8 h 43 min 
16 h 32 min 
7 h 36 min 
2 h 55 min 
Western Cape (129 462 km2) 
Tsitsikama to Cape Town 
Kliprand to Cape Town 




6 h 45 min 
4 h 22 min 
6 h 43 min 
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Provincial totals Doctors Provincial totals Doctors 
2 928 000 1 to 2.9 mil 0 2 570 000 0 0 
Free State 
Bloemfontein 1 0 Bloemfontein 3 0 
Provincial totals Doctors Provincial totals Doctors 


























Provincial totals Doctors Provincial totals Doctors 




















Provincial totals Doctors Provincial totals Doctors 
4 149 000 0 1 to 2 074 500 4 062 000 1 to 4 062 000 1 to 1 037 250 
Limpopo 
Polokwane 0 0 Polokwane 0 0 
Provincial totals Doctors Provincial totals Doctors 




0 0 Mbombela 
(Nelspruit) 
0 0 
Provincial totals Doctors Provincial totals Doctors 
1 520 000 0 0 1 564 000 0 0 
Northern Cape 
Kimberley 0 0 Kimberley 0 0 
Provincial totals Doctors Provincial totals Doctors 
398 000 0 0 408 000 0 0 
North West 
Ga Rankuwa 0 0 Ga Rankuwa 0 0 
Provincial totals Doctors Provincial totals Doctors 






















Provincial totals Doctors Provincial totals Doctors 
1 609 000 1 to 321 800 1 to 1 609 000 1 866 000 1 to 311 000 0 
South Africa 
Total 12 3 Total 17 4 
18 129 000 1 to 1 510 750 1 to 6 043 000 18 795 000 1 to 1 105 588 1 to 4 698 750 
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Table 9: The number of paediatric surgeons in each province between 2000 and 2014 
 2000  2014 














Provincial total  Provincial total  
2 928 000 1 to 732 000 2 570 000 1 to 642 500 
Free State 
Bloemfontein 1 Bloemfontein 1 
Provincial total  Provincial total  


























Provincial total Doctors Provincial total Doctors 














Provincial total Doctors Provincial total Doctors 
4 149 000 1 to 1 037 250 4 062 000 1 to 812 400 
Limpopo 
Polokwane 0 Polokwane 1 
Provincial totals Doctors Provincial totals Doctors 







Provincial totals Doctors Provincial totals Doctors 
1 520 000 0 1 564 000 0 
Northern Cape 
Kimberley 0 Kimberley 0 
Provincial totals Doctors Provincial totals Doctors 
179
Stellenbosch University https://scholar.sun.ac.za
398 000 0 408 000 0 
North West 
Ga Rankuwa 1 Ga Rankuwa 2 
Provincial totals Doctors Provincial totals Doctors 














Provincial totals Doctors Provincial totals Doctors 
1 609 000 1 to 321 800 1 866 000 1 to 311 000 
South Africa 
Total 23 Total 35 
18 129 000 1 to 788 217 18 795 000 1 to 537 000 
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Table 10: Evaluation of Paediatric oncology units according to the SIOP-PODC Resource Settings for Neuroblastoma Diagnosis, Staging, and Risk 
Stratification 
Table key: “On site” refers to services in the same hospital or same hospital complex in the same city. “Off-site” refers to services in another hospital complex, another city or province. 
Abbreviations: U/S – ultrasonography, CT – computed tomography, MRI – magnetic resonance imaging, BMT – bone marrow aspirate and trephine, mIBG - ASCT – autologous stem cell 





X-ray U/S CT/MRI BMT mIBG MYCN Chemotherapy Surgery Radiotherapy ASCT Level 
Setting 
Eastern Cape 
East London On site On site On site On site On site On site Off-site Off-site On site On site On site No 2 
Free State 










































































Polokwane On site On site On site On site On site On site Off-site Off-site On site On site Off-site No 1 
Mpumalanga, Northern Cape and North West 
































Table 11: Provincial and paediatric Oncology Unit (POU) overall survival outcomes 
N (%) 10-year
OS
Std. Error Median 
95% CI 
p-value
Lower Bound Upper Bound 
Provinces 
Eastern Cape 30 (7.8%) 10.0% 2.214 5.528 14.206 <0.001 
Free State 62 (16.1%) 21.0% 3.001 15.419 27.181 
Gauteng 75 (19.5%) 22.8% 3.129 3.001 15.266 
Kwa-Zulu Natal 55 (14.3%) 5.5% 1.271 1.709 6.691 
Western Cape 124 (32.2%) 33.9% 3.191 12.313 24.820 
Total 385 22.6% 1.238 10.807 15.660 
Paediatric Oncology Units 
Bloemfontein 62 (16.1%) 21.0% 3.001 15.419 27.181 <0.001 
Durban 49 (12.7%) 4.1% 1.960 0.000 6.441 
East London 30 (7.8%) 10.0% 2.214 5.528 14.206 
Johannesburg 51 (13.2%) 39.2% 42.383 0.000 130.070 
Pietermaritzburg 6 (1.6%) 16.7%* 1.225 3.000 7.800 
Pretoria 39 (10.1%) 5.1% 2.809 0.000 11.006 
Rondebosch 91 (23.6%) 39.6% 5.357 12.368 33.366 
Soweto 24 (6.2%) 16.7% 3.715 0.000 14.182 
Parow 33 (8.6%) 18.2% 1.589 11.253 17.480 
Total 385 22.6% 1.238 10.807 15.660 
* Although the survival curve for Pietermaritzburg had already reached its plato, the value reflects a 5-year OS (as opposed




Figure 2: Kaplan Meier curves overall survival outcomes for patients diagnosed with neuroblastoma 
between 2000 and 2014 in each province (p<0.001)




Appendix A: International Society of Paediatric Oncology (SIOP) Resource Settings for Neuroblastoma diagnosis, staging, and risk stratification 
Setting 1 Setting 2 Setting 3 Setting 4 
Diagnosis History, Physical examination, 
Histology of small round blue cell tumour or bone marrow metastases 
Urinary catecholamines (if available) 
Staging CXR and skeletal survey, 
Abdominal ultrasound, 
Bilateral BM aspirate & 
biopsy 
CT neck/ chest/ abdomen/ 
pelvis 
99mTc-bone Scan 
Bilateral BM aspirate & 
biopsy 
CT neck/ chest/ abdomen/ 
pelvis 
123I- MIBG or 18FDG-PET 
MRI head or spine if 
involved 
Bilateral BM aspirate & 
biopsy 
CT scan neck/ chest/ 
abdomen/ pelvis 
123I- MIBG or 18FDG-PET 
MRI head or spine if 
involved 
Bilateral BM & biopsy 
Laboratory CBC, liver enzymes, LDH, 
ferritin, creatinine, urinalysis 
CBC, liver enzymes, LDH, 
ferritin, 
creatinine, urinalysis 
Urine HVA/ VMA 
CBC, liver enzymes, LDH, 
ferritin, 
creatinine, urinalysis 
Urine HVA/ VMA 
Tumour lysis labs if INSS 4 
(electrolytes, Ca Mg PO4, 
uric acid) 
CBC, liver enzymes, LDH, 
ferritin, 
creatinine, urinalysis 
Urine HVA/VMA  
Tumour lysis labs if INSS 4 
(electrolytes, Ca Mg PO4, 
uric acid) 
Pathology H&E stain H&E stain 
IHC 
H&E stain, IHC 
INPC classification (if 
available) 
(differentiation grade, MKI) 
MYCN 
H&E stain, IHC 
INPC classification 
MYCN, DNA Ploidy 
segmental chromosome 
abnormalities 
Infrastructure Nursing, Inpatient Hospital Nursing, Inpatient hospital Nursing, Inpatient Hospital Nursing, Inpatient Hospital 
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Access to RBC or whole 
blood 










Isolation and Transplant 
Facility 

























Abbreviations: CT, computerized tomography; CBC, complete blood count; LDH, lactic dehydrogenase; H&E, hematoxylin and eosin stain; IHC, 
immunohistochemistry; RBC, red blood cell; HVA, homovanillic acid; VMA, vannilylmandelic acid; 123I- MIBG, meta-iodobenzylguanidine; FDG-PET, 




Interim analysis of the prospective national neuroblastoma protocol 
(SACCSG NB-2017) in South Africa 
The prospective SACCSG NB-2017 study has started recruitment in South Africa in January 2019 with 
two paediatric oncology units (POUs), respectively at Tygerberg Hospital (Cape Town) and Inkosi 
Albert Luthuli Central Hospital-Grey’s Hospital (Durban-Pietermaritzburg in Kwa-Zulu Natal). Currently 
12 paediatric oncology units (POUs) in the public sector, four POUs in the private sector and one POU 
in Namibia are participating in the study. 
The original estimated inclusion of patients has been estimated at 30-40 patients per year, based on 
the retrospective study data. There are currently only 14 patients included, which is less than those 
expected (Table 1). When evaluating the provincial study inclusions (Table 2) less than 50% of the 
potential patients have been included into the study. 
Table 1: Patients included in the SACCSG NB-2017 study since January 2019 
* patient has since relapsed and started relapse treatment
Abbreviations: DOD – Date of diagnosis; mo – months; INRG – International neuroblastoma risk group; EL – East London
Frere Hospital; TBH – Tygerberg Hospital; Bloem – Bloemfontein; Pta – Pretoria Steve Biko Academic Hospital; RBH –
Rondebosch Private Hospital, PE – Port Elizabeth Provincial Hospital, F – female; M – male; Abd – Abdominal; PS – paraspinal;
Thx – thorax; NA – not amplified, Amp – amplified, HR – high-risk, IR – intermediate risk, ASCT – autologous stem cell
transplant.
There was a male predominance with a male to female ratio of 1.3:1, and patients had been most 
frequently diagnosed in the 18-60-months category (n=7; 50.0%). The median age was 26 months 
(range 7 months - 8 years, mean 43.1 months). 
SACCSG NB-2017 
ID nr Hospital DOD Sex Age 
(mo) 
Primary Stage MYCN INRG Current phase of 
treatment 
Outcome 
NB-0001 EL 15/03/2019 F 67 Neck [R] 4 NA HR Completed* Alive 
NB-0002 EL 03/05/2019 F 7 Abd 4 NA HR Induction Died 
NB-0003 TBH 25/04/2019 M 19 PS 4 NA HR Maintenance Alive 
NB-0004 Bloem 24/06/2019 M 8 Abd 4 NA HR ASCT Alive 
NB-0005 KZN 06/04/2019 M 53 Abd 3 NA IR Post treatment Alive 
NB-0006 KZN 03/07/2019 M 86 Abd 4 Amp HR Palliation Died 
NB-0007 KZN 09/07/2019 M 23 Abd 4 Amp HR Palliation Died 
NB-0008 Pta 15/05/2020 F 58 Thx 4 NA HR Induction Alive 
NB-0009 Bloem 25/06/2020 F 8 Abd 4 NA IR Induction Alive 
NB-0010 Bloem 27/08/2020 M 76 Abd 4 Amp HR Induction Alive 
NB-0011 Bloem 04/07/2020 M 26 Abd 4 NA HR Induction Alive 
NB-0012 Bloem 06/02/2020 M 50 Abd 4 Amp HR Induction Alive 
NB-0013 RBH 3/1/2020 F 96 Abd 4 NA HR ASCT Alive 
NB-0014 PE 1/10/2020 F 26 Abd 4 T/F HR Induction Alive 
Patients on prospective protocol not yet registered 
 Patients 9 
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The most common site of the primary was an abdominal tumour (n = 11; 78.6%) with 92.8% (n=13) of 
patients were diagnosed with stage 4 disease. MYCN was amplified in 69.2% (n=9/13) of tumours. The 
cohort was dominated by patients with HR disease (n=13, 92.8%). Three (21.4%) patients have died 
and one (7.1%) relapsed with a parietal bone lesion. 
Table 2: Patients included in the SACCSG NB-2017 study since January 2019 according to provinces 
Expected number per year 




10.5/ mil per 
year 
SA* 
2.7/ mil per year 
Study per year 
(Total) ** 
EC 2 218 998 (14.9) 23.3 6.0 2 (4) 
FS 833 571 (5.6) 8.8 2.3 2.5 (5) 
GP 2 647 499 (17.7) 27.8 7.1 4 (8) 
KZN 2 593 861 (17.4) 27.2 7.0 1.5 (3) 
LP 1 971 421 (13.2) 20.7 5.3 0 (0) 
MP 1 381 452 (9.2) 14.8 3.7 No POUs 
NC 374 996 (2.5) 3.9 1.0 0 (0) 
NW 1 203 386 (8.0) 12.6 3.2 0(0) 
WC 1 710 772 (11.5) 18.0 4.6 1.5 (3) 
Total SA 14 935 956 (100) 157.1 40.2 11.5 (23) 
* incidence based on reports by Stefan. et al. 2015
** Includes patients identified for the study without a study number
Abbreviations: EC – Eastern Cape; FS – Freestate; GP – Gauteng; KZN – Kwa-Zulu Natal; LP – Limpopo; MP – Mpumalanga; 
NC- Northern Cape; NW – North West; WC – Western Cape, SA – South Africa, POUs – Paediatric oncology units
Challenges since the opening of the study 
a) Ethics applications (see Chapter 9 for an extended discussion)
South African Universities have no common or standardised ethics application procedure. Neither is 
reciprocal ethics approval between universities established. The differences in ethical applications 
included: a) whether the principal investigator or hospital investigator had to complete the application 
differed between committees, b) whether a new academic evaluation had to be done, even after a 
full academic and ethical evaluation was done at the primary site, differed between committees, c) 
reciprocal agreement was not standard practice, d) the application forms and requirements differed 
between committees. Where the same documentation was needed, the format requirements 
differed. The implication was that a single document had to be reworked multiple times, e) the 
hospital approval differed between sites: either hospital superintendents, departmental heads or 
academic heads were responsible, but was not clear to applicant whom to direct requests to.  
b) Personal experience
Some patients have not been included, because participating POUs have felt the psycho-emotional 
situation such as pre-terminal presentations, not conducive for including patients on the palliative 
aspect of the study. One hospital investigator felt that including a patient for trial purposes in 
proximity to a poor prognostic or palliative intent conversation with a parent was difficult to do and 
might be insensitive to the family.  
c) Reluctance of medical staff in research participation
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The SACCSG decided that during all national prospective studies, that at least one paediatric oncologist 
from each POU should be part of the working group to lead the study in each hospital. This person 
would make sure that the multidisciplinary team in their hospital could manage the patients according 
to the protocols. The degree of participation from working group members have varied for a number 
of reasons: 1) NB was not a particular interest for some of the member. 2) Closely linked to the subject 
matter is the interest to do research. A number of physicians chose to be clinicians and do not want 
to undertake research but find themselves in tertiary or academic centres where research is expected 
as part of their employment requirements. 3) With a limited number of physicians in each POUs, some 
have felt they had to take on responsibilities outside of their interest. 4) One site had difficulty in 
securing a dedicated hospital investigator due to rotating staff. 5) Some investigators found it difficult 
to communicate about the recruitment or avoided the subject. 6) Historically POUs developed in 
autonomous settings with limited co-operative research done on national level. POUs were 
accustomed to developing local protocols for the management of malignancies and may find it 
challenging to adapt to the new trial. 7) Obtaining consent for treatment in South Africa with 11 official 
languages can be challenging. To add the complexity of a trial, even as basic as a single arm, standard 
care protocol, adds a degree of complexity.  
d) Low level of compliance monitoring
The responsibility of familiarising oneself with a new national treatment trial paired with the 
infrequent diagnosis of a patient with NB per POU contributes to low retention of the study protocol. 
Hospital investigators reported that clinical burdens limited the ability to refamiliarize themselves to 
the protocol. This frequency of support by the principal investigator should be increased.  
e) The corona-pandemic
The daily clinical burdens have also been cited not to include patients. Since the outbreak of the 
COVID-19 pandemic an already overburdened South African medical system, increased pressures 
arose. This had the effect that academic and administrative responsibilities were secondary to 
pandemic prevention responsibilities. South Africa measures were very strict and protracted [1]. The 
lockdown commenced on 25 March 2020 and the first de-escalation from level 5 to level 4 on 1 May 
2020 [1]. During lockdown interprovincial travel was not permitted except for personal emergencies 
which had to be approved by governmental institutions [1]. This excluded medical emergencies. 
Interprovincial travel was resumed from the initiation of level 2 lockdown on 18 August 2020 [1]. The 
effect on patients needing trans-provincial services is not clear, but the expectation that delayed 
diagnoses and relapses will increase. The Kingdom of Lesotho, an example of a country landlocked by 
a single country, mostly refers patients to Bloemfontein, South Africa. NB patients were still permitted 
to receive their treatment in South Africa with hospital documentation stating the need for cross-
border travel [1]. New cases of NB could still be transferred to South Africa, but the administrative 
conditions were stricter and new patients had to be isolated until proven negative for COVID-19 since 
Lesotho is graded as a high-risk (red) country according to South African legislation [1]. 
Discussion 
Research trough trials is important for the translation of knowledge to clinical practice [2]. Recruiting 
patients into trials demands a number of resources which includes obtaining consent during inclusion 
[3]. Consent is an ethical requirement for trial inclusion but is time-consuming [4]. It requires a 
motivated research to ensure a high level of inclusion and to maintain that motivation [3]. Research 
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in diverse ethnic settings and minority groups is less than westernised settings [2]. One factor, relevant 
to the South African setting, is the language barriers between the investigator and patient and family 
[2]. A translator may not be available and even if available could be challenging [2].  
The judgement regarding inclusion of patients with advanced disease in research and the feelings of 
medical staff regarding the appropriateness to offer inclusion in research during pre-terminal stages, 
have been documented [5]. Lower than expected number of included patients have been reported in 
palliative research [5]. The unpredictable course and stage of the disease was also identified as a 
barrier [5]. A study by Steele; et al. reported that ethics boards and physicians were reluctant to 
approve and participate in paediatric palliative care research siting the burden on families as one 
reason [4]. The study concluded that families with children who have a life-threatening condition 
participating in research is both acceptable to parents and have a positive effect on the family [4]. 
Low investigator enthusiasm is well described to contribute to lower patient recruitment [5]. This 
factor is closely associated with trial experience and confidence in running a trial [6]. Consistantly 
having the same investigator improves both the recruitment rate and the consistency of data [6]. A 
consistent research team aids communication, especially for problem solving and for the continuity of 
research [7]. To ensure investigator compliance is maintained and/or improves, an initial orientation 
towards the protocol with continuing education on the study tools should be a standard to increase 
the level of compliance increases and maintain the intrest for participation [8]. 
The corona virus pandemic impacted the care for patients diagnosed with NB, and associated 
research, threefold: 1) Patients not yet diagnosed had to rely on accessible medical care, often primary 
care, in their local communities to distinguish symptoms from other common childhood diseases. 2) 
Patients already diagnosed with NB experienced added challenges to ensure that therapy was 
continued. 3) POUs had to adapt service delivery according to guidelines for the prevention of further 
infections. 
Making the diagnosis 
Solid tumours such as NB, often have an indolent onset [9] Therefore symptoms are not directly 
attributed to malignancies [9]. It is only when acute symptoms are present, for example symptoms 
associated with intestinal obstruction, respiratory distress or spinal compression, that medical 
services are sought [10]. Offenbacher et al. concluded that haematological malignancies often present 
with acute symptoms compared to solid tumours [10]. For this reason, they observed a decrease in 
solid tumour diagnosis, but not in haematological malignancies [10]. In the pandemic seeking help for 
minor symptoms were often delayed [11]. 
Access to medical care 
At the peak of the epidemic in Italy and USA, POUs noted a reduction in the diagnoses of solid tumours 
[10,12]. In Milan, a national referral centre for Italy, a 45.7% reduction of solid tumour cases, which 
included NB, were observed during lockdown compared to the same months in previous years (Fisher 
exact test P-value 0.0416) [12]. The decrease was due to a decrease in interregional transfers [12]. In 
the South African retrospective study 70% of NB diagnosis were stage 4 disease [13]. The interim 
analysis showed 92.8% of patients presented with stage 4 disease, before and during lockdown. We 
postulate that with restricted movement during lockdown, the challenges that already existed in an 
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inequitable system, will be increased. The question might not be in the increase advanced staged 
disease, but the increase of deaths due to advanced disease, patients that died from complications of 
pancytopaenia post chemotherapy and abandonment of treatment. The decreased access to 
healthcare could have made access to life saving health care more difficult. 
POUs adapting services 
The main reasons POUs had to adapt their services in South Africa, as in many LMICs, were due to 1) 
personnel shortages, 2) insufficient equipment and 3) continued patient burden [14]. The South 
African health system had to contend with a high number of personnel having to isolated due to 
sickness, quarantine due to exposure or personnel that died due to coronavirus infections [14]. Like 
other LMICs, personnel had to be deployed to other overburdened services as well [14,15]. With a 
severe shortage of personal protective equipment (PPE’s) and still having to maintain Occupational 
Health and Safety policies, service delivery had to be reorganized to maintain social distancing and 
hygiene precautions [14,15]. 
The pandemic affected all aspects of management including the diagnostic process. A study evaluating 
services in 194 retinoblastoma centres concluded that services that involved anaesthesia were partly 
or completely unavailable in 44.8% of POUs [16]. NB is in large dependent on tumour biopsies for 
diagnosis and genetic evaluation for risk stratification [17]. This further impacts the access to resection 
of primary tumours [18]. In India the care of patients with solid tumours were modified according to 
their ability to access health care [19]. For NB patients that could access health care the standard 
protocol was administered to patients that lived in the capital city of a POU were given chemotherapy 
at reduced dosages while patients that traveled from other states were given oral Cyclophosphamide 
and Etoposide [19]. 
To prevent the spread of the disease increased patient screening for COVID-19 was implemented and 
isolated COVID-19 units were established with separate management by dedicated staff [15]. 
Unnecessary displacement of patients or where travel was not possible, the role of telemedicine was 
increased during the lockdown. Patient contact was continued by telephone and internet-based 
services [20]. Patients that did not have access to internet were therefore further disadvantaged by 
mobility restrictions [20]. 
The impact on supportive care and co-morbidities 
It has been estimated that overall survival in adult cancer patients will decrease by up to 10% due to 
the effects of the coronavirus pandemic [21]. In regions where food shortages, nutritional diseases 
and poverty are high, will see a decrease of income and a deepening of these health emergencies 
including in patients with neuroblastoma [22]. 
With travel restrictions the delivery of chemotherapy, antibiotics, anti-fungals and anti-viral supplies 
will most probably be disrupted [22]. In a region where HIV has a high incidence and patients might 
default treatment, HIV-related and associated malignancies might increase. Blood donation will 
decrease due to mobility restrictions with an eminent or increased shortage of blood products [22]. 
Therefore, patients on treatment intensive HR-NB protocols could face increased morbidity and 
mortality due to these shortages. 
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Not least of all these challenges, there will be an increased psycho-emotional burden on families due 
to decreasing resources, deaths due to the coronavirus and still having to cope with a neuroblastoma 
diagnosis [23]. 
Conclusion: 
Many factors contribute to running a successful trial and recruitment patients. This is evident from 
the interim analysis of the SACCSG NB-2017 clinical trials and the sub-optimal inclusion of patients. 
The factors that contribute to investigator trial participation are systemic, institutional and individual 
to investigators.  Although many factors can be mitigated, other factors are not and flexibility towards 
the research should be adopted with a greater emphasis on co-operative participation.  
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Conclusions and recommendations 
As there was little published data regarding neuroblastoma in Africa and specifically South Africa, a 
systematic investigation into the incidence and management of neuroblastoma in South Africa has 
been conducted towards this PhD dissertation. When collectively viewing the results of the various 
studies, the results indicate that South Africa faces similar challgenges as most LMIC with the 
management of neuroblastoma. The main elements are the underdiagnoses of cases, proportionately 
higher number of high-risk disease and poor outcomes.  
This dissertation further has been able to reproduce the following findings similar to international 
studies: 1) the cut-point values for LDH with values of more than 750U/l and ferritin with values of 
more than 120ng/dl which indicate poor prognosis1; 2) the importance of local control measures in 
the absence of autologous stem cell transplantation; and 3) the predictive values of prognostic factors 
age, stage, biology and metastatic remission status to predict overall survival. Our research 
demonstrates the disparity in NB management in South Africa between the different POUs, between 
risk groups and especially in patients with high-risk disease. Furthermore, the approach to advanced 
disease has not been uniform in South Africa with variable outcomes between POU. The knowledge 
generated has assisted in the development of a national neuroblastoma treatment protocol as a single 
arm clinical trial. In the process the process exposesthe the resource challenges faced by a 
disproportionately funded system, but positively lays the basis for standardizing the approach to 
neuroblastoma in the country.     
The strength of the research is present in the explorative approach to subject matter with lack of data 
from LMIC for a large cohort with neuroblastoma. The data collected to evaluate the various 
management approaches in South African POUs has assisted in comparing different treatment 
protocols and assisted with the planning of the national NB protocol by providing evidence for 
potentially the best treatment protocol for the local context. The most crucial finding is the role of 
induction chemotherapy for high-risk disease and use of additiveradiotherapy if surgery is not 
possible. The retrospective quality of the research has introduced limitations in certain aspects of the 
research, which include non-standardized risk stratifications and management definitions. 
Although South Africa is a middle-income country, not all recommendations can directly be 
extrapolated to all LMICs. However, the approach applied to improve management of NB in the South 
African context may be replicated in other LMICs through evaluation of the local settingand the 
utilisation of local resources for clinical and research purposes.   
A major recommendation is to implement a single standard of care protocol or clinical trial, which is 
sustainable in all the POUs in South Africa, even with resource differences, to improve the outcome 
of children with neuroblastoma. Previous studies indicate that to be truly successful in the 
improvement of outcomes, it is be necessary to participate in collaborative clinical trials in childhood 
cancer39. This study has proven that the risk stratification as per PODC recommendations is 
appropriate to use for prognostic purposes with the use of LDH and ferritin as surrogate tumour 
markers for MYCN and genetic mutations, in settings where it cannot be done. The LR and IR treatment 
compares to the PODC recommendations, but the South African guidelines for HR disease are 
platinum based without doxorubicin as platinum-based treatment protocol has been found to be less 
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toxic in the local context. Future research should also include the meticulous documentation of 
outcomes and optimization of national resources including stem cell transplant and mIBG-therapy 
with utilisation of the diagnostic and post induction IDRF4, international neuroblastoma response 
criteria (INRC)28 and the fastidious application of ASCT indications in HR disease as recommended in 
the SIOP-PODC protocols.  
Recommendations for South Africa with relevance to LMICs 
South Africa has great potential for national research related to NB. The focus should be on developing 
platforms that include various resource settings and strengthening the capacities of individual POUs 
to perform clinical trials related to NB. All disciplines involved in NB care should be part of the protocol 
development. The collaboration should include surgeons, radio-oncologists, laboratory and imaging-
based physicians, thereby increasing the experience and capacity of treatmenting teams40,41, with the 
interdependency of medical, surgical and radiology clinicians’ interpretation of image defined risk 
factors for risk stratification and surgical planning are crucial4,42.  
Achieving early diagnosis remains a challenge in LMICs and especially in South Africa.  It is therefore 
crucial to improve public awareness and include the warning signs of childhood cancer in the 
integrated management of childhood illnesses (IMCI) to assist primary health care workers to 
recognize childhood cancer early with speedy referral43.  
Current and future data-based systems should adopt a more research-orientated management of 
resources to ensure the provision of evidence for interventions implemented in the management of 
neuroblastoma. To improve NB cure requires the inclusion of advanced, expensive therapies such as 
ASCT, with clear indication for HR disease with the potential of cure. The handling and access of data 
inherently has ethical restrictions; yet the process of accessing this information should be made 
efficient to aid research rather than impeding the development or overburdening settings with high 
clinical responsibilities44.  
The surgery for NB is complex due to the encasing nature of the tumour45. If an experienced surgeon 
is not available, patients should be referred to a center with the necessary expertise in NB in the best 
interest of the child to ensure the most beneficial resection between 90% - 100% resection46. LMICs 
can rely on the subjective evaluation of surgeons, as was concluded in the HR-NBL1/SIOPEN trial47, 
rather than through imaging. Standardized reporting should be part of the holistic surgical care48. By 
optimizing the utilization of national treatment modalities for chemotherapy, surgery and 
radiotherapy with considered indications for all treatment modalities, but especially autologous bone 
marrow transplantation, national resources could potentially be utilized responsibly and 
sustainably49,50. 
Of importance is the access to medicines for maintenance and relapse treatment. Cis-retinoic acid, in 
conjunction with an autologous transplant, can improve survival of up to 15 -20% in HR-NB through 
maturation therapy and is available in South Africa4. Topo-isomerase inhibitors, such as irinotecan and 
topotecan, and temozolomide have shown promise in the refractory, residual and relapse setting51. 
None of these medicins are currently on the essential medicine list for the treatment of 
neuroblastoma in South Africa but is potentially available with special motivation.  
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Palliative care options should be explored in South Africa for advanced disease and access to mIBG-
therapy as a palliative treatment option may be a valuable treatment option52. With international 
collaborative groups exploring mIBG as part of upfront treatment and in the context of resistant 
disease53, mIBG therapy in South Africa may be underutilized and could be part of innovative 
applications52.  
This study has proven the value of LDH and ferritin as tumour markers in the absence of access to 
determination of MYCN and can be implementd in LMICs.  
Crucial long-term follow-up is necessary for all children treates with platinum-based treatment 
protocols, especially hearing and kidney function 54,55.   
Greater initiatives towards bio-banking should be started. With the diversity of the genetic landscape 
in South Africa and the ever-increasing research into genetic and epigenetic targets in NB, biological 
knowledge could contribute to a greater understanding in the outcome variations as well as research 
into the pharmacokinetics and dynamics in the treatment of NB53. 
In conclusion, the approach to NB in resource restrained settings should focus on establishing a basis 
for management that will optimally use available resources in local settings. Recording data on the 
management and focus on the stepwise improvement of NB services in conjunction with other 
childhood malignancies should be part of the national health care system’s overall management 
strategy. Such approaches will address the need to improve survival rates of children with cancer in 
alignment with the global World Health Organization 2030 oncology objectives. 
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1 .  P R E M I S E  
 
Neuroblastoma (NB) is a childhood malignancy with significant difference in prognostic outcomes 
between stages and biological characteristics, from a good prognosis in stage 1 disease and an 
especially poor prognosis in stage 4 disease [1,2,3], even in high-income countries (HICs). Without high 
intensity treatment, advanced stage disease has a poor outcome in low- and middle-income countries 
(LMICs), with treatment being palliative rather than curative [4,5]. 
It is the aim of the South African Children’s Cancer Study Group (SACCSG) to launch a national 
multimodality treatment protocol for children diagnosed with NB. The protocol provides guidelines 
for standardised curative treatment for all patients, irrespective of risk assignment. It also provides 
guidelines for and documentation of palliative treatment options. 
The joint national study of NB in South Africa will promote more accurate analysis of national data 
with regard to this rare childhood malignancy. It will form the basis for further study questions in 
improving the early diagnosis of and care for children with NB, especially children with advanced-stage 
disease. 
 
2 .  B A C K G R O U N D  
 
Definition: 
NB, along with Ganglioblastoma and Ganglioneuroblastoma, form a group of neural crest malignancies 
that mainly originate from the adrenal gland but also from the sympathetic chains. It extends from 
the base of the skull, down the upper neck through the thorax and abdomen to the coccyx, forming 
the unpaired coccygeal ganglion [3]. NB is the most common extracranial solid tumour in childhood 
[2]. It is an aggressive, metabolically active and complex disease that clinically mimics many other 
diseases. The heterogeneous pathophysiological presentation of neuroblastoma, paired with the 
diverse prognostic outcome in different stages of the disease, makes the treatment of this disease an 
oncological challenge [4,5]. Not only in low- and middle-income settings, where advanced disease is 
the norm, but also in high income countries, this tumour poses several clinical and management 
challenges [5]. 
Incidence and epidemiology: 
The peak incidence is between 2–5 years of age in the sympathetic (adrenal) lineage of the 
neurological system [2,3]. Worldwide, NB accounts for more than 7% of childhood cancers, with an 
international prevalence of 1 in 7000 live births in developed countries [3]. It contributes to 




A familial predisposition has been identified at an incidence of <5%. The penetrance follows an 
autosomal dominant pattern with incomplete penetrance [7]. Syndromes associated with NB include 
Beckwith-Wiedemann syndrome, von Recklinghausen syndrome, Hirschsprung’s disease, Rubenstein-
Taybi syndrome [7], Neurofibromatosis and Pheochromocytoma [8]. 
 
NB has a slight male predominance with a 1.2:1 ratio. NB has always been viewed as a rare malignancy 
in African children [9,10], yet statistical inaccuracy was always cited for the incidence. This difference 
is less obvious in reports from North America and the United Kingdom [11,12]. Internationally there is 
a predominance in Caucasian children but with higher-risk disease characteristics in other ethnicities 
such as black children and children from indigenous ethnicities [13].  
Although conclusive epidemiological data regarding South African NB patients is not available, data 
from 1987 to 2007 has reported the estimated incidence in South Africa to be nearly 6% of all 
childhood malignancies [14]. 
Tumour biology and genetics: 
NB has both germline and somatic mutations that are expressed in the clinical phenotype of the 
disease. 
Germline mutations:  
The aggressiveness of the tumour is determined by genetic changes. NB develops from a germline 
deletion at the 1p36 or 11q14-23 locus [15,16]. Yet a family history is only identified in 2% of patients, 
with heritable mutations being in the anaplastic lymphoma kinase (ALK) gene [17]. Another mutated 
gene found in the familial type NB is PHOX2B [18].  
The development of NB is dependent on an accumulation of mutations where the pre-malignant cells 
rapidly replicate in proliferating tissue during embryogenesis in the central nervous system [19,20]. In 
NB the MYCN proto-oncogene is overexpressed in neurogenesis for the rapid expansion of progenitor 
cell populations [20,21]. Epidermal growth factor receptor (EGFR) gene and PHOX2B gene have also 
been associated with the development of NB and contributing to the development of oncogenic 
elements in the microenvironment of the tumours [20,22,23]. 
Somatic mutations: 
The majority of NB cases are due to the development of somatic mutations. Sporadic mutations have 
been used in the prognostication, the identification of new targets for drug therapy as well as the 
prediction of clinical response due to drug-resistant genetic trades [24]. There is a paucity of mutations 
rather than a recurrent mutation of genes, suggesting an epigenetic regulation of gene expression [24] 
which explains the heterogeneous clinical presentation of the disease. 
Two major subtypes of somatic mutations have been identified which have been linked to the 
development of favourable and unfavourable biological characteristics [25]. 
Type 1 is characterised by whole chromosomal gains and losses and few segmental alterations, which 
predispose to favourable biology like hyperdiploidy and MYCN-negative tumours [24]. These tumours 
express high levels of TrkA receptor [26].  
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Type 2 is characterised by segmental alterations of unbalanced deletions and alterations, with or 
without whole chromosome changes [24]. A further subtype 2A is mainly the 3p and 11q segmental 
deletions without MYCN amplification [24]. Subtype 2B is MYCN amplified with 1p deletion and 
unbalanced 17q gain, whilst expressing TrkB receptor. Subtype 2A is the most aggressive [24,27].  
When NB cells acquire extra copies of the oncogene MYCN, it signifies more rapid tumour growth, 
which is associated with a resistance to treatment and a less favourable prognosis [19]. By comparison 
the NTRK1 gene (which synthesises the TrkA protein), when overactive in the cells of NB, portends a 
more favourable outcome [20]. 
Tumour genetics is also important in identifying genomic characteristics that lead to drug resistance 
and poor treatment response [30]. 
Tumour pathology: 
The diagnosis of NB, a small blue round cell tumour, is made on the basis of pathology, which includes 
immunohistochemistry staining. The hallmark finding on pathology is Homer-Wright rosettes that 
stain positive for tyrosine hydroxylase, CD56 and synaptophysin [5,31]. The tumour histopathological 
behaviour varies from spontaneous regression and local maturation to aggressive proliferation of 
immature cells that disseminate and cause a high mortality rate [2,3]. By using the Modified Shimada 
or International Neuroblastoma Pathology Classification (INPC), classification histology is classified 
into favourable and unfavourable prognostic classifications [32].  
The INPC system comprises three important aspects. This biologically based classification system takes 
age and morphologic features into consideration to prognosticate the outcomes of neuroblastic 
tumours [33,34,35,36]. This is achieved by using haematoxylin and eosin stains [34,35,36]. Firstly, the 
tumour is graded, distinguishing between poorly differentiated, differentiating and undifferentiated 
histology [34,35,36]. Secondly, it describes Schwann-like and stromal features of a spectrum between 
mature Ganglioneuroblastoma to immature NB [34,35,36]. Thirdly, the mitosis-karyorrhexis index of 
low, intermediate and high index is determined and included in the classification [34,35,36]. These 
aspects are then grouped to identify favourable and unfavourable histology utilised in the 
prognostication of NB in the INSS and the INRGSS classification [34,35,36]. 
The classical clumping of NB cells can also be found in metastatic bone marrow disease [32]. The 
hallmark rosette small, blue, round cells can be viewed under light microscopy. For the best yield, 
bilateral bone marrow aspirate and bone core biopsy are indicated [33,37,38]. Identifying the 
presence of NB cells in the bone marrow is the hallmark investigation for diagnosing stage 4 disease 
[33,37,38], and bone marrow is a ready source for genetic analysis such as MYCN determination 
[33,37,38]. 
In the micro-environment of the malignancy, tumour-associated macrophages (TAMs) can be seen 
[39,40]. This is due to the pro-inflammatory pathophysiology of the tumour to evade detection by the 
host immune response and to create chemotherapy resistance [39,40]. Immunohistochemistry to 
detect CD33, CD16, IL6 R, IL10 and FCGR3 is the main diagnostic tool for TAMs [39,40,41]. The TAMs 
in histological samples have been assessed in prognostication to have a poorer outcome [39,40]. The 
higher the infiltration with TAMs in NB, the poorer the prognosis, as opposed to osteosarcoma, where 
the higher the infiltration with TAMs, the better outcomes can be expected [41]. The postulated 
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pathogenesis in murine NB is the promotion of MYCN expression due to NB cell and macrophage 
interaction [42].  
Furthermore, immature NB microenvironments are characterised by neovascularisation. Vascular 
endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2), stimulators of angiogenesis, 
and tissue inhibitors of matrix metalloproteinases (MMPs) have been detected in NB tumours. High 
tumour vascularity correlates with unfavourable prognostic characteristics such as metastatic disease, 
MYCN amplification and unfavourable histology. The opposite is true for tumours with little 
vascularity. These tumours have favourable characteristics, such as a localised disease and favourable 
histology [43,44].  
Clinical presentation:  
The diagnostic dilemma lies in the diverse nature of the clinical presentation. Although nearly 65% of 
tumours present in the abdomen, other sites include the anatomical distribution of the sympathetic 
chain from the brain to the kidneys, including pelvic sites [2,3].  
The most common clinical presentation is a local suprarenal mass originating from the adrenal glands 
[6], yet the features mostly associated with presentation are due to metastatic manifestations such 
as bilateral proptosis, racoon eyes, bone pain, pancytopaenia and constitutional symptoms (fever and 
loss of weight). NB primarily spreads to the bone marrow, with subsequent complete invasion of bone, 
lymph nodes and liver [3]. Other sites like the lungs, intra-abdominal seeding and brain have also been 
described [3].  
Two paraneoplastic syndromes associated with NB are Vaso-intestinal peptide (VIP) syndrome and 
Opsoclonus/Myoclonus syndrome (OMAS) [6,45,46]. Both syndromes mimic common childhood 
illnesses like infective diarrhoea and intracranial pathology. Other neurological presentations include 
Horner syndrome, due to tumours in the neck [47], and compression associated with paraspinal 
symptomatology. Patients with stage 4S disease represent a special group in which, apart from the 
primary adrenal lesion, infants under 12 months of age may present with cutaneous lesions, bone 
marrow infiltration of less than 10% and/or liver lesions [3]. 
A simplified presentation of NB would classify the disease as either local disease, metastatic disease 
or stage 4S disease. The clinical presentation will then be dependent on the locality of the tumour 
from local pressure effects like paraspinal disease to a disseminated toxic presentation [5,6].  
During growth, NB encases many vital structures like blood vessels, impairing the function of vital 
organs like the kidneys and the liver, necessitating monitoring of renal and liver functions during 
diagnostic and treatment phases [3,4,5]. Coagulopathy is frequently present in metastatic NB with 
hyper- or hypocoagulability as frequent findings [49]. Increased concentrations of fibrinopeptide A as 
an indicator of thrombin production, disseminated intravascular coagulation and bleeding tendencies 
due to infections could potentially complicate management, especially peri-surgical procedures [49, 
50]. 
Screening: 
As NB is a tumour of the sympathetic chain, predominantly of the adrenal glands, it excretes 
catecholamine hormones. Homovanillic acid (HVA) and vanillylmandelic acid (VMA) function as 
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specific tumour markers for diagnostic purposes and can be traced in an acidified urine sample. The 
same tumour markers can be used as a screening tool for monitoring treatment, at follow-up and in 
the event of a relapse [31]. 
Screening for NB in under-1-year-old infants [51]: 
During the period 1984–2003 Japan screened 6-month-old infants for NB for VMA and HVA with high-
performance liquid chromatography and published reports that there was a reduction in the death 
rates of NB due to screening. The natural evolution of NB tumour biology predicts that many tumours 
spontaneously regress before 1 year of age [51]. Thus, although death rates were increased, many 
unnecessary surgical interventions may have taken place on tumours that would have regressed [51].  
In 2002, studies in Germany and Canada concluded that they could not reproduce the results from 
Japan [51]. They concluded that screening did not reduce the death rate in NB but did contribute to 
overdiagnosis of NB that would regress spontaneously and never have clinical significance [3]. 
In 2004 Japan reviewed their results and elected to stop the national screening for NB [51]. The 
tumours in infants with small, asymptomatic, low-stage adrenal NB, detected by screening or during 
prenatal ultrasound or incidental abdominal ultrasound examination, spontaneously regress [3]. 
In LMICs NB is underdiagnosed, especially in the first year of life, as children under 5 years more often 
present with infective and feeding problems or because NB is misdiagnosed for other sarcomas [52]. 
Laboratory evaluation and tumour markers: 
VMA and HVA are the primary markers for NB diagnosis [53]. In addition, combined determination of 
normetanephrine with VMA (in children under 1 year of age) or normetanephrine with HVA (in 
children older than 1 year of age) produces an age-specific diagnostic sensitivity and specificity of 
100% [53]. Other studies have suggested that either dopamine (DA) in combination with VMA and 
HVA [54] or noradrenaline (NAdr) [55] may be the preferred markers to determine the diagnosis. 
Zambrano et al. describe an age correlation similar to previous studies but include DA and NAdr in the 
1-year age watershed [55]. 
Furthermore, the same group describe that unfavourable biology, like NMYC amplification, and 
unfavourable histology are associated with catecholamine level changes [55]. The study suggests that 
patients with stage 3 and 4 disease had increased ratios of catecholamines compared to patients with 
stage 1 and 2 disease [55] and, specifically, that patients with advanced disease had DA levels >2 times 
the upper limit of normal compared to only 8% of patients with low-stage disease [55]. Similar trends 
were shown in the two groups with regard to VMA: patients with stage 3 and 4 disease had VMA levels 
>10 times higher than the upper limit of normal compared to those patients with stage 1 and 2 disease, 
where the same phenomenon was seen in only one patient [55]. 
Lastly, chromogranin A may also be used as a tumour marker. It is an acidic protein that is stored with 
VMA and HMA in vesicles and is elevated in NB [56]. Hsiao et al. found that chromogranin A as a 
correlate for disease was 91% sensitive and 100% specific [56].  
Bone marrow and bone are the most common sites of metastasis in NB. Microscopically, bone marrow 
aspirate with invaded malignant cells has the characteristic pattern of clusters or groups of cells with 
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granular chromatin and cytoplasmic projections that sometimes form a pseudorosette [57,58]. In the 
absence of a primary tumour the pathology, biological and genetic diagnosis of NB can be done on 
bone marrow [57,58]. 
 
Imaging: 
Diagnosis and staging of tumours are important for the management, treatment response evaluation 
and follow-up of patients. Basic radiography like x-rays and abdominal ultrasound may be used to 
document thoracic and abdominal pathology [59], but it lacks the sensitivity to detect metastasis in 
the lymph nodes and lungs or to fully image the encasing nature of NB for staging and pre-operative 
planning [59]. A skeletal survey with radiographs for bone disease is possible but is less sensitive than 
a 99mTc phosphonate bone scan with 26% versus 59% of lesions identified for skeletal involvement 
[60,61].  
 
To improve the sensitivity of 99mTc phosphonate bone scan, computerised tomography (CT) with 
intravenous contrast of neck, chest, abdomen and pelvis is advisable [62]. This also improves the 
evaluation of anatomic locations, image-defined risk factors (IDRF) for staging and surgery, and 
metastasis. CT is more sensitive for skeletal involvement than radiographic images [63,64]. Magnetic 
resonance imaging (MRI) is the study of preference for abdominal images, to evaluate soft tissue 
components as well as bone marrow infiltration [63,64]. MRI also provides less radiation exposure 
[64]. With suspected spinal involvement an MRI should be obtained to assess invasion of the neural 
foramina and spinal cord compression [63,64]. 
 
To aid in the diagnosis of NB the type 1 catecholamine transport uptake mechanism of the tumour 
cells has the unique ability to concentrate Iodine-123-metaiodobenzylguanidine [65]. Thus 123I-MIBG 
is a valuable diagnostic tool to identify the presence of the tumour in the body. Furthermore, it can 
be used to stage NB. In a Cochrane review of 11 studies, the sensitivity of MIBG varied between 67%–
100% [66]. In 20% of histologically proven NB the MIBG scan will be negative. Although MIBG has a 
specificity of 100% [62,65,66] some studies have shown these scans to illustrate less disease process 
than seen on CT scans [62,65]. Even with these limitations MIBG scans have a high sensitivity to detect 
post-treatment metastatic disease [67]. This characteristic is vital in the utilisation of reviewing 
treatment response [65]. 
 
Although 18F-FDG Positive emission tomography (PET) scan is not considered the main nuclear 
diagnostic study, its utility in NB is well documented. It uses glucose receptor transport mechanisms 
in tumours to diagnose the presence of malignancies [67,68]. This is the reason why the specificity of 
86% [67,68] is not as accurate as an MIBG-scan. It can concentrate radioactive isotopes in 
physiologically active sites, such as areas of inflammation and/or infection, giving a false positive 
reading [67.68]. MIBG-scans are still superior in terms of detecting stage 4 disease in bone and bone 
marrow due to their higher specificity and sensitivity in these tissues [66,67,68] 
MIBG is not just used as a diagnostic test, as a tool to determine treatment response or as a treatment 
modality but can be applied in the determination of prognosis [69,70]. Both SIOPEN and the Children’s 
Oncology Group (COG) have developed scoring methods, using MIBG in semi-quantitative methods. 
Both systems divide the body into segments. The Curie score (COG) divides the body into 9 segments 
(with 4 degrees), whereas the SIOPEN divides the body into 12 segments (with 6 degrees) [69,70]. The 
223
Stellenbosch University https://scholar.sun.ac.za
Curie score was assessed as a prognostic marker for response and survival in NB with MIBG-avid 
disease. Patients with a Curie score greater than 2 after induction therapy had a significantly worse 
event-free survival (EFS) of 15% than those with scores less than 2, whose EFS was 45% [69]. 
 
Bleeker et al. studied the metastatic pattern of MIBG distribution in stage 4 NB and found two distinct 
patterns. The two patterns were a “limited and focal” pattern, found mainly in patients with amplified 
MYCN NB that correlated with prognosis, and an “extensive and diffuse” pattern, found mainly in 
patients with single-copy MYCN NB [71]. One implication is whether MYCN activity is responsible for 
the focal growth of metastatic lesions and determines the affected body segments [71]. 
 
In a study done by the German Pediatric Oncology Group the prognostic values of the Curie and 
SIOPEN scoring methods were compared. A Curie score of 2 or less and a SIOPEN score of 4 or less at 
diagnosis correlated with significantly better EFS and overall survival as compared with higher scores. 
After four cycles of induction, those with complete response on MIBG testing had a better outcome 
than those with residual uptake [70]. 
 
Staging and risk classification: 
Management of the disease is based on risk stratification that is determined by clinical, pathological, 
biological and genetic features of each tumour. Two internationally recognised staging systems are 
the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Risk 
Group (INRG) [2,3]. The first main difference between the two staging systems is that INSS is a surgical 
outcome-based system and the INRG is a pre-surgical assessment predicated on imaging, bone 
marrow morphology and nuclear studies. The second difference is the inclusion of a very low risk 
group in the INGR classification [2,3]. The INSS has been used since 1986 with great variation in 
utilisation, since staging is dependent on the surgical skill [64]. It was reviewed in 1994 and it was 
determined that the diagnosis of NB could be made on histopathology of a specimen or cells in a bone 
marrow aspiration in combination with elevated catecholamine levels in the urine [72]. Furthermore, 
staging required bone marrow aspirate, CT scan and nuclear imaging [72]. It included the involvement 
of lymph nodes and tumours crossing the midline [64]. 
INRG utilises IDRFs such as the encasement, compression and infiltration of structures in local areas 
to define the staging [32,73]. It is better utilised as a pre-operative staging and aids in pre-operative 
planning, avoiding operative morbidity of vital structures [64] 
Staging is performed by a combination of clinical examination and using various investigation 
modalities which include chest X-ray, abdominal ultrasound, CT, MRI and MIBG scan as well as bilateral 
bone marrow biopsies [5,62,74].  
Owing to the diverse nature of this malignancy, many biochemical and biogenetic markers have been 
identified that contribute to the diagnosis and prognostication during treatment. Tumour markers 
associated with OS and EFS include MYCN copy number and proliferation, ploidy and deletion or loss 
of heterozygosity of chromosome 1p and gain of chromosome 17q [3,33]. These biological and genetic 




A third staging system was developed by SIOP-PODC. The aim was to develop a graduated staging and 
treatment protocol for resource- and expertise-limited settings [5]. This staging system provided a 
base for staging and diagnosis within the capabilities of various predetermined settings according to 
resources [5]. This staging system incorporates lactate dehydrogenase (LDH) and ferritin as surrogate 
prognostic markers in settings where advanced biological and genetic techniques are not available [5].  
Prognostic considerations: 
Age and stage are still the two most important prognostic factors [5,31,75]. Other prognostic factors 
that determine the outcome of treatment in NB are translocations, ploidy and the presence of MYCN. 
MYCN is an adverse prognostic marker in the NB context. In LMICs where either fluorescent in vitro 
hybridisation (FISH) or polymerase chain reaction (PCR) studies to detect the presence of MYCN are 
not available, ferritin and/or LDH can be used as surrogate markers to indicate an adverse prognosis 
[5,76]. 
MYCN amplification is a genomic expression in NB that is present in advanced disease and in rapidly 
progressive disease [77,78]. Prognostication with MYCN amplification has been found to be adverse 
and correlates with other poor prognostic markers such as advance disease, older age and 
unfavourable histology [77,78]. The percentage MYCN expression in stages 1 to 3 varies, but in stage 
4 disease it peaks at 65% [77,78]. MYCN amplification is rarely seen in Ganglioneuroblastoma (3.1%) 
and almost never in Ganglioneuromas [77,78]. Furthermore, tumours are found with extra MYCN 
copies. This genomic aberration seems to carry a better prognosis than with MYCN amplification 
[77,78].  
Treatment: 
The treatment of NB is very diverse and thus necessitates a multidisciplinary team approach. It is 
essential that the planned treatment protocol include local disease control, e.g. surgery and 
radiotherapy [2,3]. Complete excision of the tumour is vital to cure. In many situations surgery is not 
a feasible therapeutic modality due to the encasing macroscopic nature of the tumour. When vital 
structures are encased, surgery becomes challenging, with a high surgical morbidity and mortality 
[2,3]. NB is very radiosensitive with a high proliferation index and is therefore sensitive to 
radiotherapy, which can be used if surgery cannot provide local control [79]. 
The treatment of NB was mainly spearheaded by two philosophies of the North American co-
operatives (and the subsequent regions with twinning programs) versus the SIOP group which mainly 
originate in Europe [3,4,5]. 
The historical development of NB treatment has mainly been dictated by the risk group stratifications 
[80,81]. The risk groups not only determine the utilisation of the various treatment modalities but also 
the intensity of the chemotherapy used, for systemic treatment in the neo-adjuvant and adjuvant 
setting is predicated on all the risk factors. Each patient is grouped in a very low-, low-, intermediate- 
or high-risk group [3].  
In the low- and intermediate-risk groups the main treatment modalities are chemotherapy, surgery 




In the low-risk group patients, especially stage 1 treated for surgery alone without adverse prognostic 
markers, the 5-year survival nears 96% [2]. With the added treatment of chemotherapy and with stage 
3 disease, the intermediate-risk group patients achieve a 5-year survival of 90% in both COG and SIOP 
studies [2]. It is the metastatic disease patients with high-risk grouping who fare poorer with 50%–
60% 5-year survival in HICs and a 20% or less survival in LMICs [2,5].  
The risk groups also determine the number of cycles and the duration of the chemotherapy drugs 
Cisplatin (P) or Carboplatin (J), Vincristine (V), Etoposide (E) and Cyclophosphamide (C) in regimes like 
OJEC/OPEC and rapid COJEC. Some co-operative groups advocate the inclusion of Adriamycin (A) or 
adaptions of the COG studies for the SIOP-PODC guidelines that advise Ifosfamide as part of the high-
risk regimes [2,3,5]. 
In general, low-risk disease benefits from surgery, radiotherapy and chemotherapy, but high-risk 
disease necessitates increased treatment intensity. High-risk NB is treated with neoadjuvant 
chemotherapy (induction), surgery, radiotherapy and autologous transplant (consolidation), and 
immunotherapy with maturation therapy (maintenance) [43,79]. Due to varying resources the 
treatment in HICs and LMICs differs [5,35,79]. 
The induction phase aims to reduce tumour bulk and clear metastatic disease, especially bone marrow 
involvement, to under 2%–5% [3]. During this phase neo-adjuvant chemotherapy is also utilised to 
optimise the tumour site for surgical intervention. During the consolidation phase an autologous 
transplant after surgery with radiotherapy forms the main part of treatment. When there is no 
transplant option, radiotherapy and surgery consolidate treatment [35,82,83]. The goal of 
consolidation is to eliminate resistant tumour clones that were resistant to reduction phase treatment 
[3,35]. Thereafter minimal residual disease is treated with anti-GD2 therapy (immunotherapy), and 
maturation therapy of cis-retinoic acid (CRA) is the maintenance [35,79].  
Observation only: 
In patients younger than 6 months, especially perinatal patients, small adrenal masses found 
incidentally on ultrasound may safely be observed without obtaining a definitive histologic diagnosis 
and without surgery [3]. In the COG-ANBLOOP2, 81% of patients demonstrated spontaneous 
regression while avoiding surgical intervention. Only 19% ultimately underwent surgery with a 3-year 
EFS of 97.7% and OS of 100% [84]. 
Chemotherapy: 
Chemotherapy administration is determined by risk group. 
Low-risk disease: 
In both POG and COG trials patients with local disease have excellent survival of up to 98% with surgery 
alone [85,86]. Even resected stage 1 tumours with residual disease with favourable biology (MYCN 
negative and favourable histology) have good outcomes, with EFS above 90% and OS of 99%–100% 
[85]. Stage 2 disease has lower outcomes of an EFS of 81% and OS of 98% [85]. This was especially true 
in patients with tumour MYCN amplification, older than 2 years of age and with either unfavourable 




As demonstrated in the COG-P9641 trial, chemotherapy in low-risk disease is restricted to patients 
with unfavourable biology such as MYCN-amplified stage 1 and 2 disease and MYCN non-amplified 
stage 2B disease older than 18 months who have unfavourable histology or diploid disease [86]. 
Unfavourable histology had significantly lower EFS of 72% and OS of 86%, as did diploid tumours with 
EFS of 75% and OS of 84% [3,80,81].  
The outcome of patients with stage 2B diploid tumours with unfavourable histology was poor, with 
EFS of 54% and OS of 70%. There were no survivors in patients with additional 1p loss of heterozygosity 
and all in children older than 18 months of age [3,80,81]. Furthermore, chemotherapy is also reserved 
for low-risk patients who are symptomatic in cases with spinal cord compression and stage 4S 
respiratory compromise secondary to hepatic infiltration [3]. In the SIOPEN studies INES99.2 and 
INES99.3, good 2-year OS of 97.6% and EFS of 96.4% were obtained with surgery alone and 
carboplatin-and-etoposide-only chemotherapy for symptomatic patients or advancing disease [59]. 
Intermediate-risk disease: 
The basis for treatment in intermediate disease relies strongly on tumour biology. The intermediate-
risk group patients have three treatment strategies. Chemotherapy can be administered with or 
without surgery, infants can be operated on and then observed, and radiotherapy is only used in 
emergency situations [3,80]. 
Chemotherapy can be administered with or without surgery: 
In the POG 8743 study, patients with intermediate risk disease were stratified by MYCN amplification 
and tumour cell ploidy [87]. Hyperdiploid tumours were treated with cyclophosphamide and 
doxorubicin, and diploid tumours received cisplatin and teniposide after an initial course of 
cyclophosphamide plus doxorubicin [87]. OS rates were 95% for hyperdiploid tumours and 52% for 
diploid tumours. MYCN copies and LDH levels during the same study augmented the hypothesis that 
adverse biology warranted more intense chemotherapy [87]. 
In CCG trials, patients were treated with a four-drug chemotherapy regimen, surgery, and local 
radiation to residual disease [8]. Non-MYCN-amplified tumours had a 3-year EFS rate of 93% and 
MYCN-amplified tumours had a 10% rate [88]. Whilst Japanese studies by Lehara et al. with 414 
patients have indicated that MYCN-negative stage 3 patients can be treated with fewer cycles of 
chemotherapy [89]. It was during the COG-A3961 studies that it was determined that intermediate-
risk patients with favourable biology did well with just four cycles of chemotherapy, and patients with 
unfavourable biology needed eight cycles [90] to prevent acute and long-term complications without 
compromising high cure rates [91]. In the COG-A3961 studies the 5-year OS in patients with favourable 
biologic features who received eight cycles of chemotherapy was 100% as compared with those who 
received four cycles with a 5-year OS of 96% [90]. The Japanese study distinguished between 6 cycles 
versus 8 cycles and mainly looked at MYCN amplification and surgical resectability for treatment 
determinants [89]. The NB95-S and NB97 studies from GPOH, SIOPEN and Euro-INF-NB-99 also proved 
that infants with favourable biology had a more than 90% survival rate with surgery and reduced 
chemotherapy treatment [92,93,94]. 
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The current LINES study of the SIOPEN group bases surgical and chemotherapy treatment on the basis 
of tumour biology [95]. The current ANBL1232 North American trial is a response- and biology-based 
risk-factor guided therapy for non-high-risk NB [3].  
 
Infants can be operated on and then observed: 
Two separate European studies showed favourable outcomes in asymptomatic infants with stage 3 or 
4 disease. This raised the question if surgery and observation was a viable option [92]. This is 
controversial as the view is not shared in North America. 
In the SIOPEN study there was very little difference in the outcomes in early survival between the 
involvement of metastasis on bone scan with a 97% 2-year OS and a 100% OS without lesions [92]. 
The same was true between primary resection and without resection with a 2-year OS of 100% versus 
97% respectively [92].  
The NB95-S and NB97 German prospective studies with 340 infants concluded that the 3-year OS 
survival differed little between infants with unresected tumours with a 99% OS, infants with resected 
tumours with a 98% OS and infants receiving chemotherapy with a 95% OS [94]. 
A French study concluded the difference in survival of stage 4 patients to be the presence or absence 
in cortical bone changes on radiographic or scintigraphic evidence. The EFS was 90% for non-cortical 
bone involvement as opposed to 27% if there was bone involvement [96]. 
In the current LINES study, only infants with favourable biology without symptoms are observed. 
Children with INSS stage 1 NB, MYCN amplified, were previously observed according to the LNESG 1-
2. In the LINES study they will receive adjuvant treatment [95]. 
Radiotherapy is only used in emergency situations or progression: 
In The COG-A3961, unresectable tumours with favourable biology were spared radiotherapy as local 
treatment with favourable outcomes. Radiotherapy was limited to 2.5% of the 479 patients. The 3-
year EFS of the whole group was 88%, and OS was 95% [90]. 
High-risk disease: 
High-risk disease is defined as Stage 2A and 2B patients with MYCN amplification as well as 
unfavourable histology, Stage 3 disease with MYCN amplification regardless of age, and Stage 3 
disease without MYCN amplification but with unfavourable histology. The Stage 4 disease with high 
risk classification is limited to the infants less than 1 year of age with MYCN amplification and Stage 4 
patients over 1 year of age regardless of MYCN and histological status. Stage 4S infants with MYCN 
amplification are regarded as high risk [3,35,79]. 
Induction phase chemotherapy: 
The development of high-risk NB treatment has been characterised by the delivery of increasingly 
intensive multimodality therapy. During induction, European approaches under the EU-20592 or 
CCLGNB-1990-11 studies have studied increasing rapid administration of maximum doses of 
chemotherapy. Originally chemotherapy was administered in 28 day-cycles, then 21-day cycles and 
currently every 10 days with rapid COJEC [97]. Rapid COJEC was devised as a protocol to increase the 
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treatment intensity by decreasing the chemotherapy-free periods. In the rapid COJEC protocol, 
chemotherapy is administered every 10 days, regardless of toxicity, as opposed to every 21 days. 
Although this ensures that a patient reaches the consolidation treatment phase sooner, it is with a 
greater burden of chemotherapy-induced toxicity [98]. Even though myelo-suppressive arms of 
vincristine, carboplatin and etoposide, or vincristine, cyclophosphamide and etoposide, and less 
myelo-suppressive arms of vincristine and cisplatin, are alternated, the incidence of febrile 
neutropenia and infectious complications during rapid COJEC induction is high [97].  
In a Cochrane review there was no clear evidence of a difference between the OJEC/OPEC and rapid 
COJEC treatment groups in complete response, treatment-related mortality, overall survival and 
event-free survival [99] due to the limited number of studies. Yet prospective trials were advised due 
to the low level of evidence and the changes in risk classifications during the trial periods [99]. The 
review relied mainly on the CCLG-ENSG-5 randomised controlled trial of 262 patients with high-risk 
NB. In the study 132 patients were randomised to receive standard OPEC/COJEC and 130 patients to 
receive rapid COJEC induction chemotherapy [99]. Pearson et al., however, conclude in the study that 
there was an increasing difference in EFS after 3 years with the rapid COJEC induction protocol. With 
the same total dose, rapid COJEC at 10-day cycles had better EFS of 27% at 10 years versus the 21-day 
cycle at 18% [98]. The study postulates that the earlier start of myelo-ablative therapy (MAT) 
contributed to this outcome [100]. During European HR-NBL1/SIOPEN, patients were randomly 
assigned to primary prophylactic versus G-CSF. The patients with G-CSF had fewer febrile neutropenic 
episodes, days with fever and hospital- and antibiotic days [97]. 
North American approaches were based on treatment designed in Memorial Sloan Kettering hospital. 
The N6 protocol included doxorubicin during induction where SIOP did not include the drug [97]. With 
the 7 cycles in the N6 protocol, 87% of patients achieved either complete remission (CR) or very good 
partial response (VGPR) [101]. In the N7 protocol a reduction from 7 to 5 cycles of chemotherapy 
resulted in outcomes of 79% CR or VGPR and less toxicity [102]. Both studies were single-institution 
trials. 
Currently SIOPEN is randomising a modified N7 induction protocol with Rapid COJEC in the HR-NBL-
1.7/SIOPEN study [103]. The modified N7 induction is a dose-intensive induction chemotherapy 
regimen including high-dose cyclophosphamide plus doxorubicin or vincristine and high-dose cisplatin 
or etoposide [103]. The original regimen of 7 cycles was modified by reducing the number of cycles to 
5 and lowering the vincristine dose. The use of G-CSF is included [103]. 
Consolidation phase chemotherapy: 
In the development of consolidation in the CCG-3891 study, patients were randomised to receive a 
more intensive arm of consolidation therapy, which included MAT plus autologous bone marrow 
transplant, versus a less intensive arm of conventional-dose chemotherapy [104]. The same study 
introduced a randomisation of 13-CRA versus no CRA in patients who were disease free after 
consolidation [104]. The more intense treatment showed improved results with 5-year OS outcomes 
of 30% versus less than 20% for the non-intensive arm [104]. 
The modalities of surgery, radiotherapy and transplant are discussed as part of consolidation under 
the respective subheadings. A multimodal approach is of prognostic importance in the treatment of 
high-risk NB. If a patient only receives chemotherapy, surgery and radiotherapy, the 5-year 
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prognostication is 20%–30% [2]. With the inclusion of an autologous stem cell transplant as 
consolidation therapy, the OS is improved with approximately 20% in stage 4 patients [105,106]. The 
outcome with the drug repositioning of CRA is improved when used post transplantation [107]. The 
role in a non-transplant setting has not been established. CRA matures the rapidly dividing NB cells 
into more indolent ganglionic cells and plays a significant role in addressing minimal residual disease 
in patients who are in complete remission [5,107]. 
Stage 4S and infants: 
Patients with stage 4S disease, despite tumour bulk, are associated with a favourable outcome [108]. 
Since patients are less than 1 year of age the potential risks of treatment must be weighed up against 
the benefits. With disease progression, intervention is important [86]. 
The patients who are very young and are symptomatic or have unfavourable biology do better with 
chemotherapy [86]. In the COG-P9641 the 5-year EFS was 63% and OS was 84% for infants with 
asymptomatic stage 4S NB treated with surgery alone, and the EFS was 95% and OS was 97% for 
infants treated with surgery and chemotherapy. 
In symptomatic low-risk patients with stage 4S hepatic infiltration and respiratory distress as well as 
spinal cord compression, chemotherapy is indicated as an emergency measure according to the 
Philadelphia Score system [108]. Chemotherapy is administered in lower doses to prevent toxicity 
[86]. 
Surgery: 
The goals of surgery are diagnostic and curative [3]. A biopsy for histological confirmation as well as 
genetic determination plays a primary role in surgery [3]. Resection of the tumour is vital to cure and 
determines the feasibility of transplant options [3]. In many situations surgery is not a feasible 
therapeutic modality due to the encasing macroscopic nature of the tumour. When vital structures 
are encased, surgery becomes challenging, with a high surgical morbidity and mortality [2,3]. Apart 
from resection, another important role of surgery is to evaluate the spread of the tumour. Evaluating 
the lymph nodes is important to promote maximum resection of the tumour [3,79].  
The evidence regarding gross total resection is conflicting. Retrospective studies at Memorial Sloan 
Kettering have proven superior survival outcomes in complete surgical resections (CSR) versus partial 
surgical resections (PSR) in especially metastatic disease [109,110]. In the study, 1-, 2- and 3-year 
survival rates were compared between CSR and PSR, and survival rates were shown of 100% versus 
77% 1-year survival, 80% versus 38% 2-year survival and 40% versus 15% 3-year survival [110]. 
Chamberlain et al. reproduced the conclusion that CSR was superior to PSR [111]. This was also proven 
in the stage 4 NB patients with BMAT involvement [111].  
In contrast, the Great Ormond Street experience did not prove an advantage of CSR over PSR of the 
primary tumour [112]. A possible explanation is the MYCN proliferation positivity of the tumour. The 
survival outcomes of NB with MYCN proliferation were proportional to surgical outcomes from PSR to 
CSR [113].  
In low-risk patients, tumours are evaluated for complete resection by excluding image-defined risk 
factors and the surgical ability of the surgeons [3]. Even in the presence of residual tumour, but in 
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favourable histology, outcomes with EFS are in excess of 90% and OS is 99% to 100% [3]. Patients need 
not undergo complete resection of disease to be cured by surgery alone [3]. Perez et al. conclude that 
patients with stage 1 and 2 NB have 98% survival with surgery alone as primary therapy, with 
supplemental treatment needed in 10% of stage 1 patients and 20% of stage 2 patients [85]. In stage 
2 disease, unfavourable biology, positive lymph nodes or age over 18 months had a higher risk [85]. 
In stage 3 disease it was proven to be dependent on age, unfavourable biology, lymph node 
involvement and ferritin levels [91]. 
Matthey et al. proved that survival outcomes of more than 80% in stage 2 NB were independent of 
tumour biology and radiotherapy with surgery alone [85,114]. This provides evidence that even for 
high-risk stage 2 patients, there is no indication for radiotherapy [115]. Due to the encasement nature 
of NB around vital structures, surgical complications and morbidity can be up to 25% [110]. This is in 
relation to the aggressiveness of surgical intervention even after neo-adjuvant chemotherapy to 
shrink the tumour size [110,111]. Another factor, especially in stage 4S, is the surgical difficulty 
operating on children under the age of 1 year old [110,112].  
Radiotherapy: 
Neuroblastoma is very radiosensitive, with a high proliferation index. The role of radiotherapy has 
been investigated in emergency presentations, palliation and local and metastatic disease in relation 
to chemotherapy and surgery, as has the role of radiotherapy in the transplant setting [3,33]. 
In low-risk disease the application of radiotherapy is in local recurrence that does not respond to 
surgery and/or chemotherapy [33,85]. The second indication is where function of life is threatened 
during spinal compression or hepatomegaly-induced respiratory compromise [33,85]. 
For all other situations surgery alone is adequate, with specific-situation chemotherapy if needed. 
Added radiotherapy has no added survival benefit but does add to long-term complications 
[33,85,114]. 
The evidence for using radiotherapy in the intermediate-risk group is varied due to the inconsistency 
of trials over the years [3]. This makes comparing data a challenge and creates a difficulty in setting 
down recommendations [33,79]. What is clear is that stage 3 patients with residual tumour after 
surgery with unfavourable biology (non-hyperdiploidy, MYCN positive, unfavourable histology) have 
an increased chance of survival with radiotherapy. It is unclear if this translates to regional lymph node 
involvement. The COG A3961 study had a greater than 90% survival in the abdominal lymph node 
involved stage 3 group on only chemotherapy and surgery. 
It is clear in all studies that radiotherapy plays a significant role in high-risk disease [33,79,91]. 
Originally total body irradiation (TBI) was used during transplant regimes [74], but it limited the dose 
toxicity of chemotherapy needed during myelo-ablation [79,116,117]. Although TBI became obsolete 
during older protocols, there is great evidence for the use of local radiotherapy, especially in bulky 
disease to prevent relapse [3,79]. Higher doses in two separate trials with doses up to 21 Gy on the 
pre-chemotherapy pre-surgery volume prevented high local relapse rates [33,115]. Local relapse rate 
is in the region of 70% with an MYCN amplified tumour [33,115]. Thus, local radiotherapy of 10 Gy 
above TBI is advised with MYCN disease [33,115]. 
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Stage 4S disease is a very specific clinical entity. As these patients are less than 1 year of age, 
radiotherapy poses a significant problem due to size and physiology [79]. Thus, the routine use is 
discouraged. Indications for radiotherapy is in palliative situations or in life-threatening situations such 
as with tumour-induced hepatomegaly [3,79] that causes respiratory compromise, inferior vena cava 
obstruction, compromised renal perfusion, disseminated intravascular coagulation (DIC) or 
gastrointestinal obstruction [3,79]. Since most of these patients are 2–4 months of age at diagnosis, 
the risk of late effects and radiotherapy treatment benefits must be weighed.  
The clinical picture of children with CNS metastasis is varied and the radiotherapy treatment unclear 
[79]. Primary CNS disease is rare. Yet CNS is the most common metastatic progression or relapse site 
[79]. In children older than 1 year this spread is mainly hematogenous spread, whereas in children less 
than 1 year it is due to non-hematogenous spread [79]. Prophylactic CNS radiotherapy is not indicated 
due to the rare nature of CNS metastasis [79], and the treatment guidelines for CNS relapse are unclear 
[79]. 
In palliative treatment situations, radiotherapy has a very specific role. Although systemic 
chemotherapy should always be started first in situations where function is threatened, for example 
vision with orbital metastasis, cord compression or in cases of severe pain, radiotherapy is effective 
as treatment [33,79]. Pain responds completely or partially in up to 60% of painful sites as well as 
nearly 60% soft tissue sites tumour reduction were noted in a study done by Duke [118]. Paulino 
describes successful treatment response rates to radiotherapy in various tissues that promoted 
positive palliative care [119].  
Autologous transplantation: 
High-risk disease further receives consolidation treatment consisting of a single or tandem myelo-
ablative stem cell transplant, followed by treatment for minimal residual disease and cell maturation 
maintenance therapy [116]. With the inclusion of an autologous stem cell transplant as consolidation 
therapy, the OS is improved by approximately 20% in stage 4 patients from 20% with chemotherapy, 
radiotherapy and surgery to approximately 40% with MAT [106,120]. Individual co-operatives have 
had a 3-year EFS of more than 50% with tandem transplants, with low transplant mortality rates [115]. 
A COG group study proved 3-year EFS from diagnosis was 50% in the standard treatment group single 
transplant arm and 68% in the tandem MAT group. The 3-year OS rate was 69.1% in the standard 
treatment group compared to 74% in in the standard tandem group [121]. COG A3973 proved no 
survival benefit of purged cells during transplantation versus unpurged cells [115]. 
The main development with regard to transplant was the evaluation of the role of TBI as part of 
conditioning before haematopoietic stem cell transplantation (HSCT). TBI-containing regimens were 
developed to eradicate micro-metastases [117]. In a review of European transplant cases between 
1978 and 2006, TBI regimens produced a significantly worse OS rate of 34% in comparison with an 
OS of 41% for regimens not including TBI [116,117]. A chemotherapy-only conditioning regimen was 
the standard of care. It has also been concluded that there was no survival benefit between 
autologous or allogeneic stem cell transplantation [116,117].  
When comparing the results of the SIOPEN trial with previous COG research in which the 3-year EFS 
for the CEM group was 33% for the SIOPEN group, but 46% for the COG group, it was postulated that 
the rapid COJEC induction regimen used in the SIOPEN trial could have a negative interaction with 
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CEM [122,123]. The COG induction phase did not include carboplatin and had used lower doses of 
cisplatin and etoposide than the rapid COJEC regime [122,123].  
In their own randomisation, SIOPEN studies have shown that in a cohort of 1577 patients randomised 
to receive either BuMel (busulfan and melphalan) or CEM (carboplatin, etoposide and melphalan) as 
conditioning therapy before HSCT, patients treated with BuMel had a significantly better outcome 
compared to those treated with CEM [116,117]. The EFS at 3 years was 49% (BuMel) versus 33% 
(CEM), and OS at 3 years was 60% versus 48% [116,117]. The study also concluded that overall BuMel 
was less toxic than CEM [116,117]. 
Maturation therapy: 
The improvement of outcome with the medicine repositioning of CRA has been studied in the post-
transplantation setting of high-risk and very-high-risk patients [124,125]. Two randomised controlled 
trials of high-risk patients receiving CRA post autologous transplant versus no CRA proved the benefit 
of maturation therapy. The UKCCSG group trial included 175 children from 10 countries, concluding 
with a 3-year EFS for patients receiving CRA, with 46% versus 43% patients receiving placebo [124]. A 
CCG study showed a 3-year EFS rate of 46% for patients assigned to receive CRA versus 29% for those 
assigned to receive no further therapy [126]. 
The role in a non-transplant setting has not been fully established. CRA matures the rapidly dividing 
NB cells into more indolent ganglionic cells and plays a significant role in addressing minimal residual 
disease in patients who are in complete remission [5,124]. CRA use outside an autologous transplant 
setting has more short-term survival benefits [78]. Yet by expert consensus it is recommended by the 
SIOP-PODC working group to included CRA as maintenance outside of a transplant setting [5, 127]. 
Biologicals and targeted therapy: 
Post-consolidation therapy treatment is aimed at clearing minimal residual disease [6,72]. Targeted 
therapies have started playing an increasingly important role in this aspect of treatment. In the line of 
targeted therapies, anti-GD2 therapy is an immunotherapy which improved the OS to 60% 5-year 
survival [128]. Other targeted therapies for NB include ALK-inhibitors, which show great promise in 
pre-clinical trials [129]. A disialoganglioside that is expressed in NB is GD2. A targeted therapy of a 
chimeric murine-human antibody ch14.18 or anti-GD2 has been developed [72,128]. Initial trials have 
combined immunotherapy with transplantation [72,128] or added IL-2 for greater lymphocyte-
mediated effect [72]. A COG phase I study is currently investigating anti-GD2-IL as first line relapse 
strategy [72,128]. 
Other: 
A therapeutic approach for high-risk NB, especially refractory NB, is iodine-131 meta-
iodobenzylguanidine (131I-MIBG) therapy as targeted radiotherapy followed by an autologous HSCT 
[130]. Promising response rates of more than 30% were observed [130]. Currently SKION and COG are 
studying 131I-MIBG in combination with myelo-ablative therapy and hematopoietic stem cell rescue in 




Metronomic therapy is a palliative strategy of the continuous administration of low doses of oral 
chemotherapy drugs designed to target the endothelial cells lining the blood vessels supplying tumour 
cells to modulate the micro-environment of the tumour for onco-static effect [132]. The efficacy of 
the continuous low-dose chemotherapy depends on the enhanced antiangiogenic and pro-apoptotic 
effects of some cytotoxic agents, in both dividing tumour cells and endothelial cells [132]. 
Furthermore, metronomic therapy stimulates both innate and acquired immunity, especially when in 
the T-lymphocytic range like NK-cells and Cytotoxic T-cells [132,133]. A substantial part of the onco-
static effect is the promotion of dormancy of oncology cells [132,133]. 
 
This palliative strategy relies on drug repositioning for indications other than their original use 
[132,133]. Drugs like cyclo-oxygenase 2 (COX 2) inhibitors also show anti-tumour activity due to 
inhibition of angiogenesis [132,133]. A low dose of cyclophosphamide leads to a decrease in the 
number of circulating T-regulatory cells and directly inhibits T-regulatory cell function [132,133].  
 
Some studies into the efficacy of metronomic therapy in children have been done. Fousseyni et al. 
conducted a study to evaluate the use of metronomic chemotherapy with vincristine, 
cyclophosphamide and methotrexate in 12 children with refractory cancer in Mali. No objective 
response was observed, but disease stabilisation was observed in 58% of the patients [133]. Wolter et 
al. and Xu et al. independently proved that propranolol induced apoptosis by inhibiting the growth of 
NB cells irrespective of MYCN status [134]. The anti-tumoural activity was dependent on inhibition of 
the β2 receptor, and that treatment resulted in activation of p53 and p73 signalling [134]. Higher 
mRNA levels of β2 adrenergic receptor correlate with improved patient survival. Propranolol leads to 




Acute and late chemotherapy and radiotherapy late effects are well documented. NB protocols 
contain doxorubicin and platin-based chemotherapy drugs like cisplatin and carboplatin. Doxorubicin 
has well-documented cardiotoxicity, whereas the platin-based chemotherapy has nephro- and 
ototoxic effects [135]. These acute effects must be monitored with serial cardiac echocardiograms, 
glomerular filtration rate (GFR) measurements and hearing screening tests respectively [136]. Other 
organ effects attributed to patients with radiation toxicity and transplant sequelae include endocrine 
dysfunctions [137]. Significant secondary malignancies attributed to etoposide treatment are 
leukaemias like AML and, in the long term, sarcomas and carcinomas [138]. 
Future research: 
Current clinical trends are to identify a subgroup in the high-risk stratification of very high-risk 
stratification [139,140,141]. Patients who are considered as very high risk are high-risk patients who 
respond poorly to induction therapy [3] and patients with combined MYCN amplification and bone 
metastases [139]. Response to treatment has been associated with outcome. The persistence of NB 
cells in bone marrow or the persistence of a 123I-MIBG-avid tumour measured as per the modified 
Curie score after induction chemotherapy is associated with a poor prognosis [96,142]. The 
pathological response of the tumour to chemotherapy has prognostic significance. An increase in 
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histologic differentiation of the primary tumour and decrease in mitosis are associated with improved 
outcomes [143]. 
When considering the micro-environment of NB tumours, irregularities in the morphological shape of 
blood vessels during neo-angiogenesis and with increased crosslinking and branching or stiff Ret Fs 
network predict a poorer outcome subgroup in the high-risk group NB [143]. By utilising ‘omics-
techniques, mRNA expression has aided in differentiating not only low-, intermediate- and high-risk 
tumours [144] more accurately than the current INSS [144], but also in differentiating the high-risk 
staging tumours that can be termed to be a very-high-risk group [144, 145]. Higher mRNA expression 
is associated with poorer outcomes [145]. Furthermore, genetics like the DKC1 gene are also 
associated with patients who respond poorly to induction and are thus a very-high-risk group [141].  
The purpose is to identify a group of patients who will benefit from novel therapies [139] and predict 
patients with a resistance to therapy [140,141], especially in a group of patients where survival is poor 
even in HICs [139,140,141].  
To be able to identify these novel therapies, new biological and genetic markers are being identified. 
With genome-wide sequencing of NB, a few molecular biological targets were identified [146]. 
Biological therapies with priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET 
bromodomain, aurora kinase, mTORC1/2), BIRC5 and checkpoint kinase 1 will potentially be 
developed [146]. A novel marker such as ALK has been identified in only 10% of NB and benefits a 
small percentage of patients for targeted therapy [146]. These drugs are currently not available in 
LMICs but might be considerations in the future. 
Liquid biopsies test circulating tumour cells (CTCs) or circulating DNA (ctDNA) shed by the tumour in 
the blood or lymph [147]. It is a minimally invasive test to diagnose and monitor NB with the main aim 
of obtaining multiple time-independent samples to improve heterogenous pathophysiological 
diagnostics rather than a single point traditional biopsy [148]. Rapid DNA and RNA sequencing, as well 
as protein analysis with proteomics, will identify new treatments, diagnostics and diagnostic markers 
[144].  
Considerations for LMICs: 
The incidence and epidemiology of NB in HICs is well documented [7,149]. Due to limitations in 
resources that prevent accurate statistical reporting, incidence and epidemiology is still not 
completely documented in many LMICs [150]. Reliable paediatric cancer registries do not exist or are 
limited to single institutions, and this makes interpretation of data difficult. Yet, internationally, NB is 
the most common sympathetic tumour in children [149]. According to the world age-standardised 
rate (WSR), Caucasian incidence is higher than other ethnicities. Yet the WSR of 10.2 per million 
person-years in black children in the USA is in contrast with the WSR of 2.7 per million person-years 
in Sub-Saharan Africa, where there is a predominantly black population [149]. The highest incidence 
of all CNS tumours was noted in HICs, which is clearly related to the wide availability of diagnostic 
facilities. The lower incidence rates in LMICs is probably due to poor access to imaging facilities, 




Thus far, epidemiological reporting of NB has been limited to single institutional publications [76,151]. 
Data from the South African Children’s Tumour Registry published in 2015 reported an age-
standardised ratio (ASR) of 3.1/1 000 000 for NB and 3.0/1 000 000 for NB and Ganglioneuroblastoma 
[14]. By institutional reporting, the outcomes for children diagnosed with NB are far poorer than other 
MICs and HICs [151]. 
Treatment in HICs aims at treatment-intense regimes with transplant and immunotherapy options [3]. 
In many LMICs, as is the case in South Africa, the treatment choices are limited to mainly 
chemotherapy, surgery and radiotherapy [5,152]. Due to advanced disease at diagnosis, tumours are 
often inoperable and treatment is therefore palliative. Other challenges for the management of NB 
include lack of surgical and radiotherapy skills or equipment, as well as lack of chemotherapy [5,152]. 
In settings where drug insecurity is high, many LMICs do not have even basic medicines for palliation 
[153]. Poor outcomes have necessitated the development of palliative strategies. 
In LMICs, many factors play a role in the optimal care for patients with NB, such as stage of disease, 
nutritional status at diagnosis, family resources, belief systems and personal autonomy. Resources, 
drug security and expertise in institutions influence treatment decisions to a similar extent as 
treatment adherence and response to treatment. The ability of facilities to provide supportive care, 
in terms of antibiotics, intensive care and granulocyte-stimulating factors (G-CSF), influences decision-
making in the intensity of treatment that patients receive [5,52]. 
 
In LMICs NB has a poor prognosis of less than 20% 5-year survival in advanced disease [52,152]. With 
the three modalities of chemotherapy, surgery and radiotherapy the prognosis varies from 96% 5-year 
OS for stage 1 to a dismal 20% 5-year OS for stage 4 [2,3,5], with limited data reporting the outcomes 
in South Africa to be lower than 20% [151].  
Currently in South Africa, as in other LMICs, the management protocols used in the treatment of NB 
have been diverse and based on experience of paediatric oncologists [155]. As collaborative efforts, 
with data from multiple centres, promote more robust data [155], the SACCSG has committed to 
developing national protocols to harmonise treatment of patients with the same cancers. This will also 
assist as guidance to the planned National Health Insurance Plan currently being developed for South 
Africa.  
Management choices: 
The proposed multi-centre SACCSG’s prospective treatment protocol aims to introduce a standard 
national management protocol for children treated for NB in South Africa to manage and treat NB 
patients uniformly, utilising the diagnostic and treatment modalities currently available nationally in 
an ethical and cost-effective manner. It also aims to accurately collect data and analyse the disease 
characteristics and treatment outcomes for South African patients to improve future outcomes.  
The limitation of the INSS and INGR staging systems is that the determination of risk stratification in a 
health system, like in South Africa, with heterogeneous services, skills, resources and access to the 
diagnostic modalities utilised in the various staging systems, makes application challenging. The INSS 
system is a post-surgical risk classification [156]. In settings where predominant presentations are with 
advanced disease, where surgery is not the first line of treatment, the classification is of limited use. 
The INRG classification-based risk groups are based on imaging as a pre-surgical risk classification 
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[156]. Translational correlation and interpretation of various diagnostic tests versus specialised 
diagnostics have not been studied. This makes the interchangeable utilisation of diagnostics and 
interpretation of results according to set stratification systems difficult. Current INRG and COG risk-
based classifications are dependent on ploidy and deletions such as 11q [2,3] with limitations for low-
resource settings. 
Due to the utilisation of different criteria according to institutional capabilities and preference, there 
are limitations to the standardisation of care, sharing national resources and the ethical distribution 
of resources. Thus, the risk classification for this protocol is based on the SIOP-PODC guidelines [5] 
and includes INSS and INRG risk classifications to support the capabilities of low- and high-resource 
units. 
The diagnostic investigations are based on the standard of care in South Africa and include validated 
investigations described in the literature for accurate staging, risk classification, exclusion of co-
morbid diseases and tumour-associated complications that will influence treatment decisions.  
The recommendations regarding basic, advanced and nuclear imaging have been chosen to facilitate 
diagnostics as well as treatment response evaluations. The recommendations include the criteria 
based on the International Neuroblastoma Response Criteria (INRC) of 1993, the revised INRC criteria 
of 2017 and the soft tissue Response Evaluation Criteria in Solid Tumours (RECIST) to accommodate 
the heterogeneous availability of resources in various oncology units [156].  
Although age and stage of disease are important prognostic factors, risk classification relies on 
pathology as well as molecular and genetic characteristics for risk stratification [2,3]. Treatment is 
increasingly guided by biological characteristics, as is evident from increased risk classification with 
unfavourable histology, MYCN amplification and targeted therapy such as anti-GD2 [72, 146]. Each 
risk group will be treated with individual protocols to address biological differences. 
Protocols for low- and intermediate-risk disease have been selected to minimise toxicity (cytopenias, 
cardiotoxicity and renal and ototoxicity), whilst still basing treatment on symptomatic tumour 
presentations and/or prognostic biological pathology in line with North American and SIOPEN trials. 
Surgery is the standard of treatment in any setting [2,3]. With the INES99.2 and INES99.3 studies, good 
2-year OS of 97.6% and EFS of 96.4% were obtained with surgery alone and carboplatin- and 
etoposide-only chemotherapy for symptomatic patients or advancing disease [59,157]. In these two 
studies, patients with poorer outcomes due to unfavourable histology are being treated as 
intermediary risk in more recent trials, as will the patients in the South African protocol.  
 
Both SIOPEN and COG use doxorubicin-based protocols. The SIOPEN LINES study relies on histology, 
molecular techniques and genetics to divide the treatment into 10 groups [95]. The treatment ranges 
from observation only to chemotherapy, surgery and radiotherapy [95]. In low-resource settings, 
determining the genetic mutations and molecular aberrations might be delayed or not possible to 
determine. The COG-A3961 approach distinguishes between favourable and unfavourable histology 
as determinants for the chemotherapy protocol and duration [90]. As histological classification is 
essential for diagnosis, the approach is advised for treatment in South Africa. 
 
For improved OS and EFS, independent of induction chemotherapy, patients must receive a gross total 
resection [109,110], local and/or metastatic radiotherapy plus a single or tandem autologous 
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transplant [121]. Further immunotherapy [128] and maturation therapy increases the OS [124]. No 
induction therapy has proved superior to obtain CR for high-risk patients [99]. Rapid COJEC only 
benefits EFS by ensuring patients are transplanted faster [99]. Yet rapid COJEC is more toxic with long 
hospital admissions for supportive treatment due to infections and cytopenias [99]. Infective 
complications of rapid COJEC due to neutropenia are decreased with the recommended inclusion of 
G-CSF [97]. G-CSF not only strains labour and financial resources but administering it is also painful to 
patients. An OJEC/OPEC or COJEC is advised to decrease resource burdens and lower toxicity. In the 
proposed protocol, OJEC/OPEC with a Carboplatin dose of 500mg/m2 is advised versus a Carboplatin 
dose of 750mg/m2 in COJEC to lessen nephrotoxicity [159]. Cumulative doses of carboplatin cause 
glomerular damage and loss of magnesium [159]. A non-Doxorubicin-based induction is preferable 
because CADO is reserved for bone marrow clearance post induction. A low cumulative dose of 
Doxorubicin is advised in the South African patient population due to complications of malnutrition 
and a risk of increased cardiotoxicity [136]. 
Topotecan in the treatment of NB has no indications for use in the South African essential medicines 
formulary [160]. This prevents availability of TVD in public hospitals in patients with a poor response 
to induction chemotherapy. Instead CADO is chosen as replacement.  
For the patients who do qualify for autologous transplant, BuMel is recommended as conditioning 
before the transplant as it has proven survival benefit above CEM and less engraftment toxicity with 
OJEC/OPEC [121]. BuMel has less risk of severe mucositis and thus infectious complications. Yet a 
higher risk for sinusoidal obstruction syndrome has been documented [121]. 
For a metronomic strategy, a regime with increased immune-modulatory and anti-angioneogenesis 
activity is favoured above other regimes such as the Metro-Mali 1 [133], Metro-Mali 2 [161] or Metro-
Mali 3, or COMBAT regime [162]. With vincristine, cyclophosphamide and methotrexate the Metro-
Mali 1 study included 12 children with relapsing or refractory nephroblastoma, retinoblastoma or NB. 
Stable disease was observed in 58% for up to 6 months, and 50% were alive after 36 months [133]. In 
the Metro-Mali 2 study, solid tumours showed favourable responses to a combination of vincristine, 
cyclophosphamide, methotrexate and Valproic acid [161]. A single metastatic NB patient had a partial 
response and 36-month follow up on the regime [161]. The COMBAT trials have had mixed results 
with a combination of celecoxib and retinoic acid alternating with etoposide and temozolomide [162]. 
The outcomes were a 2-year EFS of 10% and a 2-year OS of 30% [162]. In NB, a vascular tumour, 
propranolol is a superior anti-angiogenic agent above Valproic acid [163], and propranolol is more 
easily available to reposition for metronomic purposes than Valproic acid. Valproic acid is an HDAC 
inhibitor, and its use in preclinical NB studies has suggested it increased CD133 cells [164]. These cells 
are less sensitive to chemotherapy treatment [164]. Propranolol inhibits growth, induces apoptosis 
and decreases proliferation in NB regardless of the MYCN status [165]. In xenografts it works 
synergistically with the topoisomerase I inhibitors [163]. 
 
The proposed study will be a multi-centre South African Children’s Cancer Study Group treatment 
protocol in order to investigate the challenges of treating NB in South Africa and to treat all children 
with NB in a standard way with a prospective national management protocol.  
As patients are accrued onto the study, potential risk factors for risk stratification will be prospectively 
identified in an open-label descriptive study. Changes in the treatment will follow to optimise care to 
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a primarily curative rather than palliative outcome and create new prospective study questions with 
improved outcomes. 
 
3 .  A I M  
 
The aim is to introduce a standard national management protocol for children treated for 
Neuroblastoma in South Africa with the aim to improve overall survival (OS): 
• All children with neuroblastoma will be treated with a uniform treatment protocol. 
• Current imaging and diagnostic tests will be utilised in a uniform manner to determine the 
optimal imaging and diagnostic tests necessary in a resource-limited setting.  
• To accurately analyse the disease characteristics and the association with overall survival.  
    
4 .  O B J E C T I V E  
 
4.1) Primary objectives: 
• To implement a national prospective management protocol to improve OS and EFS at 
endpoint 2 years and 5 years post cessation of treatment. 
 
4.2) Secondary objectives: 
• To evaluate the prognostic significance of basic laboratory and imaging diagnostics in 
children treated for NB in South Africa using OS and EFS, as well as treatment response as 
predictors of outcome. 
• To describe the epidemiological profile of South African Neuroblastoma patients. 
 
5 .  M E T H O D S  
 
5.1) Study design: 
The study will be an open label, prospective, multicentre, descriptive study.  
5.2) Study size:  
The expected sample size will be 35 – 40 new patients per year. This is an estimation based on 
recent statistics publish by the SACCSG [14]. The two year early outcomes aims to include 70 – 80 
patients over this period.  
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5.3) Study period: 
Recruitment will start in August 2018. The first evaluations will be during the 2 year early outcomes 
but the protocol will be a long term protocol to include 5 year outcomes. 
5.4) Study setting: 
All POUs treating patients with NB is eligible to participate in the study. All physicians within the 
Republic of South Africa will be invited to participate as a collaborative group to provide optimal 
treatment to children with NB. 
5.5) Study population: 
5.5.1) Inclusion criteria 
• Newly diagnosed patients with NB between the ages of 0 and 18 years old at the start of 
treatment with: 
a) Biopsy proven NB or 
b) Radiological reported NB with positive urine catecholamines or BMAT with involvement of 
NB cells or 
c) BMAT with involvement of NB cells and a positive urine catecholamines (in cases where a   
biopsy is not possible, the primary tumour can’t be visualised or radiological evidence is 
inconclusive) 
d) Relapsed stage 1A or 4s patients who are chemotherapy and radiotherapy naïve.  
• With caregiver consent and patient assent (if older than 7 years of age). 
• The patient is chemotherapy naïve. 
 
5.5.2) Exclusion criteria 
• There is no caregiver consent or assent in a child capable of providing assent. 
• Patients that are not treatment naïve, in a relapse presentation or with disease          
progression. 
• Patients who are unable to follow the protocol due to medical, social or geographical 
reasons. (These patients must still be documented and registered with the National Cancer 
Registry 
 
6 .  PAT I E N T  E N R O L L M E N T  
 
All eligible patients will be enrolled when presenting to treatment centres by the primary 
physician(s) or medical practitioner (including nursing staff or auxiliary services). Parents or legal 
guardians will be asked to provide informed consent (please see Appendix A) to participate in the 
study. Where appropriate physicians will obtain signed assent from the patient older than 7 years of 




Participation will include all phases of treatment from the diagnostic, treatment and follow up 
phases of the protocol. Patients will be followed for the duration of their therapy and for as long as 
is possible (ideally at least five years) following the completion of chemotherapy. 
 
Informed consent and assent will be done in the participant’s preferred language wherever possible 
or via an interpreter proficient in the local language. The interpreter should be oriented in a medical 
capacity to insure factual accuracy. 
 
Participation is completely voluntary and participants will be free to withdraw their participation in 
the study at any time without disruption in medical care or digression from standard treatment. 
They will still be treated according to treatment protocol, but their data will not be included in data 
analysis.  
         
7 .  D I A G N O S T I C  E VA L U AT I O N  
 
7.1) History and clinical examination 
a) General History (including family history) and general examination. 
• Include  
o presenting complaints and duration 
o anamnesis and progression 
o previous medical and surgical history 
o family history, parental consanguinity, sibling history and familial 
malignancies 
o chronic illness, co-morbid diseases and current medication and 
traditional interventions  
• With attention to: weight loss, fever, night sweats, diarrhoea, nystagmus, bone 
pain, general pain hypertension, constipation, regional obstruction symptoms, 
mobility and bladder function. Note duration of these symptoms. 
b) Complete general examination documenting: 
• Anthropometry (using SD-WHO charts) including weight for age, height for age, 
weight for height and head circumference. 
• Mid-upper arm circumference (MUAC) in children 6 months – 5 years of age. 
• Blood pressure. 
• Clinical features of the tumour laterality and size. 
• Size of the liver and masses 
• Lymphadenopathy. 
• Local pressure symptoms 
• Clinical symptoms and signs of metastases and complications of metastatic 
spread. 
• Neurological signs indicative of Opsocolnus/Myoclonus Syndrome [3]. 
• Documentation of diarrhoea indicative of Vaso-Intestinal Peptide Syndrome [3]. 
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• Skin lesions. 
• Clinical indication for metastases i.e. skull nodules, racoon eyes, etc. 
• Documentation of dysmorphisms and genetic or syndromic features. 
 
c) The presence of life threatening symptoms (symptomatic tumour presentation) 
• Intraspinal neuroblastoma: symptoms of spinal cord compression or a spinal 
tumour component that occupies more than one third of the spinal canal.  
• Systemic symptoms: 
o Pain requiring opiate treatment  
o Gastrointestinal  
- Vomiting needing nasogastric/IV support  
- Weight loss >10% body weight  
- Diarrhoea with VIP does not respond to chemotherapy and is a definite 
indication for surgery  
o Respiratory  
- Respiratory distress without evidence of infection  
- Tachypnoea >60 bpm  
- Oxygen need or ventilatory support   
o Cardiovascular System  
- Hypertension  
- IVC compression +/- leg oedema  
o Renal - Impaired renal function, creatinine increased x 2 ULN  
- Poor urine output, less than 2mls/kg/day  
- Hydroureter/hydronephrosis  
o Hepatic  
- Abnormal liver function >2 ULN  
- Evidence of DIC 
o Neurological 
- Neurological sign indicative of pressure symptoms 
- Nystagmus 
 
7.2) Laboratory Investigations 
Laboratory investigations: 
These standard investigations are for the evaluation of treatment eligibility, diagnostic 
evaluation and clinical evaluation of the disease process as well as co-morbid pathology.   
• Full blood count including differential count 
• Urea, creatinine and electrolytes, calcium, magnesium, phosphate and liver enzymes 
• Clotting screen: INR, aPTT and fibrinogen (to exclude NB associated clotting 
disorders in preparation for invasive procedures). 
• Non-specific tumour markers: Uric Acid and Lactate dehydrogenase (LDH) and 
Ferritin 
• Urine analysis: Dipstix 
• Urine catecholamines (24 hours urine collection or a spot sample x 3) must be done 
to confirm the diagnosis. 
242
Stellenbosch University https://scholar.sun.ac.za
• HIV-test at diagnosis 
• Lumbar puncture: only per indication with neurological signs 
        
7.3) Radiological examination 
Radiological evaluations must be done prior to the start of any treatment interventions and 
at the point of treatment response evaluation. Identifying diagnostic characteristics and 
image defined risk factors as well as measurements for treatment response should be 
recorded  
  
Before chemotherapy and surgical treatment the following radiological investigations should 
be performed: 
• Abdominal ultrasound (in the absence of CT or MRI facilities) 
• Chest X-ray AP and lateral (AP only if a CT chest was done) 
• CT chest  
• CT abdomen or MRI abdomen  
• Echocardiography to evaluate cardiac function for the eligibility to administer  cardio-
toxic chemotherapy drugs: Shortening fraction (SF) > 28%  
• Clinical indications for brain and bone metastasis requires pathology directed 
imaging i.e. CT brain or X-ray of the bones 
• A skeletal X-ray screening of the long bones is indicated in units where nuclear 
skeletal surveillance investigations are not available at the diagnostic phase.   
7.4) Nuclear medicine studies 
Nuclear investigations are important for the diagnosis, treatment response evaluation as 
well as toxicity monitoring in the treatment of NB. 
For diagnostic purposes a 123I-MIBG scan and bone scan should be done. With limitations in 
availability 123I-MIBG scan is preferred above bone scan.  Approximately 10% of NB are not 
123I-MIBG avid [3]. In this case a PET/CT-scan can be used to document the primary tumour 
and complete the skeletal survey with a bone scan. If a tumour is confirmed on PET/CT-scan 
all follow up scans must be a PET/CT-scan.   
The same nuclear imaging test (excluding bone scan) used for diagnosis must be used to 
evaluate treatment response in the same patient. 
Two different nuclear studies may not be done on the same day to prevent the photon 







7.4.1) Diagnosis and whole body survey:  
123I-MIBG scan: 
The 123I-MIBG imaging is the primary imaging for whole body  imaging. All attempts should 
be made to use MIBG at diagnosis and for treatment response evaluation and should be 
restricted to nuclear medicine departments with appropriate facilities and staff experienced 
in paediatric imaging. 
 
Indications: 
Indications for diagnostic 123I-MIBG imaging in Neuroblastoma (NB) include 
• Diagnosis and confirmation in suspected NB 
• When the initial diagnosis of was made from a metastatic site 123I-MIBG imaging may be 
used to visualise a primary 
• Staging of NB disease 
 
Reporting: 
All MIBG scans should be evaluated according to the modified Curie-score (please see 
Appendix Q) by a Nuclear Medicine physician. 
 
Practical guidelines: 
It is preferable to do a diagnostic 123I-MIBG scan before the start of chemotherapy, but may 
be done up until a week after the start of the first dose of chemotherapy. 
For re-assessment  123I-MIBG scans should take place as close as possible before the next 




• For the documentation of the primary tumour and complete the whole body imaging  in 
a 123I-MIBG non-avid tumour 
• In patients where the primary is not found  
• Assess treatment response 
• Routine follow up in a suspected relapse setting if the restaging MIBG scan is negative 
 
Practical guidelines: 
The diagnostic PET/CT should be done before that start of chemotherapy. 
For re-assessment PET/CT scans should take place as close as possible before the next 
chemotherapy administration but not earlier than two weeks after chemotherapy. 
 
Bone scan: 
In centres where 123I-MIBG scan and/or PET/CT scan is not available a bone scan must be 
done as part of the whole body imaging.  
If a bone scan is used for the whole body imaging the primary tumour must be well 




It is preferable to do a diagnostic bone scan before the start of chemotherapy, but may be 
done up until a week after the start of the first dose of chemotherapy to prevent flare 
phenomenon [166]. 
A bone scan may not be used for re-assessment. Even without a baseline 123I-MIBG scan all 
reassessment nuclear skeletal screenings should be done by 123I-MIBG scan. 
7.4.2) Toxicity monitoring: 
GFR: 
The GFR should be recorded prior to commencing cisplatin chemotherapy and after every 
two cycles of cisplatin containing chemotherapy. The GFR should also be performed at the 
end of treatment. 
7.5) Atypical presentations 
In 10% of cases a primary can not be found – in which case diagnosis must be made on sites 
of the metastatic tumour. This can be done via the following diagnostic techniques: 
• Bone marrow and/or trephine diagnosis of small blue round cell with positive u-
catecholamine levels
• 123I-MIBG positive with positive u-catecholamine levels
• PET-scan with positive u-catecholamine levels
7.6) Eligibility of platinum alkylators chemotherapy 
a) For renal toxicity:
All children, irrespective of their chemotherapy regimen, should have a serum creatinine and 
calculated GFR performed at diagnosis and after every second course of chemotherapy. 
All children receiving cisplatin containing regimens should have: 
• a two plasma sample radioisotope GFR according to the EANM guidelines
• or a GFR using the bedside IDMS traceable Schwartz eGFR.
The Schwartz eGFR [167,168] may be used if a radio-isotope GFR cannot be performed at 
the participating institution. The GFR should be recorded prior to commencing cisplatin 
chemotherapy and after every two cycles of cisplatin containing chemotherapy. The GFR 
should also be performed at the end of treatment. 
Height (cm) X 40 
Estimated Glomerular Filtration rate (eGFR) = ------------------------------------------- 
ml/minute/1.73m2 Creatinine (μmol/L) 
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b) For ototoxicity: 
 
All children receiving cisplatin containing regimens should have an qualitative audiogram 
done prior to commencing cisplatin chemotherapy and after every 2 cycles of cisplatin 
containing chemotherapy. This should be documented again at the end of treatment. See 
Appendix P for recommendations and the Boston Ototoxicity Scale [169]. 
 
 
 8 .  PAT H O L O G Y  E VA L U AT I O N  A N D  
C E N T R A L  R E V I E W  
 
References: [170-175] 
From a histo-pathological point of view Neuroblastoma is a very heterogeneous tumour. Making a 
morphologic diagnosis and using histo-(cyto-)pathologic findings for prognostic purposes relies on 
diagnostics of the various relevant tumour areas for molecular, genetic or biological analyses and 
interpretation. 
 
Relevant tumour material from several different tumour and nodular areas should preferably be 
taken (if feasible and/or possible) for accurate histologic and molecular, genetic and/or biological 
examination. The reason is due to tumour heterogeneities at the genetic level (e.g. for the MYCN 
and/or the chromosome 1p status) and/or at the histologic level (e.g. ganglioneuroblastoma and 
nodular subtype) both of which have prognostic implications. For this purpose, the paraffin 
embedded material is of great importance.  
 
Tumour pathology will be reported in each centre according to a standardised pathology form for 
Neuroblastoma (see Appendix C) as well as biological testing will be done for prognostication.  
 
In cases where the diagnosis is not conclusive and/or for standardised reporting quality assurance, 
central pathology review may be performed by a designated pathology group, made up of 
representative(s) from a designated Department(s) of Anatomical Pathology, NHLS Laboratories; 
with the lead pathologist being based at Red Cross War Memorial Children’s Hospital. For this 
purpose a pathology block should/may be made available. 
 
8.1) Tumour diagnosis: 
There are two requirements needed for therapy in neuroblastoma: 
1. Morphological diagnosis 
2. Prognostication / molecular testing for: 
a. MYC-N (mandatory) 
b. Chromosome 1p status (optional at this stage) 
 
8.2 Method of diagnosis: 
The mode of diagnosis will depend on: 
i. Access to interventional radiologist(s),  
ii. Access to paediatric surgeon(s) and  
iii. Theatre accessibility.  
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iv. Patient functional/clinical status 
Biopsy of the primary tumour is preferable, but bone marrow and metastatic lesions are acceptable. 
 
Methods: 
The method of biopsy will depend on the access to: 
i. Radiologist and radiological capabilities 
ii. Location of tumour, tumour vascularity and accessibility to tumour via a percutaneous 
route 
iii. Theatre facilities and accessibility. 
Primary suggested method of biopsy: 
1. Ultra-sound guided core needle biopsy (preferred method of choice). 
2. Ultra-sounded guided Fine Needle Aspiration biopsy with cell block collection and onsite 
evaluation (ROSE) (alternative method) 
3. Combination of methods 1 + 2 = would constitute the gold standard for obtain 
maximum/optimal material for initial diagnosis. 
 
Additional secondary methods (not first choice): 
1. Open biopsy / laparoscopic biopsy of primary tumour. 
2. Bone marrow biopsy with bone marrow smears (unstained slides) 
3. Ultra-sounded guided Fine Needle Aspiration (FNA) biopsy with cell block collection without 
onsite evaluation (ROSE) (alternative method). 
4. Ultra-sound guided Fine Needle Aspiration biopsy with unstained smears made for 
molecular testing. 
5. Sampling of metastatic lesions.  
 
 
8.2) Ultrasound guided Core Needle Biopsy: 
Ideally more than two samples should be taken for histopathological evaluation, and preferable four 
cores. Biopsy for histopathology should be sent to the laboratory in 10% buffered formalin.  
 
If an excision or incisional biopsy is done enough tissue must be available for four samples whether it 
is from the primary tumour, metastatic tumour i.e. lymph node excision, liver biopsies or skin 
biopsies.  
The tumour must always be handled by a pathologist in order to make a morphological diagnosis 
and provide a prognosis based on pathological findings. Another function of pathologists is to 
choose the relevant tumour areas for molecular-genetic/biological analyses. 
 
During the handling of biopsy material, the pathologist or physician obtaining the biopsy should try 
to avoid artefacts due to crushing and squeezing. In addition, needle biopsies tend to stick to each 
other which may hamper the subsequent division of the material. Therefore, each biopsy should be 
kept in a separate tube in the above mentioned sterile solution. 
The samples will be for the following purposes: 
- Biologic and genetic studies 
- Tumour banking 
 
Treatment is determined by risk stratification. The information includes clinical information, imaging, 
biological and genetic testing. If tissue sampling is limited then diagnostic testing is more important 
than specialised testing.  
 
8.3) Ultrasound Fine Needle Aspiration Biopsy 
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Ultrasound guided Fine Needle Biopsy (FNAB) is a sensitive and effective method for diagnosing 
neuroblastoma. Rapid on-site evaluation should be performed when using FNA for diagnostic 
purposes as the quality of material can be assessed. 
FNAB alone is inadequate for the purposes of therapy, since additional molecular testing is needed. 
A cell block is the preferred method of choice to obtain material for immunocytochemical staining 
and molecular testing. 
Unstained, air dried slides are also possible but not the preferred method of choice. 
 
8.4) Open Biopsies:  
In case of open biopsy, at least two different areas of the tumour should be biopsied by the 
surgeon. Specimen size should equal at least 1cm³ (1cm x 1cm x 1cm).  
 
8.5) Preparing samples for molecular testing: 
Molecular testing can be performed on numerous specimen types and the method selected will 
depend on the method available to each laboratory: 
 
1. Paraffin embedded (FFPE) tissue block – most widely used and preferred method of choice. 
2. Cytology cell block in the form of paraffin embedded (FFPE) tissue block, on condition that it 
is adequately cellular. 
3. Frozen tissue block. 
4. Touch preparations 
 
Make 10 touch preparations from a freshly cut surface. The slides are air-dried and unfixed - which 
can be used for fluorescence based in situ hybridisation (FISH).  
 
8.6) Tumour Material Obtained after Cytotoxic Therapy: 
Sampling and sectioning of the tumour material in resected tumours or biopsies after cytotoxic 
therapy has been administered can be done following the same guidelines as for tumours resected 
or biopsied at diagnosis.  
It is important that the percentage necrotic areas and viable tumour cells versus normal cells be 
reported. Furthermore, the morphologic changes induced by cyto-differentiation and maturation 
must also be reported. 
  
8.7) Regional Lymph Node Examination: 
Biopsy of regional nodes, when feasible, must be done despite their appearance. The histology 
report should include information on site and number of positive nodes, type of metastatic spread, 
i.e. presence of micrometastases (less than 2 mm), intranodal parcelled metastases, intranodal 
massive metastases, nodal metastases with extracapsular extension in localisations not adherent to 
the resected tumour specimen, and morphologic description of the tumour infiltrate. 
 
8.8) Report: 
For the purposes of standardisation, the pathology report must include the following [174]: 
 
8.8.1) Immunohistochemistry: 
     Diagnostic confirmation 
     For histological diagnostics of a tumour and investigating the differential diagnosis     







   
8.8.2) Diagnostic criteria [175] 
• Composed of neuroblasts exhibiting variable degrees of differentiation up to ganglion cells  
o Neuroblasts  
 Small round nuclei with stippled ("salt and pepper") chromatin  
 Large cell/large nucleolar phenotype  
 Comprises approximately 8-10% of all neuroblastomas 
 Nuclei 1.5 to 2 times larger than those of typical neuroblastoma cells 
 1-4 prominent nucleoli 
 Usually seen in the undifferentiated and poorly differentiated 
subtypes of neuroblastoma (see below) 
 Associated with MYCN amplification and a poor prognosis 
 Scant eosinophilic cytoplasm 
 Indistinct cell borders 
o Ganglion cells  
 Large round nuclei with prominent nucleoli 
 Abundant eosinophilic cytoplasm 
 Nissl substance in cytoplasm  
 Basophilic granules/bodies composed of endoplasmic reticulum 
• Background stroma also shows different levels of differentiation  
o Schwannian stroma resembles collagen  
 Requires S100 stain (positive) for identification 
o Neuropil  
 Pink, fibrillary extracellular material 
o Dense lymphoid infiltrate occasionally present  
 Lymphoid follicles may be present 
 Often seen in patients with Opsoclonus-Myoclonus-Ataxia (OMA) [173] 
paraneoplastic syndrome 
• Seven subtypes of neuroblastic tumors are recognized according to the degree of 
neuroblastic maturation and the amount of background schwannian stroma  
o Neuroblastoma, undifferentiated  
 Composed entirely of neuroblasts, no ganglion cell maturation  
 Immunohistochemistry is often required to confirm neuroblastic 
lineage 
 Schwannian stroma poor  
 Less than 50% of background stroma is schwannian  
 May be absent 
o Neuroblastoma, poorly differentiated  
 Predominantly neuroblasts, <5% maturing/mature ganglion cells  
 At least one focus of neuropil 
 Schwannian stroma poor  
 Less than 50% of background stroma is schwannian  
 May be absent 
o Neuroblastoma, differentiating  
 Predominantly neuroblasts but >5% maturing/mature ganglion cells  
 At least one focus of neuropil 
 Schwannian stroma poor  
 Less than 50% of background stroma is schwannian  
 May be absent 
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o Ganglioneuroblastoma, nodular  
 Predominantly maturing/mature ganglion cells but at least one well 
circumscribed nodule of residual neuroblasts  
 Neuroblast nodules may correspond to hemorragic nodules in gross 
specimen 
 Schwannian stroma rich  
 50% or more of background stroma is schwannian 
o Ganglioneuroblastoma, intermixed  
 Predominantly maturing/mature ganglion cells but at >1 focus of residual 
neuroblasts intermixed with ganglion cells  
 No distinct hemorragic nodules in gross specimen 
 Schwannian stroma rich  
 50% or more of background stroma is schwannian 
o Ganglioneuroma, maturing  
 Entirely composed of maturing and mature ganglion cells, no residual 
neuroblasts  
 No distinct hemorragic nodules in gross specimen 
 Schwannian stroma rich  
 50% or more of background stroma is schwannian 
o Ganglioneuroma, mature  
 Entirely composed of mature ganglion cells, no residual neuroblasts  
 No distinct hemorragic nodules in gross specimen 
 Schwannian stroma rich  
 50% or more of background stroma is schwannian 
8.8.3) Grading of the tumour – Differentiation for prognostication according to the  
Neuroblastoma Pathology classification adapted for South Africa without mitosis-
karyorrhexis index (MKI): 
Pathology is graded according to the adapted International Neuroblastoma Pathology 
Classification. The classification groups the tumour pathology into unfavourable (UH) 
and favourable histology (FH) based on only tumour subtype and differentiation as 
well as patient age.  
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Neuroblastoma Pathology classification [172] 
adapted for South Africa 
NPC-SA 
Neuroblastoma (Schwannian stroma-poor) 
• Undifferentiated 




<1.5 yrs Poorly differentiated or 
differentiating 
FH 
1.5–5 yrs Differentiating FH 
<1.5 yrs Undifferentiated tumour UH 
1.5–5 yrs Undifferentiated or poorly 
differentiated tumour 
UH 
≥5 yrs All tumours UH 
Ganglioneuroblastoma intermixed (Schwannian 
stroma-poor) 
FH 





Ganglioneuroblastoma nodular (Schwannian 





8.8.4) Staging of the tumour 
 
The INSS staging was developed as a post-surgical staging system and correlates with outcomes [72]. 
As surgical residual disease during local therapy is an important predictor of outcome the 
documentation of degree of resection is of vital importance.  
 
International Neuroblastoma Staging System (INSS) [3] 
Stage 1 • Localized tumour with complete gross excision, with or without 
microscopic residual disease  
• Representative ipsilateral lymph nodes negative for tumour 
microscopically  
Stage 2A • Localized tumour with incomplete gross excision  
• Representative ipsilateral non-adherent lymph nodes negative for tumour 
microscopically. 
Stage 2B • Localized tumour with or without complete gross excision, with ipsilateral 
non-adherent lymph nodes positive for tumour.  
• Enlarged contralateral lymph nodes must be negative microscopically 
Stage 3 • Unresectable unilateral tumour infiltrating across the midline, with or 
without regional lymph node involvement  
• Localized unilateral tumour with contralateral regional lymph node 
involvement  
• Midline tumour with bilateral extension by infiltration (unresectable) or by 
lymph node involvement. The midline is defined as the vertebral column. 
Tumours originating on one side and crossing the midline must infiltrate to 
or beyond the opposite side of the vertebral column. 
Stage 4 • Any primary tumour with dissemination to distant lymph nodes, bone, 
bone marrow, liver, skin, and/or other organs, except as defined for stage 
4S. 
Stage 4S • Localized primary tumour, as defined for stage 1, 2A, or 2B, with 
dissemination limited to skin, liver, and/or bone marrow (by definition 
limited to infants younger than 12 months).  
• Marrow involvement should be minimal (i.e., <10% of total nucleated cells 
identified as malignant by bone biopsy or by bone marrow aspirate). More 
extensive bone marrow involvement would be considered stage 4 disease.  
• The results of the MIBG scan, if performed, should be negative for disease 










9 .  B O N E  M A R R O W  A S P I R AT E  A N D  
T R E P H I N E  G U I D E L I N E  
 
References: [176-180] 
Bone marrow and bone are the most common site of metastasis in Neuroblastoma.  Bone marrow 
aspirate and trephines (BMAT) will form part of the metastatic evaluation at diagnosis and 
treatment response evaluations. 
9.1) Number of samples:  
Bilateral BMATs should be done. Thus bone marrow aspiration and a representative bone core from 
two different sites should be collected. 
9.2) Sample technique:  
Bone marrow aspirate: A minimum of 10 slides per side should be prepared using separate syringes 
for each side. Aspirates from different sites should not be pooled that the heterogeneity of the 
Neuroblastoma cell infiltration can be recorded without underestimating the extent of bone marrow 
disease. Slides should be air-dried and stained using the May-Grünwald, Pappenheim or modified 
Wright stain for initial staging using cytological examination by light microscopy.  
 
Bone core: A 1cm bone core per site should be sampled and should immediately be placed in fixative 
and decalcified. The fixed, decalcified biopsy should be embedded in paraffin, and a minimum of 2 
separate slides should be stained with hematoxylin and eosin for histology and a minimum of 3 
slides can be used for immunohistochemistry (IHC). More slides can be stained according to 
institution protocols. 
 
9.3) Quality of the sample: 
Bone marrow aspirate is considered representative for reporting when: 
• There is >5% tumour cell infiltration.  
• When infiltration with tumour is <5% then 3 out of the following  4 criteria must be fulfilled:  
1) The presence of particles with stromal cells (e.g. histiocytes, fibroblasts, or osteoblasts) 
2) The presence of megakaryocytes 
3) Erythroblasts are >20% of the nucleated cells 
4) Peripheral blood cells are within the range for age  
 
A representative trephine should preferably contain red bone marrow parenchyma at a minimum 





Morphology: The presence of tumour cell nests or clumps or rosettes of Neuroblastoma cells 
expressed as a percentage. Other specific features e.g. nuclear moulding or characteristic NB 
findings should be recorded. 
 
Histology of trephine: Percentage of hematopoietic and tumour tissue and length of evaluable BM 
trephine recorded in mm. 
 
Immunohistochemistry of bone marrow and trephine: At least 2 antibodies investigated in a 
minimum of 3 three sections. Antibodies that may be used are synaptophysin, tyrosine hydroxylase, 
chromogranin A, CD45 and CD 56. Immunohistochemistry staining should be done according to 
institutional protocols. 
 
9.5) Reporting categories: 
Bone marrow aspirate: Both left and right sided samples should be reported separately.  
Categories: 0%, <5%, 5% to <20%, 20% to <50% and ≥50%. The bone marrow sample with the 
highest percentage of tumour infiltration is used. 
 
Histology of trephine: Both left and right sided samples should be reported separately. 
Surface area occupied by peripheral neuroblastic tumour as a percentage of bone marrow space and 
length of evaluable BM trephine in mm recorded. 
 
Immunohistochemistry: Staining should be done according to institutional protocols but the most 
involved side should take preference for staining. 
Surface area occupied by peripheral neuroblastic tumour as a percentage of bone marrow space and 
length of evaluable BM trephine in mm recorded. 
 
9.6) Bone marrow and trephine treatment response assessment: 
Treatment response should be document according to the International Neuroblastoma Response 
Criteria (INRC) revisions of 2012 (See Appendix D) [125] 
 
In cases where the diagnosis is not conclusive or for standardised reporting quality assurance, 
central pathology review will be done at the Department of Anatomical Pathology, NHLS 
Laboratories, Red Cross War Memorial Children’s Hospital. For these purposes slides should be made 
available. 
 
1 0 .  B I O L O G I C A L  A N D  G E N E T I C  M A R K E R S  
 
All diagnostic tumour samples and/or positive bone marrow and/ or trephine samples should be 
tested for biological and genetic significant markers as per current standard of care: 
  
1. Tumour sample: 
• MYCN FISH test for amplification of tumour  




2. Analysis of Bone Marrow and Peripheral Blood (in patients with bone marrow infiltration 
where no tissue biopsy was done) 
• MYCN FISH test for amplification of tumour  
• Ploidy (were possible) 
 
1 1 .  D E F I N I T I O N S  A N D  P R I N C I P L E S  O F  
M A N A G E M E N T  
 
The main aim of the diagnostic investigations is to document disease characteristics, 
evaluate the need for emergency interventions and risk stratify patients for treatment. 
11.1) CURATIVE MANAGEMENT: 





Full diagnostic panel 
Radiological assessment and age 
(INRG + IDRF) 
 
Perinatal and < 18mo age      Not resectable upfront              Resectable upfront 
         





South African Neuroblastoma Adapted risk stratification (SANARS) 
 
*Stage 4S - patients < 12 months with a primary adrenal lesion, cutaneous lesions, bone marrow 
infiltration of less than 10% and/or liver lesions. 
** Non-4S - patients 0 – 18 months that does not define as Stage 4S.   












After initial diagnosis and staging patients must be classified according to a risk classification based 
on imaging, initial surgery, age, histology and tumour markers. 
11.1.1) Risk classifications: 
 
The proposed South African Neuroblastoma Adapted risk stratification (SANARS) aims to provide a 
classification diagnosed via a medical approach, with the aid of the INRG staging, or a surgical 
diagnostic route, with the INSS staging system [2,3]. The degree of resection is also taken as risk 
factor by including the initial surgical status. Age is included due to the importance of age as risk 
factor, the definition of Stage 4s relying on age and that age plays an important part in the 
histological classification. MYCN is an important biological marker denoting a poor prognostic 
feature. It determines the difference between intermediate risk and high risk in stage 3, stage 4s and 
patients less than 18 months [5]. Histological confirmation is central to the diagnosis of NB and lends 
access to the degree of differentiation of the tumour. Histology, according to the Shimada 
classification [32], is validated prognostic factor that represents a biological factor in the risk 
classification, especially in POUs where MYCN is not available. Where MYCN is not available or the 
results are delayed, LDH and Ferritin are validated prognostic non-specific markers, easily 
determined in low resourced settings during diagnosis, that can be utilized as marker to distinguish 
between risk groups [5]. Stage 4s and patients under 18 months of age have good outcomes [86]. 
Symptomatic infants with hepatosplenomegaly, respiratory distress or coagulopathy fare poorer 
than asymptomatic infants [86]. The presence of symptoms increases the risk [5]. 
 
Clinical signs that define symptomatic tumours  are the following: 
• Deterioration of the general condition 
• Feeding difficulties leading to weight loss 
• Respiratory failure defined by oxygen requirement or carbon dioxide retention exceeding 
60mmHg  
• Circulatory failure defined by hypotension or hypertension according to the age specific 
blood pressure reference values 
• Hepatic failure defined by grade 3 toxicity of bilirubin, fibrinogen, or thrombin time  
• Renal failure defined by impaired blood urea or creatinine, new development of 
hydronephrosis or deteriorating pre-existent hydronephrosis 
• Symptomatic or asymptomatic intraspinal involvement documented by MRI 







Image Defined Risk Factor (IDRF) (Appendix F), International Neuroblastoma Risk Group (INRG)/ International Neuroblastoma Risk Group 
(INRG) Consensus pre-treatment staging system (INRGSS) (Appendix G), International Neuroblastoma Staging System (INSS) (Appendix H), 
International Neuroblastoma Pathological Classification (INPC) / Shimada classification (Appendix J), COG risk grouping (Appendix K), 
 
Table 3: Proposed South African Neuroblastoma Adapted risk stratification (SANARS) [2,3,5,32] 




LDH Ferritin MYCN Histology 
 
Risk Group 
1 Resection > 50% L1 >6mo Any Any NA Any  Low 
1 Resection > 50% L1 >6mo Any Any Amp Any High 
1 Observation L1 <6mo Any Any Any Any Very low (VLR) 
2A Resection >50% 
Asymptomatic 
L1 Any Any Any NA/EC/ 
Unknown 
Any Low 
2B Resection >50% 
Asymptomatic 
L2 Any Any Any NA/EC/Unknown Any Low 
2A Resection >50 % 
Symptomatic 
L1 Any Any Any NA/EC/ 
Unknown 
FH Intermediate 
2A Resection >50 % 
Symptomatic 
L1 Any Any Any NA/EC/Unknown UH High 
2B Resection >50% 
Asymptomatic 
L2 Any Any Any NA/EC/ 
Unknown 
FH Intermediate 
2B Resection >50 % 
Symptomatic 
L2 Any Any Any NA/EC/Unknown UH High 
2A Resection <50% L1 Any Any Any NA/EC/Unknown FH Intermediate 
2A Resection 
 < 50% 
L1 Any Any Any NA/EC/Unknown UH High 
2B Resection <50% L2 Any Any Any NA/EC/Unknown FH Intermediate 
2B Resection  
< 50% 
L2 Any Any Any NA/EC/Unknown  UH High 
2A Any resection L1 Any Any Any Amp Any High 
2B Any resection L2 Any Any Any Amp Any High 
3  L2 <18mo <750 <120 NA/EC/ 
Unknown 
Any Intermediate 
3  L2 >18mo <750 <120 NA/EC/ 
Unknown 
FH Intermediate 
3  L2 >18mo <750 <120 NA/EC/ 
unknown 
UH High 
3  L2 Any >750 >120 A/ Unknown Any High 
4  M <18mo >750 >120 A/ Unknown Any High 
4  M <18mo <750 <120 NA/EC/Unknown Any Intermediate 
4  M >18mo Any Any Any Any High 
4S Asymptomatic MS <3mo <750 <120 NA/ EC FH Low 
4S Asymptomatic MS 3-12mo <750 <120 NA/EC/Unknown FH Low 
4S Asymptomatic MS 3-12mo >750 >120 NA/Unknown FH Low 
4S Symptomatic MS 3-12mo <750 <120 NA/EC FH Low 
4S Asymptomatic MS 3-12mo Any Any NA/EC/Unknown UH Intermediate 
4S Symptomatic MS 3-12mo <750 <120 Unknown Any Intermediate 
4S Asymp/ Symp MS 3-12mo Any Any Amp Any High 
4S Symptomatic MS <3mo Any Any Any Any High 
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Adapted Risk Stratification and Treatment Assignment for Neuroblastoma in LMIC (Appendix L) and the International Neuroblastoma Risk 
Group (INRG) Pretreatment Classification Schema for Stage 4S Neuroblastoma and Children’s Oncology Group (COG) Neuroblastoma Stage 
4S Group Assignment Schema Used for COG-P9641, COG-A3961, and COG-A3973 Studies. 
11.1.2) Definitions of response to treatment: 
The aim of the treatment response criteria is to ensure uniform assessment of tumour response. The 
criteria are based on the International Neuroblastoma Response Criteria (INRC) of 1993 [181], the 
revised INRC criteria of 2017 [182] and the soft tissue Response Evaluation Criteria in Solid Tumors 
(RECIST) to accommodate the heterogeneous availability of diagnostic and imagining techniques 
[183]. 
Measurement: 
123I-MIBG scan with CT or MRI- scan should be used as primary imaging techniques to evaluate soft 
tissue sites. FDG-PET can be used in MIBG- non-avid lesions. The measurement of non-nodal target 
lesions should be based on the longest single diameter whereas discrete lymph nodes are assessed 
using the short axis as a single dimension. 
 
Response assessment should include anatomic imaging for primary and metastatic soft tissue 
disease, nuclear medicine imaging using 123I-MIBG scan or FDG-PET scan for assessment of soft tissue 
and bone disease and bilateral bone marrow aspirates and trephine biopsies for assessment of 
marrow and skeletal disease.  
Tissue biopsies may be used as an adjunct to verify the presence of metabolically active or viable 
Neuroblastoma or Ganglioneuroblastoma. 
Urine catecholamine levels will be included to evaluate response but will only be used as supportive 
evidence in centres where other imaging techniques are not immediately available or delayed. Urine 
catecholamine levels lack of standardization in specimen collection and analysis and the influence of 
diet and sample handling have an effect on results. 
 
Subsequent evaluations: 
Subsequent evaluations of tumour response should always be done with the same imaging and 
diagnostic techniques used during the diagnostic phase to ensure comparable measurements and 
evaluations. 
 
Anatomic imaging will not be used to evaluate osteo-medullary lesions, because these lesions may 
not shrink in size using CT/MRI scans even in the absence of residual viable tumour. Osseous lesions 
without a soft tissue mass are considered non-measurable 
According to RECIST criteria. Extra-medullary soft tissue components of bone lesions that are 






Defined as:  
• Disease sites that meet criteria of measurable size  
- non-lymphoid soft tissue mass ≥10 mm in longest dimension or  
- lymph node ≥15mm in short axis  
AND 
• as well as either uptake on MIBG (or FDG-PET scan for MIBG non-avid tumors)  
OR  
• Biopsy positive for Neuroblastoma or Ganglioneuroblastoma 
Non-target lesions:  
Lesions that are considered to be active tumour sites but do not meet target lesion criteria for 
include cytology positive ascites, tumour positive cerebrospinal fluid, leptomeningeal tumour 
(meningitis carcinomatosis) and pleural effusion with positive cytology. 
 
Discrete lymph node: Single lymph node that can be discretely identified measure by short axis. 
 
The sum of diameters: The sum of the short axis of discrete lymph nodes added to the sum of the 
longest diameters of non–lymph node soft tissue metastases. 
Conglomerate masses of non-discrete lymph nodes (i.e. multiple contiguous retroperitoneal nodes) 
will be measured using longest diameter. 
 
Criteria: 
• Primary (soft tissue) Tumour Response 
• Tumour Response at Metastatic Soft Tissue and Bone Sites 
• Bone Marrow Metastasis Response 
• Determination of Overall Response 
Abbreviations: 
CR – Complete response; MD – Minimal disease; MR – Minimal response; NI – not involved;  
PD – progressive disease; PR – partial response; VGPR – very good partial response;  










Anatomic + 123I-MIBG (FDG-PET) Imaging 
 
CR Assessment with: 
• 10 mm residual soft tissue at primary site  
               AND 
• Complete resolution of 123I-MIBG or FDG-PET (for 123I-MIBG-nonavid 
tumours) uptake at primary site. 
 
If no 123I-MIBG or FDG-PET scan available: 
• 10 mm residual soft tissue at primary site  
AND 
• Urine catecholamine levels normal. 
 
VGPR Assessment with: 
• Primary tumour decreased by 90% to 99%   
AND 
• Urine catecholamine levels normal. 
 
Supporting evidence: 





• 30% decrease in longest diameter of primary site  
              AND 
• 123I-MIBG or FDG-PET uptake at primary site stable, improved, or 
resolved. 
 
PD Assessment with: 
• 20% increase in longest diameter taking as reference the smallest sum 
on study (this includes the baseline sum if that is the smallest on 
study) 
              AND 
• Minimum absolute increase of 5 mm in longest dimension 
SD 
 
Neither sufficient shrinkage for PR nor 













Anatomic + 123I-MIBG (FDG-PET) Imaging 
 
CR Resolution of all sites of disease defined as: 
• Non-primary target and non-target lesions measure 10 mm 
               AND 
• Lymph nodes identified as target lesions decrease to a short 
               axis 10 mm  
               AND 
• 123I-MIBG uptake or FDG-PET (for 123I-MIBG-non-avid tumours) 
uptake of non-primary lesions resolves completely 
 
If no 123I-MIBG or FDG-PET scan available: 
• Resolution of all sites 
                AND 





• No tumour 
AND 
• Catecholamines normal 
AND 





• >30% decrease in sum of diameters of non-primary target lesions 
compared with baseline  
               AND  
• All of the following: 
- Non-target lesions may be stable or smaller in size AND 
- No new lesions AND 
- >50% reduction in MIBG absolute bone score (relative MIBG 
bone score > 0.1 to < 0.5) or > 50% reduction in number of FDG-
PET–avid bone lesions 
 
PD Any of the following: 
• Any new soft tissue lesion detected by CT/MRI that is also MIBG avid 
or FDG-PET avid 
• Any new soft tissue lesion seen on anatomic imaging that is biopsied 
and confirmed to be Neuroblastoma or Ganglioneuroblastoma 
• Any new bone site that is MIBG avid 
• A new bone site that is FDG-PET avid (for MIBG non-avid tumours) 
AND has CT/MRI findings consistent with tumour OR has been 
confirmed histologically to be Neuroblastoma or 
Ganglioneuroblastoma 
• 20% increase in longest diameter taking as reference the smallest 
sum on study (this includes the baseline sum if that is the smallest 
on study) AND minimum absolute increase of 5 mm in sum of 
diameters of target soft tissue lesions 
• Relative MIBG score > 1.2 
SD 
 
Neither sufficient shrinkage for PR nor sufficient increase for 












CR Bone marrow with no tumour infiltration on reassessment, 




Any of the following: 
• Bone marrow without tumour infiltration that becomes > 5% 
tumour infiltration on reassessment OR 
• Bone marrow with tumour infiltration that increases by > two fold 
                and has > 20% tumour infiltration on reassessment. 
 
MD Any of the following: 
• Bone marrow with < 5% tumour infiltration and remains > 0 to < 5% 
tumour infiltration on reassessment OR 
• Bone marrow with no tumour infiltration that has < 5% tumour 
infiltration on reassessment OR 




Bone marrow with tumour infiltration that remains positive with >5% tumour 















PR in at least one component and all other components are either CR, MD 
(bone marrow), PR (soft tissue or bone), or NI; no component with PD. 
 
MR PR or CR in at least one component but at least one other component with SD; 




SD in one component with no better than SD or NI in any other component; no 
















11.2) PALLIATIVE MANAGEMENT: 





Full diagnostic panel 
 
 
Palliative chemotherapy                              Symptomatic palliation  
* Document protocol  
 
1 2 .  T H E R A P E U T I C  A L G O R I T H M S  
 
12.1) EMERGENCY PRESENTATIONS  
12.1.1) Spinal cord compression 
NB is the most common malignant cause of spinal cord or nerve root compression in the 
pediatric population with extension of the intervertebral foramina and/or the spinal canal 
being present in 10–15% of patients. 
 
Since the survival is independent from the type of primary intervention [3], considerations in 
the choice for initial treatment modality are the risk group, the resectability of the tumour 
and the neurological symptomatology.  
 
Chemotherapy is the treatment of choice above surgery in order to prevent long term spinal 
deformities. An osteoplastic laminectomy is the preferred surgical intervention. 
Radiotherapy has limited application in spinal cord compression. 
 
Steroid therapy must be started immediately in conjunction with more definitive therapy.  
 
Steroid therapy: 
Indications for steroid therapy: 
- Asymptomatic spinal canal involvement (threatening spinal cord compression) 
- Acute symptomatic spinal cord compression 
- Progressive symptomatic spinal compression 
















Dexamethasone 2mg/kg/day in three divided doses IV or PO (with gastric protection therapy 
according to unit policies) with a taper period in relation to the duration of treatment. 
 
Dexamethasone should be administered until asymptomatic or a maximum of 14 days by 
which time chemotherapy should have commenced. If surgery has taken place or 
chemotherapy has been started prior to 14 days, Dexamethasone must be tapered from the 
day of surgery or the last day of chemotherapy over 3 days. 
 
Non-steroid therapy:  
Indications for treatment in NB with spinal cord compression. Chemotherapy is prescribed 
according to risk group stratification. 
 
Risk group Clinical presentation Treatment modality 
High risk  • Asymptomatic 
• Longstanding 
neurological symptoms 





High risk • Acute neurological 
symptoms  





Intermediate risk • Asymptomatic 
• Longstanding 
neurological symptoms 





Intermediate risk • Acute neurological 
symptoms  





Low risk Primary resectable Surgery 
Low risk Primarily not resectable Chemotherapy 
 
Radiotherapy: 
Radiotherapy is not the main treatment of choice in spinal compression presentations in 
children. The reason is due to a higher rate of spinal deformities incurred with additional 
chemotherapy and future surgery. 
In a setting where acute neurological symptoms and/or rapid neurological progression is 




• Emergency 2,5Gy x 4 days with dexamethasone cover 2mg/kg/day in three divided 
doses 






Other clinical presentations: 
Biopsy: 
When a biopsy is the only confirmatory test surgery can be considered as the primary 
treatment modality. 
 
Severity of disease: 
The choice of therapy is directed by the feasibility in terms of the clinical presentation. 
 
12.1.2) Respiratory distress 
 
The management of respiratory distress in patients with Neuroblastoma is determined by 
the following aspects: 
• Anatomical site – intrathoracic tumour, cervical region (Horner syndrome), 
abdominal or critical hepatomegaly with diaphragmatic impingement. 
• Resectability of the tumour 
• Clinical presentation of the child  
The following guidelines may be applied: 
• Evaluate the need for cardio-respiratory support and initiate supportive 
measurements. 
• Initiate diagnostic evaluation with the purpose of evaluating the possibility of 
resection as an emergency procedure and to exclude non-neuroblastoma 
malignancies such as lymphomas or other benign tumours. 
• Evaluate the safest intervention such as surgical resection or chemotherapy. 
• If dexamethasone is considered other malignancies such as lymphomas should be 
excluded first. 
12.1.3) Abdominal obstruction 
 
The management of intestinal obstruction in patients with Neuroblastoma is determined by 
the following aspects: 
• Anatomical site – organ enlargement such as the liver or pelvic tumours causing 
obstruction 
• Resectability of the tumour 
• Clinical presentation of the child  
The following guidelines may be applied: 
• Evaluate the need for cardio-respiratory support and initiate supportive 
measurements such as nasogastric tubes and intravenous resuscitation. 
• Evaluate pain management needs. 
• Initiate diagnostic evaluation with the purpose of evaluating the possibility of 
resection as an emergency procedure and to excluded non-Neuroblastoma 
malignancies such as lymphomas or other benign tumours 
• Evaluate the safest intervention such as surgical resection or chemotherapy. 
• Consider stool softening treatment in cases of partial obstructions. 
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12.2 TREATMENT STRATEGIES        
12.2.1) LOW RISK (LR-SA) 
Patients under 6 months with FH, asymptomatic disease as well as completely resected FH, 
asymptomatic, MYCN non-amplified disease at any age can be observed. With progression 
and/ or symptomatic disease chemotherapy is indicated.   
With progression surgery can be done upfront or after neoadjuvant chemotherapy if surgery 
is possible. If a response is achieved after 4 cycles, a further 3 cycles can be administered.   
 
Regimen: 
Low risk disease and symptomatic, MYCN non-amplified, favourable histology  and 
progressing Stage 4S disease 
- Chemotherapy is administered every 21 days for 4 cycles 
- If the tumour response is favourable a further 3 cycles may be administered to a 
maximum of 7 cycles 
- Chemotherapy is administered with bone marrow recovery on rising counts of 
neutrophils of 1.0 x105/L and platelets of 100 x 105/L 
Doses: 
Carboplatin 600mg/m2 IV over 2 hours x 1 day 
Etoposide 175mg/m2 IV over 4 hours x 1 day 
Dose modifications: 
Infants and low weight children: 
- Body weight below 12kg should be dosed according to their weight (kg) instead of 
their body surface area (m²) according to the known formula of 30 kg= 1 m2.  
- Infants with a weight equal and < 5kg: 
- The dose in mg/kg with a further 1/3 dose reduction is advised. 
 
Carboplatin dose (mg) = Target AUC (5) X GFR (ml/min) + [0.36 X body weight (kg)]                                     
                                            over 2 hours x1/day 




Infection support: Timely antimicrobial interventions according to standard guidelines  
Nutritional support: Naso-gastric nutritional support must be started before starting 
chemotherapy and weekly measurements and monitoring must take place 
12.2.2) INTERMEDIATE RISK (IR-SA)  
Flow diagram 3: Intermediate disease is treated according to biological features. 
            
            
            
            
            
            
            
            
          Resectable 
            
            
            
      Unresectable     
 





























Chemotherapy should be administered with the aim to resect the tumour. In favourable 
histology (FH) tumours evaluation for resectability may be done after 4 cycles. In 
unfavourable histology tumours (UH) evaluation should take place after 8 cycles 
 
Regimen: 
- Chemotherapy is administered every 21 to 28 days for 4 or 8 cycles (according to 




- Prophylactic G-CSF should be administered to patients < 3 months after every course at 
5µg/kg SC. 
Doses: 
Carboplatin 560mg/m2 IV over 2 hours x 1 day 
Etoposide 120mg/m2 IV over 4 hours x 3 day (360mg/m2 x 1 day) 
Doxorubicin 30mg/m2 over 2 hours x 1 day 
Cyclophosphamide 1000mg/m2 over 2 hours x 1 days 
Dose modifications: 
Infants and low weight children: 
- Body weight below 12kg should be dosed according to their weight (kg) instead of 
their body surface area (m²) according to the known formula of 30 kg= 1 m2.  
- Infants with a weight equal and < 5kg: 
- The dose in mg/kg with a further 1/3 dose reduction is advised. 
 
Carboplatin dose (mg) = Target AUC (5) X GFR (ml/min) + [0.36 X body weight (kg)]                                     
                                            over 2 hours x1/day 
 
Etoposide 4mg/kg IV over 4 hours x 3 day 
Doxorubicin 1mg/kg over 2 hours x1 day 
Cyclophosphamide 33mg/kg over 2 hours x 1 days 
Approach: 
Surgery and chemotherapy: 
If CR is possible surgery should be attempted.  
- With R0 or R1 resection and FH – no chemotherapy and follow up 
- With R2 resection or UH – 8 cycles of chemotherapy 
If CR is not possible a biopsy should be done to determine FH/ UH. In the absence of 
histology tumours must be treated as UH.      
Radiotherapy: 
The indications for radiotherapy are the following: 
- Progressive disease 





Infection support: Timely antimicrobial interventions according to standard 
guidelines.  
Re-evaluation 
The following tests should be done at re-evaluation: 
• Tumour markers 
• Urine – catecholamine levels 
• 123I-MIBG scan (PET – scan in 123I-MIBG non avid tumours or nuclear imaging test used 
during diagnosis) 
• Bilateral BMAT (stage IV with bone marrow and skeletal involvement) 
• Local evaluation with CT/MRI scan   
12.2.3) HIGH RISK (HR-SA) 
The treatment for high-risk disease should start with induction phase with an OJEC/OPEC regime. 
Treatment should take place as per flow diagram. If patients do not have a good response post 
induction a further extended induction should be given. Further treatment includes surgery, 
radiotherapy and possibly an autologous bone marrow transplant (MAT) in the consolidation phase. 
MAT is dependent on availability of transplant centres to do the transplant. Every HR patient should 
be discussed with a transplant centre regardless of the possibility of the transplant. All HR patients 
should receive radiotherapy and surgery for local measures during the consolidation phase. If 
surgery is not possible then radiotherapy must be done as a local measure. Maintenance therapy 









All patients diagnosed with high risk disease starts with OJEC/OPEC. 
 
Regimen: 
- Chemotherapy is administered every 21 days for 7 cycles 
- Chemotherapy is administered with bone marrow recovery on rising counts of 
neutrophils of 1.0 x105/L and platelets of 100 x 105/L 
Doses: 
Vincristine 1.5mg/m2 IV stat (max 2mg) x 1 day 
Carboplatin 500mg/m2 IV over 2 hours x 1 day 
Etoposide 200mg/m2 IV over 2-4 hours x 1 day in a 1:2 dilution 
Cisplatin 20mg/m2 IV over 3 hours x 4 days (Total 80mg) 
Cyclophosphamide 600mg/m2 over 1 hour x1 day 
Dose modifications: 
Infants and low weight children: 
- Body weight below 12kg should be dosed according to their weight (kg) instead of 
their body surface area (m²) according to the known formula of 30 kg= 1 m2.  
- Infants with a weight equal and < 5kg: 
- The dose in mg/kg with a further 1/3 dose reduction is advised. 
 
Vincristine 0.05mg/kg IV stat (max 2mg) x 1 day 
Carboplatin dose (mg) = Target AUC (5) X GFR (ml/min) + [0.36 X body weight (kg)]                                     
                              over 2 hours x1/day 
Etoposide 5.8mg/kg IV over 2-4 hours x 1 day 
Cisplatin 2.6mg/kg IV over 24 hours x 1 day 





- Prehydration for cisplatin 
Infused at 200 ml/m²/hr for at least  3 hours with 0.9% sodium chloride with 20 mmol/l 
potassium chloride 
 
- Posthydration for cisplatin 
 
Infuse at 3 litres/m2. To each litre add 10ml KCl (max 20ml), 5ml Ca gluconate (10% solution) 
or 250mg/L and 2ml (1-2g/L) MgSO4. Post hydrate for 12 hours following each cisplatin dose. 
 
- A target urine volume of 400ml/m2/6h must be maintained  
 
When a target volume is not reached administer hydrochlortiazide (HCTZ) 1mg/kg/dose 
PO/IV 2x/d max 50mg per dose [185]. 
 
Infection support: 
- Timely antimicrobial interventions according to standard guidelines  
Toxicity Monitoring 
- A GFR by radio-nucleotide measurement (and calculated GFR) should be done prior to 
commencing cisplatin chemotherapy, after every 2 cycles and again at the end of 
treatment. 
- An audiogram should be done prior to commencing cisplatin chemotherapy, after every 
2 cycles and again at the end of treatment.  
B) TUMOUR RESPONSE EVALUATION [181-183] 
Response to treatment has been associated with outcome. The tumour response to chemotherapy 
should take place at pre-determined points in the treatment. Response assessment should include 
anatomic imaging for primary and metastatic soft tissue disease, nuclear medicine imaging for 
assessment of soft tissue and bone disease and bilateral bone marrow aspirates and trephine 
biopsies for assessment of marrow disease.  
 
Tissue biopsies may be used as an adjunct to verify the presence of 
viable neuroblastoma or ganglioneuroblastoma that is evaluable for response. 
 
Urine catecholamine levels will be used to evaluate response as supporting evaluation especially in 
units where the availability of other tests are limited, because of a lack of standardization in 
specimen collection and analysis and the influence of diet on results positive urine catecholamine 
level s alone are not indicative of treatment response failure.  
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The following tests must be done at re-evaluation: 
• Tumour markers 
• Urine – catecholamine levels 
• 123I-MIBG scan (PET – scan in 123I-MIBG non avid tumours or nuclear imaging test used 
during diagnosis) 
• Bilateral BMAT (stage IV) 
• Local evaluation with CT/MRI scan 
 
Time point Reason Action 
Induction   
After cycle 4 OJEC/OPEC Evaluation for 
resectability 
Resectable  
Proceed to surgery and 
complete induction post 
surgery 
  Unresectable 
Continue induction and 
evaluate after recycle 7  
 If MAT option available If BMAT CR first 
opportunity for stemcell 
harvest  
After cycle 7 OJEC/OPEC Evaluation for 
resectability and MAT 
(MAT option available) 
Resectable  
Proceed to surgery 
  Second opportunity for 
stemcell harvest 
 
Proceed to MAT 
 Evaluation for 
resectability and MAT 
(MAT option not 
available) 
Resectable 
Proceed to surgery and 
radiotherapy 
  Unresectable 
Continue to extended 
induction 
Extended induction   
After cycle 4 CADO Evaluation for 
resectability and MAT 
(MAT option available) 
Resectable  
Proceed to surgery 
  Third opportunity for 
stemcell harvest 
 
Proceed to MAT 
 Evaluation for 
resectability and MAT 
(MAT not option 
available) 
Resectable 
Proceed to surgery and 
radiotherapy 
  Unresectable 
Continue to radiotherapy 
*Post transplant  Continue to radiotherapy 
and maintenance 
Post radiotherapy  Continue to maintenance 




B) EXTENDED INDUCTION 
 
Extended induction is a CADO-based regime where 4 cycles should be administered and a disease 
response re-evaluated. Extended induction is for children with a disease response < CR after cycle 4 









- Chemotherapy is administered every 21 days for 4 cycles 
- Chemotherapy is administered with bone marrow recovery on rising counts of 
neutrophils of 1.0 x105/L and platelets of 100 x 105/L 
Doses: 
Vincristine 1.5mg/m2 IV stat (max 2mg) x 1 day 
Doxorubicin 35mg/m2 IV in 5% DW over 30 minutes x 1 day 
Cyclophosphamide 350mg/m2 PO x 5 days 
 
Dose modifications: 
Infants and low weight children: 
- Body weight below 12kg should be dosed according to their weight (kg) instead of their body 
surface area (m²) according to the known formula of 30 kg= 1 m2.  
- Infants with a weight equal and < 5kg: 
- The dose in mg/kg with a further 1/3 dose reduction is advised. 
 
Vincristine 0.05mg/kg IV stat (max 2mg) x 1 day 
Doxorubicin 1.2mg/kg IV in 50ml 5% Dextrose over 1 hour 
Cyclophosphamide 12mg/kg  PO x 5 days 
Precautions: 
Infection support: Timely antimicrobial interventions according to standard guidelines  
Cycle Day 1 2 3 4 
Vincristine 1 * * * * 
Doxorubicin 1 * * * * 




Consilidation consists of three parts. 
1. Surgery (if it is possible to perform) 
2. Radiotherapy 
3. Myelo-ablative therapy (MAT) or autologous stemcell transplantation (if the option is 
available to the patient) 
 
1) SURGICAL GUIDELINES [186-199] 
 
Surgery plays many roles in the management of Neuroblastoma  including biopsy, surgical resection, 
second look surgery as well as surgical interventions in emergency clinical presentations. 
 
Neuroblastoma either requires upfront surgery, if complete resection is possible, or delayed surgery 
after induction chemotherapy for the purpose of cyto-reduction which may facilitate complete 
resection at a later stage. 
 
Aims of surgery: 
• Assist in the diagnosis of Neuroblastoma by providing sufficient histological material for 
basic and advanced histo-pathological, cytological, molecular and genetic diagnosis. 
• Intervene in the acute treatment of emergency presentations to aid further treatment and 
prevent long term co-morbidities.  
• Definitive local treatment by ensuring, within non-maleficent measures, to achieve complete 
surgical excision via: 
o Primary resection 
o Post induction chemotherapy resection 
o Second look surgery for the purpose of complete resection   
 
Surgical technique: 
Both laparotomy and laparoscopy are acceptable as long as all oncological principals are adhered to.  
  
Suggested techniques: 
Abdominal tumours    
A transverse laparotomy incision is recommended which can be extended to a thoraco-abdominal 
approach if needed. 
 
Pelvic tumours  
A midline incision is the access of choice. A combined laparotomy and posterior sagittal approach 
may be required for some low lesions.  
 
Cervical and thoracic tumours   
It is suggested that thoracic lesions may require a double thoracotomy over a distance of up to 3 
intercostal spaces. A soft tissue incision or a thoraco-abdominal approach is recommended if the 
lesion is just above the diaphragm.  
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For lesions in the apex of the thorax and/or thoracic inlet require alternative approaches may be 
considered 
 
Timing of surgery: 
Primary surgical interventions: 
- Upfront resection takes place if the primary tumour is resectable and there are no 
metastases  
- After induction chemotherapy if surgical indications are met. In HR disease after cycles 4 of 
OJEC/OPEC, completed OJEC/OPEC and extended induction are opportunities for resection if 
tumours are resectable. 
Primary and metastatic tumours: 
- Surgery may happen synchronous 
- Or in stages 
 
Considerations for second-look surgery are to obtain a complete resection after MAT. 
 
The role of image defined risk factors (IDRF) (see Appendix F): 
IDRF is a guideline of the documentation of the pre-treatment extent of disease. It also guides the 
surgeons in the pre-operative evaluation of resectability of tumours in preventing surgical co-
morbidity and minimizing subtotal resections.  
 
IDRF and INRG staging should be done by the MDT which at minimum should include a radiologist, 
surgeon and treating physician. 
 
INSS surgical definitions: 
Table 8: Terminology related to the degree of the surgical resection [186] 
Level of resection Description of resection 
Complete surgical resection (CR) Macroscopic total removal of all visible tumour and nearby 
abnormal lymph nodes 
Near-complete gross resection 
(NC-GR) 
Resection of tumour leaving a minimal macroscopic residue 
Gross total resection (GTR) Removal of >90 % of the visible tumour 
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Incomplete resection (ICR) 
Subtotal resection (STR) Removal of >50 % but <90 % of the visible tumour 
Less than STR Removal of <50 % of the visible tumour/ biopsy 
 
Surgical and pathological resection margins: 
 
Table 9: Classification of margins [186] 
Classification Meaning  
R0 Resection for cure or complete remission CR 
R1 Microscopic residual tumour NC-GR 
R2 Macroscopic residual tumour GTR or ICR 
 
In the South African context, the aim for surgery should be an R0 resection or an R1 resection (with 
radiotherapy) to ensure local control. 
 
An R2 resection with a GTR is only indicated for emergency purposes, with control for symptoms or 
when second look surgery is an option with the aim for CR. 
 
Indications for surgical procedures: 
a) At presentation 
• Resection:   L1 by INGR – local tumour: IDRF negative 
• Biopsy only:  L2 by INGR – local tumour: IDRF positive 
M or MS by INGR – if the local tumour is IDRF negative a primary 
resection may be termed as an excision biopsy 
• Observation only: An adrenal mass in selected infants under 90 days of age at  
presentation < 5cm 
• With symptomatic  primary tumour where surgery is preferred above chemotherapy. 
 
b) Excision of primary mass should be attempted 
• Persistent or enlarging adrenal mass in infants under 90 days, following a period of 
observation, provided the tumour is IDRF negative. In IDRF positive infants resection may 
still be recommended if resection of the primary tumour suggests that the risk to life or a 
major functional loss is less than leaving residual disease. With a positive IDRF the aim 
should be GTR without a threat to life even if residual tumour is left behind. 
• Enlarging renal mass at presentation in infants under 90 days of age, provided the tumour is 
IDRF negative. In IDRF positive infants resection may still be recommended after a failed 
attempt to cyto-reduce the tumour with chemotherapy if the evaluation of the primary 
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tumour suggests that the risk to life or a major functional loss, is less risk than leaving 
residual disease.  
• With L2 tumours 
o In patients under 18 months old at presentation, where the IDRF become negative 
after chemotherapy or natural involution 
o In patients over 18 months old at presentation 
 With differentiating tumours which became IDRF negative after 
chemotherapy 
 With undifferentiated or poorly differentiated tumours irrespective of IDRF 
status 
 With tumours of unknown differentiation irrespective of IDRF status after 
chemotherapy 
o In IDRF positive tumours, regardless of differentiation, even after chemotherapy, 
resection may still be recommended if the evaluation of the primary tumour 
suggests that the risk to life or a major functional loss, is less risk than leaving 
residual disease or the complications with persisting symptoms due to tumour 
effect. 
• With bone, lung and/or central nervous system metastatic tumours (M) of children under 18 
months of age at presentation, with no evidence of metastatic residual (liver excluded) 
irrespective of IDRF status. 
• Ms tumours of children under 18 months of age at presentation that still progress or are 
symptomatic after chemotherapy. Surgery must only be attempted if a GTR is possible 
without a threat to morbidity or mortality. 
 
c) Other: 
• In cases where repeat histology is of value 
• For symptom control during palliation  
 
Contra-indications to surgery: 
• M tumours in children who still have metastatic disease, other than resectable liver or lung 
metastases, at the end of induction chemotherapy.  
• L2 tumours with IDRF after chemotherapy still encasing major blood vessels [200]. 
 
Biopsy: 
Neuroblastoma is a very heterogeneous tumour with multiple clinical presentations. Surgery plays a 
very important role in the diagnosis, staging and treatment of NB. Initially if the presentation does not 
necessitate emergency intervention due to compression or obstruction, a core biopsy is important to 
provide enough tissue sample for diagnostic confirmation and biologic testing.  
The biopsy sampling must be done by an experienced clinician, preferably under ultrasound 
guidance, with sedation or under anaesthetics within local protocols. The biopsy must be done in a 
safe and effective manner especially in the neck and thoracic region close to vital structures. 
All retroperitoneal tumours must be biopsied retroperitoneally. This prevents upstaging to stage III 
due to the creation of a biopsy tract through the peritoneal cavity or causing peritoneal leakage. If a 





Only 20-40% of children present with local disease and most cases can not be resected as a primary 
treatment modality. The pathophysiological nature of NB is to grow intimately with vital structures 
like blood vessels and nerves which present great challenges during resection.  If initial resection is 
attempted the surgeon must ensure that there is no metastatic disease present and local resection 
must be done with the aim as little co-morbidity and collateral damage as possible to vital structures. 
 
The aim is complete resection (CR) especially in stage I – III tumours. In stage IV tumours either CR or 
gross total resection (GTR) of 95% is recommended. The COG A3973 study concluded that even GTR 
of >90% ensures a better survival [188]. A poorer prognosis is likely with a gross total resection of 
<90%. Secondary to surgical resection age and tumour biology play the most important prognostic 
roles in the prognosis of NB. 
 
All studies include that metastatic control is more important than resection [196,198].  
 
Local relapse plays a major role in mortality especially in high risk patients. Local relapse rates of 20 - 
80% have been recorded even with the adjunct of radiotherapy and myeloablative therapy (MAT) 
when ICR was done.  
 
The debate of resectability is of importance even in the advent of myeloablative therapy and 
immunotherapy. Yet when these modalities are not available, as in LMIC setting, resectibility plays an 
even more important role in the prevention of relapse [199]. This is important in the extent of surgical 
resection when different treatment modalities are involved: 
• When there is a possibility for MAT complete surgical resection should not include 
nephrectomy unless renal function is not salvageable. 
• A nephrectomy during second look surgery to achieve CSR after a MAT is advised. 
• When there is no possibility for MAT complete surgical resection, including nephrectomy, 
should be considered. 
 
For patients with stage I and stage II disease the cure rate reaches 85 – 90% [3]. Complete, margin 
free resection ensures the need for less intensive chemotherapy without radiotherapy. In stage III 
patients obtaining CR ensures a better survival in patients with especially unfavourable tumour biology 
[192, 193]. 
 
During resection the following should be done: 
• inspection of and biopsy of any ABNORMAL appearing peritoneal surfaces. 
• inspection of and biopsy of any ABNORMAL appearing lymph nodes. 
• inspection of and biopsy of any ABNORMAL appearing omentum. 
• inspection of and biopsy of any ABNORMAL appearing contralateral adrenal glands 
• in stage I – III a CR must be done  
• in stage IV tumours GTR of the primary tumour >90% without collateral damage to vital 
structures or organs and resection of metastasis. 
There is no indication for surgical resection in a stage IV patient if there are still distant metastases 
present. Surgery is purely palliative. 
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However if a CR of distant metastases (medically or surgically) have been achieved, surgery to the 
primary tumour is indicated if CR of the metastases is proven with:  
• bilateral bone marrow aspirate and trephine biopsy AND  
• bone scan or 123MIBG scan  
Even with high intensity treatment such as autologous transplants or immunotherapy, less than GTR 
doesn’t provide any survival benefit and debulking has no role to play in a LMIC setting. 
Second look surgery: 
Neo-adjuvant chemotherapy and radiotherapy may cause significant interval regression of primary 
tumour. Surgery may be applied to ensure a complete response. In prognostic terms this improves 
survival. Performing surgery after chemotherapy may improve the ease of resectability and decreases 
surgical complications. 
Second look surgery is a possibility post MAT to achieve CSR in metabolically active tumours but should 
only done by experienced surgeons. Referral to surgical centers with the adequate experience to 
perform the surgery.  
Lymph nodes adjacent or adherent to primary tumours are of uncertain prognostic implication. During 
surgery all attempts must be made to sample these nodes for radiotherapy purposes. If a lymph node 
is clinically pathological, it must be removed and evaluated for histology. 
Unnecessary aggressive surgical techniques to ensure gross total resection are not warranted, 
especially is the intervention will cause significant co-morbidity. 
In dumbbell tumours surgery is a two stage procedure where the extra-spinal component of the 
tumour is removed before the extradural, intra-spinal component. 
Emergency procedures: 
a) Spinal cord compression 
With spinal cord compression it is important to note the duration of the symptoms and if the clinical 
situation is life threatening. If the symptoms are longstanding and not life threatening, chemotherapy 
and/or radiotherapy is the treatment of choice for the cyto-reduction of the tumour followed by 
surgery. 
Surgery is not the primary treatment choice for decompression due to severe late effects from the 
surgery but a laminectomy is performed first even if an osteoplastic laminotomy minimizes 
deformities. 
If with chemotherapy/ and or radiotherapy the symptoms resolve and the extraspinal component 
becomes resectable i.e. IDRF negative then a surgical resection of the extraspinal component should 
take place. There is no indication to surgically resect the residual spinal canal component of a 
dumbbell tumour. 
b) Respiratory distress 
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Rapidly enlarging tumours due to liver metastases in stage 4S patients compromise respiratory 
function with pressure on the diaphragm or compression on the inferior vena cava. The primary 
treatment of choice is chemotherapy and radiotherapy but if reduction is slow a silastic sheet may be 
inserted in the abdominal wall. Resection can be done if the patient is still symptomatic after 
chemotherapy and radiotherapy intervention. 
Major surgical complications: 
• Serious haemorrhage due to the vascularity of the tumours >30% blood volume. 
• Vascular injury with tissue loss 
• Nerve damage and spinal cord injury 
• Organ failure 
• Surgical inoperability 
Post-surgery complications: 
After surgery there are common complications that need to be monitored. 
a) Bleeding 
Neuroblastomas surround the major abdominal vessels like the coeliac trunk and the superior 
mesenteric artery. Major vessel injuries can occur during resection.  
A hallmark of NB is the vascular nature due to angioneogenesis. This predisposes to bleeding during 
surgery. This predisposes the patient to post surgical bleeding as well. 
 
b) Diarrhoea [187] 
In 30% of patients intractable diarrhoea follows retroperitoneal nerve injury postoperatively. Large 
volumes of diarrhoea may lead to intravenous support of the patient. 
 
c) Adrenal insufficiency 
Various studies documenting endocrinological late effects in patients treated for Neuroblastoma and 
nephroblastoma have been published. This includes decreased levels of glucocorticoid and 
mineralcorticoid steroids. Late effects such as decreased bone density, disregulation in glucose 
metabolism and blood pressure instabilities are a few. In later life fertility and metabolic syndromes 
are important co-morbidities.  These are inevitable if both adrenals are resected. 
2) RADIOTHERAPY GUIDELINES  
 
RATIONALE FOR RADIOTHERAPY (RXT) 
Neuroblastoma is a radiosensitive disease. However routine use of radiotherapy was not practiced 
historically in European trials. American trials in neuroblastoma used radiotherapy routinely and 
local relapse rates were noted to be lower in these series’. However, the trials used varying staging 
systems, indications, doses and systemic treatment, so that the role of radiotherapy remains 
unclear. Radiotherapy was routinely introduced into SIOPEN protocols in 2002. Dosage and 




The indications for radiotherapy (RT) in NB are varied.  It has a place in emergency treatment, local 
primary control, metastatic treatment and palliative treatment. 
 
INDICATIONS FOR RADIOTHERAPY IN LOCALISED NB:  
Neuroblastoma is defined by SIOPEN as low, intermediate or high risk, and overall treatment is 
determined based on these: 
  
Low risk disease: 
RT generally not indicated except for: 
• In clinical presentations where function is threatened and no improvement is seen with 
chemotherapy: 
o Acute spinal cord compression 
o Respiratory compromise with tumour induced hepatomegaly, if chemotherapy is 
ineffective. 
 
Intermediate risk disease: 
Only selected patients in this group should receive radiotherapy: 
• Localised unresectable, or residual disease (stage L2) or 
• Patient>18 months or 
• Poorly or undifferentiated histology 
 
High risk: 
• Stage 4 (Stage M) >1 year old with good response and limited disease 
• Stage 2,3 (stage L2) MYCN amplified, any age 
 
Stage 4S: 
• For palliation 
• In life threatening or function-limiting situations e.g. tumour induced hepatomegaly causing 
respiratory compromise, inferior vena cave obstruction, compromised renal perfusion, DIC 
or gastro intestinal obstruction that does not respond to chemotherapy. 
 
Technique of radiotherapy: 
The radiotherapy dose and volume is determined by risk group, surgical outcome and options for 
transplant. 
 
Equipment and Technique: 
In younger children sedation maybe required for the simulation and treatment and when Paediatric 
anaesthetists are available as a resource, the treatment is stream lined. 
Ideally, patients should be CT planned (ideal slice thickness 3mm-5mm). If not available, then virtual 
simulation or conventional simulation is acceptable. Accurate positioning is necessary. 
Linac radiotherapy with an energy of >4 MV is suggested with a 6MV usually sufficing for planning. 
Cobalt radiotherapy may also be used if Linac not available. 
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Patient should be positioned supine in a reproducible and comfortable position and a 3-point set up 
used.  
For metastases, relevant anatomical areas may require a foam or thermoplastic cast. 
Timing of radiotherapy: 
a) In patients without an option of myelo-ablative therapy (MAT): 
• Resectable tumours: 
Radiotherapy is started after surgical recovery, usually at 2 weeks but no later than 30 days 
after surgery 
• Non-resectable tumours: 
Radiotherapy must still be considered to the primary tumour and metastatic sites even 
without surgical resection in the following situations: 
o If a tumour is irresectable after induction chemotherapy and radiotherapy is 
logistically possible after evaluation of the primary tumour suggests that the risk to 
life or major functional loss, is less from radiotherapy than from the disease OR for 
persisting symptoms due to tumour effect. 
o If there is limited metastatic tumour, and radiotherapy is logistically possible. 
 
b) In patients with an option of MAT: 
Radiotherapy will be given to the initial diagnostic primary tumour site as well as to limited post 
induction metastatic sites after MAT and according to suggested radiotherapy dosages the interval 
should be greater than 60 days but before 90 days post transplantation in order to prevent 
chemotherapy-induced radio-toxicity. 
 
Radiotherapy of primary site: 
Volumes are based on post-chemotherapy, pre-surgical disease as seen on MRI/CT. 
 
Technique: 
Planning may be done by simulation, virtual simulation or 3-D planning depending on site-specific 
availability. Planning with 3-D allows for DVH evaluation of tumour and critical organs at risk (OAR). 
 
Volumes for 3-D CRT: 
Gross tumour volume (GTV): 
• Pre-surgery/ post- neo-adjuvant chemotherapy volumes are used, taking original tumour 
volumes into account. 
• If post resection, then there is no GTV, but tumour bed (TB) is determined using pre-op 
scans and clips, as well as operative notes and histology. 
 
Clinical target volume (CTV) 
• This is a margin that is added to the GTV or tumour bed, and accounts for possible 
microscopic tumour extension. 
 
CTV= GTV+ 1cm margin 
 
PTV (Planning target volume) 
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This is a margin that is added to account for physiological motion and set up error (this is 
institutional). 
PTV= CTV + 1 cm 
In addition, in growing children, bones must be symmetrically irradiated and therefore the entire 
vertebral column must be delineated, and a margin added for set-up/movement. This is PTV2, and 
should be added to the main PTV: 
 
Total PTV= PTV1 + PTV2 
 
 
• OAR are delineated 
• For neuroblastoma this includes: 
o Kidneys (R&L) 
o Liver 




Field arrangement is frequently AP/PA or opposing oblique fields in order to minimise 
kidney/ovarian dose. 
Differential field weighting may be used if planned. 




If volumetric modulated arc therapy (VMAT) is available, this may be used in order to allow better 
tumour volume coverage [201]. 
If planning is done with simulation alone: 
Clips are identified and pre-op scans/op note/pathology are used to localise tumour bed. 
A margin of 1-2cm around tumour bed is give, incorporating the entire width of the vertebral 
column. 
AP/PA fields are delivered with shielding to kidneys after tolerance reached. 
Dose: 
1. After complete resection (CR):
1.5 Gy x 14#= 21 Gy in 5x per week (lower dose per # because bowel in field) 
Dose is prescribed to either mid-plane (central) dose (if simulated), to ICRU point (=100%) if 3-D 
planned radiotherapy, or to mean tumour dose for VMAT prescriptions. 
Radiotherapy should be delivered in less than 21 days. 
2. For incomplete surgical resection:
 1.8 Gy x 12 #= 21.6 Gy, 5x per week 
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A boost may be added as per new SIOPEN protocols but this is not yet standard practice 
Boost 1.8 Gy x 8#= 14,4 Gy (8 fractions) to any gross residual tumour 
Total dose =36 Gy in 20 fractions. 
A simultaneous integrated boost (SIB) may be planned with a maximum daily dose limited to 2.1 Gy. 
 
Table 10: Radiotherapy doses 
Normal dose by site Target volume Dose/Fraction Number of fractions 
Primary site 21.6 Gy PTV1 1.8 Gy 12 
Primary site boost 14.4 Gy PTV2 1.8 Gy 8 
Metastatic site 21.6 Gy  1.8 Gy 12 
 
3. Tumour response with limited surgical possibility: 
Patients with a CR or VGPR on induction chemotherapy or with IDRF that prevents surgical 
intervention should still receive radiotherapy for local control as for incomplete surgical resection.  
 
Stage 4S hepatic RXT (Functional impairment): 
• A dose of 2-6 Gy (2-4 fractions) to whole liver (1.5 Gy x3# = 4.5 Gy on 3 consecutive days) 
• Allow for 2-3 weeks to assess response to RXT. If needed the dose may be repeated to a max 
cumulative dose of 12 Gy. 
• Primary (Asymptomatic Stage 4S – no radiotherapy) 
 
Metastatic sites: 
Post induction chemotherapy MIBG non-active sites – no RT 
Post induction chemotherapy oligo metastases: MIBG active sites – 21,6 Gy (in 12 fractions) 
 
Palliative RT (Pain relief): 
Small fields – 16-20 Gy (4-5 Gy per fraction) 
Large fields – 20-30 Gy (2-3 Gy per fraction)  
Alternative is 8 Gy single fraction for patients with limited life expectancy. Response is good but 
lesion may return sooner than with greater total dose. 
 
Spinal compression: 
• Emergency 2,5 Gy x 4= 20Gy over 4 days with dexamethasone cover 2 mg/kg TDS [184] 
• A maximum dose of 21Gy for any length of spinal cord is permitted  
 
Other sites: 
If the gonads are in the field a dose <5 Gy is permitted 
 
Dose Modifications for OAR (as per COG guidelines) 
 
Peritoneal Cavity 







No more than 1500 cGy shall be given if two-thirds (2/3) or more of the lung volume must be 
included in the target volume. 
 
Liver 
No more than 1500 cGy shall be given if two-thirds (2/3) or more of the liver volume must be 
included in the target volume. 
 
3) MYELO-ABLATIVE THERAPY GUIDELINES AND STEM CELL HARVEST [103] 
An autologous transplant as myelo-ablative therapy consolidates the treatment of Neuroblastoma 
(NB) after the induction phase and local control of the tumour. An autologous transplant improves 
the OS by up to 20% 5-year survival [126]. There is no literature available for the experience of 
autologous transplants in South Africa. 
Indications for an autologous transplant: 
1. The patient is a high-risk NB patient  
- All non-stage IV high risk NB patients 
- Stage IV high risk NB patients are selected by treatment response and clinical elligibility 
2. The patient must not have any co-morbidities that are a contra-indication for an 
autologous transplant. 
3. A patient must have received a gross total resection (>90% resection) or 
the tumour must have CR or VGPR with neo-adjuvant chemotherapy and surgery is not 
possible due to an inoperable small residual tumour mass.  
4. The patient must have a complete remission of all distal metastasis (according to INSS 
criteria).  
• This must be proven by an I123 MIBG for skeletal response 
•  and cytomorphological and histological bilateral bone marrow and trephine 
response (negative BM and trephine involvement). 
5. The patient must have adequate post transplantation follow-up options. 
 
Timing of Peripheral Stem Cell Harvest (SCH): 
The disease response status should be evaluated before performing the PBSC harvest procedure. 
There are various time points for stem cell collection. The recommendation is to start early with 
harvest efforts. The first harvest option is following recovery from aplasia after the end of induction 
(Rapid COJEC or OJEC/OPEC) before surgery and radiotherapy. 
Patients achieving CR at metastatic sites on MIBG or bone scan and no positive bone marrow 
aspirate and trephine on bilateral biopsy will be eligible for peripheral stem cell harvest.  
• Mobilisation of stem cells, with a protocol according to institutional preference, may take 
place after cycle 4 of OJEC/OPEC or post surgery.  
• Steady state mobilisation (defined as >1,0 neutrophils and >100 platelets x 109/l) after 




A minimum of 10-20 CD34+ cells/μL are required to start the first leukapheresis. The number of 
collections depends on the quantity of peripheral blood stem cells harvested, 
evaluated by the number of CD34 positive cells. 
The aim of the peripheral SCH: 
A sufficient number of blood progenitors must be collected by apheresis to allow safe and prompt 
haematological recovery following the high dose chemotherapy of a BuMel regimen and autograft. 
• Dose of progenitor cells:
CD34+ cells is ≥ 2-3 x 106 CD34 positive cells/kg for one BuMel (or Melphalan based
protocol)
• A circulating level still higher than 10 - 20 CD34 positive cells per µL the leukapheresis
procedure should be started
• A second procedure on the next day is recommended, if the amount of first apheresis is near
by or less than 2-3 x 106 CD34 positive cells/kg.
• The total harvest should always be divided into minimum two bags. The amount of dimethyl
sulphoxide (DMSO) should not be more than 1g/kg body weight (bw) for one reinfusion per
day to avoid toxicity.
• There is no ideal timing for PBSC harvest in patients with metastatic NB, except that early
collection increases the risk of tumour cell contamination and later ones of poor progenitor
cell collection. The monitoring of both tumour cell contamination and progenitors in the
graft.
Timing of autologous transplant (MAT): 
Autologous transplant should be done after surgery of the tumour.  The BuMel myelo-ablative 
regime has proven to have a superior outcome above other conditioning regimes in NB. 
The BuMel MAT regime consists of Busulfan and Melphalan followed by a reinfusion of stem 
cells.  
The BuMel MAT - regimen  
The regime consists of intravenous administration of Busulfan as a two-hour infusion every 6 
hours over 4 (or 5) consecutive days through a central venous catheter only. After a day of rest it 
is followed by an intravenous infusion of Melphalan. 
In case of body weight below 12kg the Melphalan dose calculation is recommended 
to be dosed by per kg. 
For Infants with a weight < or equal to 5 kg, a further 1/3 reduction is advised. 
After the chemotherapy the stem cells are infused on the following day. 
The dosage: 
  Peripheral stem cells 
  A minimum of 2 - 5 x 106 CD34 cells/kg should be used. 
  A maximum of 10 x 106 CD 34 cells/kg should be used. 
  Bone marrow collection 
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       A minimum of 3 x 108 mononuclear bone marrow cells/kg or > 8 x 10 4 CFU-GM/kg 
should be used. 
 
Timing: 
 Reinfusion of stem cells will be infused intravenously on Day 0 with specified rest, according to     




DRUG DOSE                                    DAY -8 -7 -6 -5 -4 -3 -2 -1 0 
Busulfan An IV dose every 6 hours for 
16 doses: 
< 9 kg: 1.0mg/kg 
9 kg to < 16 kg: 1.2 mg/kg 
16 kg to 23 kg: 1.1 mg/kg 
>23 kg to 34 kg: 0.95 mg/kg 
















   
Melphalan IV: 140mg/m2 over 15min not 
before 24 hours after busulfan 
       
* 
 
Hydration 3L/m2 (125ml/hr) till 24 hours 
after melphalan infusion 
 
 
       
Clonazapam 0.025 – 0.1 mg/kg/day 
IV: total dose as a continuous 
infusion  
PO: divided in 3 doses/day 
Dose can be reduced if the 




































Ursodiol 300 mg/m²/day PO 
150 mg/m²/day PO 
(Day -8 till day 80) 
* * * * * * * * * 
Stem cells As per regime dose         * 
 
Supportive treatments: 
• Anti-emetics Ondansetron 5mg/m² (0.15mg/kg) [185] every 12 hours PO or IV as anti-emetic 
(maximum single dose 8mg) 
• Adequate hydration is crucial prior to and following chemotherapy especially prior to 
Melphalan administration due to bladder irritation from high urine concentrations of the 
drug.  
• Minimal urine output immediately prior to and 24 hours following Melphalan administration 
should be more than 90 ml/m²/hr. To achieve this urine output, give IV hydration at 125 
ml/m²/hr. 
• Ursodiol: The administration twice per day during the entire prophylactic period, even in the 
case of mucositis, from day -8 until day 80 post stem cell reinfusion is of major importance. 
• G-CSF 5μg/kg/day IV will be given daily beginning on Day +5. G-CSF will continue until a 
stable increase of WBC > 5 x 109/l or ANC >0.5 x 109/l 
• All blood products (packed red blood cells, platelets) must be irradiated with and be 
leucocyte depleted (ideally CMV negative). It is recommended that patients receive red 
packed blood cells to maintain haemoglobin > 8.0g/dl. 
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• Stop Co-trimoxazole prophylaxis from day 0 until at least day +10 or until WBC ³1.0 x 109/l. 
• Prophylactic antifungal treatment with Ketoconazole, Itraconazole or Fluconazole should be 
avoided, because of the increased risk of VOD with these drugs in particular in association 
with Busulfan. For proven fungal infection Amphotericin is advised. 
• Antibiotics and antivirals should be given in line with the institutional policy whenever 
Indicated.  
 
D) MAINTENANCE or MATURATION THERAPY  
Cis-retinoic acid (CRA) is used as maintenance therapy with the aim of maturing remaining 
undifferentiated cells.  
 
Regime:  
CRA is started no sooner than 14 days after radiotherapy to avoid radiotherapy related toxicity. 
 
CYCLE DAY 1 - 14 D 15 - 28 
 CRA  REST 
  
Starting Criteria: 
• Neutrophils > 500 Platelets > 50  Hemoglobin > 8 g/dl 
• Normal ALT and AST 
• Normal renal function 
• Normal serum calcium and urate 
• Triglycerides must be < 2 x normal 
 
Starting Dose (if > 12kg): 
CRA 80 mg/m2 PO 2x/d  
 
Cycles 
6 cycles will be administered 
Each cycle consists of CRA D1-14 and then resting D15-28 
Dose adjustments: 
With the following criteria CRA must be stopped and reintroduced at 60mg/m2 PO 2x/d  
• Hemoglobin < 8 g/dl 
• Platelets < 25 
• Neutrophils < 500 
• AST or ALT > 5 x normal 
• Total bilirubin > 1.5 x normal 
• Hypercalcaemia 
• Erythema multiforme 
• Severe vomiting and/or abdominal pain 
• Urethritis and/or dysuria 
• Severe cheilitis 
• Severe conjunctivitis 
• Severe headache or vertigo 
• Persistent muscle cramps requiring sustained symptomatic care 
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After completion of 6 cycles management must continue according to the long term follow up 
schedule. 
 
12.2.4) STAGE 4S 
Patients with Stage 4S NB is a unique clinical entity that should be managed different from stage 4 
NB. If a patient < 1 year presents with Neuroblastoma but do not fulfil the diagnostic criteria for 4S 
the standard NB protocol must be followed with appropriate dose modifications.  
 
Diagnostic criteria: 
• Age < 1 year of age and 
• Meets the diagnostic criteria for neuroblastoma and  
• Spread to the skin, liver or bone marrow (<10%), but not to bone 
 
Management: 
The majority of patients with stage 4S neuroblastoma do not require therapy. There are three 
patient groups who are at an increased mortality risk: 
• symptomatic due to an evolving hepatomegaly or organ compromise  
• tumours with unfavourable biology (pathology and genetics) 
• patients less than 2 months of age 
Patients are treated according to risk classification. 
 
Modified from the International Neuroblastoma Risk Group (INRG) Pretreatment Classification Schema for Stage 4S Neuroblastoma and 
Children’s Oncology Group (COG) Neuroblastoma Stage 4S Group Assignment Schema Used for COG-P9641, COG-A3961, and COG-A3973 
Studies
 
Table 11: Proposed South African Neuroblastoma Adapted risk stratification (SANARS) [2,3,5,32] 




LDH Ferritin MYCN Histology 
 
Risk Group 
4S Asymptomatic MS <3mo <750 <120 NA/ EC FH Low 
4S Asymptomatic MS 3-12mo <750 <120 NA/EC/ 
Unknown 
FH Low 
4S Symptomatic MS 3-12mo <750 <120 NA/EC FH Low 
4S Asymptomatic MS 3-12mo <750 <120 NA/EC/Unknown UH Intermediate 
4S Symptomatic MS 3-12mo <750 <120 Unknown Any Intermediate 
4S Asym/ symp MS 3-12mo Any Any Amp Any High 
4S Symptomatic MS <3mo Any Any Any Any High 
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Flow diagram 5: Treatment of Stage 4s disease 
 
Guidelines of symptomatic stage 4s disease: 
Progression in stage 4s NB is common. Clinical deterioration will need chemotherapy intervention.  
Especially infants under 3 months of age are at high risk of mortality without chemotherapy 
intervention. 
Clinical signs that indicate progressive disease are the following: 
• Deterioration of the general condition 
• Feeding difficulties leading to weight loss 
• Respiratory failure defined by oxygen requirement or carbon dioxide retention exceeding 
60mmHg  
• Circulatory failure defined by hypotension or hypertension according to the age specific 
blood pressure reference values 
• Hepatic failure defined by grade 3 toxicity of bilirubin, fibrinogen, or thrombin time 
according to the NCI-CTC toxicity criteria [202] 
• Renal failure defined by impaired blood urea or creatinine, new development of 
hydronephrosis or deteriorating pre-existent hydronephrosis 
• Symptomatic or asymptomatic intraspinal involvement documented by MRI 
• Failure of other organ systems. 
Indications for chemotherapy treatment is based on the Philadelphia score system. Chemotherapy 






Table 12: Philadelphia score system [203] 
Clinical entity Grade Score 
GI-tract 
Emesis of > 10% of intake  








Tachypnoe over 60/min and O2 supplementation 








Leg oedema  








Oliguria with output < 2 ml/kg/hr  

















In infants under 3 months of age should be started on the high-risk protocol and infants of 3 months 
and more should start with the CE-regime. If there is no clinical response on the CE regime the infant 
must be considered high risk. 
Chemotherapy: 
CE regimen  
Drug Dose Days 
Carboplatin 6.6 mg/kg D1-3 
Etoposide 5 mg/kg D1-3 
 
Repeated after 21 days for 4 cycles  
Follow up: 
Up to 3 years of age 
At every visit the following investigations should be done: 
• Clinical examination for new masses 
• BP  
• FBC, U&E, creatinine, LDH, Uric acid and ALP 
• CXR and abdominal US every visit (abdominal US only in abdominal and pelvic primary) 
• U-catecholamine 
• Skeletal survey is only advised if the clinical information indicates an MIBG scan or bone scan   
The follow up schedule: 
End of treatment 
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3 monthly for 1 year 
Then 6 monthly for 1 year  
Then yearly thereafter 
 
12.2.5) PERINATAL NEUROBLASTOMA 
In NB there is a high rate of spontaneous regression of small tumours in infants. Several oncology 
study groups have reported the spontaneous regression of larger tumours that were observed after 
diagnostic biopsies or PR. 
 
Therefore, it is safe to observe perinatal tumours. Tumours included are the following: 
• Patients < 6 months 
• Asymptomatic 
• Non-stage 4 or stage 4S – thus a negative skeletal screening 
• Tumour size of smaller than 5cm x 5cm x 5cm (75ml) 
• Restricted to the adrenal glands – no suspicious lymph nodes or extra adrenal extension 
• Not crossing the midline 
• Chemotherapy and radiotherapy naïve 
Observation schedule and tests: 
Period in weeks 0 3 6 12 18 30 42 66 90 
Abdominal U/S  X X X X X X X X X 
U-catecholamines X X X X X X X X X 
Abdominal CT/MRI X   X     X 
 
Method: 
• Abdominal CT/ MRI is done for accurate staging  
• U-catecholamine levels and abdominal U/S is done for monitoring purposes 
• If a tumour increases by 50% or the u-catecholamine levels increase by 50% the tumour is 
resected immediately 
• If a tumour becomes symptomatic the tumour is resected immediately 
• A tumour is monitored at first in 3 weekly visits. After a tumour is stable for two consecutive 
visits – visits are scheduled 6 weekly. After two stable visits – visits are scheduled 12 weeks 
apart until 90 weeks. 
• If tumour increases but not > 50% visits are scheduled at 3 weeks 
• After 90 weeks the patient is managed according to the standard post treatment follow up. 
Criteria for active treatment: 
1) Evidence of persistent tumour growth 
• A >50% increase in the volume of the mass or 
• A >50% increase in either VMA or HVA, neither returns to baseline/nadir within 12 weeks, 
and the value is above the upper limit of normal for that metabolite or 
• The VMA/HVA <0.5 (and HVA greater than upper limit of normal) and does not increase 
above 0.5 within 6 weeks or 
• Progression, secondary malignancy, or metastasis 
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2) Symptomatic tumour 
When a tumour becomes symptomatic  
- the tumour must be resected and managed according to risk group 
- if the tumour is unresectable the low-grade chemotherapy can be administered before 
resection. After resection the patient will be managed according to risk group. 
 
12.2.6) PALLIATIVE STRATEGIES 
If the treatment intent is palliative the following should be documented  
• The reasons for the palliative decision must be documented 
• The clinical symptoms that have to be treated 
• The modality of palliative intervention 
- Palliative chemotherapy/ metronomic therapy/ radiotherapy/ surgery 
- Non-chemotherapy symptomatic palliation 
• Which protocol was used 
Even if a palliative approach is chosen a full diagnostic work-up must be done (within reasonable 
limitations of the patient’s presentation). 
Flow diagram 6: Palliative strategy 
 












- Chemotherapy is administered every 21 days for 10 cycles 
(Note that if CADO is used for palliation post treatment with an extended induction of CADO or post 
IR-SA to adapt number of cycles to a max of max tolerated dose of 300mg/m2) 
- Chemotherapy is administered with bone marrow recovery on rising counts of neutrophils of 
1.0 x105/L and platelets of 100 x 105/L 
Doses: 
Vincristine 1.5mg/m2 IV stat (max 2mg) x 1 day 
Doxorubicin 35mg/m2 IV in 5% DW over 30 minutes x 1 day 
Cyclophosphamide 350mg/m2 PO x 5 days 
Dose modifications: 
Infants and low weight children: 
- Body weight below 12kg should be dosed according to their weight (kg) instead of their body 
surface area (m²) according to the known formula of 30 kg= 1 m2.  
- Infants with a weight equal and < 5kg: 
- The dose in mg/kg with a further 1/3 dose reduction is advised. 
 
Vincristine 0.05mg/kg IV stat (max 2mg) x 1 day 
Doxorubicin 1.2mg/kg IV in 50ml 5% Dextrose over 1 hour 
Cyclophosphamide 12mg/kg PO x 5 days 
Precautions: 
Infection support: Timely antimicrobial interventions according to standard guidelines.  
Nutritional support: Naso-gastric nutritional support must be started before starting chemotherapy 





12.2.7) METRONOMIC THERAPY GUIDELINES 
The metronomic therapy guidelines should be used according to POUs management resources as an 
optional treatment option during palliation. 
The aim of metronomic therapy is in the palliative, relapse or refractory setting as a low dose 
continuous chemotherapy option to modulate the micro-environment of the tumour. 
Metronomic therapy (M-NB-SA) 
 
Regimen: 
Palliative, relapse or refractory setting 
- Chemotherapy is administered after cardiac function screening 
- Chemotherapy is administered with bone marrow recovery on rising counts of neutrophils of 
1.0 x105/L and platelets of 100 x 105/L 
Doses: 
Propranolol 3mg/kg PO daily (see precautions)  
Cyclophosphamide 30mg/m2 PO daily – 1 week on, 1 week off 
Vinorelbine 15mg/m2 PO daily – 3 weeks on, 1 week off 
Alternative to oral Vinorelbine: 
If oral vinorelbine is not available the suggested replacement is intravenous vinblastine  
Vinblastine 3mg/m2 IV over 30 min x 1 day – monthly. 
 
Dose modifications: 
Infants and low weight children: 
Body weight below 12kg should be dosed according to their weight (kg): no dose reductions 
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14… 
Propranolol * * * * * * * * * * * * * * 
Cyclophosphamide *  *  *  *  *  *  *  
Vinorelbine * * *  * * *  * * *  * * 
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14… 
Vinblastine *    *    *    *  
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Infants with a weight equal and < 5kg: no dose reductions 
 
Precautions: 
- Before starting Propranolol, cardiac function should be evaluated with echocardiogram and 
ECG.  
- Administration starts with 1mg/kg/d. With stable blood pressures according to age and 
glucose levels daily doses can be increased by 1mg/kg/d till 3mg/kg/d [185] 
 
1 3 .  D O S E  M O D I F I C AT I O N S  F O R  T O X I C I T Y  
 
13.1) NEPHROTOXICITY 
In patients with pelvic tumours with renal failure from obstructive uropathy, carboplatin can still be 
administered according to GFR measurements. It can also be administered if renal failure is severe 
enough to require dialysis. 
A recommendation for adults is as follows: 
Table 13: Adjustment of carboplatin dose according to BSA (mg/m2) in renal failure 
Cr Cl (ml/min) Starting dose (mg/m2) 
>60 No dose reduction 
41-59 250 
16-40 200 
<15 No information available 
 
Cr Cl = N (Sex) X (140-Age) X weight (kg) / serum creatinine (micromoles/l), where N = 1.04 for males 










The recommendation for adjustment of cisplatin dose in adults with renal impairment is shown in 
table 14.  
TABLE 14: Adjustment of cisplatin dose according to BSA (mg/m2) in renal failure 
Cr Cl (ml/min) Dose (mg/m2) 
>60 100% 
45-59 75% of cisplatin dose or change to carboplatin if 
available. 
<45 Hold cisplatin or delay with additional fluids or 
change to carboplatin if available. 
 
Cr Cl = N (Sex) X (140-Age) X weight (kg) / serum creatinine (micromoles/l), where N = 1.04 for males 
and 1.23 for females. 
13.2) MYELOTOXICITY 
Every cycle of chemotherapy is given 21 days apart. An absolute neutrophil count of 1 X 109/L and 
platelets of >100 X 109/L is required. If the count is not sufficiently recovered by day 21, the patient 
should be rested until count recovery occurs, usually less than a week.  
13.3) OTOTOXCITY 
In children with hearing impairment secondary to cisplatin treated with cisplatin-containing regimens, 
carboplatin can be substituted on day 1 (AUC 5), except in children who have already been upgraded 
to the HR regimens for poor response to carboplatin at first evaluation according to the SIOP Boston 
Ototoxicity Scale (see Appendix N). A change from carboplatin to cisplatin is warranted if the hearing 
impairment is grade 3 or more. 
13.4) CARDIOTOXICITY 
All patient should have a cardiac evaluation with an echocardiogram (other test as per unit protocols) 
before the start of chemotherapy.  
Schedule:  
• Before the start of chemotherapy and end of chemotherapy regimens (even non-Doxorubicin 
containing regimens) 
• Doxorubicin containing regimens: 
- Before the start of a CADO regime and after every 6th cycle and 8th cycle  
- At cumulative dose of 200mg/m2 and the maximum cumulative dose of 280mg/m2 






IR-SA: Total 150mg/m2 (5 x 30mg/m2) 
HR-SA extended induction: Total 140mg/m2 (4 x 35mg/m2) 
CADO: 6th cycle (or extended HR-SA + 2 cycles): 210mg/ m2, 8th cycle (or extended HR-SA + 4 cycles): 
280mg/m2  
Minimum requirements during echocardiogram studies: 
- Left ventricular functioning:   
• Shortening fraction (SF)  
• Ejection fraction (EF) 
- Anatomical defects/ physiological that prevent chemotherapy administration due to the 
risk of cardiomyopathy 
Normal pre-chemotherapy cardiac function: 
SF > 28% 
EF > 50% 
 
Management of cardiotoxicity: 
Grade 0 toxicity:  Normal 
   No action 
Grade 1 toxicity: Asymptomatic decline of resting SF or EF of >10% but <20% of  
baseline value.  
Wait 1 week and re-evaluate if not improved omit single dose anthracycline. 
Echocardiogram before next planned dose. 
Grade 2 toxicity: Asymptomatic decline of resting SF or EF >20% but <25% of baseline value.  
Omit next anthracycline. Echocardiogram before next planned dose. 
Grade 3 toxicity: Responsive cardiac failure or decline of resting SF or EF > 25% 
 Requiring therapy and definitely stop anthracyclines 
Grade 4 toxicity: Severe cardiac failure requiring intensive care 
   Stop anthracyclines 
With symptomatic toxicity consult a paediatric cardiologist and/or evaluate for supportive drug 




1 4 .  D O S E  M O D I F I C AT I O N S  F O R  I N FA N T S  
 
Infants of less than 6 months and low weight children: 
- Body weight below 12kg should be dosed according to their weight (kg) instead of their body 
surface area (m²) according to the known formula of 30 kg= 1 m2.  
- Infants with a weight equal and < 5kg: 
The dose in mg/kg with a further 1/3 dose reduction is advised. 
 
Per chemotherapy drug: 
Please see section 12 as per risk stratification 
Carboplatin: 
Carboplatin dose calculations are done using the Calvert formula modified for the use in children: 
Carboplatin dose (mg) = Target AUC (5) X GFR (ml/min) + [0.36 X body weight (kg)] 
For AUC 5 maximum carboplatin dose should be capped at 750mg. Paediatric dosing tables are 
available for comparison.  
Cisplatin: 
See individual treatment schedule. 
Vincristine: 
See individual treatment schedule. 
Doxorubicin: 
See individual treatment schedule. 
Cyclophosphamide: 




1 5 .  E N D  O F  T R E AT M E N T  E VA L U AT I O N S  
 
This should consist of the following: 
• A clinical examination 
• Nutritional assessment  
o Anthropometry and  
o MUAC measurements 
o Biochemical evaluation 
• Appropriate tumour markers to document normal values 
o U-catecholamines 
o LDH, Ferritin, ESR 
• Imaging with an appropriately comparable modality (chest X Ray, abdomino-pelvic 
ultrasound, CT or MRI) 
• Skeletal survey: MIBG scan and/or bone scan 
• Bone marrow biopsy is not routinely advised but should be performed only if an 
abnormal full blood count cannot be explained by any other phenomenon e.g. bleeding. 
       
1 6 .  L O N G  T E R M  F O L L O W  U P  
 
At every visit the following investigations should be done: 
• Clinical examination for new masses 
• BP  
• FBC, U&E, creatinine, LDH, Uric acid and ALP 
• CXR and abdominal US every visit (abdominal US only in abdominal and pelvic primary) 
• U-catecholamine 
• Skeletal survey is only advised if the clinical information indicates an MIBG scan or bone scan   
The follow up schedule: 
End of treatment 
3 monthly for 2 years 
Then 6 monthly for 3 years 
Then 6 monthly for 3 years 




1 7 .  S TAT I S T I C A L  C O N S I D E R AT I O N S  
 
17.1) Overview: 
The hypothesis of the study that will be addressed is an improved survival outcome with the national 
protocol and identification of treatment risk factors as well as a correlation between clinical aspects 
and special investigations. The aim of the statistical design and analysis of this study is to evaluate a 
response-based approach to therapy of NB in childhood. 
 
17.2) Accrual and study duration: 
Based on accrual rates from the South Africa Children’s Tumour Registry [14] the anticipated 
contribution will be a minimum 35-40 patients per year with an expected 70 -80 patients over 2 
years and 200 patients over 5 years. 
 
The duration of the study will be to adequately study 2 year and 5 year survival outcomes with the 
following study end points: 
• Efficacy endpoints 
The endpoint for analysis is event-free survival (EFS) and overall survival (OS). For the 
palliative group progression free survival (PFS) will be a primary endpoint. 
This will include the minimum time from study entry, time of response assessment or 
treatment failure i.e. disease progression, disease recurrence, biopsy positive residual after 
completion of all protocol therapy, occurrence of a second malignant neoplasm, or death 
from any cause.  
 
• Toxicity endpoints 
 
The primary endpoint for toxicity analysis will be occurrence of any mayor toxicity that 
prevents further oncological management or cause a toxic death. Toxicity will be defined 
according to The National Cancer Institute Common Terminology criteria for Adverse events 
version 5.0 [202]. 
 
17.3) Data collection: 
 
Data will be collected by each individual unit and collated in a central, anonymous database 
managed by the principle investigator. 
 
17.4) Data analysis: 
 
• Statistics will be done by a qualified statistician associated with the University of the 
primary investigators 
• Data will be analysed using Stata 13.1 SE (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP.).  
• Continuous variables will be summarised using mean and standard deviation (SD). If 
any continuous variables are skewed, then medians and interquartile ranges will be 
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presented instead. Categorical data will be presented using frequency tables. 
Association between two categorical variables will be assessed using the standard 
Pearson’s chi-square (χ2) test. If expected cell count in the cross tabulation contains 
fewer than 5 observations (sparse numbers) then the Fisher’s exact test will be 
employed. The standard t-test will be used to compare the mean of continuous 
explanatory variables by dichotomous outcome classification (e.g. mortality or 
remission). If the normality assumption is not upheld, then the non-parametric 
equivalent Wilcoxon rank-sum test (Mann Whitney U test) will be used instead. 
Comparison of means by 3 or more groups (e.g. risk classification of low, 
intermediate, high) will be performed using one-way analysis of variance (ANOVA) 
with post hoc pairwise comparison using Bonferroni correction. If the data are not 
normal, then the Kruskal-Wallis equality-of-populations rank test will be used 
instead. Time to event (survival) analysis will also be employed.  
• Kaplan-Meier survival curves will be developed and differences by groups assessed 
using a log rank test. This will be extended to a multivariable proportional hazards 
(Cox) regression model to adjust for confounding factors and test for potential 
interactions. The proportional hazards assumption of the model will be assessed to 
confirm adequacy. If this assumption is not upheld, then a semi-parametric and/or 
parametric survival model will be used instead. An adjusted p-value of <0.05 will be 
considered statistically significant. 
          
1 8 .  D I S S E M I N AT I O N  P L A N  
 
• The information will be used in the PhD thesis of the principal investigator 
• The aim is to publish findings with the PhD student as first author in collaboration with 
participating members of the SACCSG.  
• The principal investigator will present the information at international and national meetings 
under the SACCSG.    
       
1 9 .  F U N D I N G  
 
The treatment is current standard treatment available in all government and private sector 
hospitals. No additional funding is required as it is in line with the current standard of care, although 
there is currently not a uniform treatment protocol, but the same medicines are used in the current 
treatment protocols of international origin.      
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2 0 .  C O N F L I C T  O F  I N T E R E S T  
 
The investigators wish to declare no conflict of interest in terms of this study.   
 
2 1 .  E T H I C A L  C O N S I D E R AT I O N S  
 
All research conducted during this study will be done according to the benchmarks for research in 
LMIC [204]. 
Collaborative partnership: 
The research is a national, multi departmental study which includes multiple hospital sites. The study 
is a joint partnership between pediatric oncologists, radiologists, surgeons, nuclear medicine 
physicians as well as staff active in the care of patients and diagnostics such as laboratories.  
Social value: 
The proposed management protocols will be sustainable treatment interventions. Future 
suggestions for management adaptations will benefit the South African population and needs. 
Scientific validity: 
The risk of intervention and scientific validity is according to acceptable standard medical care for all 
children diagnosed with NB. All treatments and palliation will be standard of international care with 
practical application to South African health care guidelines and resource restraints. 
Study results will be given to participating parties and the data will be discussed in academic 
meetings and congresses, thesis purposes and published in peer reviewed journals. 
Fair selection of study population: 
All patients diagnosed with NB will be invited to participate in the study as part of a fair selection 
process. 
Favourable risk benefit ratio: 
Untreated NB is a terminal disease. The aim of the study is to improve outcomes as well as improve 
palliative care for patients without further treatment options. All interventions will only be done to 
benefit the patient and treatment above the negative effects of the treatment or interventions on 
the patient.   
Independent review: 
Applications for ethical approval will be submitted at the Health Research Evaluation Committee of 
respective universities attached to participating POUs. The ethical approval from respective 




Written consent will be obtained from participant’s caretakers as well as assent in children older 
than 7 years old. Assent from children below 7 years of age will not be taken, however the 
willingness to participate in the management will be taken into consideration. Participation in the 
study is voluntary. Participants or their parents may withdraw at any stage of the study. All consent 
and assent will be obtained according to age, education and language sensitive requirements. 
Respect for the recruited participants and study communities: 
Where there is the possibility of discomfort or emotional distress all efforts will be made to minimize 
the discomfort without hazardous effects.  
Each patient will receive a unique study number. A list linking the name and the unique study 
number will be kept separate in the individual POU and not be used in the analysis. The data will be 
collected prospectively and analysed without the name or any identifiable data of the individual 
patient to ensure confidentiality. 
The electronic information will be kept in each POU on a password protected computer that will only 
be accessible by the staff participating in the study. The main data base will be kept by the principle 
investigator at Grey’s Hospital on a password protected computer. 
Human tissue and biological samples will be collected and treated according to the ethical guidelines 
of the ethical committees of participating Universities and guidelines of the Health Professions 
Council of South Africa.   
All interventions and management recommendations will be done with consideration to social and 
cultural aspects of each patient. 
All investigator are GCP compliant.  
     
2 2 .  A P P E N D I C E S  
 
Appendix A:  Informed Consent        
Appendix B:  B1 Informed Assent Age 7-13       
  B2 Informed Assent Age 13-16     
Appendix C:  Pathology Form 
Appendix D: Bone Marrow aspirate and trephine form      
Appendix E:  Patient Clinical Record Form (CRF)      
Appendix F:  Image Defined Risk Factor (IDRF)     
Appendix G:  International Neuroblastoma Risk Group (INRG) Consensus pre-treatment staging 
system (INRGSS)   
Appendix H:     International Neuroblastoma Staging System (INSS)  
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Appendix I:     Neuroblastoma Pathologival Classification adapted for South Africa (NPC-SA)   
Appendix J: International Neuroblastoma Pathological Classification (INPC) /  
Shimada classification  
Appendix K:  COG risk grouping    
Appendix L:  Adapted Risk Stratification and Treatment Assignment for Neuroblastoma in LMIC  
Appendix M:   South African Neuroblastoma Adapted risk stratification (SANARS) 
Appendix N:  Drug information sheets       
 N1 Busulfan 
N2 Carboplatin        
N3 Cisplatin 
N4 Cis-retinoic acid (CRA) 
N5 Cyclophosphamide 
N6 Doxorubicin       
N7 Etoposide 
N8 Melphalan        
N9 Vincristine       
Appendix O:  Short version protocols       
  O1 CE (LR – SA) 
  O2 Intermediate risk (IR – SA)  
   O3 OJEC/OPEC (HR –SA) 
  O4 CADO 
  O5 BuMel 
O6 CRA 
O7 Metronomic therapy (M-NB-SA)    
Appendix P:  Boston Ototoxicity Scale and Audiology Recommendations  
Appendix Q:  Modified Curie-Score for 123I-MIBG scan 
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Information Sheet and Consent to Participate in Research 
 
Date_______________ 
Dear parent /caregiver 
You are being invited to consider participating in a study that involves research on 
behalf of your child (name of patient)___________________________________ The 
aim and purpose of this research is to offer all children across South Africa 
standardised treatment according to the nature of their cancer and to use this 
information for research purposes. In your child’s case it is a cancer that originates 
from the adrenal glands and the main nerve that supplies the adrenal gland called 
Neuroblastoma.  
The study does not have any randomisation which means that you will not be assigned 
different treatments by chance but rather your child will receive what is considered to 
be standard of care according to the risk group of your child’s clinical presentation. In 
Neuroblastoma this might include surgery with or without intensive chemotherapy, 
radiotherapy and a bone marrow transplant.  
The study is expected to enrol 200 patients over 5 years and patients will be enrolled 
across the country at 11 different sites in both private and state hospitals where 
children with cancer are cared for. After 2 years an interim evaluation of the information 
will be done. The purpose of the study is to provide uniform care to all children with 
Neuroblastoma and to improve the outcomes of children with these cancers. None of 
the procedures that your child undergoes will be experimental.  
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Tissue obtained during diagnosis might be sent to other medical facilities for a second 
opinion and if needed retested to confirm the diagnosis or determine further 
information regarding your child’s cancer. With this testing you will not incur additional 
costs. 
You are free to withdraw from the study at any point. Your child’s care will be no 
different whether you choose to participate in the study or not or once your child is part 
of the study, stay in the study or to leave. The intention of the study is to follow your 
child’s progress through the treatment and then after treatment to at least five years 
from the end of therapy. This is to ensure that any complications which may arise at a 
later stage can be detected early and that we can intervene. 
At this point the study is not externally funded and all therapy will be for according to 
the determinations of state payment scales or according to private medical funding if 
you belong to a private medical aid. The study itself does not incur any additional costs 
to you. 
The study may involve no additional risk or discomfort outside of what would 
reasonably be expected in this instance. The treatment plan which involves surgery 
and in some cases chemotherapy or bone marrow transplant will be explained to you, 
you will receive a copy of the chemotherapy protocol as well as drug information 
sheets which explain possible drug complications (attached). Disclose in full any 
appropriate alternative procedures and treatment etc. that may serve as possible 
alternate options to study participation.  
This study has been ethically reviewed and approved by an ethical committee: 
_________________________________________________________________ 
With approval number_____________________ 
In the event of any problems or concerns/questions you may contact the researcher 
at Jaques.vanheerden@uza.be or Human Research Ethics Committee contact details 
as follows:  
RESEARCH ETHICS ADMINISTRATION 
Address 




Email:   
 
It important for you to know that:   
1. That participation in this research is completely voluntary. 
2. That you may withdraw your participation at any point. 
3. That in the event of refusal/withdrawal of participation you will not incur any 
penalty or loss of treatment or other benefit to which they are normally entitled.  
4. No additional costs (outside of what would normally be expected) will be 
incurred by you as a result of participation in the study.  
5. There are no financial incentives or reimbursements for participation in the 
study. 
6. All your medical information will be completely confidential. All data will be de-
identified using numerical descriptors. All data will be entered into a central 
database which will only be accessible to your local physician and the study co-
ordinator / principal investigator.  
7. After a certain period of time data will be analysed to assess whether the 
standardised treatment approach has improved survival of patients.  
8. Information gathered from this study will be used to improve the care provided 
for children with Neuroblastoma across South Africa.  
 
I (Name of caregiver) ______________________________________ have been 
informed about the study entitled:  
Treatment of Neuroblastoma in South Africa, SACCSG NB-2017 
By (Name of researcher) __________________________________________ 
I understand the purpose and procedures of the study. 
I have been given an opportunity to answer questions about the study and have had 
answers to my satisfaction. 
I declare that my participation in this study is entirely voluntary and that I may withdraw 
at any time without affecting any treatment or care that I would usually be entitled to. 
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If I have any further questions/concerns or queries related to the study I understand 
that I may contact the researcher at______________________________________: 
RESEARCHER 
Principal Investigator 
Room Paediatric Haematology Oncology Service, Koningin Mathilde Mother and  
Child Hospital, 10 Wilrijk Street, Edegem, Belgium, 2650 
Tel +32 3 821 3000, jaques.vanheerden@uza.be 
 
If I have any questions or concerns about my rights as a study participant, or if I am 
concerned about an aspect of the study or the researchers then I may contact: 
RESEARCH ETHICS ADMINISTRATION 
Address 
Tel:   
Fax:  
E-mail:   
 
____________________     ____________________ 
Signature of Participant                            Date 
____________________   _____________________ 
Signature of Witness                                Date 
____________________   _____________________ 











Do you know what RESEARCH is? 
Research is something we do to find new knowledge about the way things (and people) work.  
We use research projects or studies to help us find out more about diseases or illness. 
Research also helps us to find better ways of helping, or treating children who are sick. 
What are we doing this research project? 
I want to invite you to be part of a study that will treat children with your illness. We then 
use this information to learn more about your illness. 
Why have I been invited to take part in this research project? 
You have an illness called neuroblastoma and it is something growing in your body that should 
not be there. The treatment is given to stop the growth. This means we want to make you 
better. 
Who is doing the research? 
Doctor Jaques van Heerden from the Department of Paediatrics, Koningin Matilde Mother 
and Child Hospital in Belgium and Doctor ____________________________________, who 
is treating you. 
What will happen to me in this study? 
The treatment involves (taking blood, operations and medication) to make you better.  
• The different drugs and their names are Carboplatin and/or Cisplatin, Etoposide, 
Vincristine and Cyclophosphamide. Sometimes we use Doxorubicin as well.  
• How it is given? After applying some local anaesthetic to your skin (cream or patch) 
we will insert a needle in your arm on day 1 to give you the drugs through a drip which 
is a long plastic line attached to a bag of fluid. You will not feel the medication running 
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in apart from it being a little cold. It will not make your arm feel strange or sore. 
Sometimes this medication can make you feel nauseas or cause vomiting. To prevent 
that we will give you some medication in the drip before the chemotherapy starts to 
stop you from feeling nauseas and vomiting. 
• The chemotherapy will take a few hours to run into your body.  
Can anything bad happen to me? 
You may have problems due to the drugs, which the doctors will help to manage. You need 
to inform the doctors if there is a problem so that they can help you. The problems are: 
• Nausea and vomiting and being unable to eat. We will give you tablets or medicine in 
the drip to help with this problem. 
• You may develop a fever and need antibiotics because the chemotherapy may lower 
your white blood cells. Your white blood cells are in your blood and are the soldiers of 
your body which fight infections. 
• Tiredness, which is due to low red blood cells. Red blood cells are found in the blood 
and carry the oxygen from the lungs to the rest of the body. You may need a red blood 
cell transfusion. 
• Bleeding due to low platelets. Platelets are found in the blood and normally form a 
plug to stop bleeding. You will know it as the scab that forms on a skin wound. 
• Hair loss. The drugs cause the hair to stop growing. You will notice that your hair will 
begin to fall out about 2-3 weeks into chemotherapy. Fortunately, the hair will grow 
back normally after the drugs are stopped. 
• Some of the medication can cause you not to hear well and therefore you will regularly 
tested for hearing.  
Can anything good happen to me? 
The medicine we give you will hopefully make your cancer small enough to remove so that 
you will be healthy again. It will also mean that once you feel better you will be able to see 
friends, start playing sport and be able to go back to school. 
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Will anyone know I am in the study? 
The data will be kept confidential, which means nobody but the treating doctor will know who 
you are. Your name will not appear on the data sheet where we look whether you have 
become better.   
Who can I talk to about the study?  
You can speak to anyone but your doctor or your parents may be the best people to start off 
with. Feel free to ask any questions at any time. Sometimes writing down questions can help 
us to remember what to ask. 
What if I do not want to do this? 
You get to choose whether or not you want to be in the study. If you say “yes” we can collect 
your information about how you respond to the treatment. We will use this information to 
help other children with the same cancer. If you say “no” you will still get the same treatment 
and care from us. 
I understand that by signing I do not give up my legal rights.  
Ethics Review 
The (Name of the Research Ethics Committee) makes sure that the doctor researchers will 











Do you understand this research study and are you willing to take part in it?   
YES  NO 
Do you understand that information about your illness will be used?   
YES  NO 
Has the researcher answered all your questions? 
YES  NO 
Do you understand that you can pull out of the study at any time? 
YES  NO 
 
_________________________  ____________________  
Signature or thumb print of Child   Date 
_________________________  ____________________  
Signature of Doctor     Date 
_________________________  ____________________  
Signature of Witness     Date 
_________________________  ____________________ 





























International Neuroblastoma Respons Criteria: 
Abbreviations: 
CR – Complete response; MD – Minimal disease; MR – Minimal response; NI – not involved;  
PD – progressive disease; PR – partial response; VGPR – very good partial response;  
SD – stable disease 
 
Definitions:  
Target lesions: Disease sites that meet criteria of measurable size (non-lymphoid soft tissue mass 
≥10 mm in longest dimension or lymph node ≥15mm in short axis) as well as either uptake on MIBG 
(or FDG for MIBG non-avid tumors) OR biopsy positive for neuroblastoma or ganglioneuroblastoma 
 
Non-target lesions: Lesions that are considered to be active tumor sites but do not meet target 









Anatomic + 123I-MIBG (FDG-PET) Imaging 
 
CR Assessment with: 
• 10 mm residual soft tissue at primary site  
               AND 
• Complete resolution of 123I-MIBG or FDG-PET (for 123I-MIBG-nonavid 
tumours) uptake at primary site. 
 
If no 123I-MIBG or FDG-PET scan available: 
• 10 mm residual soft tissue at primary site  
AND 
• Catecholamines normal. 
 
VGPR Assessment with: 
• Primary tumour decreased by 90% to 99%   
AND 
• catecholamines normal. 
 
Supporting evidence: 





• 30% decrease in longest diameter of primary site  
              AND 
• 123I-MIBG or FDG-PET uptake at primary site stable, improved, or 
resolved. 
 
PD Assessment with: 
• 20% increase in longest diameter taking as reference the smallest sum 
on study (this includes the baseline sum if that is the smallest on 
study) 
              AND 
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• Minimum absolute increase of 5 mm in longest dimension 
SD 
 
Neither sufficient shrinkage for PR nor 









Anatomic + 123I-MIBG (FDG-PET) Imaging 
 
CR Resolution of all sites of disease defined as: 
• Non-primary target and non-target lesions measure 10 mm 
               AND 
• Lymph nodes identified as target lesions decrease to a short 
               axis 10 mm  
               AND 
• 123I-MIBG uptake or FDG-PET (for 123I-MIBG-non-avid tumours) 
uptake of non-primary lesions resolves completely 
 
If no 123I-MIBG or FDG-PET scan available: 
• Resolution of all sites 
                AND 





• No tumour 
AND 
• Catecholamines normal 
AND 





• >30% decrease in sum of diameters of non-primary target lesions 
compared with baseline  
               AND  
• All of the following: 
- Non-target lesions may be stable or smaller in size AND 
- No new lesions AND 
- >50% reduction in MIBG absolute bone score (relative MIBG 
bone score > 0.1 to < 0.5) or > 50% reduction in number of FDG-
PET–avid bone lesions 
 
PD Any of the following: 
• Any new soft tissue lesion detected by CT/MRI that is also MIBG avid 
or FDG-PET avid 
• Any new soft tissue lesion seen on anatomic imaging that is biopsied 
and confirmed to be Neuroblastoma or Ganglioneuroblastoma 
• Any new bone site that is MIBG avid 
• A new bone site that is FDG-PET avid (for MIBG non-avid tumours) 
AND has CT/MRI findings consistent with tumour OR has been 
confirmed histologically to be Neuroblastoma or 
Ganglioneuroblastoma 
• 20% increase in longest diameter taking as reference the smallest 
sum on study (this includes the baseline sum if that is the smallest 
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on study) AND minimum absolute increase of 5 mm in sum of 
diameters of target soft tissue lesions 
• Relative MIBG score > 1.2 
SD 
 
Neither sufficient shrinkage for PR nor sufficient increase for 











CR Bone marrow with no tumour infiltration on reassessment, 




Any of the following: 
• Bone marrow without tumour infiltration that becomes > 5% 
tumour infiltration on reassessment OR 
• Bone marrow with tumour infiltration that increases by > two fold 
                and has > 20% tumour infiltration on reassessment. 
 
MD Any of the following: 
• Bone marrow with < 5% tumour infiltration and remains > 0 to < 5% 
tumour infiltration on reassessment OR 
• Bone marrow with no tumour infiltration that has < 5% tumour 
infiltration on reassessment OR 




Bone marrow with tumour infiltration that remains positive with >5% tumour 















PR in at least one component and all other components are either CR, MD 
(bone marrow), PR (soft tissue or bone), or NI; no component with PD. 
 
MR PR or CR in at least one component but at least one other component with SD; 




SD in one component with no better than SD or NI in any other component; no 
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Image Defined Risk Factor (IDRF) 
IDRFs include the following:  
• Ipsilateral tumour extension within two body compartments: neck and chest; chest and 
abdomen; abdomen and pelvis. 
• Infiltration of adjacent organs/structures: pericardium, diaphragm, kidney, liver, duodeno-
pancreatic block, mesentery. 
• Encasement of major vessels by tumour: vertebral artery, internal jugular vein,  subclavian 
vessels, carotid artery, aorta, vena cava, major thoracic vessels, branches of the superior 
mesenteric artery at its root and the coeliac axis, iliac vessels. 
• Compression of trachea or central bronchi. 
• Encasement of brachial plexus. 
• Infiltration of port hepatic or hepato-duodenal ligament. 
• Infiltration of the costo-vertebral junction between T9 and T12. 
• Tumour crossing the sciatic notch. 
• Tumour invading renal pedicle. 
• Extension of tumour to base of skull. 
• Intraspinal tumour extension such that more than one-third of the spinal canal is invaded, 
leptomeningeal space is obliterated, or spinal cord MRI signal is abnormal. 
 
APPENDIX G 
International Neuroblastoma Risk Group Staging System (INRGSS) 
STAGE DESCRIPTION 
L1 Localized tumor not involving vital structures as defined by the list of image-defined risk 
factors and confined to one body compartment 
L2 Locoregional tumor with presence of one or more image-defined risk factors 
M Distant metastatic disease (except stage MS) 
MS Metastatic disease in children younger than 18 months with metastases confined to skin, 
liver, and/or bone marrow 
IMPORTANT: Patients with multifocal primary tumors should be staged according to the greatest extent of disease as 





International Neuroblastoma Staging System (INSS) 
Stage 1 • Localized tumour with complete gross excision, with or without 
microscopic residual disease  
• Representative ipsilateral lymph nodes negative for tumour 
microscopically  
Stage 2A • Localized tumour with incomplete gross excision  
• Representative ipsilateral non-adherent lymph nodes negative for 
tumour microscopically. 
Stage 2B • Localized tumour with or without complete gross excision, with 
ipsilateral non-adherent lymph nodes positive for tumour.  
• Enlarged contralateral lymph nodes must be negative microscopically 
Stage 3 • Unresectable unilateral tumour infiltrating across the midline, with or 
without regional lymph node involvement  
• Localized unilateral tumour with contralateral regional lymph node 
involvement  
• Midline tumour with bilateral extension by infiltration (unresectable) 
or by lymph node involvement. The midline is defined as the vertebral 
column. Tumours originating on one side and crossing the midline 
must infiltrate to or beyond the opposite side of the vertebral column. 
Stage 4 • Any primary tumour with dissemination to distant lymph nodes, bone, 




Stage 4S Localized primary tumour, as defined for stage 1, 2A, or 2B, with dissemination 
limited to skin, liver, and/or bone marrow (by definition limited to infants 
younger than 12 months). Marrow involvement should be minimal (i.e., <10% 
of total nucleated cells identified as malignant by bone biopsy or by bone 
marrow aspirate). More extensive bone marrow involvement would be 
considered stage 4 disease. The results of the MIBG scan, if performed, should 


























Neuroblastoma Pathological Classification (NPC-SA)  
adapted for South Africa 
International Neuroblastoma Pathology 
classification adapted for South Africa 
INPC-SA 
Neuroblastoma (Schwannian stroma-poor) 
• Undifferentiated 





<1.5 yrs Poorly differentiated or 
differentiating 
FH 
1.5–5 yrs Differentiating FH 
<1.5 yrs Undifferentiated tumour UH 
1.5–5 yrs Undifferentiated or poorly 
differentiated tumour 
UH 
≥5 yrs All tumours UH 
Ganglioneuroblastoma intermixed (Schwannian 
stroma-poor) 
FH 






Ganglioneuroblastoma nodular (Schwannian 
stroma-rich/stroma-dominant and stroma-poor) 
UH 
 





International Neuroblastoma Pathological Classification (INPC)/Shimada classification 




Neuroblastoma (Schwannian stroma-poor) 
• Undifferentiated 




<1.5 yrs Poorly differentiated or 
differentiating & low  
or intermediate MKI tumour 
 FH 
1.5–5 yrs Differentiating & low MKI tumour  FH 
<1.5 yrs a) undifferentiated tumour 
b) high MKI tumour 
  
UH 
1.5–5 yrs a) undifferentiated or poorly 
differentiated tumour 





≥5 yrs All tumours  UH 















Ganglioneuroblastoma nodular (Schwannian stroma-








COG Risk grouping: 
INSS Age MYCN Shimada DNA ploidy Risk group 
1 Any Any Any Any Low 
2A/2B <365d Any Any Any Low 
>365d Nonamplified Any - Low 
>365d Amplified FH - Low 
>365d Amplified UH - High 
3 <365d Nonamplified Any Any Intermediate 
<365d Amplified Any Any High 
>365d Nonamplified FH - Intermediate 
>365d Nonamplified UH - High 
>365d Amplified Any - High 
4 <548d Nonamplified Any Any Intermediate 
<548d Amplified Any Any High 
>548d Any Any - High 
4S <365d Nonamplified FH >1 Low 
<365d Nonamplified Any 1 Intermediate 
<365d Nonamplified UH Any Intermediate 
<365d Amplified Any Any High 
Low risk 
 All children who are Stage 1
 Any child who is Stage 2A or 2B and younger than age 1
 Any child who is Stage 2A or 2B, older than age 1, whose cancer has no extra copies of
the MYCN gene
 Any child who is Stage 4S (younger than age 1), whose cancer has favorable histology, is
hyperdiploid (excess DNA) and has no extra copies of the MYCN gene
Intermediate risk 
 Any child who is Stage 3, younger than age 1, whose cancer has no extra copies of
the MYCN gene
 Any child who is Stage 3, older than age 1, whose cancer has no extra copies of the MYCN gene
and has favorable histology (appearance under the microscope)
 Any child who is Stage 4, younger than age 1, whose cancer has no extra copies of
the MYCN gene
 Any child who is Stage 4S (younger than age 1), whose cancer has no extra copies of
the MYCN gene and has normal DNA ploidy (number of chromosomes) and/or has unfavorable
histology
High risk 
 Any child who is Stage 2A or 2B, older than age 1, whose cancer has extra copies of
the MYCN gene
 Any child who is Stage 3, younger than age 1, whose cancer has extra copies of the MYCN gene
 Any child who is Stage 3, older than age 1, whose cancer has extra copies of the MYCN gene
 Any child who is Stage 3, older than 18 months of age, whose cancer has unfavorable histology
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 Any child who is Stage 4, whose cancer has extra copies of the MYCN gene regardless of age 
 Any child who is Stage 4 and older than 18 months 
 Any child who is Stage 4 and between 12 and 18 months old whose cancer has extra copies of 
the MYCN gene, unfavorable histology, and/or normal DNA ploidy (a DNA index of 1) 
 Any child who is Stage 4S (younger than age 1), whose cancer has extra copies of 




Adapted Risk Stratification and Treatment Assignment for Neuroblastoma in LMIC 
 
VLR - very low risk LR - low risk IR - intermediate risk; HR - high risk; A - Amplified; NA - Non-










INSS Initial Status Risk Group Age (yr) LDH Ferritin MYCN Rx 
1 Resection Low 0.5-21 Any Any Any 
1 Observation VLR < 0.5 Any Any Any 
2A/2B Resection >50% 
asymptomatic 
Low Any Any Any Unknown 
2A/2B Resection 50% 
symptomatic 
Intermediate Any Any Any NA/ 
Unknown 
2A/2B Resection <50% 
asymptomatic 
Intermediate Any Any Any NA/ 
Unknown 
2A/2B Any resection High Any Any Any Amplified 
3  Intermediate <1.5 <750 <120 NA/Unknown 
3  Intermediate >1.5 <750 <120 NA/Unknown 
3  High Any >750 >120 NA/Unknown 
4  High <1.5 >750 >120 NA/Unknown 
4  Intermediate <1.5 <750 <120 NA/Unknown 
4  High >1.5 Any Any Any 
4S Asymptomatic Low <1 <750 <120 NA/Unknown 
4S Symptomatic Intermediate <1 <750 <120 NA/Unknown 







Proposed South African Neuroblastoma Adapted risk stratification (SANARS) 




LDH Ferritin MYCN Histology 
 
Risk Group 
1 Resection > 50% L1 >6mo Any Any NA Any  Low 
1 Resection > 50% L1 >6mo Any Any Amp Any High 
1 Observation L1 <6mo Any Any Any Any Very low (VLR) 
2A Resection >50% 
Asymptomatic 
L1 Any Any Any NA/EC/ 
Unknown 
Any Low 
2B Resection >50% 
Asymptomatic 
L2 Any Any Any NA/EC/Unknown Any Low 
2A Resection >50 % 
Symptomatic 
L1 Any Any Any NA/EC/ 
Unknown 
FH Intermediate 
2A Resection >50 % 
Symptomatic 
L1 Any Any Any NA/EC/Unknown UH High 
2B Resection >50% 
Asymptomatic 
L2 Any Any Any NA/EC/ 
Unknown 
FH Intermediate 
2B Resection >50 % 
Symptomatic 
L2 Any Any Any NA/EC/Unknown UH High 
2A Resection <50% L1 Any Any Any NA/EC/Unknown FH Intermediate 
2A Resection 
 < 50% 
L1 Any Any Any NA/EC/Unknown UH High 
2B Resection <50% L2 Any Any Any NA/EC/Unknown FH Intermediate 
2B Resection  
< 50% 
L2 Any Any Any NA/EC/Unknown  UH High 
2A Any resection L1 Any Any Any Amp Any High 
2B Any resection L2 Any Any Any Amp Any High 
3  L2 <18mo <750 <120 NA/EC/ 
Unknown 
Any Intermediate 
3  L2 >18mo <750 <120 NA/EC/ 
Unknown 
FH Intermediate 
3  L2 >18mo <750 <120 NA/EC/ 
unknown 
UH High 
3  L2 Any >750 >120 A/ Unknown Any High 
4  M <18mo >750 >120 A/ Unknown Any High 
4  M <18mo <750 <120 NA/EC/Unknown Any Intermediate 
4  M >18mo Any Any Any Any High 
4S Asymptomatic MS <6mo <750 <120 NA/EC FH Low 
4S Asymptomatic MS <12mo <750 <120 NA/EC/ 
Unknown 
FH Low 
4S Symptomatic MS <12mo <750 <120 NA/EC FH Low 
4S Asymptomatic MS <12mo <750 <120 NA/EC/Unknown UH Intermediate 
4S Symptomatic MS <12mo <750 <120 Unknown Any Intermediate 






Also called Busulfex, Myleran. Busulfan can be given by mouth and intravenous injection or infusion. 
 
Following a dose of Busulfan, some patients may experience: 
 
a. Immediate: 
1. Nausea and vomiting (in the first 3 - 5 days). 
2. Diarrhea (in the first 3 - 5 days). 
3. Poor appetite. 
 
b. Delayed: 
1. Hair loss. 
2. Mouth sores. 
3. Low blood counts. 
4. Liver problems. 
5. Convulsions. 
6. Increase risk of secondary cancers. 
7. Infertility. 
 
c. Less frequent side effects: 
1. Discoloration of the skin, especially in the creases of the hands and nail beds. 
2. Skin rash 
3. Itching 
 
Contact your doctor if you notice: 
1. Fever 
2. Nausea (interferes with ability to eat and unrelieved with prescribed medication). 
3. Vomiting (vomiting more than 4-5 times in a 24 hour period). 
4. Diarrhea (4-6 episodes in a 24-hour period). 
5. Unusual bleeding or bruising 
6. Black or tarry stools, or blood in your stools 
7. Blood in the urine 
8. Pain or burning with urination 
9. Extreme fatigue (unable to carry on self-care activities) 
10. Dizziness 
11. Mouth sores (painful redness, swelling or ulcers) 
12. Yellowing of the skin or eyes 
13. Swelling of the abdomen 
14. Regular blood counts and other tests will be done to check on possible side effects and 
treatment will be adjusted accordingly. 
15. Any other problem or have questions. 
 
Special instructions: 
1. Leaking of this drug outside the vein may cause pain and skin damage similar to a burn. 
Contact your doctor IMMEDIATELY if pain, redness or swelling occurs near the injection site. 
 
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and 






Carboplatin is usually given by intravenous infusion. 
Following a dose of carboplatin, some patients may experience: 
a. Immediate:
1. Nausea and vomiting
b. Delayed:
1. A drop in blood cell counts
2. Taste changes
c. Less frequent side effects:






7. Sensory loss, numbness and tingling, and difficulty in walking may last for at least as long as
therapy is continued.
8. Central neurotoxicity: dizziness, confusion, visual changes, ringing in the ears.
9. Kidney problems
10. Liver problems
11. Allergic reaction may occur with itching, rash, shortness of breath or dizziness.
Contact your doctor if you notice: 
1. Fever of 38°C or higher
2. Severe nausea and vomiting
3. Bruising or bleeding
4. Any other problems or have questions
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and
treatment will be adjusted accordingly.
2. In addition, regular tests of kidney function will be done to make sure that no damage is







A platinum compound. Cisplatin is only given by intravenous infusion. 
 
Following a dose of cisplatin, some patients may experience: 
 
a. Immediate: 
1. Nausea and vomiting. This may begin within 2 hours and last for from one to several days. 




1. Low blood counts 
2. Kidney problems 
3. Hearing loss and/or ringing in the ears. 
4. Low magnesium, low calcium, low potassium 
 
c. Less common side effects: 
1. Hair loss 
2. Liver problems 
3. Peripheral sensory loss 
4. Taste changes 
 
Contact your doctor if you notice: 
1. A fever of 38°C or higher 
2. Nausea (interferes with ability to eat and unrelieved with prescribed medication) 
3. Vomiting (vomiting more than 4-5 times in a 24 hour period) 
4. Diarrhea (4-6 episodes in a 24 hour period) 
5. No urine output in a 12 hour period 
6. Blood in the urine 
7. Pain or burning with urination 
8. Unusual bleeding or bruising 
9. Black or tarry stools, or blood in your stools or urine 
10. Extreme fatigue (unable to carry on self-care activities) 
11. Swelling, redness and pain in one leg or arm and not the other 
12. Yellowing of the skin or eyes 
13. Mouth sores (painful redness, swelling or ulcers) 
 
Special instructions 
1. Abundant fluid intake prior to and after cisplatin administration and frequent voiding of 
large volumes of urine is extremely important to protect against kidney damage. 
2. Take anti-nausea medications as directed. 
3. If needed, magnesium tablets or syrup should be taken as directed. 
 
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and 
treatment will be adjusted accordingly. 
2. In addition, regular tests of hearing and of kidney function will be done to make sure there is 




13-CIS-RETINOIC ACID (CRA) 
 
Also called Accutane. CRA can only be given by mouth. 
 
Following a dose of CRA, some patients may experience: 
 
a. Immediate: 
1. Allergic reaction 
 
b. Delayed: 
1. Headache  
2. Fever  
3. Dry skin  
4. Dry mucous membranes (mouth, nose)  
5. Bone pain  
6. Nausea and vomiting  
7. Rash  
8. Mouth sores  
9. Itching  
10. Sweating  
11. Eyesight changes 
 
c. Less frequent side effects: 
1. Back pain  
2. Pain in muscles and joints 
3. Abdominal pain 





9. Numbness and tingling of hands and feet 
10. Weakness 
11. Depression 
12. Hair loss (thinning) 
13. Dry eyes, sensitivity to light (see eye problems) 
14. Decreased night vision, which may persist after treatment is stopped 
15. Swelling of the feet or ankles 
16. Low blood counts. Your white and red blood cells and platelets may temporarily 
decrease.  This can put you at increased risk for infection, anemia and/or bleeding.  
17. Abnormal blood tests: increased triglyceride, cholesterol and/or blood sugar levels.  
18. Increases in blood tests measuring liver function 
 
Contact your doctor is you notice: 
1. Shortness of breath, wheezing, difficulty breathing, closing up of the throat, swelling of facial 
features, hives (possible allergic reaction) 
2. Fever of 38°C or higher, chills (possible signs of infection) 
3. Having thoughts or feeling like you may want to harm yourself or others 
4. Difficulty breathing, sudden weight gain, swelling, vision changes 
5. Severe abdominal pain 
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6. Black or tarry stools, or blood in your stools or urine 
7. Unusual bleeding or bruising 
8. Abdominal cramping 
9. Nausea (interferes with ability to eat and unrelieved with prescribed medications) 
10. Vomiting (more than 4-5 episodes within a 24-hour period) 
11. Diarrhea (more than 4-6 episodes in a 24-hour period) 
12. Mouth sores (painful redness, swelling or ulcers) 
13. Extreme fatigue (inability to perform self-care activities) 
14. Anxiety, changes in thinking or mood, confusion, difficulty concentrating or trouble sleeping, 
aggressive or violent behavior, or suicidal thoughts. 
15. Depressed (interfering with your ability to carry on your regular activities) 
16. Ringing in the ears, problems with hearing 
17. Yellowing of the skin or eyes 
 
Special instructions: 
1. Before starting CRA treatment, make sure you tell your doctor about any other medications 
you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).  
2. Do not take vitamin A supplements with CRA. Taking both together may increase your 
chance of getting side effects. 
3. Do not receive any kind of immunization or vaccination without your doctor's approval while 
taking CRA. 
4. Inform your health care professional if you are pregnant  
 
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and 
































Also called Cytoxan. Cyclophosphamide can be given by intravenous injection, infusion or by mouth. 
 
Following a dose of Cyclophosphamide, some patients may experience: 
 
a. Immediate: 
1. Nausea and vomiting 
2. Loss of appetite 
 
b. Delayed: 
1. Low blood counts 
2. Loss of hair 
3. Discolouration of the nails 
4. Infertility 
 
c. Less frequent side effects: 
1. Mouth sores 
2. Bladder irritation 
3. Secondary malignancies 
 
Contact your doctor is you notice: 
1. Fever above 38°C.  
2. Nausea (interferes with ability to eat and unrelieved with prescribed medication). 
3. Vomiting (vomiting more than 4-5 times in a 24 hour period). 
4. Diarrhoea (4-6 episodes in a 24-hour period). 
5. Unusual bleeding or bruising 
6. Black or tarry stools, or blood in your stools. 
7. Blood in the urine. 
8. Pain or burning with urination. 
9. Extreme fatigue (unable to carry on self-care activities). 
10. Mouth sores (painful redness, swelling or ulcers). 
 
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and 



















This is a red coloured drug which can only be given by intravenous injection. 
Following a dose of Doxorubicin, some patients may experience: 
a. Immediate: 
1. Nausea and vomiting in the afternoon following the injection 
2. Pink, orange and red coloured urine on the night, or the day following the injection 
3. A low grade fever 
4. Rash or urticarial (itchy red spots) at the injection site immediately after the dose is given 
5. Burning at the site of infusion 
b. Delayed: 
1. Drop in blood cell counts, 7 to 10 days after treatment is started. 
2. Mouth ulcers. 
3. Hair loss (2 to 3 weeks after treatment). 
c. Less frequent side effects: 
1. Heart damage (rare - see below). 
2. Darkening of the skin 
Contact your doctor if you notice: 
1. Mouth ulcers 
2. Fever of 38°C or higher 
3. Any other problems or questions 
Special instructions: 
Leaking of this drug outside the vein may cause pain and skin damage similar to a burn. Contact your 
doctors immediately if pain, redness or swelling occurs near the injection site. 
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and 
treatment will be adjusted accordingly. 
2. In addition, regular tests of heart contraction and function will be done to check that no 
damage is detectable and that it is safe to give more doses. The total dose is limited to 










VP-16 can be given by intravenous infusion 
 
Following a dose of VP-16, some patients may experience: 
 
a. Immediate: 
1. Nausea, vomiting and loss of appetite 
 
b. Delayed: 
1. A drop in blood cell count 
2. Infertility 
3. Low blood pressure 
4. Metallic taste in the mouth  
5. Secondary malignancies 
 
c. Less frequent side effects: 
1. Mouth ulcers 
2. Diarrhoea  
3. Hair loss 
4. Possible allergic reactions during infusion (fever, rash, shortness of breath, dizziness due to 
lowered blood pressure). 
 
Contact your doctor if you notice: 
1. Fever of 38°C or higher 
2. Severe nausea or vomiting 
3. Any other problems or have questions 
 
Special instructions: 
1. In addition to capsules, VP-1 6 injection vials can sometimes be given by mouth. To minimise 
the unpleasant taste, the drug should be mixed into a glass of fruit juice. 
 
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and 















Also called Alkeran. Melphalan can be given by mouth or intravenous injection or infusion. 
 
Following a dose of Melphalan, some patients may experience: 
a. Immediate: 
1. Nausea and vomiting (in the first 3 - 5 days). 
2. Diarrhea (in the first 3 - 5 days). 
3. Poor appetite. 
4. Allergic reaction. 
 
b. Delayed: 
1. Hair loss. 
2. Mouth sores. 
3. Low blood counts. 
4. Kidney problems. 
5. Heart arrhythmias 
6. Increase risk of secondary cancers. 
7. Infertility. 
 
c. Less frequent side effects: 
1. Abdominal cramps 
 
Contact your doctor is you notice: 
Immediately: 
1. Shortness of breath,  
2. Wheezing,  
3. Difficulty breathing,  
4. Closing up of the throat,  




Other reasons to contact your doctor: 
1. Nausea (interferes with ability to eat and unrelieved with prescribed medication). 
2. Vomiting (vomiting more than 4-5 times in a 24 hour period). 
3. Diarrhea (4-6 episodes in a 24-hour period). 
4. Unusual bleeding or bruising 
5. Black or tarry stools, or blood in your stools 
6. Blood in the urine 
7. Pain or burning with urination 
8. Extreme fatigue (unable to carry on self-care activities) 
9. Dizziness 
10. Mouth sores (painful redness, swelling or ulcers) 
11. Yellowing of the skin or eyes 
12. Swelling of the abdomen 
13. Regular blood counts and other tests will be done to check on possible side effects and 
treatment will be adjusted accordingly. 





1. Leaking of this drug outside the vein may cause pain and skin damage similar to a burn. 
Contact your doctor IMMEDIATELY if pain, redness or swelling occurs near the injection site. 
 
Monitoring: 
1. Regular blood counts and other tests will be done to check on possible side effects and 













































Also called Oncovin or Pericristine.  Vincristine can only be given by intravenous injection or infusion. 
 
Following a dose of Vincristine, some patients may experience: 
 
a. Immediate: 
1. Aches and pains in the limbs, jaw and/or abdomen, developing a 3 to 5 days after an 
injection. 
2. Constipation (3 to 5 days after an injection). 
 
b. Delayed: 
1. Hair loss (2 to 3 weeks after a dose). 
2. Muscle weakness (noted as difficulty walking up stairs or getting up off the floor), tingling 
pain in the hands, fingers and toes. 
 
c. Less frequent side effects: 
1. Abdominal cramps. 
2. Difficulty walking. 
 
Contact your doctor is you notice: 
1. The patient has not moved his or her bowels for greater than 36 hours in the 2 to 7 days 
following a dose, or complains of abdominal pain or diarrhoea. 
2. The patient has severe tingling in the fingers, decreased manual dexterity, muscle weakness 
or jaw pain. 
3. Severe nausea or vomiting. 
4. Any other problem or have questions. 
 
Special instructions: 
1. Leaking of this drug outside the vein may cause pain and skin damage similar to a burn. 
Contact your doctor IMMEDIATELY if pain, redness or swelling occurs near the injection site. 




1. Regular blood counts and other tests will be done to check on possible side effects and 




































































































































SIOP Boston Ototoxicity Scale 




















>40dB HL (i.e. 45dB HL or more) SNHL at 2,000 Hz and above 
NOTE: scale is based on sensorineural hearing thresholds in dB hearing level (HL; bone conduction 
or air conduction with a normal tympanogram). Bone conduction thresholds are used to 
determine the grade in the case of abnormal tympanometry and/or suspected conductive or 
mixed hearing loss. Even when the tympanogram is normal, bone conduction is strongly 
recommended at the single frequency that is determining the ototoxicity grade to fully confirm 
that the hearing loss at that frequency is sensorineural. Temporary, fluctuating conductive hearing 
loss due to middle ear dysfunction or wax impaction is common in the paediatric population, and 
decreases in hearing thresholds that include conductive hearing losses do not reflect ototoxicity 
to the cochlear. 
SNHL – sensorineural hearing loss 
 
Diagnostic Paediatric Protocol 
Infants younger than 6 months of age: 
• Child and family history 
• Electrophysiological measure of threshold such as ABR using frequency specific stimuli, 
• Diagnostic OAEs, 
• Assessment of middle-ear functioning, 
• Acoustic reflex thresholds, 
• Observation of the infant’s behavioural response to sound, 
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• Parental report of emerging communication and auditory behaviours. 
 
Infants and toddlers between 6 through 36 months of age: 
• Child and family history 
• Diagnostic OAEs, 
• Assessment of middle-ear functioning, 
• Acoustic reflex thresholds, 
• Ear-specific behavioural response audiometry according to the  
child’s developmental age (visual reinforcement or conditioned play audiometry), 
• Speech detection and recognition measures, 
• Parental report of auditory and visual behaviours, 
• Screening of communication and language milestones. 
 
Children 36 months and older: 
• Child and family history 
• Ear-specific behavioural response audiometry according to the  
child’s developmental age (visual reinforcement or conditioned play audiometry), 
• Speech detection and recognition measures, 
• Parental report of auditory and visual behaviours, 
• Screening of communication and language milestones. 





Appropriate measures of middle-ear functioning include tympanometry with high frequency probe 
tones of 660 or 1000 Hz, but preferably 1000 Hz, for children younger than 8 months of age corrected 
for prematurity. For children 9 months and older conventional 226 Hz probe tone tympanometry can 
be used. Pressure sweep should be positive to negative from +200 to - 400 daPa. 
 
Acoustic Reflexes 
Acoustic reflexes in children younger than 8 months (corrected for prematurity) must be determined 
using a 1000Hz probe tone. A conventional probe tone of 226 Hz can be used in children 8 months 
and older. The stimuli to be used can vary from broadband noise as a general screening stimulus to 
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frequency specific tones from 500, 1000, 2000 and 4000 Hz. Measurements should be made 
contralaterally and/or ipsilaterally as time permits 
Diagnostic Oto-acoustic emission: 
Transient Evoked (TE) or Distortion Product (DP) oto-acoustic emissions (OAE) may be used for 
diagnostic testing. Click stimuli can be used for the TEOAE measurements and DPOAE measurements 
should be conducted from 750 – 8000 Hz. 
 
Auditory evoked potentials: 
Auditory brainstem response 
Auditory brainstem response (ABR) measurements are the most widely used auditory evoked 
potential test for estimating hearing loss. The following minimum protocol is recommended for ABR 
testing for infants and young children: 
• Frequency-specific measurements using toneburst (TB) ABR must be conducted to provide 
threshold information across the frequency spectrum (At least between 500 – 4000 Hz) 
• A click stimulus may be used for assessing neurological integrity,  
cross-checking results, and for monitoring the cochlear microphonic response. 
• A cochlear microphonic response must be evaluated by changing stimulus  
polarity at high intensities for children with absent or abnormal ABR waves. If  
supra-aural earphones are used the stimulus artefact may obscure the  
cochlear microphonic response and therefore insert earphones are recommended. 
• If conductive hearing loss is suspected bone conduction ABR measurements  
     are recommended to provide frequency-specific bone-conduction  
thresholds. Auditory steady-state response 
 
The auditory steady-state response (ASSR) is a useful measure for frequency-specific threshold 
estimations in infants and children. The following minimum protocol is recommended for ASSR testing 
in infants: 
• Frequency specific tones modulated between 70 – 110 Hz should be used  
for assessing young infants preferably between 500 – 4000 Hz. 
• If extended periods of averaging is not utilized at low intensities the  
technique cannot differentiate between mild hearing loss and normal  
hearing thresholds in infants and children. 
• Since it does not provide information regarding neural integrity it should be used in 
combination with at least one ABR measurement (a click or  
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high-frequency toneburst). This will ensure an indication of neural integrity  
as determined by the ABR waves or lack thereof in addition to a test for a  
cochlear microphonic response when waves are absent or abnormal. 
• Bone conduction ASSR measurements often result in artefactual responses and is not 
recommended as a clinical technique at this stage. 
 
Referral protocol upon diagnosis of a hearing loss: 
• All children (regardless of age) MUST be referred to Hi-Hopes upon diagnosis of a permanent 
hearing loss (SNHL or CHL). A detailed audiogram must accompany the referral, and placed in 
the Hi-Hopes referral box. 
• All children under the age of 3 with a confirmed permanent hearing loss (SNHL or CHL) MUST 
be referred to the Carel du Toit CHAT Centre, regardless of the caregiver’s financial situation, 
or the presence of multiple pathologies. 
• All children up until Grade 3 with a confirmed permanent hearing loss (SNHL or CHL) MUST be 
referred to Carel du Toit School for a school-based assessment. 
 
With kind permission from Silvia Kuschke, Chief Audiologist, Red Cross War Memorial Children’s 




























The scoring system divides the skeleton into 9 compartments. 





Scoring of MIBG scan  
Level of lesion certainty: 
0 = unknown  
1 = possible  
2 = probable  
3 = definite  
 
Extent of uptake: 
0 = no uptake/ no foci per segment  
1 = one focal lesion per segment  
2 = more than one focal lesion per segment  
3 = diffuse involvement (≥50% of segment  
       involved)  
 
Intensity of uptake: 
 
0 = no sites of uptake 
1 = doubtful uptake  
2 = obvious but mild uptake  
3 = obvious and intense uptake 
 
Soft-tissue lesions scoring system: 
0 = no MIBG involvement 
1 = one MIBG-avid soft-tissue lesion present  
2 = more than one MIBG-avid soft-tissue lesion   
       present  
3 = MIBG avidity in a soft-tissue lesion that  
       occupies 50% of the chest or abdomen  
 
*Maximum attainable score is 30  
*Focal uptake: uptake with clearly defined 
margins  
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Philadelphia score system for symptomatic stage 4s Neuroblastoma 
 
Clinical signs that indicate progressive disease are the following: 
• Deterioration of the general condition 
• Feeding difficulties leading to weight loss 
• Respiratory failure defined by oxygen requirement or carbon dioxide retention exceeding 
60mmHg  
• Circulatory failure defined by hypotension or hypertension according to the age specific 
blood pressure reference values 
• Hepatic failure defined by grade 3 toxicity of bilirubin, fibrinogen, or thrombin time 
according to the NCI-CTC toxicity criteria  
• Renal failure defined by impaired blood urea or creatinine, new development of 
hydronephrosis or deteriorating pre-existent hydronephrosis 
• Symptomatic or asymptomatic intraspinal involvement documented by MRI 
• Failure of other organ systems. 
Indications for chemotherapy treatment is based on the Philadelphia score system. Chemotherapy 
should be started on a Philadelphia score of 2 or more. 
Philadelphia score system  
Clinical entity Grade Score 
GI-tract 
Emesis of > 10% of intake  








Tachypnoe over 60/min and O2 supplementation 








Leg oedema  








Oliguria with output < 2 ml/kg/hr  
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ALK   Anaplastic lymphoma kinase 
CT   Computer tomography 
COG   Children’s Oncology Group 
COJEC   Cyclophosphamide, Vincristine, Carboplatin, Etoposide, Cisplatin 
EFS   Event free survival 
FISH   Fluorescent in situ hybridization 
HIC   High income countries 
HVA   Homovanillic acid 
IDRF   Image defined risk factors 
INPC   International neuroblastoma pathologic classification 
INRG   International neuroblastoma risk group 
INSS   International neuroblastoma staging system 
LDH   Lactate dehydrogenase 
LMIC   Low- and middle-income countries 
MIBG   Meta-iodobenzylguanidine 
MKI   Mitotic Kyrotosis Index 
MRI   Magnetic resonance imaging  
MUAC   Mid upper arm circumference   
NB   Neuroblastoma 
OJEC    Vincristine, Carboplatin, Etoposide, Cyclophosphamide 
OPEC   Vincristine, Cisplatin, Etoposide, Cyclophosphamide 
OMAS   Opsoclonus/ Myoclonus Syndrome 
OS   Overall survival 
PCR   Polymerase chain reaction 
PODC   Paediatric oncology in developing countries 
POU   Paediatric oncology unit 
SIOP   International Society of Paediatric Oncology 
SACCSG   South African Children Cancer Study Group 
TSF   Triceps skin fold 
VIP   Vaso-intestinal peptide 






Worldwide neuroblastoma accounts for more than 7% of childhood cancers but contributes to 
approximately 15% of all childhood cancer deaths [1]. Available data regarding the incidence in South 
Africa estimates it to be nearly 6% of all childhood malignancies reported from 1987 to 2007 [2]. 
Neuroblastoma (NB) is a neural crest malignancy that mainly originates from the adrenal glands. It is 
the most common extracranial solid tumour in childhood [3].  The heterogeneous pathophysiological 
presentation of neuroblastoma, paired with the diverse prognostic outcome in different stages of the 
disease, makes the treatment of this disease an oncological challenge [3,4]. The problem of diagnosis 
is in the diverse nature of the clinical presentation. The peak incidence is between 2 – 5 years of age 
in the sympathetic (adrenal) lineage of the neurological system [3,4]. Although nearly 65% of tumours 
present in the abdomen other, sites include the anatomical distribution of the sympathetic chain from 
the brain to the kidneys and includes pelvic sites [4].  
The most common clinical presentation is an abdominal mass [1] yet the most common features of 
presentation are due to metastatic manifestations such as bilateral proptosis, racoon eyes, bone pain, 
pancytopaenia and constitutional symptoms (fever and loss of weight). Two paraneoplastic 
syndromes associated with NB are Vaso-intestinal peptide (VIP) syndrome and 
Opsoclonus/Myoclonus syndrome (OMAS) [1,5,6]. Other neurological presentations are Horner 
syndrome, due to tumours in the neck [7], and paraspinal symptomatology. In stage 4s infants may 
present with cutaneous lesions [4]. A simplified presentation of NB would classify the disease as either 
local disease, metastatic disease or stage 4s disease. The clinical presentation will then be dependent 
on the locality of the tumour from local pressure effects like paraspinal disease to a disseminated 
presentation [1,8].  
Two internationally recognised staging systems are the International Neuroblastoma Staging System 
(INSS) and the International Neuroblastoma Risk Group (INRG). The main difference between the two 
staging systems is that INSS is a surgical outcome-based system and the INRG is a pre-surgical 
assessment predicated on imaging, bone marrow morphology and nuclear studies. INRG utilises image 
defined risks factors (IDRF) such as the encasement, compression and infiltration of structures in local 
areas to define the staging [9,10]. The staging is performed by clinical examination and using various 
investigation modalities which includes chest X-ray, abdominal ultrasound, computed tomography 
(CT), magnetic resonance imaging (MRI), meta-iodobenzylguanidine (MIBG) scan as well as bilateral 
bone marrow biopsies [8,11]. 
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The diagnosis of NB, a small blue round cell tumour, is made on the basis of pathology which includes 
immunohistochemistry staining. The hallmark finding on pathology is Homer-Wright rosettes that 
stain positive for tyrosine hydroxylase, CD56 and synaptophysin [8,12]. The tumour histopathological 
behaviour varies from spontaneous regression, local maturation or to aggressive proliferation of 
immature cells that disseminate and cause a high mortality rate [3,4]. By using the Shimada or INPC 
classification histology is classified into favourable and unfavourable prognostic classifications [9]. The 
classical clumping of neuroblastoma cells can also be found in the bone marrow in metastatic disease 
[9].   
The aggressiveness of the tumour is determined by genetic changes. NB develops from a germline 
deletion at the 1p36 or 11q14-23 locus [13,14]. A family history is only identified in 2% of patients with 
heritable mutations in the anaplastic lymphoma kinase (ALK) gene [15]. Another mutated gene found 
in the familial type neuroblastoma is PHOX2B [16]. When NB cells have extra copies of the oncogene 
MYCN; it signifies a more rapid tumour growth and the tumour potentially become resistant to 
treatment [17]. In contrast the NTRK1 gene (which synthesises the TrkA protein) is often overactive in 
the cells of NB with a more favourable outcome [18]. 
As NB is a tumour of the sympathetic chain, predominantly of the adrenal glands, it excretes 
catecholamine hormones. Homovanillic acid (HVA) and vannilylmandelic acid (VMA) are the two main 
hormones that function as specific tumour markers for diagnostic purposes which can be traced in an 
acidified urine sample. The same tumour markers can be used as a screening tool for treatment 
monitoring and follow up for relapse [12]. 
Age and stage are still the two most important prognostic factors [8,19,20]. Other prognostic factors 
that determine the outcome of treatment in NB are translocations, ploidy and the presence of MYCN. 
MYCN is an adverse prognostic marker specific to NB. In LMIC where either fluorescent in vitro 
hybridization (FISH) or polymerase chain reaction (PCR) studies to detect the presence of MYCN are 
not available, ferritin and/or lactate dehydrogenase (LDH) may be used as surrogate markers to 
indicate an adverse prognosis [8,21]. 
The treatment of NB is very diverse which necessitates a multidisciplinary team approach. It is 
essential that the planned treatment protocol include local disease control e.g. surgery. Complete 
excision of the tumour is vital to cure. In many situations surgery is not a feasible therapeutic modality 
due to the encasing macroscopic nature of the tumour. When vital structures are encased surgery 
becomes challenging with a high surgical morbidity and mortality [3,4]. NB is very radio-sensitive with 
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a high proliferation index and therefore sensitive to radiotherapy, which can be used if surgery cannot 
provide local control. 
The chemotherapy used, for systemic treatment, in the neo-adjuvant and adjuvant setting is 
predicated on risk stratification. Taking in consideration all the risk factors each patient is grouped in 
a low, intermediate and high-risk group. The risk groups determine the amount of cycles and duration 
the chemotherapy drugs Cisplatin (P) or Carboplatin (J), Vincristine (V), Etoposide (E) and 
Cyclophosphamide (C) in regimes like OJEC/OPEC and rapid COJEC. Some co-operative groups 
advocate the inclusion of adriamycin or adaptions of the COG studies for the SIOP-PODC guidelines 
that advise ifosfamide as part of the high-risk regimes [3,4,8]. 
In the low risk group patients, especially stage I treated with surgery alone without adverse prognostic 
markers, the 5-year survival nears 96% in HIC [3]. With the added treatment of chemotherapy and 
with stage III disease, the intermediate group patients achieve a 5-year survival of 90% in both COG 
and SIOP studies [3]. It is the metastatic disease patients with high risk grouping that fare poorer with 
50 – 60% 5-year survival. If a patient only receives chemotherapy, surgery and radiotherapy the 5-year 
prognostication is 20 – 30% [3]. With the inclusion of an autologous stem cell transplant as 
consolidation therapy, the OS is improved with approximately 20% in stage IV patients [22,23]. The 
outcome with the drug repositioning of Cis-retinoic acid is improved when used post transplantation 
[24]. The role in a non-transplant setting has not been established. Cis-retinoic acid matures the 
rapidly dividing neuroblastoma cells into more indolent ganglionic cells and plays a significant role in 
addressing minimal residual disease in patients who are in complete remission [8,24]. 
Other therapies include therapeutic MIBG scans which work on the premise of neurotrophin receptor 
specific affinity as a form of targeted therapy in relapse and refractory settings. The response rates in 
patients are approximately 15% and 30% respectively [25,26]. MIBG therapy poses great logistic 
challenges to administer significant doses of radio-isotopes into children [25,26]. In the line of targeted 
therapies anti-GD2 therapy is an immunotherapy which improved the OS to 60% 5 year survival [27]. 
Other targeted therapies for NB include ALK-inhibitors which has great promise in pre-clinical trials 
[28].  
In LMIC the treatment choices are limited to mainly chemotherapy, surgery and radiotherapy. Due to 
advanced disease at diagnosis, tumours are often inoperable and treatment is therefore palliative. 
Other challenges for the management of neuroblastoma include lack of surgical and radiotherapy skills 
or equipment, as well as lack of chemotherapy [8,29]. In settings where drug insecurity is high many 
LMIC do not have even basic medicines for palliation. 
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In LMIC many factors play a role in the optimal care of patients with neuroblastoma, such as stage of 
disease, nutritional status at diagnosis, family resources, belief systems and personal autonomy. 
Resources, drug security and expertise in institutions influence treatment decisions to a similar extent 
as treatment adherence and response to treatment. The ability for facilities to provide supportive care 
in terms of antibiotics, intensive care and granulocyte stimulating factors (GCSF), influences decision 
making in the intensity of treatment that patients receive [8]. 
Most published data is from high income countries (HIC) where the five year survival is around 60% 
for all stages, including advanced stage of the disease [29,31]. In contrast low- and middle-income 
countries (LMIC) neuroblastoma has a poor prognosis of approximately 20% 5-year overall survival 
(OS) in advanced disease [29,30]. With the three modalities of chemotherapy, surgery and 
radiotherapy the prognosis varies from 96% 5-year OS for stage I to a dismal 20% 5-year OS for stage 
IV [3,4,8]. In LMIC these three modalities are the only modalities available. In some centres not all the 
modalities are available. This reserves the intensive treatment of NB with autologous transplants, 
immunotherapy and MIBG therapy for HIC, patients with private funds or medical insurance. 
Currently in South Africa, the management protocols used in the treatment of NB have been varied 
and based on the experience of paediatric oncologists. As collaborative efforts, with data from 
multiple centres, promotes more robust data, the SACCSG has committed to developing national 
protocols to treat patients with the same malignancies in a homogenous manner.  
The proposed study will be a multi-centre South African Children’s Cancer Study Group review in order 
to investigate the challenges of treating neuroblastoma in South Africa and will inform the 
development of a prospective national management protocol to ensurehigh quality, uniform 
treatment for all children treated with NB in South Africa. 
AIM 
To determine the incidence and investigate the management of neuroblastoma in South Africa. 
OBJECTIVES 
Primary objectives: 
1. To determine the incidence and epidemiology of NB in South Africa  






1. To evaluate outcomes linked to the different chemotherapy protocols used in the treatment 
of children with NB in South Africa. 
2. To analyse data for the development of future treatment protocols. 
3. To retrospectively evaluate the predictive value of clinical symptomatology and special 
investigations in prognostication in NB with the help of multivariate analysis. 
METHODOLOGY 
Design: 
The study will be a retrospective, multi-centre, patient record review of all children treated for 
neuroblastoma in South Africa and the primary outcome will be evaluated at two time points to 
identify early survivors and defining cure with: 
a) two-year overall survival (OS) and event free survival (EFS). 
b) five-year overall survival (OS) and event free survival (EFS). 
Setting: 
All POUs in South Africa treating children with NB will be invited to participate in the study. 
Paediatric Oncology Units are: 
University of Cape Town 
- Groote Schuur Hospital, Cape Town 
- Red Cross War Memorial Children’s Hospital, Cape Town 
-Rondebosch Hospital, Cape Town 
University of the Freestate   
- Universitas Hospital, Bloemfontein 
University of KwaZulu-Natal   
- Inkosi Albert Luthuli Central Hospital, Durban 
- Pietermaritzburg Metro Complex, Pietermaritzburg 
University of Pretoria 
-Steve Biko Academic Hospital, Pretoria 
- Unitas Hospital, Pretoria 
University of Limpopo 
 - Polokwane Provincial Hospital, Polokwane 
Sefako Makgatho Health Sciences University 
 - George Mukhari Hospital, Ga-Rankuwa   
University of Stellenbosch 
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- Tygerberg Hospital, Stellenbosch 
Walter Sisulu University 
-Frere Hospital, East London 
-Port Elizabeth Provincial Hospital, Port Elizabeth 
University of Witwatersrand 
-Chris Hani Baragwanath Academic Hospital, Johannesburg 
-Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg 
-Wits Donold Gordon Medical Centre, Johannesburg 
Private units 
             -Parklands Netcare Hospital, Durban 
Sample: 
Inclusion criteria: 
All patients ≤ 18 years treated for NB from 2000 – 2014 
a) Biopsy proven NB or 
b) Radiological reported neuroblastoma with positive u-catecholamine or 
c) BMAT with involvement of NB and a positive u-catecholamine (in cases where a biopsy of 
the primary tumour is not possible or radiological evidence is inconclusive) 
Exclusion criteria: 
1) Patients with indeterminate or inconclusive histology results. 
2) All patients who completed treatment before 2000.  
3) All patients who have not completed first line treatment by 31 December 2014. 
Sample size: 
The sample size depends on the number of patients treated in participating POUs. Literature suggests 
35 to 40 NB cases per year [2]. Statistics will be calculated on a minimum of 10 years’ data. 
A two-sided logrank test with an overall sample size of 350 subjects (~35 per year x 10 years) achieves 
80% power at a 0.05 or 5% significance level to detect a minimum hazard ratio of 1.4 when the control 
group hazard rate is a hazard ratio of 1.00. If it is anticipated that the proportion of subjects having 
the event during the study is 0.50 or 50% for the lower risk group and 0.70 or 70% for the higher risk 
group then a two-sided test of whether the hazard ratio is one with an overall sample size of 350 
subjects (~35 per year x 10 years) achieves 80% power at a 0.05 or 5% significance level when the 
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hazard ratio is approximately 1.47 (i.e. minimum detectable hazard ratio). These results assume that 
the hazard ratio is constant throughout the study and that Cox proportional hazards regression is used 
to analyze the data [32,33]. 
Data collection: 
1) Data will be collected at all POUs in South Africa with patients that meet the study criteria – 
see Appendix F for data sheet. 
2) Data will be collected by the investigators into an Excel® spreadsheet which will be identical 
for all POU.  
3) Institutions will assign a numerical identifier to each case in order to blind the principal 
investigator.  
4) All data collection will be centralised at Grey’s Hospital, Pietermaritzburg. 
Analysis: 
1) Data will be analysed using Stata 13.1 SE (StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP.).  
2) Continuous variables will be summarised using mean and standard deviation (SD). If any 
continuous variables are skewed then medians and interquartile ranges will be presented 
instead. Categorical data will be presented using frequency tables. Association between two 
categorical variables will be assessed using the standard Pearson’s chi-square (χ2) test. If 
expected cell count in the cross tabulation contains fewer than 5 observations (sparse 
numbers) then the Fisher’s exact test will be employed. The standard t-test will be used to 
compare the mean of continuous explanatory variables by dichotomous outcome 
classification (e.g. mortality or remission). If the normality assumption is not upheld, then the 
non-parametric equivalent Wilcoxon rank-sum test (Mann Whitney U test) will be used 
instead. Comparison of means by 3 or more groups (e.g. risk classification of low, 
intermediate, high) will be performed using one-way analysis of variance (ANOVA) with post 
hoc pairwise comparison using Bonferroni correction. If the data are not normal then the 
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Kruskal-Wallis equality-of-populations rank test will be used instead. Time to event (survival) 
analysis will also be employed.  
3) Kaplan-Meier survival curves will be developed and differences by groups assessed using a log 
rank test. This will be extended to a multivariable proportional hazards (Cox) regression model 
to adjust for confounding factors and test for potential interactions. The proportional hazards 
assumption of the model will be assessed to confirm adequacy. If this assumption is not 
upheld then a semi-parametric and/or parametric survival model will be used instead. An 
adjusted p-value of <0.05 will be considered statistically significant. 
Budget: 
As this is a retrospective record review no additional cost will be incurred above the standard care of 
treatment currently received in South Africa. 
DISSEMINATION OF INFORMATION 
• The aim is to publish results in a major international journal, e.g. Pediatric Blood and Cancer 
or Journal of Clinical Oncology for peer review and/or degree purposes.  
• An abstract will be submitted for oral presentation at the SIOP international 2017 meeting. 
• Data will be presented in academic forums at local institutions. 
CONFLICT OF INTEREST 
The investigators wish to declare no conflict of interest in terms of this study. 
ETHICAL CONSIDERATIONS 
• Confidentiality and anonymity will be guaranteed by numerical identifiers in the database 
both for institutions and patients. 
• All data will be securely stored in locked premises and password protected computers. Only 
the investigator will have access to both the premises and computer. 
• Ethical and scientific approval for the study will be sought by all participating POU under the 
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International Neuroblastoma Staging System (INSS) 
Stage 1 • Localised tumour with complete gross excision, with or without
microscopic residual disease
• Representative ipsilateral lymph nodes negative for tumour
microscopically
Stage 2A • Localised tumour with incomplete gross excision
• Representative ipsilateral non-adherent lymph nodes negative for
tumour microscopically.
Stage 2B • Localised tumour with or without complete gross excision, with
ipsilateral non-adherent lymph nodes positive for tumour.
• Enlarged contralateral lymph nodes must be negative microscopically
Stage 3 • Unresectable unilateral tumour infiltrating across the midline, with or
without regional lymph node involvement
• Localised unilateral tumour with contralateral regional lymph node
involvement
• Midline tumour with bilateral extension by infiltration (unresectable)
or by lymph node involvement. The midline is defined as the vertebral
column. Tumours originating on one side and crossing the midline
must infiltrate to or beyond the opposite side of the vertebral column.
Stage 4 • Any primary tumour with dissemination to distant lymph nodes, bone,
bone marrow, liver, skin, and/or other organs, except as defined for
stage 4S.
Stage 4S Localised primary tumour, as defined for stage 1, 2A, or 2B, with dissemination 
limited to skin, liver, and/or bone marrow (by definition limited to infants 
younger than 12 months). Marrow involvement should be minimal (i.e., <10% 
of total nucleated cells identified as malignant by bone biopsy or by bone 
marrow aspirate). More extensive bone marrow involvement would be 
considered stage 4 disease. The results of the MIBG scan, if performed, should 




International Neuroblastoma Risk Group (INRG) 
Appendix C 
Image Defined Risk Factor (IDRF) 
IDRF include the following: 
• Ipsilateral tumour extension within two body compartments: neck and chest;
chest and abdomen; abdomen and pelvis.
• Infiltration of adjacent organs/structures: pericardium, diaphragm, kidney,
liver, duodeno-pancreatic block, mesentery.
• Encasement of major vessels by tumour: vertebral artery, internal jugular vein,
subclavian vessels, carotid artery, aorta, vena cava, major thoracic vessels,
branches of the superior mesenteric artery at its root and the coeliac axis,













L1/L2 GN maturing 
GN intermixed 
A – very low 
L1 Any except 
GN maturing 
GN intermixed 
N/A B – very low 
L2 <18 Any except 
GN maturing 
Amp K – high 
GN intermixed N/A No D – low 
>18 GNB nodular  Differentiating Yes G –intermediate 
neuroblastom
a 
N/A No E – low 
Poorly 
differentiated  
Yes H –intermediate 
or undifferentiated N/A H – intermediate 
M <18 Amp N – High 
<12 N/A Hyper F – Low 
12 to <18 N/A Diploid I – Intermediate 
<18 N/A Diploid J –Intermediate 
>18 Amp O – High 
MS <18 P – High 
N/A C – very low 
Q – High 




• Compression of trachea or central bronchi. 
• Encasement of brachial plexus. 
• Infiltration of port hepatic or hepato-duodenal ligament. 
• Infiltration of the costo-vertebral junction between T9 and T12. 
• Tumour crossing the sciatic notch. 
• Tumour invading renal pedicle. 
• Extension of tumour to base of skull. 
• Intraspinal tumour extension such that more than one-third of the spinal canal  
is invaded, leptomeningeal space is obliterated, or spinal cord MRI signal is  











L1 Localised tumour not involving vital structures as defined by the list of IDRF and 
confined to one body compartment. 
L2 Loco-regional tumour with presence of one or more IDRF 
M Distant metastatic disease (except MS). 
MS Metastatic disease in children younger than 18 months with metastases confined to 




International Neuroblastoma Pathological Classification (INPC)/Shimada classification 










<1.5 yrs Poorly differentiated or 




1.5–5 yrs Differentiating & low 
MKI tumour 
FH 
<1.5 yrs c) undifferentiated
tumour
d) high MKI tumour
UH 







≥5 yrs All tumours UH 












Ganglioneuroblastoma nodular (Schwannian 
stroma-rich/stroma-dominant and stroma-
poor) 
Stroma-rich Nodular UH 




COG Risk grouping: 
INSS Age MYCN Shimada DNA ploidy Risk group 
1 Any Any Any Any Low 
2A/2B <365d Any Any Any Low 
 >365d Non-amplified Any - Low 
 >365d Amplified FH - Low 
 >365d Amplified UH - High 
3 <365d Non-amplified Any Any Intermediate 
 <365d Amplified Any Any High 
 >365d Non-amplified FH - Intermediate 
 >365d Non-amplified UH - High 
 >365d Amplified Any - High 
4 <548d Non-amplified Any Any Intermediate 
 <548d Amplified Any Any High 
 >548d Any Any - High 
4S <365d Non-amplified FH >1 Low 
 <365d Non-amplified Any 1 Intermediate 
 <365d Non-amplified UH Any Intermediate 
 <365d Amplified Any Any High 
 
Low risk 
 All children who are Stage 1 
 Any child who is Stage 2A or 2B and younger than age 1 
 Any child who is Stage 2A or 2B, older than age 1, whose cancer has no extra copies of 
the MYCN gene 
 Any child who is Stage 4S (younger than age 1), whose cancer has favourable histology, is 
hyperdiploid (excess DNA) and has no extra copies of the MYCN gene 
Intermediate risk 
 Any child who is Stage 3, younger than age 1, whose cancer has no extra copies of 
the MYCN gene 
 Any child who is Stage 3, older than age 1, whose cancer has no extra copies of the MYCN gene 
and has favourable histology (appearance under the microscope) 
 Any child who is Stage 4, younger than age 1, whose cancer has no extra copies of 
the MYCN gene 
 Any child who is Stage 4S (younger than age 1), whose cancer has no extra copies of 
the MYCN gene and has normal DNA ploidy (number of chromosomes) and/or has 
unfavourable histology 
High risk 
 Any child who is Stage 2A or 2B, older than age 1, whose cancer has extra copies of 
the MYCN gene 
 Any child who is Stage 3, younger than age 1, whose cancer has extra copies of the MYCN gene 
 Any child who is Stage 3, older than age 1, whose cancer has extra copies of the MYCN gene 
 Any child who is Stage 3, older than 18 months of age, whose cancer has unfavourable 
histology 
 Any child who is Stage 4, whose cancer has extra copies of the MYCN gene regardless of age 
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 Any child who is Stage 4 and older than 18 months
 Any child who is Stage 4 and between 12 and 18 months old whose cancer has extra copies of
the MYCN gene, unfavourable histology, and/or normal DNA ploidy (a DNA index of 1)
 Any child who is Stage 4S (younger than age 1), whose cancer has extra copies of
the MYCN gene
Appendix F 
If any aspect is not done please fill NotD 
Data sheets codes: 
Information Classification Code 





Race: (Statistical purposes) African 
Indian 








Date of birth (DOB): yy/mm/dd 
Age (months): 





BMI (Will be determined by the 
PI) 
MUAC 
TSF (Triceps skin fold) 
















Duration of symptoms: 
(From onset of disease related 
symptoms till diagnosis) 







OMAS (Opsoclonus Myoclonus Syndrome) 




Emergency Spinal compression 
Hepatic pain 
Respiratory distress 
Horner Syndrome/ Airway compromise 













TB status Positive – New 









Other infectious diseases:   
Co-morbid disease or Syndromes 
(Sxd) (Specify): 
  
Site of primary Adrenal 
Abdominal (other than adrenal) 
Chest 
Neck 








Stage (INSS): Please see appendix A  
Stage (INRG): Please see appendix B  
Image defined risk factors (IDRF): Please see appendix C  
































LDH (value):   
Ferritin (value):   
ESR (value):   
Haptoglobin (value):   
ALP (value):   






State raised: R   
Not raised: N 
















Other X-rays: bone involvement Describe main areas  




(Example for adrenal primary with 




        Adrenal 
        Non adrenal 




















End of treatment 
Bone Marrow involvement: 





End of treatment 
Describe main areas  




BMAT involved reassessment: No 
Yes 












BM aspirate reassessment: No 
Yes 
















Trephine reassessment: No 
Yes 























(INSS or INRG) 




















Abandonment of treatment 





































Describe presence during induction 
treatment thus Rapid COJEC and 
OJEC/OPEC or institutional induction 
when other protocols used) 
 
Palliation (please state): 














     Primary site 
     Metastatic site  
Alive (>5 years post last treatment) 
Dead 
 








Date last seen (DLS): yy/mm/dd   
Date of Death: (DODx): yy/mm/dd   
Reason for death Disease 
Toxicity (Specify) 
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ALK   Anaplastic lymphoma kinase 
BMAT   Bone Marrow aspirate and trephine 
CT   Computer tomography 
COG   Children’s Oncology Group 
CSR   Complete surgical resection 
DIC   Disseminated intravascular coagulation 
EBRT   External beam radiotherapy 
EFS   Event free survival 
EGFR   Epidermal growth factor receptor 
FISH   Fluorescent in vitro hybridization 
GaTATE   Gallium-68 DOTA-Octreotate 
GC-MS   Gas chromatography spectrometry 
HIC   High income countries 
HVA   Homovanillic acid 
IDRF   Image defined risk factors 
IMRT   Intensity modulated radiotherapy 
INRG   International Neuroblastoma risk group 
INSS   International Neuroblastoma staging system 
IORT   Intra-operative radiotherapy 
ITCC   Innovative Therapies for Children with Cancer 
LDH   Lactate dehydrogenase 
LMIC   Low- and middle-income countries 
MIBG   Meta-iodobenzylguanidine 
MRI   Magnetic resonance imaging 
MRS   Magnetic resonance spectroscopy 
NANT   New Approaches to Neuroblastoma Treatment Consortium 
NA   Noradrenalin 
NB   Neuroblastoma 
OMAS   Opsoclonus/ Myoclonus Syndrome 
OS   Overall survival 
PCR   Polymerase chain reaction 
PET   Positron emission tomography 
PFS   Progression free survival 
PRT   Proton beam radiotherapy 
PhRT   Photon beam radiotherapy 
PODC   Paediatric oncology in developing countries 
POU   Paediatric oncology unit 
PSR   Partial surgical resection 
SIOP   International society of paediatric oncology 
SIOPEN   SIOP European Neuroblastoma group 
SACCSG   South African children cancer study group 
TAMs   Tumour associated macrophages 
VIP   Vaso-intestinal peptide 








Neuroblastoma (NB) is a childhood malignancy with a poor prognosis, especially stage 4 disease 
[1,2,3], even in high income countries (HIC). Without high intensity treatment advanced stage disease 
has a poor outcome in low- and middle-income countries (LMIC) with treatment being palliative rather 
than curative [4,5]. 
The heterogeneous clinical presentation of NB and the diverse pathophysiological disease 
characteristics makes staging and treatment challenging [5,6]. 
Yet Neuroblastoma has a diverse pathophysiology that includes metabolic, inflammatory and genetic 
components [7,8] which has not been fully studied in a Sub-Saharan context. 
SUBJECT REVIEW 
Definition: 
Neuroblastoma commonly presents in children with a peak incidence between 2 – 10 years of age 
[2,3]. The primary lesions develop along the sympathetic chain and the adrenal glands, yet up to 60% 
of children present with primary metastatic disease [10]. 
The most common clinical presentation is an abdominal mass [4] and features of metastatic 
manifestations such as bilateral proptosis, racoon eyes, bone pain, pancytopaenia and constitutional 
symptoms (fever and loss of weight). In stage 4s infants may present with cutaneous lesions [9]. A 
simplified presentation of NB would classify the disease as either local disease, metastatic disease or 
stage 4s disease. Metastatic disease involves primarily the bone and bone marrow [3,9]. In stage 4s, 
apart from the primary lesion, infants of under 12 months may present with cutaneous lesions, bone 
marrow infiltration of less than 10% and/or liver lesions [3, 9]. 
Pathophysiology: 
The development of NB is dependent on accumulation of mutations where the pre-malignant cells 
rapidly replicate in proliferating tissue during embryogenesis in the central nervous system [11,12]. In 
NB the NMYC proto-oncogene has traditionally been overexpressed in neurogenesis for the rapid 
expansion of progenitor cell populations [12,13]. Epidermal growth factor receptor (EGFR) gene and 
PHOX2B gene has also be associated with the development of NB [12,14,15]. 
The diagnosis and staging of NB require many non-invasive and invasive investigations. The gold 
standard for the diagnosis of NB is histology [16,17].  The diagnosis of NB, a small blue round cell 
tumour, is made on the basis of pathology which includes immunohistochemistry staining. The 
hallmark finding on pathology is Homer-Wright rosettes that stain positive for tyrosine hydroxylase, 
CD56 and synaptophysin [5,18]. The tumour’s histopathological behaviour varies from spontaneous 
regression, local maturation or to aggressive proliferation of immature cells that disseminate and 
cause a high mortality rate [3,4]. The Modified Shimada or International Neuroblastoma Pathology 
Classification (INPC) histology classification system is used not only for diagnosis but for the distinction 
into favourable and unfavourable prognostic classifications [19]. 
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For staging purposes, it is necessary to investigate the potential NB infiltration into the bone and bone 
marrow via a bone marrow aspirate and bone core trephine (BMAT) [20]. Before nuclear medicine 
imaging, bone marrow aspirate was the gold standard for diagnosing metastasis. Yet BMATs are site 
specific investigations [20]. An Iodine-123-Meta-iodobenzylguanidine (123I-MIBG) scan is more reliable 
because the whole body is screened for metastasis [21, 22]. The limitation of 123I-MIBG scan is that it 
can’t detect small clusters of cells like with BMATs [20, 21, 22]. Many studies have compared 123I-MIBG 
scan to BMAT for the diagnosis of metastasis, and in the monitoring of treatment response and 
diagnose relapse [19,23]. Hero et al had proven in a study with 367 unselected stage 4 NB patients, 
treated according to the German cooperative trial NB90 at diagnosis, 123I-MIBG scan was positive in 
306 patients (92%), borderline in seven patients (2%), and negative in 19 patients (6%) whilst bone 
marrow aspirates were cytologically positive in 292 patients (84%) and negative in 57 patients (16%) 
[24]. This study concluded that low frequency 123I-MIBG -scan might be false negative and that a 
supplemental bilateral bone marrow was still important [24]. 
Nuclear medicine and imaging in management: 
Two isotopes 123I-MIBG and 131I-MIBG are selectively taken up by tumour cells of sympatho-adrenal 
origin [25, 26, 27]. To aid in the diagnosis and detect metastases of NB the type 1 catecholamine 
transport uptake mechanism of the tumour cells has the unique ability to concentrate especially 123I-
MIBG [28]. In a Cochrane review of 11 studies the sensitivity of MIBG varied between 67 -100% [29]. 
In 20% of histologically proven NB the MIBG scan may be negative. The lower radiation dose and 
optimal imaging characteristics of 123I-MIBG in comparison to 131I-MIBG, makes 123I-MIBG the preferred 
radiopharmaceutical for imaging of Neuroblastoma [30]. Even with a high sensitivity and specificity in 
10% of Neuroblastomas MIBG is not taken up because of a low expression of the norepinephrine 
transporter [31]. 
 
Other staging imaging studies include magnetic resonance imaging (MRI), computer tomography (CT) 
and positron emission tomography (PET) scans. The information is important for anatomic imaging 
such as determination of size of primary tumours, extent of regional disease and in detecting distant 
metastases [32]. This is reflected in the INRG image defined risk factors [33]. MRI and CT detect the 
encasement of vital structures and involvement of cortical bone metastases in NB. There were many 
limitations including availability, radiation doses and detection is limited to the actual fields scanned. 
CT and MRI have sensitivities of 43% and 97% respectively for detecting stage 4 disease and 
specificities are reported to be 97% and 88% respectively. Yet combined with 123I-MIBG scans the 
sensitivity and specificity of disease detection in Neuroblastoma increase to 99% and 95% respectively 
[32]. Thus, metabolic and pathophysiological aspects for the detection of metastases are combined 
[32] with a high sensitivity to detect post treatment metastatic disease [34]. This characteristic is vital 
in the utilization of reviewing treatment response [28]. 
 
123I-MIBG scan is not just used as a diagnostic test or a tool to evaluate treatment response but can 
assist in determination of prognosis. [35,36] Both International Society of Paediatric Oncology 
European Neuroblastoma group (SIOPEN) and Children’s Oncology Group (COG) developed scoring 
methods using 123I-MIBG in semi-quantitative methods to use as a prognostic marker for response and 
survival in Neuroblastoma with 123I-MIBG -avid disease. 
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Both scoring systems divide the body into segments. The Curie score (developed by COG) divides the 
body into 9 segments (with four degrees of nuclear differentiation) where the SIOPEN scoring system 
divides the body into 12 segments (with six degrees of nuclear differentiation) [35,36]. 
 
In terms of prognostication patients with a Curie score greater than 2 after induction therapy, had a 
significantly worse 3 years event-free survival (EFS) of 15% than those with scores less than 2 of 45% 
[35]. The German Pediatric Oncology Group investigated the prognostic value of both the Curie and 
SIOPEN scoring method, as well as comparing them. Both scoring systems proved good 
prognostication tools for outcome [36]. A Curie score of 2 or less and a SIOPEN score of 4 or less at 
diagnosis correlated to significantly better with event free survival (EFS) and overall survival (OS) as 
compared with higher scores. After four cycles of induction, those with complete response on MIBG 
testing had a better outcome than those with residual uptake [36]. 
The limitation of the Curie score and the SIOPEN score is that both do not take in consideration the 
collection of radio-isotopes in the soft tissue. Subsequently the Curie score includes a 10th segment 
for soft tissue involvement and is known as the modified Curie score [36]. The modified Curie score 
not only takes in account the bone and bone marrow distribution but soft tissue involvement as well 
without losing prognostic relevance [36]. 
 
Yanik and colleagues studied 280 patients with stage 4 neuroblastoma who were on Children Oncology 
Group (COG) protocol A3973. They reported that in 52 patients with a Curie score > 2 had a decreased 
event free survival (EFS) compared to the 185 patients those with Curie scores ≤ 2 after induction 
therapy with 3-year EFS of 15.4% ± 5.3% vs. 44.9% ± 3.9% (p = 0.001) [35]. In the same study tumour 
reduction of more than 50% in the Curie score from diagnosis to after induction had a much better 
survival when compared to those with less than 50% reduction [35]. Katzenstein et al studied 29 
patients with NB to determine the prognostic significance of 123I-MIBG scan scores [28]. By using a 
scoring scheme that divided the skeleton into 10 segments it was concluded that the post induction 
scan predicted prognosis as 123I-MIBG score ≥ 3 after induction therapy was associated with a 
significantly worse event free survival [28]. 
 
Perel et al reported that an abnormal post induction chemotherapy 123I-MIBG scan was associated 
with a poor outcome [25]. However, Andrich et al did not find post therapy 123I-MIBG imaging findings 
to be predictive of prognosis [37]. It is important to note that residual 123I-MIBG avid disease on the 
post induction chemotherapy 123I-MIBG scan predicts poor outcome after allogenic stem cell 
transplant [22] and relapse after high dose therapy with peripheral blood stem cell rescue, local 
radiotherapy, and cis-retinoic acid [28]. 
 
Two distinct metastatic patterns of 123I-MIBG distribution in stage 4 NB where found by Bleeker et al 
[34]. The two patterns were a “limited and focal” pattern found mainly in patients with amplified 
MYCN Neuroblastoma that correlated with prognosis and an “extensive and diffuse” pattern found 
mainly in patients with single copy MYCN Neuroblastoma [34]. One question is whether MYCN activity 
is responsible for the focal growth of metastatic lesions and determines the affected body segments 
[34]. Patients with MYCN amplified tumours and those with focal lesions had an improved event free 
survival (EFS) and overall survival (OS) than those in the other metastatic groups with 5-year EFS 
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respectively [34]. Exclusively focal pattern of uptake was not associated with a better overall survival 
in patients with MYCN amplified disease [34]. 
 
In low- and middle-income countries the data on the role of 123I-MIBG scans is very limited. This is 
possibly due to the scarcity of nuclear imaging facilities, as well as logistic problems in obtaining radio-
pharmaceuticals [38]. 
Although 18F-fluorodeoxyglucose (FDG)- Positron emission tomography (PET) scans is not considered 
the main nuclear diagnostic investigation, its utility in NB is well documented. It uses glucose receptor 
transport mechanisms in tumours to diagnose the presence of malignancies [38]. This is the reason 
why the specificity of 86% [39, 40] is not as accurate as an 123I-MIBG -scan. 18F-FDG PET is taken up in 
areas of infection and inflammation and has high normal physiological uptake in certain organs which 
may lead to false positive results [39, 40]. 
A Cochrane review concluded that in patients with a negative 123I-MIBG scan, it is advisable to perform 
a second confirmatory test such as 18F-FDG-PET/CT [41]. Yet diagnostic accuracy of 18F-FDG-PET/CT in 
these cases have not been determined [41]. Comparative studies between 18F-FDG-PET/CT and ¹²³I-
MIBG SPECT/CT scintigraphy imaging for detecting a neuroblastoma tumour and its metastases are 
limited [41]. 
Role of tumour markers in management: 
The presence of tumours in the body can be detected by non-imaging modalities. Tumour markers are 
substances found in tissue, blood or body fluids that may indicate the presence of cancer in the body. 
They may be derived from normal cells or cancer cells and can be genetic, hormonal, immune or 
inflammatory in nature [5,42]. Non-specific tumour markers are produced either by the tumour or by 
the body in response to the cancer but may be produced in benign conditions where high numbers of 
cells is generated [43]. 
Two non-specific tumour markers of prognostic significance are Lactate dehydrogenase (LDH) and 
Ferritin [5]. In the International Neuroblastoma risk group (INRG) database 959 patients were 
identified with an increased diagnostic LDH and 666 patients were identified to have an increased pre-
treatment Ferritin. Analysis showed that a Ferritin level between 90-140ng/ml (median 120ng/ml) and 
an LDH level between 580–1000IU/L (median of 750IU/L) had prognostic significance [5]. Ferritin had 
a 5-year EFS of 77% versus 61% for associated with a value of lower than 96 ng/ml versus a value 
higher than 96 ng/ml (P<0.001) [5]. Similarly, the 5-year EFS for patients with an LDH less than 580 U/L 
versus a value higher than 580 U/L was 78% versus 67% (P<0.0001) [5]. 
 
MYCN is a diagnostic tumour marker of NB [3]. MYCN is a V-myc myelocytomatosis (viral-related 
oncogene) neuroblastoma derived gene and is amplified in 20% of NB tumours and denotes a poor 
prognosis [43]. In NB it is linked to increased angiogenesis and vascularization, decreased apoptosis, 
the ability to escape immune surveillance, increased tumorigenic proliferation and ability to 
metastasise due to the presence of MYCN [43].  MYCN amplification is a genomic expression in NB 
that is present in advanced disease and in rapidly progressive disease [44,45]. Prognostication with 
MYCN amplification has been found to be adverse and correlates with other poor prognostic markers 
such as advance disease, older age and unfavourable histology [44,45]. The percentage MYCN 
expression in stages 1 to 3 varies but in stage 4 disease has peaks up to 65% [41,42]. Furthermore, we 
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find tumours with extra MYCN copies. This genomic aberration seems to carry a better prognosis than 
with MYCN amplification [44,45]. 
In LMIC where either fluorescent in vitro hybridization (FISH) or polymerase chain reaction (PCR) 
studies to detect the presence of MYCN is not available, ferritin and/or LDH can be used as surrogate 
markers to indicate an adverse prognosis [5,47]. 
As NB is a tumour of the sympathetic chain, predominantly of the adrenal glands, it excretes 
catecholamine hormones. Homovanillic acid (HVA) and vannilylmandelic acid (VMA) are the two main 
hormones that function as specific tumour markers for diagnostic purposes which can be traced in an 
acidified urine sample. The same tumour markers can be used as a screening tool for treatment 
monitoring and follow up for relapse [18]. 
Vanillylmandelic (VMA) and homovanillic acids (HVA) are the best markers [48]. In addition, combined 
determination of normetanephrine with vanillylmandelic acid, in children under 1 year of age, or 
normetanephrine with homovanillic acid, in children older than 1 year of age, the diagnostic sensitivity 
and specificity of age group depend testing is 100% [48]. In another studies it has been suggested that 
dopamine (DA) is the preferred marker to determine diagnosis with VMA and HVA [49] or 
Noradrenaline [50]. Zambrano et al described an age correlation similar to previous studies but 
included DA and NA in the 1 year of age watershed [50]. 
Strenger et al suggested that urine catecholamines have prognostic capabilities. In the study sensitivity 
of VMA, HVA, and DA was 80.7, 71.9, and 61.3%, respectively [49]. In 114 patients with NB high VMA 
levels were associated with favourable biological features and high DA levels were associated with 
unfavourable biology [49, 50]. Patients with normal HVA levels had a significant better outcome [49]. 
For disseminated Neuroblastoma of infancy (stage 4 and stage 4s) the DA:VMA ratio proved to have 
value in the discrimination of stage 4 versus stage 4s [49]. Laug et al concluded that the HVA:VMA 
ratio had prognostic predictive value in disseminated disease [51]. It was further concluded that the 
presence of the DA, VMA, as well as increased amounts of cystathionine and VMA or low levels of 
VMA indicated poor prognosis [51]. 
Previous studies found that increased urinary DA:NA ratios have been associated with poor prognosis 
and low DA:NA ratios have been associated with longer disease-free survival [50]. 
Zambrano et al further described that unfavourable biology like MYCN and unfavourable histology. 
The study suggested that stage 3 and 4 disease had increased ratios of cathecholamines as opposed 
to stage 1 and 2 disease [50]. Their study results suggested that stage 3 and 4 cases had DA levels >2 
times the upper limit of normal, where only 8% of stage 1-2 cases had DA levels twice the upper limit 
of normal [50]. In stage 3 and 4 cases the VMA level was >10 times the upper limit of normal as 
opposed to stage 1 and 2 cases where only one patient had VMA levels >10 times the upper limit of 
normal [50]. 
Even though tumour markers in the management of NB can predict outcome they are poor predictors 
for relapse or progression [52]. Simon et al proved the difference in diagnostic and relapse or 
progression prediction of tumour markers. At diagnosis the study found abnormal results in 75% for 
serum VMA and/or HVA, 92% for urine VMA and/or HVA, 90% for neuron specific enolase (NSE), and 
81% for LDH. Yet the study found a lower incidence of abnormal results at relapse or progression with 
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40% for serum VMA and/or HVA, 54% for urine HVA and/or VMA, 61% for NSE, and 48% for LDH [52]. 
Hsiao et al described that serum Chromogranin A had a sensitivity of 91% and specificity of 100% [53]. 
The level of Chromogranin A at diagnosis correlated with outcomes. Levels <190ng/ml correlated with 
a good prognosis and levels >190ng/ml with a poor outcome [53]. 
In the study of Simon et al NSE was found to be the most sensitive marker for localised relapses (42%), 
combined local and metastatic relapses (77%) and of metastatic recurrences (69%) of NB [52].  
Sensitivity of all markers was higher for metastatic disease compared with local recurrence [52]. In all 
these studies relapse and progression could not be predicted by tumour markers alone. Imaging 
studies must be done in con junction with tumour markers for accurate prediction [49]. 
 
Many clinical aspects, histology and imaging techniques are applied to prognosticate the outcomes in 
NB [54]. Yet identifying novel techniques refine earlier prognostic determinants and treatment 
responses could change the application of treatment [54]. Furthermore, it could aid in the risk 
classification of NB especially in the high-risk tumours that would benefit from novel first line 
treatments like immunotherapy with Anti-GD2 antibodies and IL-1 [54]. 
Although much has been published regarding the prognostication of each of these diagnostic 
modalities very little is known how they relate to each other in prognostication. Recent studies suggest 
that the levels of mRNA in the blood from NB patients could distinguish an ultra-high-risk group from 
a high-risk group [55]. The same risk distinction was concluded by a study of the pattern of 123I-MIBG 
scans [34]. What is not known is whether there is a correlation between high mRNA levels and the 
patterns of 123I-MIBG scans. Yet other tumour markers have not been correlated to imaging studies to 
assess the relation with regards to prognostication. 
If the knowledge we gain from specific tumour markers in the laboratory is subjected to the principles 
of translational oncology in relation to sensitive and specific diagnostic techniques in nuclear 
medicine, the question can be asked if these specific tumour markers and diagnostic techniques can 
indicate various levels of risk in non-specific tumour markers. 
As these non-specific tumour markers are more affordable and available in LMIC as risk classification 
for treatment, it can be utilised in more evidence-based treatment decisions. 
AIMS AND OBJECTIVES 
Aim: 
The aim of the study is to determine the association between prognostic clinical characteristics and 
special investigations of children diagnosed with neuroblastoma by using treatment response and 
OS as measurement for outcome. 
Objectives: 
a) To determine the association between the prognostic value of non-specific tumours and 
specific tumour markers with the prognostic value of 123I-MIBG-scan. 
b) To evaluate how the pattern of metastatic distribution in 123I-MIBG scan relates to treatment 






The study will be a national multicentre, retrospective chart review and part of a prospective 
national treatment protocol. Data will be sourced from a completed retrospective study: A 
retrospective analysis of the management and outcome of Neuroblastoma (NB) in South African 
Children 2000-2014 (approved by UCT HREC 308/2017) and from a standard of care prospective 
treatment protocol for all children diagnosed with neuroblastoma in South Africa. 
Study setting: 
All Paediatric Haematology and Oncology Units in South Africa and associated Nuclear Medicine 
departments will be invited to participate in the study. 
 
 The Nuclear Medicine Departments are: 
University of Cape Town 
- Groote Schuur Hospital, Cape Town 
- Red Cross War Memorial Children’s Hospital, Cape Town 
University of the Freestate   
- Universitas Hospital, Bloemfontein 
University of KwaZulu-Natal   
- Inkosi Albert Luthuli Central Hospital, Durban 
University of Pretoria 
-Steve Biko Academic Hospital, Pretoria 
University of Limpopo 
 - Polokwane Provincial Hospital, Polokwane 
University of Stellenbosch 
- Tygerberg Hospital, Stellenbosch 
University of Witwatersrand 
-Baragwanath Hospital, Johannesburg 
-Charlotte Maxeke Academic Hospital, Johannesburg 
 
Paediatric Oncology Units are: 
University of Cape Town 
- Groote Schuur Hospital, Cape Town 
- Red Cross War Memorial Children’s Hospital, Cape Town 
- Rondebosch Medical Centre, Cape Town 
University of the Free State   
- Universitas Hospital, Bloemfontein 
- Kimberley Provincial Hospital 
University of KwaZulu-Natal   
- Inkosi Albert Luthuli Central Hospital, Durban 
- Pietermaritzburg Metro Complex, Pietermaritzburg 
University of Pretoria 
-Steve Biko Academic Hospital, Pretoria 
- Unitas Hospital, Pretoria 
University of Limpopo 
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 - Polokwane Provincial Hospital, Polokwane 
Sefako Makgatho Health Sciences University 
 - George Mukhari Hospital, Ga-Rankuwa   
University of Stellenbosch 
- Tygerberg Hospital, Stellenbosch 
Walter Sisulu University 
-Frere Hospital, East London 
-Port Elizabeth Provincial Hospital, Port Elizabeth 
University of Witwatersrand 
-Baragwanath Hospital, Johannesburg 
-Charlotte Maxeke Academic Hospital, Johannesburg 
-Donnie Gordon Private Hospital, Johannesburg 
Private units 
             -Parklands Netcare Hospital, Durban 
 
Study population and sampling: 
 
Patients will be recruited both retrospectively and prospectively. Prospective patients will be recruited 
as part of a national NB treatment protocol. 
 
Inclusion criteria: 
All patients ≤ 18 years at diagnosis from 2000 – 2016 and completed treatment by December 2016 as 
well as patients diagnosed from August 2018 with: 
a) Biopsy proven NB or 
b) Radiological reported neuroblastoma with positive u-catecholamines or 
c) BMAT with involvement of NB and a positive u-catecholamines (in cases where a biopsy is 
not possible or radiological evidence in inconclusive) 
 
Exclusion criteria: 
1) Patients with indeterminate or inconclusive histology results and/or BMAT and u-
catecholamines to diagnose NB. 
2) Poor quality investigations or investigations that provide incomplete information for study 
purposes. 






All charts of participants will be reviewed for information and collected according to a data collection 
sheet (see Appendix A). The dataset is standardised for both the retrospective and prospective 
participants. 
MIBG-scan evaluation: 
Each patient’s pre-treatment and reassessment 123I-MIBG scan (if available) during induction, 
regardless of treatment protocols, will be:  
a) Scored according to the modified Curie score (see Appendix B) and
b) The investigation of metastatic patterns on MIBG-avid skeletal lesions will be categorized as
“focal” or “diffuse”.
Definitions: 
Focal metastases are MIBG-avid spots with clear margins distinguishable from the background 
and/or located to a single region. 
Diffuse metastases will be view as MIBG-avid regions with no clear margins and/or spread 
throughout body segment(s).  
Reporter bias: 
Two independent observations will be documented to exclude reporter bias. The first will be 
documented from the report of the treating POU and the second will be documented by a review 
Nuclear physician. 
Correlation studies: 
a) The prognostic value of the diagnostic LDH and Ferritin values will individually be correlated with
the prognostic value of the diagnostic modified-Curie scores.
b) The clinical presentation, age, LDH, Ferritin and MYCN will be correlated with the findings in the




In South Africa between 30 – 40 new cases of NB are diagnosed per year [56]. Correlating the 
Paediatric oncology units (POU) where patients can access 123I-MIBG scan with the incidence 
from 2000 – 2016, it is expected to identify 80 – 90 patients eligible from retrospective data. 
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Prospectively over a 2-year period another 40 - 50 may be eligible for the study. Thus, an 
expected 120 – 140 patients can potentially be included into the study. 
Data collection: 
• Data will be collected by each individual participating unit and collated in a central
anonymous database, managed by the principle investigator.
• Anonymity will be assured by awarding a unit specific number to each patient. The list
of patients with their unique number will be kept in a password protected computer
in a locked location. This information will only be known by the participating health
care provider in each unit.
• The PI will only receive data with a site-specific identifier without knowledge of the
patient’s identity.
• Data will be stored in a password protected computer only accessible by the PIs in a
locked office accessible by only the PIs.
Data analysis: 
4) The data will be analysed using Stata 15.0 and R statistical package 3.5.  (StataCorp. 2017.
Stata Statistical Software: Release 15. College Station, TX: StataCorp LP.).
5) Sample mean, median and standard deviations will be described. Normally distributed data
will be presented as mean ± standard deviation (SD) and skewed data as median and range.
Different degrees of OSA will compared by using Mann-Whitney test/Jonckheere-Terpstra
Test or X² test. Spearman correlations will be performed between LDH, Ferritin and MYCN
with the modified Curie score and pattern of distribution of diagnostic 123I-MIBG scans. All
analyses will be analysed with a significance was set up at p <0.05. In view of prediction of
treatment outcome, multiple logistic regression analysis will be used.
6) We will attempt to analyse and compare those subjects with missing values to those
without in terms of demographics and the outcome measures in an attempt to assess
whether any potential selection biases are present in the data and to check the missing-at-
random assumption. Sequential regression multivariate imputation will also be employed to
constitute key markers with high missingness. The Youden index will be used to identify the
optimal breakpoints for non-specific tumour markers and prognosis/outcome. The
discriminatory power for each marker will be evaluated using the area under the ROC curve
(AUC), and a comparison between the curves will be performed for significant differences. An
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AUC value of value ≥0.8 will be targeted as an accepted cut-off for good to excellent predictive 
capability. Sensitivity, specificity, predictive positive value (PPV) and negative predictive value 
(NPV) based on the optimal cut-points will be estimated with associated 95% confidence 
intervals (CI’s). To account for multiple comparison, we will also adjust p-values for multiple 
testing using a Bonferroni or related correction factor.  Once highly predictive factors are 
identified we will extend to a multivariable logistic regression to create weighted risk scores 
and compare to unweighted scores of tumour markers for predictive capability. 
7) If expected cell count in the cross tabulation contains fewer than 5 observations (sparse
numbers) then the Fisher’s exact test will be employed. The standard t-test will be used to
compare the mean of continuous explanatory variables by dichotomous outcome
classification (e.g. mortality or remission). If the normality assumption is not upheld, then the
non-parametric equivalent Wilcoxon rank-sum test (Mann Whitney U test) will be used
instead.
8) Kaplan-Meier survival curves will be developed and differences by groups assessed using a log 
rank test. This will be extended to a multivariable proportional hazards (Cox) regression model 
to adjust for confounding factors and test for potential interactions. The proportional hazards 
assumption of the model will be assessed to confirm adequacy. If this assumption is not 
upheld then a semi-parametric and/or parametric survival model will be used instead. An 
adjusted p-value of <0.05 will be considered statistically significant. 
RELEVANCE 
With a growing number of children in LMIC settings the burden of cancer in children will rise. This 
will be the first comprehensive multi-institutional, interdepartmental, retrospective and prospective 
study describing the role of 123I-MIBG scans in NB in South Africa and Sub-Saharan Africa. The study 
will improve the understanding of the pathophysiology of NB in the South African context. 
ETHICAL CONSIDERATIONS 





The research is a national, multi departmental study which includes multiple hospital sites. The study 
is a joint partnership between pediatric oncologists, radiologists, surgeons, nuclear medicine 
physicians as well as staff active in the care of patients and diagnostics such as laboratories.  
Social value: 
The proposed management protocols will be sustainable treatment interventions. Future 
suggestions for management adaptations will benefit the South African population and needs. 
Scientific validity: 
The risk of intervention and scientific validity is according to acceptable standard medical care for all 
children diagnosed with NB. All treatments and palliation will be standard of international care with 
practical application to South African health care guidelines and resource restraints. 
Study results will be given to participating parties and the data will be discussed in academic 
meetings and congresses, thesis purposes and published in peer reviewed journals. 
Fair selection of study population: 
All patients diagnosed with NB will be invited to participate in the study as part of a fair selection 
process. 
Favourable risk benefit ratio: 
Untreated NB is a terminal disease. The aim of the study is to improve outcomes as well as improve 
palliative care for patients without further treatment options. All interventions will only be done to 
benefit the patient and treatment above the negative effects of the treatment or interventions on 
the patient.   
Independent review: 
Applications for ethical approval will be submitted at the Health Research Evaluation Committee of 
respective universities attached to participating POUs. The ethical approval from respective 
Departments of Health will be obtained. The study will be open for regular review or audits. 
Informed consent: 
Informed consent will be waived on the retrospective data (as per HREC 308/2017 approval). The 
prospective data forms part of a standard of care prospective management protocol for which 
written consent will be obtained for the complete management from participants’ caretakers as well 
as assent in children older than 7 years old. Assent from children below 7 years of age will not be 
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taken, however the willingness to participate in the management will be taken into consideration. 
Participation in the study is voluntary. Participants or their parents may withdraw at any stage of the 
study. All consent and assent will be obtained according to age, education and language sensitive 
requirements.  
Respect for the recruited participants and study communities: 
Where there is the possibility of discomfort or emotional distress all efforts will be made to minimize 
the discomfort without hazardous effects.  
Each patient will receive a unique study number. A list linking the name and the unique study 
number will be kept separate in the individual POU and not be used in the analysis. The data will be 
collected prospectively and analysed without the name or any identifiable data of the individual 
patient to ensure confidentiality. 
The electronic information will be kept in each POU on a password protected computer that will only 
be accessible by the staff participating in the study. The main data base will be kept by the principle 
investigator at Grey’s Hospital on a password protected computer. 
Human tissue and biological samples will be collected and treated according to the ethical guidelines 
of the ethical committees of participating Universities and guidelines of the Health Professions 
Council of South Africa.  
All interventions and management recommendations will be done with consideration to social and 
cultural aspects of each patient. 
SIGNIFICANCE OF THE STUDY 
National resources should be utilised efficiently especially in regards to rare diseases. More 
specialised tests are developed to improve diagnostics and evaluation of treatment and outcomes. 
Yet less specialised tests with proven prognostic values have not been correlated with these 
specialised tests to assess the comparative use in the clinical setting. 
By understanding how easily accessible tests in lower resourced settings relate to advanced tests 
more affordable management of patients is possible without compromising on patient care. 
The importance of this study is to attempt to determine which investigations should be done in a 
setting with limited resources. 
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LIMITATIONS OF THE STUDY 
Neuroblastoma is a rare disease and the sample size is small. As the study is retrospective the quality 
of the data might be poor or lacking in regards to the objectives. The retrospective nature of the 
study implies limitations associated with this study design. This data can be compared to the data 
gathered in the prospective management protocol.  
As many of the investigations and interpretation is user dependent a degree of intra and inter 
reporter variability might exist and introduce bias into the information set of the study. 
DISSEMINATION PLAN 
The information will be distributed in four ways: 
• Aim to publish the data in a medical journal with an impact factor.
• Present the findings at the SACCSG National meeting.
• Present the data in a dissertation in fulfilment of a PhD degree of the PI.
• Present the findings at International congresses such as SIOP-Africa or SIOP-International
BUDGET 
The study will not generate any additional cost in terms of patient care as data will be gathered from 
files. There will be no additional administration costs as all data will be electronic. The study is based 
on the standard of care in public hospitals in South Africa and no added resources utilised in the 
management of patients. 
CONFLICT OF INTEREST 
The investigators wish to declare no conflict of interest in terms of this study. 
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APPENDIX A: Data collection sheet 
Data sheets codes: 
Information Classification Code 





Race: (Statistical purposes) African 
Indian 








Date of birth (DOB): yy/mm/dd 
Age (months): 





BMI (Will be determined by the 
PI) 
MUAC 
TSF (Triceps skin fold) 
(Will be determined by the PI) 
Presenting symptoms: 












Duration of symptoms: 
(From onset of disease related 
symptoms till diagnosis) 







OMAS (Opsoclonus Myoclonus Syndrome) 




Emergency Spinal compression 
Hepatic pain 
Respiratory distress 
Horner Syndrome/ Airway compromise 













TB status Positive – New 







Other infectious diseases: 




Site of primary Adrenal 
Abdominal (other than adrenal) 
Chest 
Neck 







Stage (INSS): Please see appendix A 
Stage (INRG): Please see appendix B 




































ALP/ ALT (value): 
Albumin (value): 





State raised: R   
Not raised: N 














Other X-rays: bone involvement Describe main areas 




(Example for adrenal primary with 
liver and node involvement: Adr, 
L, M 
Or 
















CT scan bone involvement: Specify sites 
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Pre-treatment MIBG scan: 
Modified Curie score (value) 
Pre-treatment MIBG scan: 






Modified Curie score (value) 
Reassessment MIBG-scan: 
Pattern of metastases: 








Describe main areas 




BMAT involved reassessment: No 
Yes 












BM aspirate reassessment: No 
Yes 
















Trephine reassessment: No 
Yes 























(INSS or INRG) 




















Abandonment of treatment 


























Outcomes: Remission (<5 years post last treatment) 
Relapse 
  Primary site 
  Metastatic site 











Date last seen (DLS): yy/mm/dd 
Date of Death: (DODx): yy/mm/dd 
Reason for death Disease 
Toxicity (Specify) 






APPENDIX B:  
123I-MIBG SCORING SHEET 
Data Options Code 
Source code 
Induction regime Rapid COJEC 
OJEC/OPEC 
Other (please specify) 
rCJ 
JP 
Type of scan Pre-treatment scan 
Post induction treatment scan 







The scoring system divides the skeleton into 9 compartments. 
A 10th compartment represents the soft tissue lesions.  
Scoring of MIBG scan  
Level of lesion certainty: 
0 = unknown  
1 = possible  
2 = probable  
3 = definite  
Extent of uptake: 
0 = no uptake/ no foci per segment  
1 = one focal lesion per segment  
2 = more than one focal lesion per segment  
3 = diffuse involvement (≥50% of segment  
       involved)  
Intensity of uptake: 
0 = no sites of uptake 
1 = doubtful uptake  
2 = obvious but mild uptake  
3 = obvious and intense uptake 
Soft-tissue lesions scoring system: 
0 = no MIBG involvement 
1 = one MIBG-avid soft-tissue lesion present  
2 = more than one MIBG-avid soft-tissue lesion  
       present  
3 = MIBG avidity in a soft-tissue lesion that 
       occupies 50% of the chest or abdomen  
*Maximum attainable score is 30 
*Focal uptake: uptake with clearly defined
margins





































PATTERN OF UPTAKE 
Focal metastases  
(Clear margins distinguishable from the background and/or located to a single region) 
or 
Diffuse metastases 
(No clear margins and/or spread throughout body segments) 
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Appendix G: Research and congress abstracts 
Congress abstracts 
1. Age at diagnosis as prognostic factor in South African children with neuroblastoma – SIOP
International, Toronto, Canada 2020
2. Favourable outcomes in children and adolescents with sex cord stromal tumours (1990-2015):
First report by the South African Children’s Cancer Study Group - SIOP International Lyon,
France 2019
3. Favourable Outcomes for South African Children and Adolescents with Mature and Immature
Teratomas (1990-2015): First Report by the South African Children Cancer Study Group - SIOP
International Lyon, France 2019
4. The prognostic significance of surgery and radiotherapy for cure in high risk neuroblatoma in
South Africa – SIOP International, Lyon, France 2019
5. The management of neuroblastoma in South Africa between 2000 and 2014 – SIOP
International Lyon, France 2019
6. Collaborative National Protocol Design – SACO, Cape Town, South Africa 2019
7. Favourable outcomes in children and adolescents with sex cord stromal tumours (1990-2015):
First report by the South African Children’s Cancer Study Group – SACO, Cape Town, South
Africa 2019
8. Favourable outcomes for South African children and adolescents with mature and immature
teratomas (1990 -2015): First report by the South African Children Cancer Study Group –
SACO, Cape Town, South Africa 2019
9. Carboplatin-based chemotherapy delivers superior results in children and adolescents with
extracranial germ cell tumours: First report by the South African Children’s Cancer Study
Group, 1990-2015 – SACO, Cape Town, South Africa 2019
10. The role of surgery and radiotherapy in the management of Neuroblastoma in South Africa –
SACO, Cape Town, South Africa 2019
11. The management of neuroblastoma in South Africa between 2000 and 2014 – SACO, Cape
Town, South Africa 2019
12. Iron deficiency anaemia: the forgotten culprit of thrombocytopenia in female adolescents -
Annual Congress of the Belgium Society of Paediatrics 2019
Publications 
1. Van Heerden J, Zaghloul M, Neven A, de Rojas T, Geel J, Patte C; et al.: Pediatric Oncology
Clinical Trials and Collaborative Research in Africa: Current Landscape and Future
Perspectives. JCO Global Oncology. 2020; 6:1264-1275.
2. Eelen Y, Norga K, Verlooy J, Tousseyn T, Van Heerden J. Primary Thyroid Lymphoma in an
Adolescent with Hashimoto’s Thyroiditis and Congenital Deafness. Journal of Clinical Oncology 
and Research. 2020; 3(5): 2-5.
3. Lopes L, Verlooy J, Norga K, van Heerden J. The multifactorial etiology and approach to iron
deficiency anemia in adolescent girls. International Journal of Case Reports. 2020; 4:130.
4. J van Heerden, R Delport, M Kruger. The ability of children to consent to medical procedures.
South African Journal of Child Health. 2020;14(1):25-29.
5. T. Van Genechten, J. van Heerden, T. Bauters, C. Dhooge. Successful treatment of adenovirus
infection with Brincidofovir in an immunocompromised patient after hematological stem cell
transplantation. Case Reports of Infectious diseases. 2020;2020.
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6. Van Heerden J, Tjelma W. The multidisciplinary approach to ovarian masses in children and
adolescents. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2019;
243(10): 103-110.
7. Claes L, Dendooven A, van Heerden J. The Challenges of diagnosing ectopic thymic tissue in
children. BMJ Case Reports CP 2019;12: e228807.
8. Jaques van Heerden, Hansraj Mangray, Fernando Ghimenton, Deneys Reitz. Significant
haematuria caused by a pseudo-aneurysm in nephroblastoma. Pediatric Surgery Case Reports.
2019; 41(2): 30-32.
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